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Abstract 
A series of progesterone-4-ovalbumin conjugates with different length 
intermediate linkers were applied as coating antigens in an enzyme-linked 
immunosorbent assay (ELISA) format to determine antibody-binding 
performance and assay parameters in cow whole milk. The use of an 18-atom 
linker gave higher binding than 4- or 11-atom linkers but no further increase was 
seen with increasing linker length. An ELISA constructed with the 18-atom linker 
conjugate gave a detection limit of 0.089 ng/mL progesterone and correlated well 
to an established radioimmunoassay procedure (r = 0.94). The assay has the 
advantages of a wide linear range (0.1 to 100 ng/mL) enabling full profiling of 
bovine estrous cycles, use of whole milk directly without extraction or pre-
dilution, and employing more easily purified protein conjugates as coating 
antigens compared with commercial progesterone-enzyme conjugates. 
Thioether-bridged derivatives of 17~-estradiol and estrone were produced with 
attachment at the 4-position of the aromatic A-ring using aromatic substitution of 
the corresponding bromoestrogens. These thioether derivatives were then 
modified further to attach oligoethylene glycol or polyethylene / polypropylene 
glycol chains of varying length (n = 3 and n = 15-19). The estradiol-oligoethylene 
glycol derivative was immobilised in situ in a surface plasmon resonance (SPR) 
biosensor and its antibody binding compared to conjugations through the steroid 
2-position by Mannich reaction and the 3-position by hemisuccinate conjugation. 
2-position conjugation gave 19% more binding than 4-position and 3-position 
hemisuccinate gave negligible binding to the antibody raised to a 6-position 
conjugate. The chip surfaces were then used to construct SPR assays of estradiol 
with and without secondary antibody signal enhancement and gave limit of 
detection (LOO) as low as 25 pg/mL. 
Thioether-bridged derivatives of the catecholamines dopamine, nor-
epinephrine and epinephrine were synthesised by electrolysis of the parent 
catecholamine to produce the corresponding o-quinone and then simply adding a 
thiol of three or 11-carbons in length with a terminal carboxylic acid function. A 
convenient cationic exchange method was developed for purification of the 
dopamine and nor-epinephrine products, whilst the epinephrine derivatives could 
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be purified on normal-phase silica. These reactions and separations were 
followed by reversed-phase HPLC. The dopamine propionate derivative was 
applied as coating antigen by in situ surface assembly with two different linkers 
and compared to conjugation through the amine. The antibody raised to a 
glutaraldehyde-linked conjugate showed highest binding to the amine-conjugated 
surface. 
New surface plasmon resonance biosensor formats were developed using gold 
nanoparticles to amplify the binding signal of progesterone / antibody binding 
interactions. A very stable sensor surface with progesterone immobilised via an 
oligoethylene glycol chain was produced capable of withstanding more than 1100 
binding and regeneration cycles without appreciable loss of binding capacity. 
Gold labelling of the monoclonal antibody was achieved via a biotin/streptavidin 
couple in both a preincubation of biotinylated antibody with streptavidin gold and 
a sequential addition of antibody and then gold label. Preincubation gave no 
signal enhancement but lowered the detection limit of the assay to 143 pg/mL 
compared with previous reports which had detection limited to l ng/mL. 
Sequential labelling resulted in a two-fold enhancement of signal and the 
detection limit was reduced to 23.l pg/mL. Labelling with a secondary antibody 
alone produced signal enhancements of eight-fold and when secondary antibody 
was conjugated to colloidal gold it produced enhancements of 13-fold. The 
secondary antibody-gold labelling gave LOO of 8.6 pg/mL. There was no 
difference in enhancement between 10 and 20 nm colloid for the biotin/ 
streptavidin couple and colloid size did not affect enhancement for the secondary 
antibody-mediated format. This study is the first successful development of 
nanoparticle signal-enhanced immunoassay for small molecules using SPR and 
demonstrates how assay performance may be improved to levels comparable to or 
better than existing ELISA. 
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Chapter 1 - Introduction 
This chapter will cover firstly the basic theory and technology behind modem 
biosensors before moving on to showing how these technologies have been 
applied to the target molecules of relevance to this thesis, i.e. the steroid hormones 
and catecholamines. This is followed by a more detailed analysis of the chemistry 
of steroid hormone and catecholamine conjugation as applicable to biosensors and 
the chapter finishes by examining how this thesis covers several opportunities in 
optical biosensor research for small molecule analytes. 
1.1 Biosensor Technology 
1.1.1 Biosensing and Biomimetic Sensing 
A biosensor may be defined as a system that converts biochemical states and 
changes in these states into an electrical response1 with the purpose of gathering 
information concerning parameters in a sample. Biosensors should consist of a 
site (usually a modified surface) in which a biochemical interaction takes place, a 
system for delivering components to this site, e.g. a microfluidics system, a signal 
transduction device to convert the biochemical changes into an electrical signal, a 
data display and / or storage system and usually a system for regenerating the 
sensor ready for the next cycle. Biosensors may be represented schematically by 
the box diagram in Figure 1.1. The normal parameter being measured is the 
concentration of a particular analyte or analytes in a given sample. Biosensors 
may be classified according to the type of biochemical interaction employed, the 
type of signal transduction system used and according to the sensor target or 
analyte. 
The most common biochemical interaction employed in diagnostics is the 
binding of an antibody to its target in the sample being analysed. This interaction 
is mostly used in immunoassays such as enzyme-linked immunosorbent assay 
(ELISA) but is also widely used in biosensors called immunosensors. Other 
2 
biosensor interactions can include enzyme catalysis and receptor / target 
interactions as well as microbe-mediated and deoxyribonucleic acid (DNA)-
mediated interactions.2 Transduction systems for immunoassays and biosensors 
include a wide range of technologies such as colorimetric changes catalysed by 
enzymes conjugated to antibodies as in ELISA, changes in electrical properties of 
the detection surface as in printed electrode systems, or changes in optical 
properties of the surface as in surface plasmon resonance (SPR) and spectroscopic 
properties as in surface-enhanced raman spectroscopy (SERS). 
( 
Change in Physical 
Parameter 
• 
Functionalised Binding Surface 
Transducer 
Figure 1.1 Biosensor Box Diagram 
Signal 
~~~--•- Processor 
Immunosensors and immunoassays will form the main discussion in this thesis 
but it is worthwhile to consider the other biological interactions possible. 
Enzyme-based sensors were the first biosensors and are highly favoured due to 
their high specificity and the possibility to quite simply follow the throughput of 
chemicals in the active site. The usual methods of transduction are via 
amperometric or potentiometric determinations. Such systems have found wide 
application in detection of neurotransmitters and most famously in glucose 
sensors. It is also possible to use these systems to determine quantities of 
enzyme-inhibiting compounds. Microbe-based biosensors utilise the physiological 
changes in specific microorganisms to determine the quantities of the substances 
inducing these changes. 
DNA biosensors utilise the specific binding interaction between 
complementary strands of DNA to detect the target. This technique is very useful 
for specifically identifying DNA strands that may be specific to a particular 
3 
organism3 or even to bind to intercalating targets such as certain aromatic 
compounds.4 Variations in just one base pair can greatly compromise binding 
giving rise to excellent specificity. This field is presently underdeveloped and is 
emerging as an important new biosensing platform. Nanotechnology is further 
boosting the options for biosensors with the unique electrical properties of carbon 
nanotubes being utilised to produce highly specific biosensors.5 
As well as a vast number of proper biosensing systems there is also growing 
interest in biomimetic sensors, which employ chemical systems designed to 
mimic a biological recognition system. Perhaps the most well known of these 
systems are the molecularly imprinted polymer (MIP) sensors. These sensors 
employ a specially constructed polymer, which contains binding sites specific to a 
particular chemical compound. 6 
Immunosensors are a large and growing field and incorporate the advantages of 
high specificity, high binding affinity, broad applicability to any compound of 
sufficient size and functional characteristics and a wide range of applicable 
transduction technologies. Allied to the field of biosensors is that of 
immunoassays, techniques for the detection of concentrations of a target analyte 
by utilising the binding interaction between antibody and target. Biosensors are 
normally applied with the intention of using them in on-site or in-the-field 
situations whereas immunoassay includes the fields of ELISA and 
radioimmunoassay (RIA). In order to understand the functioning of immuno-
detection systems it is necessary to have knowledge of antibody theory. 
1.1.2 Antibody Theory 
An antibody is a protein synthesised by the B-lymphocytes and subsequently 
excreted into plasma.7 They are produced by the body of a vertebrate in response 
to a foreign agent and are generally referred to as immunoglobulins (lg). In their 
monomeric state, lg molecules are composed of two identical halves that are 
bound to each other via disulphide bridges. Each half consists of two chains, a 
heavy glycosylated chain (about 50 kDa) and a light non-glycosylated chain 
(about 25 kDa) connected by one disulfide bridge to be found close to the 
carboxyl end of the light chain. Altogether the molecule has a Y-shaped 
configuration and is about 150 kDa. The heavy chain can also be further 
subdivided into the Fe and Fab regions. The Fe region is located at the carboxyl 
terminal and is bound to carbohydrate chains. The Fab region is located at the 
amino terminal. Each chain can also be divided into domains of -110 amino acid 
residues. For immunoglobulin G (lgG) antibodies there are four in the long chain 
and two in the short. Basic IgG structure is shown in Figure 1.2 
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There are also constant regions of low amino acid variability (constant or C 
region) and of high amino acid variability (variable or V region) from molecule to 
molecule. Protein folding of the variable regions of one light (V L) and one heavy 
(VH) chain forms a groove that can accommodate the antigen. In an IgG 
molecule, two antigen molecules can be bound. The antigen is held into place by 
the antibody through several interactions: 
1. Hydrogen bonding: between carboxyl oxygens and amino groups 
5 
2. Ionic interactions: these include electrostatic interactions between protein 
antigens and antibody amino acid residues 
3. Hydrophobic interactions: if an antigen orients its non-polar groups 
inwards and its polar functionalities outwards into the polar aqueous 
solvent then a hydrophobic pocket would be established enabling 
thermodynamically favourable binding to the hydrophobic antibody 
binding site.8 
The constant region is used for certain secondary biological functions such as 
complement and macrophage binding. There are five main classes of 
immunoglobulin: IgG, IgD, IgM, IgE and IgA and these are distinguished by the 
type of heavy chain (y, &, µ, £, a respectively). The light chains can also be 
divided into two classes (K and A) the ratio of which can vary from species to 
species. Each of these classes is known as an isotype. 
Antibodies are employed as part of what is known as an immune response, 
defined as "altered reactivity to a specific molecular configuration that develops 
following contact with it".8 To be immune the response must also be specific to a 
certain molecular structure and be repeated through successive exposures to this 
structure. An immune response can be humoral, as in the case of antibody 
immune responses, or cell-mediated. The substance that, when introduced to an 
organism, elicits an immune response is known as an antigen and can be said to be 
immunogenic. Immunogenic antigens must be of a molecular mass greater than 
about 2 kDa; smaller compounds must be coupled to a large carrier (usually a 
protein) in which case they are known as haptens, e.g. 17j3-estradiol - bovine 
serum albumin (BSA) conjugates. Smaller molecules are not immunogenic, 
usually because they do not have suitable sites for simultaneous binding of a class 
II protein and a T-cell receptor, a vital part of antibody production. 
1.1.3 Monoclonal Antibodies 
Antibodies produced by simple immunisation of vertebrates will lead to 
production of polyclonal antibodies, that is a mixture of different antibody types 
directed to different parts of the antigen (antigenic determinants). Each antibody 
has somewhat different specificities and affinities and so this may cause problems 
in certain assay formats where discrete specificities and affinities are required. 
Monoclonal antibodies, immunoglobulins with a discrete affinity and specificity 
directed to one epitope of the antigen, are produced by fusing B lymphocyte cells 
from the spleen with myeloma cells (cancerous immune system cells) after 
immunisation. The fused cells are then screened for correct antibody production, 
isolated and cloned and re-tested before culture as required, thus allowing large-
scale production of the desired monoclonal antibody. Monoclonal antibodies are 
the preferred choice for immunoassay and are used for immunoassays described 
throughout this thesis. 
1.1.4 Radioimmunoassay 
Having discussed the basic theory of antibodies it is now best to consider the 
ways in which antibodies may be employed in immunoassay formats. 
Immunoassay relies upon a means of transduction and it is this that generally 
defines the types of immunoassay. The earliest form of immunoassay is 
radioimmunoassay, which detects binding between antibody and antigen by 
means of labelling either the antibody or the antigen with a radiochemical label, 
the radiation of which can be easily detected. 
The first radioimmunoassay was developed for insulin in plasma by Berson 
and Yallow in 19609 and the technique has since then expanded greatly into a 
range of target antigens and radiolabels. The basic principle is to attach a label 
containing a radioactive isotope (commonly 3H or 1251) to the target analyte with 
some kind of molecular spacer in between to ensure antibody binding is not 
inhibited. Bound labelled antigen can then be determined by scintillation 
counting where counts will be inversely proportional to the amount of antigen 
present in the sample. 
The usual format for such assays has the antibody bound to a solid surface, 
usually a customised micro-well plate and the labelled antigen passed over the 
surface either at the same time as the sample (competitive format) or after the 
antigen present in the sample has had time to bind (sequential non-competitive 
format). The antigen is incubated to allow time to bind and then un-bound 
7 
material is washed off the plate and the counts determined. These formats are 
illustrated in Figure 1.3. 
f [> e-t> [> 
::c :r: :r: :r: :r: :r:): 
1 
Competitive RIA 
Y Antibody [> Antigen • Label 
[> [> 
21: :r: :r: :r: :r: :r: :r: 
f ! ' 
21: f :r: f :r: :r: :r: 
l:r:r:i:r:l:r: 
Non-Competitive RIA 
Figure 1.3 Competitive and Non-Competitive RIA 10 
RIA has several advantages, mainly very good sensitivity (down to a few 
picograms of analyte per well with high affinity antibodies) and with detection 
limits of the order of 10-100 pg/mL in the case of certain steroidal sex 
hormones. 11 RIA is now well established and has been successfully applied in a 
range of media including blood and milk. There are however several major 
disadvantages including the need to use and dispose of hazardous radioisotopes, 
their relatively high cost ($15-20 per sample) due to the radiolabels, and their 
limited shelf life. The radiolabelled compounds are often hard to completely 
purify and radiolabels can have a significant effect on antigen binding to 
antibodies. These restrictions have prevented radioimmunoassays being adapted 
successfully as biosensors for on-site use and has restricted them to laboratory-
based assays only. 
8 
1.1.5 Enzyme Immunoassay 
The breakthrough that helped enable future practical immunobiosensor 
technology was the development of the enzyme immunoassay (EIA) which was 
first produced for progesterone in 1975 by Dray et al. 12 The principle is much the 
same as that for radioimmunoassay except that the radiolabel is replaced by an 
enzyme label (commonly horseradish peroxidase (HRP)). The enzyme serves to 
catalyse signal generation in three main types of signal agent - colorimetric, 
fluorometric and chemiluminescent agents. By so doing, the enzyme produces a 
signal far larger than that of the background and enables detection whereby the 
response is inversely proportional to the concentration of target analyte in the 
sample. There has been a great deal of study in the area of enzyme immunoassay 
and these systems may be categorised according to their analyte (antigen or 
antibody), the labelled reactant (antigen or antibody), the method of incubation 
(competitive or non-competitive) and the way in which the bound and free label 
are separated from each other. 13 
Enzyme labelling can be of the antigen or of the antibody and usually, 
especially in the case of the antigen, a spacer is inserted between the two to 
prevent the label from sterically inhibiting the binding interaction. The most 
common method employed is to immobilise the antibody on the surface of a 
special microwell plate at appropriate pH by electrostatic interactions and 
incubate the sample over the surface either in the presence of the enzyme labelled 
antigen or separately (competitive and non-competitive respectively). In this case 
the response will be inversely proportional to the concentration of analyte. 
Competitive formats are usually used for small molecule antigens, as it is usually 
difficult to separate out the antibody/antigen conjugate. 14 
An alternative, lesser-used format is to immobilise the antigen on the surface 
and then expose the enzyme-labelled antibody simultaneously with the sample to 
the surface either after or during a period of incubation between antibody and 
sample. This method has been previously employed by the author in assay 
formats for progesterone. 10• 15• 16 This format requires that for small-sized antigens 
they be attached to the surface via a protein that has the required large number of 
ionic functionalities for surface attachment. This is done in the form of a protein 
conjugate where the attached analyte is referred to as a hapten. These different 
formats can be seen in Figure 1.4. In all plate EIA the un-bound portions of the 
plastic wells must be blocked with protein (usually BSA, ovalbumin (OVA) or 
milk protein) to prevent non-specific binding that would compromise signal 
distinction. Between each stage of the assay the plate is washed thoroughly to 
remove un-bound material. 







Figure 1.4 Antibody Bound (A) and Antigen Bound (B) EIA 
0 Antigen 
To improve signal to noise ratios it is wise to carefully choose the enzyme label 
to ensure that it has a high turnover number, a low Km for the substrate and a high 
Km for the product and that it is highly stable under the conditions of the assay. 17 
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Enzyme labelling of the antibody may be effected either directly through chemical 
modification of the antibody (usually also with an intermediate linker) or through 
use of a secondary antibody, i.e. an anti-immunoglobulin antibody conjugated to 
the enzyme. The latter method of enzyme labelling enables greater specificity as 
it improves the antibody binding cross-section, as there are two specific antibody 
binding steps18 and so overall binding specificity is greatly improved. The 
secondary antibody-enzyme conjugate does not compromise the ability of the 
primary monoclonal antibody to bind either by chemically denaturing the 
antibody, blocking the binding site of the antibody by being attached over it or 
sterically disfavouring approach of the antigen. Enhancements in specificity are 
particularly important when considering complex biological media. The 
secondary antibody is always used somewhat in excess so its immunoreactivity 
can be slightly reduced. 
In the case of larger molecules (> 2 kDa) it is possible to perform a different 
assay format known as a sandwich EIA (Figure 1.5). In this case the antibody is 
immobilised to the surface and the sample alone incubated with the antibody. The 
surface is then exposed to enzyme-labelled antibody that binds the already bound 
antigen, which is of sufficient size to bind to two antibody units at different non-
overlapping epitopes simultaneously. In this format one has the advantage that 
the enzyme signal is directly proportional to the amount of analyte, hence one is 
directly measuring the analyte concentration rather than doing so indirectly 
through measuring the vacant antibody binding sites. A recent example of this 
format is the sandwich assay for hepatitis C virus (HCV) core protein from single 
hepatocytes. 19 One can also use antibodies that recognise primary antibody / 
antigen complexes such as for digoxin measured clinically.20 
One can classify EIA also according to the separation steps employed. 
Heterogeneous EIA has the enzyme label retaining activity after binding to the 
antibody/antigen system. This is the more common variety and includes the 
much-used ELISA, a schematic example of which is found in Figure 1.6. ELISAs 
rely upon the enzyme catalysing the conversion of a substrate that has little or no 
colorimetric or fluorescent signal to one that has intense signal. Such substrates 
include the common 3, 3', 5, 5'-tetramethylbenzidine (TMB) using a peroxide 
initiator along with HRP to tum from colourless to intense blue, and then to 
yellow upon stopping with acid. Other substrates can produce fluorescent or 
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chemiluminescent responses and include aequorin, a calcium-activated 
photoprotein. The move from colorimetric to fluorescent to chemiluminescent 
systems can greatly increase assay sensitivities to the extent that 
chemiluminescent detection can give detection limits better than RIA. 
+ 
Figure 1.5 Sandwich EIA 13 
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Figure 1.6 Heterogeneous EIA 
Homogeneous EIA exposes the sample to an enzyme or modulator-labelled 
analyte or antibody that is activated in one solution including the reagent for 
signal development of the enzyme. This is known as direct signal modulation. 
This obviates the need for washing labelled analyte or antigen away making the 
assay much simpler. Modulation of the enzyme may occur by use of steric, 
allosteric or ionic effects, enzyme inhibitors, activation of apoenzymes or 
cofactors, use of enzyme antibodies and complexing of multiple enzyme systems 
by use of a channelling technique. An example is sol particle immunoassay 
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(SPIA) for measuring serum cystatin C, whereby the anti-cystatin C antibodies are 
coated on colloidal gold particles and the binding to the protein in the sandwich 
format is observed directly. 21 Figure 1.7 shows another example, enzyme 
multiplied immunoassay technology (EMIT), which functions by an enzyme label 
being inhibited by binding of antibody to antigen. 
~~lgen Antigen • ----
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Figure 1. 7 EMIT Homogeneous EIA 13 
There are many advantages in the use of EIA, principally, the sensitivity is 
high (in the case of chemiluminescent assays now generally better than RIA), 
reagents are less expensive and last longer, many simultaneous assays can be 
done, there is no radioactive hazard, many different formats are available and they 
are rapid and simple. Thus far we have considered the range of immunoassays 
available as RIA and EIA. However, these assays cannot be practically converted 
to use in on-site applications, they are restricted to laboratory use only. They are 
often labour intensive, usually take from several hours to two days making them 
unsuitable for applications that require timely results, and require a trained 
operator. Also, transport to a central laboratory can compromise samples. ELISA 
kits have been commercialised for use in certain applications on-site, e.g. milk 
progesterone determination for farmers, but have not seen widespread commercial 
success due mainly to their high labour requirements and lack of precision. 
Another factor to consider is the matrix effect whereby substances present in the 
background matrix of the sample can interfere with signal intensity. This can be 
minimised to a certain extent by increasing the sensitivity and thus reducing the 
volume of matrix per weII.22 
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A further method for improving sensitivity is to use direct labelling of antigen 
or antibody with chemiluminescent or fluorescent labels such as the fluorescent 
0-(fluoresceinylmethyl)oxime-progesterone steroid conjugate23 or 
chemiluminescent acridinium oxime-steroid conjugates24 that can be applied in 
immunoassay like a radiolabel. EIA can also be adapted to amperometric assays 
as has been done for human chorionic gonadotrophin (hCG) on the Clarke oxygen 
electrode. 25 
Immunoassay is of vital importance to the diagnostic market and dominates 
such areas as biomedical laboratory testing. Immunoassays, principally through 
sandwich ELISA and new signal enhancement labels, are constantly being 
developed. Whilst they are not practical for on-site use their principles of 
operation are directly applicable to the design and science of biosensors and they 
provide an invaluable means of conducting fundamental studies into antibody / 
antigen binding interactions. Plate-based immunoassays are static 
immunosensing platforms in that the fluid-containing sample and labelled antigen 
or antibody does not flow over the immobilised surface in a concerted way. In 
most biosensor formats however, the sample and other components do flow over 
the immobilised surface as part of an in-line or on-line sensing system and as such 
ELISA models do not always match flow biosensor models. Surface plasmon 
resonance (SPR) biosensors are one such type of flow-biosensors with many 
advantages over ELISA. 
1.1.6 Surface Plasmon Resonance 
1.1.6.1 The Fundamental. Principles 
Surface Plasmon Resonance (SPR) is a quantum optical-electrical phenomenon 
that occurs at the surf ace of a SPR active substance when photons of light are 
incident upon its surface. 26 When a photon of light is incident upon a noble metal 
surface it can couple with the electrons in that metal and transfer its energy to 
them. This coupling occurs at a specific wavelength that is known as the 
resonance wavelength. The electrons then become excited and move as a single 
electrical entity known as a plasmon. Coupling will occur when the momentum 
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of the incoming photon equals that of the plasmon. The plasmons will move along 
the metal setting up an electrical field that extends for about 300 nm from the 
surface. If the surface features within 300 nm change, such as in the binding of 
proteins, then the plasmon will be perturbed and the wavelength needed for 
resonance will shift. Surface plasmon resonance is essentially a charge-density 
oscillation existing at the interface of media with dielectric constants of opposite 
sign. This charge density wave is associated with an electromagnetic wave and 
collectively can be termed a surface plasma wave.27 It is possible to determine the 
resonance wavelength optically as other wavelengths will be simply reflected; 
hence a plot of reflected light intensity vs wavelength will show a distinct dip at 
the point of resonance. The surface is held in a fixed position and the plasmons 
are confined to the plane of the surface, so the resonance wavelength can be 
determined by scanning through angles of the incident photon beam to the surface 
until the resonance angle (0r) is found. 28 The resonance angle will then correspond 
to the angle at which the plane parallel component of the photon momentum 
equals the momentum of the plasmon. The angle must be greater than that 
required for total internal reflection and the illumination is from the back-side and 
is p-polarized onto the prism-coupled gold film. 29 Changes in resonance angle 
with changing surface coating can be expressed in terms of resonance units (RU) 
whereby 1 RU is said30 to be roughly equivalent to a mass change on the surface 
of 1 pg/mm2• SPR measurements are effectively measurements of changes in the 
refractive index of the surface with 1 RU unit being 1 x 10-6 of a refractive index 
unit allowing much finer measurement than would ever be possible with a 
refractomer. A computer plot can then be made of SPR response (RU) vs time 
and is known as a sensorgram. A schematic of the SPR system is given in Figure 
1.8. 
The most commonly used metal that exhibits SPR is gold. In most SPR set-ups 
a chip or plate is constructed with a thin layer of gold supporting a polymeric 
matrix that has functional groups needed to immobilise coating antigens or 
antibodies. A number of "home-made" SPR apparatus have been constructed due 
to their comparative simplicity31 • 32 but perhaps the dominant use of SPR is in 
biomolecular interaction analysis using the commercial BIAcore ™ format. 
BIAcore is extensively used as a research tool for examining antibody/ antigen33, 
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receptor I target34, oligonucleotide / complementary oligonucleotide35 interactions. 
Host I guest binding interactions have also been examined by SPR.36 
S' 
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Figure 1.8 SPR Schematic Showing Binding Surface and Sensorgram37 
Other companies have developed SPR systems of lower cost than the BIAcore 
system, such as Texas Instruments and their Spreeta ™ Cell38• 39 and Windsor 
Scientific's IBIS system.38 BIAcore continues to dominate the research 
publications however due to its patented carboxy-methylated dextran coated chips 
and fluidic control systems. 
1.1.6.2 BIAcore 
The BIAcore system works on the basis of a removable self-contained sensor 
chip. These chips consist of a glass plate coated with a 50 nm thick gold film and 
encased in a plastic covering that can be slotted into the machine. On the gold 
surface is a layer of carboxy-methylated dextran with exposed carboxylic acid 
groups. The chip when inserted is in intimate contact with a milli-fluidics system, 
111\JlVF=:RSrf'r OF 1/VAll'\tl.l() 
1 IRRAP' 
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which has four interconnected channels through which solutions may be passed. 
The chip is incubated at a set temperature (usually 25 °C) and is fed by an 
injection system, which can take fluids from racks of vials or from a 96-well 
microtitre plate. The systems available range from BIAcore X, which is manually 
fed, to BIAcore 3000, which is highly automated and can be used for screening of 
drug candidates. The binding is observed in real-time by a sensorgram, which is a 
plot of the response units vs time. 
Either target or recognition compound may be immobilised on the sensor 
surface by first activating the carboxylic acid functions by applying N-ethyl-N-(3-
dimethylaminopropyl)-carbodiimide (EDC) with N-hydroxysuccinimide (NHS) to 
produce the active ester. The compound to be immobilised is then passed over the 
surface at the pH that will produce maximum binding and amide linkages can be 
formed with the amino groups of the compound. The optimum pH for 
immobilisation can be determined by "pH scouting", that is passing solutions of 
the compound at various pHs over the non-activated surface and assessing the pre-
concentration sensorgrams observed. The compound is concentrated by ionic 
interactions with the surface. Optimum pH should give a high sensorgram with an 
approximately 45° angle in the binding response. Once the compound has been 
immobilised then the remaining un-reacted carboxylic acid functions are 
deactivated by reaction with ethanolamine to ensure minimal non-specific binding 
and no further immobilisation. Immobilisation can be done automatically to a set 
response target or simply through multiple injections of the compound. Upon de-
activation with ethanolamine, normally about 25% of the initial binding response 
is lost. Macromolecules are normally immobilised at low concentrations (20-100 
µg/mL). 40 Immobilisation of macromolecules should be done at a pH below the pl 
of the protein in question to ensure adequate concentration of the protein in the 
dextran layer.41 Immobilisation can also be done through disulphide bridges 
formed between thiolated ligand and disulphide modified binding compound or 
vice versa.42 Some immobilisation techniques are shown in Figure 1.9. 
A newly immobilised sensor surface may require a period of washing to 
remove unbound material and several binding cycles may need to be done to 
ensure repeatable response. The binding cycle consists of first setting the flow 
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rate over the surface; slower flow rates will enable higher binding but naturally 
take longer. The normal running buffer is a N-[2-hydroxyethyl]piperazine-N'-[2-
ethanesulfonic acid] (HEPES)-buffered saline with ethylenediaminetetra-acetic 
acid (EDTA) and P-20 surfactant (pH 7.4) (HBS-EP). The sample to bind is then 
injected and the binding response followed by the rising sensorgram. Once the 
binding is finished one will normally observe dissociation of the bound material 
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Figure 1.9 Immobilisation by Active Ester (Left) or Ligand Thiol Coupling 
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Once binding is over then the surface must be regenerated. This is done using 
a regeneration cocktail and there is an extensive range of these used.43 Common 
cocktails include glycine, NaOH, HCl, sodium acetate and chaotrophic reagents43 
such as acetonitrile. Choice of regeneration cocktail is very important as it must 
properly regenerate the surface every time with no residual bound material but 
must not strip immobilised compound from the surface. Acidic pHs are favoured 
over basic. The regeneration process will ultimately destroy the chip with most 
chips only lasting for about 100 cycles. Binding responses are naturally highly 
dependent upon pH, temperature, and concentration of both immobilised 
compound and binding compound and flow rate. The total binding cycle is 
represented in Figure 1.10. 
Activation i EDC + NHS 
__ r?.:? _____ 0 
Immobilisation ! Monoclonal Antibody 
Binding + Progesterone-Protein Conjugate 
Regeneration i IOmM glycine pH=2 
Figure t.10 Activation, Immobilisation, and a Complete Binding and 
Regeneration Cycle Using B1Acore10 
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As mentioned above, the chips have four flow cells that can be monitored 
simultaneously. One flow cell is kept as a blank reference cell by activating and 
deactivating the chip without immobilisation of antibodies or analytes, so that it 
can be used to reference subtract bulk effects in the refractive index changes that 
could otherwise swamp the binding interactions. SPR in most applications is only 
essentially detecting mass changes on the surface and so small molecules binding 
will not be visible to the instrument and cannot be seen in the sensorgrams except 
at high concentrations. In order to get good signal one must usually use 
compounds of >2 kDa. If one wants to detect small molecule binding to 
immobilised antibody then one would have to conjugate the molecule to an 
appropriate high mass label, usually a protein. Alternatively of course, one could 
simply immobilise the protein conjugate and detect the antibody, which is better 
for higher signal as the antibody is larger than BSA or OVA, which are the 
common conjugate proteins. 
As well as the carboxylic acid functions, BIAcore has chips modified with 
disulphide linkages that can be used to attach compounds with thiol 
functionalities, such as certain proteins. Other formats used by Texas Instruments 
include coating the surface with avidin and then applying biotinylated proteins to 
the surf ace. 
BIAcore has proven itself to be an important research tool and as a first step to 
designing practical on-site biosensors. It enables direct monitoring of binding 
events and immunoassay in real-time including the ability to process sensorgram 
data to obtain binding kinetics information. It can be fully automated and runs 
can be set up with minimal human interference compared with labour intensive 
ELISA. The systems can be adapted to high-volume screening applications44 
particularly with the advent of BIAcore 3000.45 Other advantages include: 
1. The ability to detect in four channels simultaneously 
2. The ability to use organic solvents in the buffers 
3. The low levels of proteins required for immobilisation (-1 µg of protein is 
typically needed to coat one surface) 
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4. The system can avoid the use of labels and the synthetic complications and 
binding interferences these can involve. 
5. The amount of complex at equilibrium can be measured without disturbing 
the equilibrium even in the presence of unbound compound 
6. The stability of the immobilised ligand can be monitored continuously by 
assessing baseline stability and binding capacity with time 
The main disadvantage is that the instrument is very expensive to purchase and 
uses consumables that are also quite expensive (chips now cost NZ$200-300) and 
the machine clearly is completely laboratory based and so is only a model for 
development of on-site biosensors. Other applications of BIAcore include 
optimisation of fluorescent immunoassay parameters.46 
1.1. 7 lmmunoprobes, Electrochemical Biosensors and Developing 
Technologies 
Immunoprobes offer the ability to combine immunoassay detection with a 
small probe suitable for insertion in-vivo and can yield valuable quantitation of 
small biomolecule analytes such as hormones.47 Such probes are often connected 
to electrochemical detectors and the electrochemical detectors are quite 
widespread and make use of recent developments in electrode signal 
transduction. 48 
A field of immunosensing that is emerging as critically important in the field of 
drug screening is the miniaturized microarray-based multianalyte assays.49 These 
involve application of antibody microspot arrays for the combinatorial screening 
of potential antibody targets. The arrays are scanned by laser based confocal 
microscopes and utilise fluorescent tags. These systems have particular use in 
identification of viral antigens or allergens in media such as transfusion blood and 
require only small samples and greatly reduce laboratory Jabour.50 Another greatly 
promising field of immunosensing is in time-resolved fluorescence detection 
using labels such as the lanthanide chelates and these systems lend themselves to 
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multianalyte detection because of the number of lanthanide ions that can be 
detected simultaneously.51 
1.2 Biosensors for Steroid Hormones and Catecholamines 
Having now reviewed the concepts of biosensors and biomimetic sensors and 
reviewed immunoassay techniques and then the SPR transduction phenomenon 
and its application to biosensing in the form of BIAcore, it is now important to 
provide background in the fields of immunosensing study that this thesis will 
cover. The first of these is an examination of progesterone - protein conjugates 
applied in ELISA of whole cow milk. It is necessary therefore to discuss the 
biochemical role of progesterone in the cow and to review the application of milk 
progesterone determinations. The second area of interest is to examine biosensing 
of the estrogen class of steroid hormones, and then finally sensing technologies, 
conjugation and physiology of the catecholamines. 
1.2.1 Steroid Hormones 
1.2.1.1 Steroid Hormone Chemistry and lmmunosensing 
1.2.1.1.1 Progesterone Chemistry 
Progesterone is a non-aromatic female sex steroid hormone of the pregnane 
class, (Figure 1.11 ). It was first isolated in sow ovaries in 1934. 52· 53· 54• 55 It has a 
C-4 - C-5 unsaturation (~4) and a C-3 carbonyl (conjugated olefinic system) 
which give rise to its ultraviolet (UV) absorbance at 240 nm.56 Progesterone in 






Figure 1.11 Progesterone 
1.2.1.1.2 Bovine Estrous Cycle, Pregnancy and Progesterone 
The bovine estrous cycle refers to cyclical changes in the reproductive system 
associated with the maturing and release of an oocyte from the ovaries. The 
bovine is polyestrus, that is it goes through several such cycles each breeding 
season. The cow ovary is composed of a cortex containing the oocytes and 
covered by epithelium tissue and a medulla that has the necessary blood vessels 
and connective tissue.57 The primordial follicle (cortex and epithelium) grows and 
regresses during the estrous cycle. The estrous cycle is divided into estrus, luteal 
and pro-estrus phases with day O set at onset of estrus phase. Correspondingly, 
the follicle goes through three phases. The first is the follicular phase where the 
granulosa layer forms, the oocyte matures, a fluid filled cavity grows (antrum) and 
the follicle swells.58 At this point the follicle either undergoes atresia 
(degeneration) or enters the next phase (ovulatory phase). Atresia accounts for all 
but -0.1 % of follicles and occurs by apoptosis59• 60• If the follicle survives it 
passes through phases of growth marked as the primordial, antral and Graafian 
before it is ready to ovulate. Approaching ovulation there is swelling to up to 2.5 
cm and at ovulation the follicle ruptures and releases follicular fluid along with 
the oocyte. Ovulation occurs about 25-30 h after estrus on-set.61 The follicle then 
enters the luteal phase in which the cavity left is filled with dividing cells and 
forms the corpus luteum (CL) or "yellow body" from which progesterone is 
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secreted from about day 4 to day 17 and then the CL regresses enabling the cycle 
to start over. 
There are 2-4 growth waves of the follicle over the 7-10 days leading up to 
ovulation and atresia may occur at any stage and acts to reduce the number of 
follicles until dominant follicles are selected, only one of which will ovulate in 
each cycle.62' 63 The average estrous cycle in a cow is 21 days with a range of 18-
26 days.62 Quiescent interludes are possible where the estrous cycle stops. The 
estrus phase lasts 12-16 h and is the period of increased sexual activity, which is 
the time for mating to occur. The luteal phase matches that of the follicle and is 
the phase of progesterone control. Pro-estrous is the phase of pre-ovulatory 
follicle maturity and increases in estradiol and pre-ovulatory luteinising hormone 
(LH). 
Cyclicity m progesterone concentrations in both blood and milk reflect the 
stages of growth and regression in the CL, with near zero progesterone from days 
0-4, rising progesterone from days 4-8, plateau at days 8-16 and then decline from 
days 16-21 back to near zero in a reasonably predictable cycle, Figure 1.12. 
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1.2.1.1.3 Progesterone as a Physiological Marker 
Progesterone can be used as a marker for the estrous cycle of a cow with 
progesterone fluctuating from less than 0.1 ng/mL at estrus to greater than 6 
ng/mL at the luteal phase in blood plasma and from less than 4 nglmL65 to as high 
as around 50 ng/mL in whole milk. The exact amplitude of the fluctuation will 
vary from cow to cow. Clearly detection of progesterone in whole milk has the 
distinct advantages of higher concentrations and ability to detect it non-invasively. 
Milk progesterone levels can also be used to help determine the pregnancy 
status of cows. The bovine placenta is unable to produce adequate progesterone 
to sustain a pregnancy and so the CL retains its progesterone secreting function 
into pregnancy. Progesterone rises steadily up to mid-luteal phase concentrations 
in pregnancy and so a sustained high reading of progesterone provides an 
indication of possible positive pregnancy. Early detection of pregnancy would be 
possible theoretically by taking a milk sample 21 days after insemination. Care is 
needed however when making assessments based on milk progesterone as one can 
get embryonic mortality and irregular life-span of the CL. Progesterone levels 
can also be used to mark failure of the cow to return to cyclicity after parturition 
which is a major veterinary concern to the farmer, and such conditions as 
abnormal pregnancies, follicular cysts,66 anestrous cows67 and embryo mortality. 
Determination of milk progesterone may be used to time artificial 
insemination. Artificial insemination is now in very widespread use in New 
2.ealand and abroad but in order to work, the insemination must be timed so that it 
overlaps the life of the sperm with the life of the ovum. This requires that the cow 
be inseminated between 6 and 28 h after first onset of estrus. This timing is 
presently very poorly done with only a less than 40% success rate on first 
insemination.68 It is estimated that the US dairy industry alone loses >US$300 
million per year through misdiagnosis or failure to detect estrus.69 
1.2.1.1.4 Progesterone Detection Methods in Whole Milk 
Many different techniques have been applied to determining estrus and 
pregnancy. Estrus monitoring by behavioural analysis involves inspection of 
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cows for biological indicators such as cows standing to be mounted by a bull, 
discharge of clear mucus from cervix and uterus, restlessness, and swelling of the 
vulva.70 Techniques include pressure-activated heat mount detectors and contact 
indicating paint strips.70 Progesterone determination in whole milk is extensively 
used in some areas. 
Progesterone detection was first done by high performance liquid 
chromatography (HPLC) methods using solvent extractions from the sample and 
often multiple detector systems such as diode array with mass spectrometry.71 
Systems have been developed also for detection of progesterone metabolites in 
urine and faeces. 72 Detection however is dominated by enzyme immunoassay. 
There have been a large number of publications in the field of milk 
progesterone EIA. Dominating these publications are those for ELISA techniques 
but there are a growing number that examine other methods. In all cases there are 
a number of factors that need to be considered when examining milk progesterone 
concentration. Progesterone is a lipophilic molecule and as such it concentrates in 
the fats of the whole milk with about 80% of progesterone being present in the 
fats.73 The fat content of the milk however is a major matrix interference in the 
detection of progesterone, serving to impede binding of progesterone to its 
antibody. Many papers have sought to remove this interfering factor by using 
skimmed or de-fatted milk74 but this has the obvious major disadvantage of 
removing most of the progesterone in the sample and this becomes a particular 
problem when considering low initial concentrations of progesterone. EIA's have 
been developed that can cope with up to 10% milk fat. 75 Major studies have been 
conducted that have built up estrous cycle and postpartum milk progesterone 
profiles for herds of dairy cows.76 The use of preservatives has been found to be 
quite effective in keeping milk samples at room temperature for 10 days without 
significant changes in progesterone concentration.77 ELISA immunoassay kits are 
now widely available to farmers in the USA and elsewhere as crude indicator tests 
taking 3-22 minutes78 but are labour intensive. 
As well as EIA methods using ELISA there has been a recent move to 
developing on-line sensors for milk progesterone. The objective is to have an 
automated sensing system that can sample directly from milking lines and give 
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real-time information to the farmer about the estrus or pregnancy status of the 
cows. Such systems usually consist of a detection membrane, transducer system 
and computer.79 Claycomb et al. have developed such a system using a fluidic and 
fibre optic system for colorimetric EIA with 20 cycles per sensor.80• 81 This work 
has been further extended and allows detection within 10 min and is sufficiently 
accurate to distinguish follicular phase from mid-luteal phase concentrations.82• 83 
Pemberton et al. have produced amperometric milk progesterone biosensors based 
on competitive immunoassay84 whilst Kartoch et al. have synthesised nitroxide 
spin-labelled progesterone derivatives for use in biomembranes and 
immunoassay.85 
Surface plasmon resonance is now becoming of interest in the application to 
biosensing of cow milk progesterone. This was demonstrated in aqueous medium 
by Wu et al., 15 and a biosensor for detection in diluted cow milk was developed 
using BIAcore by Gillis et al. but suffered from a high detection limit (3.56 
ng/mL) and all the limitations of BIAcore. 86 As well as progesterone, other milk 
components have also been analysed by SPR biosensing. These include detection 
of sulfamethazone residues87 and staphylococcal enterotoxin B.88 
1.2.1.1.5 Practical Aspects of the Design of Milk Immunoassays 
Despite the large amounts of scientific study that have gone into the 
construction of milk progesterone immunoassays there is still a relative dearth of 
studies that consider: 
1. The effects of different assay formats on experimental results, for instance 
immobilisation of antigen rather than antibody on the ELISA plate 
2. The effects of the complex and often difficult to handle medium of cow 
milk on certain parameters of the immunoassay 
3. The steric factors that influence the antibody binding and assay curves in 
milk progesterone ELISA 
Existing commercial ELISAs rely on the use of progesterone-enzyme 
conjugates as competitive agents with the free milk progesterone for binding to 
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immobilised antibody.89 Such enzyme conjugates have been used extensively and 
many different examples have been synthesised, the most common being to horse 
radish peroxidase (HRP).90 The use of such conjugates has certain major 
disadvantages. There is no truly efficient and convenient method of purifying 
such conjugates. The only option to remove unbound enzyme from the reaction 
mixture is to employ affinity chromatography, which is very time-consuming and 
quite expensive, as it requires quite a lot of antibody. If the enzyme conjugates 
are not properly purified then unconjugated enzyme can bind to plate surfaces 
non-specifically producing high background signal and therefore lower signal to 
noise ratio and poorer detection capability. Furthermore, affinity chromatography 
is not usually 100% efficient in removing un-bound label. It has been found that 
some purification of progesterone-HRP conjugates with an affinity column allows 
a five-fold improvement in the detection limit.91 
The enzymes are usually conjugated to analytes via the E-amino groups of 
lysine residues. Most enzymes have multiple residues for analyte attachment. As 
the electrostatic and steric environment of the conjugated antigen greatly 
influences antigen / antibody interactions then changes to this environment can 
greatly impair the antibody binding affinity to the ligand.92 In the production of 
the conjugate the number of analyte molecules attached per enzyme molecule 
cannot be easily controlled, so irregular binding, such as binding to multiple 
recognition sites is possible thus changing the conditions for competition with the 
analyte in the sample,92 Figure 1.13. 
The simplest way to avoid the need for enzyme-analyte conjugates is to 
immobilise an analyte-protein conjugate to the surface of the plate rather than the 
antibody. Competition can then be set up between sample progesterone and 
immobilised progesterone for limited free primary antibody. The bound antibody 
can then be detected using a secondary antibody conjugated to an enzyme.90 Use 
of a secondary antibody has the following primary advantages: 
1. The antibody-enzyme conjugate could be easily purified of unbound 
enzyme by simple dialysis 
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2. Multiple attachment to one enzyme is much less likely to occur, on steric 
grounds, and consistent conjugations can be expected as the enzyme and 
antibody are much closer in size than the enzyme and small-molecule 
antigen. Some slight conjugation variability is not as important anyway as 
the secondary antibody is applied in excess and is not involved in the 
critical analyte recognition part of the assay 
3. Use of two antibodies increases the specificity of binding by increasing 
what is called the "reactive cross-section" of the binding interaction. This 
factor is of importance in complex biological media such as milk where 
many often related agents are present simultaneously. 18 
Figure 1.13 Binding Irregularities of Progesterone to Enzyme Label 
Many studies have been conducted on the effect of changing media on 
immunoassay data93 and some show large-scale changes in binding properties in 
the assay and require compensation for this. In the milk matrix there have been a 
number of early studies on the effects of changing the matrix in terms of 
parameters such as fat content and total nitrogen94' 95 but there have been no 
systematic studies of the effects of the milk matrix relative to aqueous phase on 
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binding of progesterone-protein conjugates as immobilised antigen to monoclonal 
antibody. Protein conjugates are constructed with various types of intermediate 
linker between antigen and carrier protein and there have been no studies of the 
effects of incrementally increasing this linker length on the antibody binding to 
conjugates in the milk medium. Linker length has a major effect on steric 
hindrance to binding of antigen and antibody. In the aqueous medium it has been 
shown to have no effect on antibody binding in a static assay format 15 but this 
may well not be the same for whole milk assays. 
There is clearly a need to develop and validate a protein-conjugate based 
ELISA system for the detection of whole milk progesterone and a need to study 
this format in the milk medium with respect to antibody binding properties and 
assay curve positions and shapes with incrementing linker length. The results of 
such a study could have further value in developing new biosensor formats for 
whole milk small biomolecule detection. 
1.2.1.1.6 Assay Binding Curves and Statistical Analysis 
There are a variety of different sets of data that can be obtained from 
immunoassay or immunosensor systems. The first group is data of how binding 
response (expressed as optical absorbance in ELISAs or response units (RU) in 
SPR) varies with changing concentration of either the immobilised agent 
(antibody or protein conjugate) or the free binding or competitive agent 
introduced with the sample (labelled antigen or antibody). Plots of this data may 
include plots of response vs coating protein conjugate concentration or response 
vs solution antibody concentration or dilution. Distinguishing binding response 
data points from each other using this system is comparatively easy by simply 
employing student's t-test to determine whether the response differences are 
significant. 
Greater statistical difficulty is encountered when one considers the actual assay 
standard curves. Such curves are plots of binding response vs analyte 
concentration and their form will vary depending upon the format. In a sandwich 
immunoassay one gets a standard curve that at low analyte concentration is of low 
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response and flat. When the "active region" of the assay is reached then there is 
an increase in response with increasing analyte until finally a plateau region is 
reached where there is no further signal increase, corresponding to saturation of 
immobilised antibody binding sites. Such curves have an S-shape and can be 
expected to approximate to a straight line of positive slope in the mid-region of 
the curve. 
Competitive and non-competitive non-sandwich immunoassays have a curve, 
which has high signal at low analyte and is a flat line. As the analyte is increased 
then label binding is inhibited leading to a drop in response down to near zero 
when inhibition of signal-generating binding is nearly total at which point the 
curve flattens out. This S-shaped curve is the inverse of the sandwich assay curve 
and once again approximates to a straight line in the mid-region. 
The detection limit of an immunoassay is generally defined as the analyte 
concentration corresponding to the blank reading less two standard deviations 
(sometimes three) of the mean of the blank. The sensitivity of an assay can be 
defined in one of two ways: 
1. As the slope of the active part of the curve, that is the signal change per 
unit concentration change. This is reflected in the height of the standard 
curve. 
2. As the minimum detection level of the assay, that is the detection limit. 
This is usually reflected in the overall position of the curve along the 
concentration axis. 
The linear range is the region in which data points from the standard curve may 
be fitted to a linear regression with good fit. The dynamic range refers to the 
range between 10 and 90% bound relative to the blank which is 100% bound. It is 
possible to simplify this non-linear relationship by simply considering the linear 
region and reducing all statistical consideration to a linear regression. This is not 
usually suitable though as the curve seldom fits at a wide range to a perfectly 
linear fit. It is far more common to fit a four-parameter logistic relationship to the 
data and use this to calculate concentration values from the equation of the 
curve.96• 97 The logistic fitting can be described by the equation in Figure 1.14 and 
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the graphical representation is given in Figure 1.15. Some researchers use semi-
log linear ranges but this is less common.98 Some standard curves fit better to S-
curve fittings and this may be more appropriate in certain cases. 
y = (a-b) 
l+(x/c)ct 
y = response 
x = concentration 
+b 
a = maximum response 
b = minimum response 
c = concentration at 50% response 
d = slope of the line at the mid-point 
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For the determinations of errors in the concentration determinations from these 
non-linear curves one can use a number of options. Dudley et al. suggest that as 
at any given point upon the curve a tangent to the curve will give the slope of the 
curve at that point then this tangential slope can be used to calculate the standard 
error in the concentration from the standard error in the absorbance at that point.99 
The standard deviation in the response can either be used as the actual standard 
32 
deviation of the standard curve point nearest to the concentration or else by 
developing a response-error relationship. This is where an assay is done exactly 
the same way for a large number of times and so a plot is made of the average 
determined standard deviation at certain concentrations and is plotted versus those 
concentrations. This enables one to formulate an equation relating error to 
concentration that can be used in conjunction with the equation in Figure 1.14. 
This slope system will work well for regions where the curve is not too deviant 
from a straight line but it becomes more of an approximation as one moves to the 
ends of the curve. 
There is no set procedure for dealing with errors in immunoassay 
concentrations, but given a four parameter logistic fit simple algebra suggests an 
adequate approximation would be the equation given in Figure 1.16. In such 
fittings this formula will apply quite well and has been adopted in this thesis. 
Sdx =XX sd log X = X sd(y) (1 + (X / c)d)2 
d (a-b) (X / c)d 
Where: sdx = standard deviation in x (in concentration) 
x = concentration 
sd(y) = standard deviation in y (in response) 
a, b, c, dare parameters as for Figure 1.14. 
Figure 1.16. Equation for the Calculation of Standard Deviation in Concentration 
100 From Immunoassay Curves. 
1.2.1.1.7 Estrogen Biochemistry 
Another class of compounds that is very commonly the target of 
immunosensors and immunoassays are the estrogens. The estrogens are also of 
interest for their receptor binding properties as such binding is critically important 
to the human endocrine reproductive control system. 
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The estrogens are a class of C 18 female sex steroidal hormones that are part of 
the estrane series (Figure 1.17). The principal estrogens are 17(3-estradiol and 
estrone and to a lesser extent estriol and are produced in the female ovary. 









In human pregnancy, the hCG signalling from the blastocyst results in an 
increase in secretion rates of hormones including estradiol. Estradiol levels in 
pregnancy increase in maternal serum to levels of 20-30 ng/mL, about lOOx 
higher than in a non-pregnant woman. 
Estradiol levels in serum can be closely monitored to monitor follicle 
development and maturation, predict ovulation and prevent ovarian 
hyperstimulation in anovulatory women. Such levels can also be used for 
determination of postmenopausal status and for evaluation of men with 
gynecomastia. There are a number of EIA kits available for clinical determination 
of serum estradiol. 103 
1.2.1.2 Synthetic Chemistry of the Steroids/or Antibody Interactions 
1.2.1.2.1 Labelling, Carrier Proteins and Intermediate Bridges 
As the sex steroids are of such importance in mammalian physiology, much 
research has been devoted to the production of derivatives of the steroid 
molecules for a number of different purposes. These purposes include the 
production of protein conjugates as immunogens to raise antibodies or to function 
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as coating antigens, the labelling of steroids with enzyme, fluorescent or 
chemiluminescent labels for biosensing of these steroids and the production of 
drug - steroid conjugates for specialised treatment of disease. 
When antibodies are to be raised to small molecules (<2 kDa) then it is 
necessary to link or conjugate them to carrier proteins to provide enough size for 
the immune response to occur. Such protein conjugates consist of the antigen 
linked through some site on its structure to a straight chain chemical linker or 
bridge and then to the protein, usually BSA or OVA, Figure 1.18. Such protein 
conjugates may also be used as coating antigens on the surface in ELISA or 
biosensor applications. As well as proteins, one can also use such carriers as 
nucleic acid fragments 104 or N-vinylpyrrolidone copolymer. 105 Such protein 
conjugates have even been used in studies into their physiological effects in 
mammals. 106 








Figure 1.18 Estradiol - BSA Conjugate (1) and Estrone - Chemiluminescent 
Acridinium Oxime (AO) Conjugate (2)108 
For antibody-immobilised formats for immunoassay and biosensors it is 
necessary to develop labelled antigen molecules for competition with free sample 
analyte. These conjugates consist of the antigen linked once again via a bridge to 
the label in question. Extensive studies have been done using enzyme conjugates, 
fluorescent labels 107 and chemiluminescent labels. 108 Conjugates of drugs to the 
estrogens are also of critical importance in the treatment of cancers in tissues 
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associated with estrogen receptors such as breast cancer109· 110 and enable 
cytotoxic compounds such as daunorubicin to be directed with some selectivity. 
1.2.1.2.2 Estrogen Site and Bridge Heterology 
The production of linkages to estrone and I 7~-estradiol were at first made via 
the existing functional groups in the steroids. This meant attachment via the 3-
0H or I7-0H in estradiol or the 3-0H and I7-carbonyl in estrone. Attachment 
was via a hemisuccinate bridging through the alcohols or an (0-carboxymethyl)-
oxime (CMO) through the carbonyl, Figure l.I9. The hemisuccinates of estradiol 
and estrone are widely available commercially and are a very common form of 
. . 111 112 113 Wh"l h · d h f~ conJugatton. · · 1 st sue conJugates are easy to pro uce, t ey su ,er 
from being susceptible to base-catalysed decomposition23 and compromise 
functional groups that are important in the antigenic recognition of the 
molecules.23 Carboxymethyloximes derived from steroid carbonyl groups are 
viable alternatives as has been demonstrated for several steroids including 
progesterone (3- and 20-positions), 114 cortisol (3-position)115 and testosterone (3-
position)116 as well as estrone (17-position)23· 24 (Figure l.I9). This bridge 
attachment method will naturally only work if the antigen has a carbonyl group to 
attach through or if one can be introduced, and will compromise the antigenicity 
of the antigen unless a carbonyl group is introduced to the molecule at a position 
spaced from existing functional groups. This can be done by using the 6-oxo-
estrogens that are commercially available to conjugate at the 6-position. This 
attachment has the advantage that only one stereochemical product can be 
produced and so there is no reduction in antibody recognition due to a mixture of 
stereoisomers. 
Previous studies have examined the effect of changing attachment position on 
antibody binding and specificity. To this end steroid conjugates have been made 
at the 4-, 6- and ?-positions of progesterone and compared to those at the I I-
position 117· 118· 119 for the raising of antibodies. The 4-, 6- and ?-positions are on 
the opposite side to the I I-position and it was thought that attachment on this side 
may give better antibody specificity and binding affinity. It was found that 
attachment at the 4-position resulted in no antibody cross-reactivity with phenolic 
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or C-19 steroids or with corticosterone. There was however large reactivity with 
Sa- and 5~-dihydroprogesterone that supports other observations of loss of 
specificity about the point of attachment. Hatzidakis et al. have reported for 
progesterone, that raising the antibody to a conjugate at the 7-position and using 
an enzyme conjugate at the 6-position gives greatest sensitivity and selectivity as 
opposed to conjugates attached at the 3- and l 1-positions.120 This tends to suggest 










Figure 1.19 Production of Estradiol - Hemisuccinate (Left) and Estrone -
Carboxymethyloxime (Right) Derivatives 
The overall consensus for achieving best antibody binding and specificity is to 
use heterology of some kind. 121 There are two types of heterology. The first is 
site heterology whereby the antibody is raised to a conjugate with attachment at a 
different site from the labelling or carrier protein attachment site for the assay 
antigen. Bridge heterology is where different types of intermediate chemical 
bridges are used to connect the antigen to protein for immunisation and to label, 
or protein for immobilisation. Bridge heterology is very important, as if the same 
bridge is used for both immunisation and in the assay itself, then the antibody will 
bind not only to the antigen but also to the connecting bridge and so binding will 
be stronger to the labelled antigen than to the free sample antigen and so the assay 
will be less sensitive to changes in progesterone concentration and so will produce 
an inferior assay. There have been a number of studies on this phenomenon and 
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indeed in certain cases the bridge heterology has been shown to be more 
. h h . h l 122 important t an t e site etero ogy. In the case of the milk medium, Sauer et al. 
have shown that using an 11-a-hemisuccinate bridge and an 11-a-glucuronide 
label bridge123 will greatly reduce bridge recognition. 124 
In the case of the estrogens, De Boever et al. found interestingly that raising 
monoclonal antibody to estradiol-6-carboxymethyloxime-bovine serum albumin 
(BSA) and using a homologous format with 6-carboxymethyloxime (6-CMO) 
labelling with isoluminol or HRP gave the lowest detection limit and highest 
sensitivity. 125 This is an interesting result and shows that it is possible to produce 
homologous assays with very good sensitivity and this has been confirmed by 
other reports so long as the 6-CMO attachment method is used. 126• 127 These 
results for 6-CMO have been carried through to chemiluminescent immunoassay 
also. 128 Linker and site heterologies have been employed for assaying follicular 
estradiol. Silvan et al. have used the 6-carboxymethyloxime to raise polyclonal 
antibodies and then used 3-hemisuccinate bridging for the HRP label. 129 Follicular 
fluid contains many other closely related steroids to estradiol and it was found that 
this format enabled detection of estradiol with low cross-reactivity with other 
steroids. 
Another type of site heterology employed is the use of different stereoisomers. 
Webb et al. reported the raising of antibody to the 11(3-hemisuccinate of estradiol 
and attachment of radiolabel at the 1 la-position. 130 This was compared to the 3-
and 6-positions that showed far less sensitivity. It was concluded that the bridge-
binding phenomenon was dependent upon the site of conjugation employed as a 
homologous 3-CMO conjugated testosterone had very similar results to the 
estradiol assay across antisera from several different animals. This may help to 
explain the observations of de Boever et al. 128 Taking the heterology concept even 
further, Rao et al. have raised antiserum to testosterone-19-carboxymethylether-
BSA conjugate and used 4-( 17(3-hydroxy-3-oxoestra-4,9-dien-11 J3-yl)butanoic 
acid conjugated to penicillanase as the enzyme conjugate. 131 This is an example of 
bridge, site and ring heterology and produced an assay of good sensitivity and 
selectivity. 
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Another method of conjugation that is applied to the aromatic A-ring of 
estrogens is the formation of an azo linkage, Figure 1.20. This involves 
selectively nitrating the aromatic ring at either the 2- or 4-positions, reducing the 
nitro group to an amine by reaction with sodium hydrosulfite and then formation 
of the diazide by reaction with sodium nitrite in hydrochloric acid and then 
conjugation of the diazo unit to the protein at a pH of 8.5-9.5. 132 This method has 
the clear disadvantages of needing a number of reaction steps and using diazo 
coupling which is not as consistent nor the product potentially as stable as in 
coupling via amide linkages from a carboxylic acid terminating derivative. Diazo 
coupling has also been employed for estradiol-17-glucuronides by approximately 
the same method. 133 The principal method of such diazonium conjugations is 
formation of diazo linkages with the tyrosine and histidine residues of the 
protein.90 Diazonium conjugation works well for tyrosine-containing peptide 
haptens. As tyrosine groups are usually quite rare in a given peptide hapten there 
can be consistent orientation of hapten to carrier and near-identical cross-linking. 
The problems with diazo coupling however are immense. The rate of reaction is 
so fast that most of the total coupling potential can be lost by the diazo group 
undergoing intra-molecular coupling on the carrier protein. As they are formed 
they can react with active hydrogens on the aminophenyl precursor even before 
hapten is added. Even without the second active-hydrogen containing molecule, 
the diazonium-activated molecule will tum brown/black within one hour as it self-
conjugates. Such problems lead to highly inconsistent conjugation reactions.90 
As well as diazo coupling one can also couple to the A-ring using the 
glutaraldehyde and Mannich reaction methods. In the glutaraldehyde method the 
nitro derivative is formed at the position of attachment and then reduced as for the 
diazo method to the amine and then coupled to glutaraldehyde by addition at pH 
6.8 along with the carrier protein, Figure 1.21. Once again this involves several 
steps and uses an amino group on the hapten, which is not as good for conjugation 
as a carboxylic acid as there is less control over the conjugation process. The 


















Figure 1.20 Diazo Coupling to Estrone132 
The Mannich reaction proceeds by addition of estrogen with BSA and 
formalin solution, but in order for this method to work in any good yield it is 
necessary to first cationize the carrier protein usually by addition of diamines to 
the carboxylic acids of the protein thus introducing another labour-intensive step, 
Figure 1.22. Furthermore, the position of attachment on the steroid A-ring is not 
controlled which may well compromise antibody affinity and selectivity. It is 
thought that attachment is ortho to the hydroxyl group but this could be either 2-
or 4- conjugation. The yields of conjugation are quite variable with this method 
and depend upon the reactivity of active hydrogens on the hapten.90 Such 
reactions should obviously never be used for haptens containing free amine 







Figure 1.21 Glutaraldehyde Conjugation of Estrogens to Protein 
1.2.1.2.3 Linker Length Effects 
Another area of key interest is on the effects of changing bridge or linker 
length on the amount of antibody binding and the performance of the assay. It is 
intuitive to expect that as the bridge length is incrementally increased that this will 
increase the amount of antibody binding up to a certain point as the steric 
hindrance to binding is gradually relieved. Studies of linker length effects are 
therefore of great interest not just for studying immunoassay interactions but also 
when considering the binding of conjugated targets to antibodies and receptors in 
histology and drug-delivery, Figure 1.23. In the case of steroids, it has been found 
that for cortisol and 11-deoxycortisol conjugated at the 4-position, use of a bridge 
shorter than that used to raise the antibody leads to an increase in assay sensitivity 
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whilst one longer than the immunogen has no positive effect. 134· 135 Thjs is 
intuitively reasonable as the shorter the bridge of the labelled antigen, the less the 
antibody will bind and so the more it will tend to favour free progesterone and 
thus the more sensitive it will be to changes in free progesterone concentration. 
The other factor to consider is that the shorter the linker between antigen and 
label, the lower will be the antibody binding and hence the lower the signal. This 
will have a major effect on the signal : noise-type sensitivity of the assay by 
reducing the slope of the assay curve. The same can apply when the label is on 
the antibody. Indeed, this has been found in systematic studies of the linker 
length when enzyme or microparticle label of monoclonal and polyclonal 
antibody respectively is employed. 136 When linker was increased from 9- to 23-
atoms long there was a 64% signal increase and from 9- to 30-atoms there was an 
82% signal increase for enzyme-labelled a-fetoprotein antibody. 136 
17\l~•lta<iol 
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Figure 1.22 Mannich Reaction at the 2-position of Estradiol90 
There has been an extensive study on the effects of incrementing linker length 
on antibody binding to protein conjugates attached to progesterone via the 4-
position.10 This study has found that antibody binding to conjugates ranging from 
4-atoms to 18-atoms is identical in static ELISA formats as is binding to 4- and 7-
position conjugates. However, in SPR, a flow-through format, that is one where 
one binding partner is flowed over a surface immobilised with the second partner, 
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there is a substantial increase in binding with increasing linker length and there is 
much higher binding at the four position than at the seven position.10 Studies have 
been made on estrone-protein conjugates used to raise antibodies via an azo 
bridge to the aromatic ring.137 In this case the addition of a short aliphatic chain 
(4-amino-n-butyric acid) gave antisera that cross-reacted with estrogens with D-
ring structures different to that of estrone. The explanation was given that it is 
possible for the linker chain to twist and allow the D-ring region to be surrounded 









Increasing linker length = increasing signal 
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Enzyme label or Microparticle 
P . C . to d Figure 1.23 Linker Length Effect for Progesterone- rotem onJugate an 
Antibody-Enzyme Label/ Microparticle Conjugate136 
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Polyethylene glycol (PEG) or oligoethylene glycol (OEG) polymer chains offer 
several advantages as intermediate linkers in hapten-carrier or antigen-label 
conjugates. They can lend water solubility through their multiple ether linkages 
to an analyte that might otherwise be insoluble or sparingly soluble in water. This 
can be of great advantage in protein conjugations as use of organic solvents can 
affect the repeatability of conjugations. 10 The chains have been used extensively 
in antibody binding interaction studies as they have been found to not interfere 
with antibody binding to the target analyte but rather serve to reduce non-specific 
binding. PEG chains have been attached to certain estrogens. PEG chains of n = 
66 and n = 133 have been attached to estradiol via the 3-0H in an ether 
connection 138 as has estrone139, and polyestrones have been synthesised by 
multiple conjugation to a PEG chain. 140 PEG has been used extensively in the 
immobilisation of target analytes in such applications as affinity 
chromatography141 and for the modification of proteins including enzymes and 
hormone antagonists. 142 
1.2.1.2.4 Thioether Bridging 
Thioacids have been extensively used as bridging agents in steroid conjugates. 
The coupling is via a thioether to the ring structure of the steroid with a protruding 
carboxylic acid functionality. The thiol group acts as an efficient nucleophile for 
attachment to the steroid whilst the carboxylic acid can via appropriate activation 
form an amide linkage to lysine residues in the carrier protein. Thioether 
derivatives of progesterone have been examined with carboxymethyl alkylthio 
derivatives being synthesised at the 7a.-position143 and 3-mercaptopropionic acid 
(MPA) derivatives being synthesised at the 4- and 7a.-positions144 as linkers for 
enzyme attachment, Figure 1.24. Methods for MP A attachment have also been 
developed for the 4- and 6-positions of l la.-hydroxyprogesterone. 119 Production 
of the 4- and 7-thioethers on a non-aromatic ring in a steroid proceeds by first 
brominating the steroid at the 6-position by simple reflux treatment of the steroid 
with N-bromosuccinimide (NBS). This is then followed by reflux with the 3-
mercaptopropionic acid in methanolic KOH to give the 4-thioether or treatment 
with sym-collidine to produce the diene and then addition across the 6-7 double 
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bond by treatment with the 3-mercaptopropionic acid and sodium methoxide in 










The estrogens readily form thioether conjugates in vivo by reacting with the 
thiol-containing amino acid cysteine and the tripeptide glutathione as a means of 
metabolising the steroids and eliminating them from the body. These were first 
identified by incubating 14C-estradiol with rat liver fractions. 145 2-Hydroxy-17~-
estradiol has been used to produce glutathione and cysteine conjugates by 
production of the ortho-quinone by treatment with acetic acid and sodium 
metaperiodate and then extraction into dichloromethane, followed by addition of 
glutathione or cysteine in acetic acid. 146 Such a reaction system could not be used 
to easily produce a thioether conjugate of 17~-estradiol as the product still has an 
additional hydroxyl group on the aromatic ring that cannot be removed easily 
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without damaging the thioether linkage. Furthermore, the chemistry involved does 
not have high pure yields (about 10% ), as the product does not crystallise well. 
Another method for the production of thioether estrogen derivatives from the 
aromatic ring is to start with the epoxide 4f3,5f3-epoxy-l 7f3-hydroxyestr-1-ene-3-
one and produce 4-ethylthioestradiol by stirring the epoxide with ethanethiol and 
sodium metal under nitrogen. 147 The 4-position 3-mercaptopropionic acid 
derivative of 17(3-estradiol was synthesised using the epoxide method from 19-
nortestosterone (nandrolone) by Meltola et al. in three steps, 107 Figure 1.25. This 




Figure 1.25 The Epoxide Method for Formation of Estradiol Thioether 
Rather than adopting an ortho-quinone or epoxide method it should be possible 
to utilise aromatic substitution of a halogen derivative on the aromatic A-ring as a 
means of producing thioether conjugates to the 4-position of the estrogens. 
Bromo derivatives should offer the best possibilities for this as they have 
sufficiently weak C-Br bonds but are more stable than the chloro or fluoro 
analogues. The first report of "regioselective" bromination of estradiol and 
estrone was by Slaunwhite et al. who used a method of stirring in acetic acid with 
bromine to produce bromoestrone derivatives, and refluxing with N-
bromosuccinimide for estradiol. 148 Finely divided iron powder was used to block 
production of the 4-bromo compound to get pure 2-bromo. This estrone 
bromination method has since been shown to be somewhat unreliable with 
dibromination occurring and yields being variable. The production of pure 
bromoestrones has posed a significant synthetic challenge. Most brominations 
reported have led to either an isomeric mixture of the 2- and 4-bromoestrones in 
about equal quantities or have yields that cannot be readily reproduced. 149, 14s. iso 
Page et al. have reported the production of 4-bromoestrone 5 from estrone 3 via 
2,4-dibromoestrone 4 by N-bromosuccinimide reaction in ethanolic solution 
followed by reduction of the dibromo with 10% palladium on carbon under reflux 
in formic acid and N,N-dimethylformamide (DMF)151 (Figure 1.26). It has been 
thought that production of pure 4-bromoestrone may have to proceed by a formic 
acid debromination of the 2,4-dibromoestrone over palladium on carbon (Figure 
1.26). This has also been reported by Numazawa et al. who have also produced 
the 4-bromoestradiol this way. 152 Numazawa et al. also used potassium iodide and 
ascorbic acid as dehalogenating agents. These results as well as the work of Utne 
et al. conflict with the paper of Slaunwhite et al. Utne et al. however produce 
only pure 2- and 4-bromoestradiol using N-bromoacetamide, and do so only with 
the aid of column separation. 149 
In the case of estradiol, the 2,4-dibromoestradiol can be prepared simply by 
direct bromination with bromine in near quantitative yields. 153 Formation of 4-
bromoestradiol from this dibromo- has been achieved by regioselective 
hydrogenation 154 with remarkable selectivity. 2-Bromoestradiol can also be 
synthesised by alkylation of estradiol with chloromethyl methyl ether to give 
either the 3,17(3-bis(methoxymethyl) ether or the 3-methoxymethyl ether. 153 
Either of these protected estradiols can then be used to react with butyllithium and 
then trimethylsilyl chloride to give the 2-trimethylsilyl derivatives, which can be 
converted into 2-bromo or 2-iodoestradiol. Yet another method for 2-
bromoestradiol and 2-bromoestrone synthesis is the reaction of the corresponding 
2-phenylselenyl derivatives with iodine monobromide producing compounds in 
- 70% yield. 155 Lovely et al. have very briefly mentioned a method for production 
of the 4-bromoestradiol 2 from estradiol 1 by simple bromination with N-
bromosuccinimide in ethanol 156 (Figure 1.26). Under this method the desired 4-
bromoestradiol simply precipitates out of solution upon reaction. No details of 
this synthesis were given other than the yield of 55% and so the careful control 
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Whilst there have been no reports of thioether conjugation to the A-ring of 
estrone and only one epoxide-mediated method for estradiol, there has been work 
done on uses of such a conjugation at the 7-position of 1, 3, 5 (10), 6-
estratetraenes to give estra-1, 3, 5 (10)-trienes substituted at the 7-position with 3-
thiopropionic acid side chain in a light-catalysed radical reaction yielding a and 
~-epimers. 157 These were then conjugated to BSA with 25-30 steroid residues per 
albumin molecule that was then used to raise specific antibodies. This reaction is 
the photolytic equivalent of the 7-mercaptoprogesterone reflux method mentioned 
above. Previous experiments with the progesterone conjugates have demonstrated 
that the 4-position gives much higher antibody binding than the 7-position in 
flow-through formats. 10 This method demonstrates the efficacy of the thioether 
linkage for conjugation and reinforces the possible usefulness of attachment at the 
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4-position by thioether conjugation. Numazawa et al. have also reported the 
thioether linkage at the 16-position of the androsten-17-ones 158 from the 
corresponding 16-bromo derivative by a direct SN2 displacement. Miller et al. 
have also produced 7-thiosubstituted estratriene derivatives by reacting the 6-
carbonyl 7-bromo equivalent with p-thiophenol, sodium hydride and DMF 
followed by sodium borohydride and ethanol and then TFA and Et3SiH to produce 
the p-thiophenol thioether derivative. 159 
Clearly, production of conjugates linked at the 4-position on the aromatic A-
ring of the estrogens is of great interest as this position has demonstrated superior 
antibody binding over 7- and 11-position protein conjugates of a steroid with a 
non-aromatic A-ring, progesterone. 10 Furthermore, this position is 
stereochemically fixed so there can be no contamination of different epimers at a 
saturated carbon that could reduce antibody binding affinity and I or specificity. 
Theoretically, the best attachment method would be via thioether conjugation of a 
mercapto carboxylic acid as this would produce a highly stable connection and the 
terminal carboxylic acid unit would allow easy conjugation to a protein carrier via 
N-hydroxysuccinimide activation that has been shown to be a very consistent and 
easily controlled means of conjugation. The active esters are highly reactive 
towards the amino groups of the carrier and form stable amide linkages. Previous 
studies have found this conjugation method to produce highly consistent 
. . . h h b 10 15 Th" h d II conJugattons wit respect to apten num er. · 1s met o a ows easy 
attachment of heterobifunctional linker agents to the antigen to provide spacing 
between hapten and carrier. The formation of thioether linkages should be able to 
be effected by simple aromatic substitution of the bromo-derivative. 
It has previously been found that for fluoroimmunoassays, that fluorescent 
tracers conjugated to estradiol via a C-4 thioether linkage give binding to an 
antibody raised to the 6-position whereas conjugates via the C-2 position do 
not. 107 Furthermore, C-4 conjugates were found to give more sensitive 
. h C 6 . 101 immunoassay curves t an - conJugates. 
The attachment positions that have been used to date are summarised in Figure 
1.27. 
HO # 
t OA. G} MR, TE t CMO 
HS 
HS(OH) i /0(0) 
R 
R=OH,O 
Figure 1.27 Attachment Positions to the Estrogens: DA: diazo, GA: 
glutaraldehyde, MR: Mannich reaction, HS: hemisuccinate, CMO: 
carboxymethoxime, TE: thioether 
1.2.1.3 Detection of Estrogen Binding Interactions 
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Estrogen binding interactions have been determined using a number of 
different techniques. One of the most commonly employed is the estrogen 
receptor binding assay. This involves taking a sample of estrogen receptor 
prepared from an appropriate tissue source, e.g. lamb uterine cytosol 160 and 
competing estrogen analyte with tritiated estrogen to determine the relative 
binding affinities (RBA). 159 These tests have been used by Miller et al. to 
determine the selectivity of 7-thiosubstituted estratriene derivatives159 and have 
shown that the selectivities are sensitive to the type of thioether chain used. 
A developing field of research is the use of SPR to determine estrogenic 
binding properties. SPR has been used to study the binding between 17~-estradiol 
and estrone to polyclonal antibodies 161 for homogenous energy transfer 
immunoassay and chemiluminescent estradiol conjugate antibody binding has 
been studied also. 162 Estrogen receptor binding assays have been conducted using 
estradiol immobilised to the biosensor surface via a short aliphatic spacer chain 
attached via the 17-0H of the estradiol and leaving a free amine group for 
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attachment to the biosensor surface. 163 The estrogen receptor is then used as the 
high molecular mass binding agent and dissociation constants calculated. Fractal 
analysis has also been used as a means of modelling binding and dissociation 
kinetics using SPR. 164 SPR thus offers an interesting means of studying the 
binding patterns of new estrogen derivatives or conjugates. 
1.2.2 Catecholamines 
1.2.2.1 Catecholamine Biochemistry 
Apart from the steroid hormones, another class of compound is of integral 
importance in physiological signalling within the mammalian body. A 
neurotransmitter is defined as a chemical substance that is synthesized in a neuron 
and is released at the synapse of a neuron where it influences another neuron or an 
effector cell in some particular way. 165 Further conditions include that it must be 
found in the synapses at reasonably high concentration, be blocked by agents that 
block synaptic transmission and be removed from the extra-cellular space. 165 
Broadly speaking, one can divide the neurotransmitters into two categories: the 
small molecule neurotransmitters and the neuropeptides. The former group will 
be considered here and include the class known as the catecholamines, 
compounds that contain a 3,4-dihydroxybenzene ring and an amino group. 
Examples of catecholamines include dopamine, nor-epinephrine, epinephrine and 
L-DOPA, Figure 1.28. 
1.2.2.2 Catecholamine Biosynthesis 
The catecholamines are synthesised in the nerve terminals and then packed into 
the synaptic vesicles. This synthesis allows continuous replenishment of the 
synaptic vesicles. They are produced from tyrosine by the action of tyrosine 
hydroxylase, which produces L-dopa and requires oxygen and reduced pteridine 
as cofactors. 166 The L-dopa is then decarboxylated by pyridoxal phosphate-
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dependent aromatic L-amino acid decarboxylase to dopamine. 166 In noradrenergic 
nerve terminals the dopamine is further acted upon by dopamine-J3-hydroxylase 
(DJ3H) to give norepinephrine, which is then methylated in the presence of 
phenylethanolamine-N-methyltransferase (PNMT) with methyl donation from S-
adenosylmethionine.166 
OH OH OH 
OH OH OH 
Figure 1.28 Structures of (left to right) Dopamine, Nor-epinephrine and 
Epinephrine 
1.2.2.3 Synthetic and Conjugation Chemistry of the Catecholamines 
1.2.2.3.1 Thioether-Catecholamine Synthesis 
The chemical means by which thioether conjugates of catecholamine 
compounds can be synthesised has been studied to provide standards for analysis 
of quantities of these conjugates in biological fluids and tissues ranging from 
urine through to human brain samples. The conjugates that have been synthesised 
have been the glutathione and cysteine conjugates of dopamine, nor-epinephrine 
and epinephrine. 167· 168 The first step is the formation of catecholamine o-
quinones, which is well studied. Whilst biochemical production works via 
enzymatic and electrochemical routes, the chemical processes involve electrolysis 
of the catecholamine in concentrated acid solution. 169 Shen et al. suggest 0.1 M 
HCl with 5.7 mg of dopamine in 30 mL of acid at 1.0 V for 30 min. 169 This should 
tum the solution from colourless to bright yellow. The thiol unit is then added 
and by simple stirring there is conjugation to the o-quinone and formation of the 
hydroxyl groups once again to give the thioether conjugate. 169 
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This simple reaction procedure should apply to all o-dihydroxy catecholamines 
and to all thiol molecules provided steric hindrance is not great and the 
nucleophilic interaction is strong enough. The reaction must be done under acid 
conditions not only to provide the electrolyte but also to ensure that the 
catecholamine does not undergo radical oxidation. Under basic conditions 
dopamine is rapidly oxidised by dissolved oxygen to produce hydrogen peroxide 
and dopamine o-quinone. The oxidation is mediated by superoxide that acts as 
the chain propagating radical. 170 Dopamine has been shown to be stable at 0.1 N 
HCI, pH< 1. 171 
As well as the thiol-containing amino acids, it should be possible to use this 
electrolysis technique to produce straight chain linker derivatives that terminate in 
carboxylic acid functions. Such derivatives would be of great use as drug carriers 
or probes to study receptor and antibody binding properties. This reaction method 
allows the attachment of a linker unit directly to the aromatic core of the 
catecholamine rather than through existing functional groups. 
1.2.2.3.2 Catecholamine Conjugate Chemistry for Binding Studies 
There have been very few studies of catecholamine conjugates for antibody 
binding or raising of antibodies. Protein conjugates to epinephrine, nor-
epinephrine, dopamine and L-dopa were developed to raise antibodies using 
conjugation by the Mannich technique, 172• 173 Figure 1.29. This technique suffers 
from the need to protect the amino group before conjugation. Miwa et al. have 
done this by maleylation of the primary amine but this will produce a secondary 
amine that theoretically could condense with an additional molecule of aldehyde 
and amine. 174 It is also possible for a Mannich base to condense with excess 
formaldehyde. A further problem is that the position of attachment cannot be 
determined with certainty in protein conjugation. A study was made on position 
of attachment when 4-methylcatechol is reacted with ethylamine by the Mannich 
reaction and found attachment at the 5-position, 175 but this is a very rough 
estimation and it is quite conceivable that multiple Mannich reaction products are 
formed that would greatly compromise the specificity and affinity of the antibody. 
Also, Mannich reaction without cationisation of the protein will take up to five 
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days. Dopamine antibodies were also raised using a Mannich conjugation to 
protein carrier. 176 The Mannich reaction has also been applied to production of 
protein conjugates of 3-methoxy-4-hydroxyphenylglycol (D-MHPG) in an 
analogous way. 177 Hirose et al. introduced the use of a caproic acid unit as the 
Mannich base with D-MHPG in a protein conjugate with isolation of the linker 
derivative and determination of position of attachment. 177 Position of attachment 
could not be determined if the reaction was done in one step as it usually is and if 
used with catecholamines bearing primary amine groups the amine groups would 
still need to be protected. The production of carboxyl terminals and subsequent 
NHS esterification and conjugation will give the most consistent and well-
controlled conjugation and these terminals can be produced by either using the 
thioether derivative with carboxylic acid terminal or using the Mannich reaction 
with a heterobifunctional caproate unit as the Mannich base. With both of these 
techniques one can increase the length of the spacer by simply using different 
length thioacid or caproate chains. These conjugations direct to the aromatic ring 
are clearly beneficial for production of conjugated catecholamines without danger 
of compromising existing functional groups. It is therefore of interest to study 
their binding properties to antibodies to assess their efficacy as coating antigens in 
biosensors or as immunogens in protein conjugates or their receptor interactions 
to assess their efficacy as carriers of drugs or labels to receptor sites. 
1.2.2.3.3 Purification of Catecholamine Derivatives 
The catecholamine derivatives discussed are quite polar molecules. Dopamine 
is only freely soluble in water and slightly soluble in methanol, nor-epinephrine 
only freely in water and epinephrine is only freely soluble in acid or NaOH and 
KOH solutions. 178 Any direct ring-conjugation to a carboxylic acid terminating 
thioacid would not be expected to greatly reduce the polarity. This has posed a 
problem for researchers wanting to purify catecholamines from biological samples 






Figure 1.29 Mannich Condensation to Form Protein Conjugates of Dopamine 
For catecholamines in biological samples the method of choice has been ion-
exchange chromatography. 179 This has been applied in the HPLC format 180 and as 
a separate gravity or low-pressure column. 181 The low-pressure system used with 
success uses a strong cation exchange column and elution of the compound with 
acid/organic solvent mixtures, 181 Figure 1.30. The organic solvent serves to 
compress the volumes of elution. The acid used is 4-6 N aqueous HCl and the 
solvent is ethanol. 181 It is also possible to elute such columns with NaOH182 but 
this may cause problems with base degradation of compounds. The ion-exchange 
columns have only been employed for low concentrations of catecholamines. The 
method preferred for purification of synthesised catecholamine derivatives 
appears to be preparative reversed-phase HPLC169 but this is often a very time-
consuming process that will yield only small amounts of product and often 
requires many repeated runs to get that small amount of product. 
From this background one can see that there is an opportunity to produce 
thioether-linker straight-chain catecholamine derivatives connected via the 
aromatic ring directly and with an acid functionality that could be equally used in 
protein conjugations and as a connection point for labels or drugs. It would also 
be of interest to study the antibody or receptor binding properties of these 
analogues using the SPR capabilities of BIAcore and compare them to those 
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Figure 1.30 The Separation of Catecholamines by Gravity-Fed Ion-Exchange 
Column 181 
1.2.2.3.4 SPR Studies of Receptor Binding 
55 
The advent of SPR technology has enabled real-time biointeraction analysis for 
the binding of receptors to catecholamine targets. However, there are no papers 
that report the use of this technique for catecholamines. A possible reason is that 
most such studies are done in vivo and as such cannot be done in an SPR format. 
A number of different methods have been used for receptor binding studies and 
perhaps the most common is the use of radiochemical techniques. In such 
methods a cell clone sample expressing the desired receptor is incubated with a 
3H-labelled antagonist for the receptor. The receptor/ antagonist complex is then 
incubated with the sample and the sample displaces the radiolabelled antagonist in 
proportion to its affinity for the receptor. The dissociation constant (Kc!) can be 
determined by comparison of the radioactivity after a set time to that of the 
original radiolabelled antagonist before sample incubation. 183 Such tests are now 
nearly routine and this technique has become the dominant research method. 184• 185 
Biomimetic chemical receptors for the catecholamines have been tried in 
biosensors 186 and evanescent wave biosensors have been developed for detection 
of adrenaline by absorption of the evanescent wave by adrenaline oxidation 
products at a Laccase interface. 187 
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1.3 Nanoparticle Labelling of Biomolecular Interactions 
Nanoparticle labelling of biomolecular interactions enables potentially large 
increases in binding signal in a number of different transduction formats such as 
surface plasmon resonance (SPR), and this forms another area of research in this 
thesis. This section summarises the research in this growing area. 
1.3.1 Nanoparticle Labelling 
The growing field of nanochemistry has embraced the labelling of 
biomolecular interactions such as the binding of complementary strands of DNA, 
of antibodies and antigens, of receptors and targets and of host / guest 
interactions. Perhaps the most wide spread applications of this nanobiochemistry 
are in two areas: 
1. Self-assembly of nanoparticles 
2. Signal enhancement of biomolecular interaction analysis systems 
The first area involves using biochemical binding, principally complementary 
DNA interactions 188 and antibody / antigen 189 analysis to assemble nanoparticles 
that are connected to them to produce nanoscale structures or more generally 
changes in the order or spatial arrangement of the nanoparticles. This is a very 
new and fast developing area that has already been employed in the detection of 
small quantities of specific oligonucleotide strands190 through self-assembly of 
gold colloids by binding of complementary strands (Figure 1.31 ). 
The second area is of relevance to this thesis and makes use of a wide range of 
different nanoparticle properties to detect binding interactions with much 
improved sensitivity. Perhaps the most widespread application of this is the use 
of gold colloids192 and fluorescent nanocrystals193 to amplify binding in 
microarrays for the purpose of high-throughput screening or in biological 
imaging. The use of gold colloid labels in histology for staining of tissues has 
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been well developed and employs immunolocalisation to target nanoparticles to 
specific regions of tissues. 194 The developing field of surface-enhanced raman 
spectroscopy (SERS) is also utilising nanoparticle localisation. 195 An area of 
emerging interest is the use of nanoparticles as labels to enhance the signal from 
biomolecular interactions detected by surface plasmon resonance (SPR). 
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Figure 1.31 Top: Antibody/Antigen Interactions to Order Gold Nanoparticles, 
Bottom: DNA Interactions to Order Gold Nanoparticles191 (from R. C. Mucic, J. J. 
Storhoff I Northwestern University). 
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1.3.2 Nanoparticle Enhancement of SPR Signal 
The detection of small molecule binding interactions by SPR is very 
challenging in that the small molecules by virtue of their small mass produce only 
very slight changes in refractive index of the surface upon binding. Binding of a 
small molecule ( <2 kDa) will typically produce RU changes of 10-50 RU at 
most1% and often needs a dimethylsulfoxide (DMSO) component to ensure 
solubility. 196 There have been some reports using gradient immobilisation 
(multiple flow cells with different amounts immobilised) for low molecular-
weight antigens binding to immobilised antibody but this method still produces 
very low sensitivity. 197 There are two potential ways of overcoming the problem 
of low signal. The first is to immobilise antigen and detect the compound by 
using antibody binding to the surface10 and the second is to tag the binding agent 
(antigen or antibody) with a high mass label that will enhance the observed 
binding signal intensity. 
Enhancement of binding signal intensity in SPR has two functions in 
improving biosensor sensitivity. The enhancement will increase the slope of the 
calibration curve allowing for finer distinction of different concentrations and 
secondly it will allow lower concentrations of bound material to be distinguished 
from the background. In short, the enhancement increases the changes in 
resonance angle (~8,) enabling one to measure this change more accurately. In 
the case of a sandwich immunoassay, this means that smaller concentrations of 
analyte bound can be distinguished from zero analyte bound as the bound analyte 
signal is amplified. For inhibition assays such as those for small molecules, the 
signal enhancement will mean that smaller amounts of inhibition will be able to 
be distinguished from 100% bound. In both these cases, signal amplification 
should result in a drop in detection limit. 
The signal that is obtained upon the binding of a large molecule or binding 
complex in solution to an immobilised SPR chip surface agent is dependent upon 
several factors: 
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1. The total mass of the chemical entity binding to the surface, the larger the 
mass the greater the response 
2. The extent to which the binding agent is able to undergo surface plasmon 
resonance itself 
3. The distance of the binding agent's centre of mass and / or surface 
plasmon resonance active component from the gold surface. 
A number of different types of nanoparticle have been suggested for use as signal 
enhancement tags. These include liposomes, latex particles, proteins and gold 
colloids. The first three classes of tag rely solely upon their large mass to induce 
larger changes in refractive index on the gold surface and hence enhance 
biomolecular binding interaction signals. The gold colloids however are capable 
of employing not only large mass but also a reinforcing SPR effect in the 
nanoparticles themselves that will yield an enhancement much greater than that 
expected by mass increases alone. 
Liposomes (large membrane-like spherical units that assemble from 
phospholipid molecules) have been used to enhance signal (Figure 1.32). 
Liposomes range in size from 100-1000 nm and Wink et al. have used them as 
labels of protein immunoassays by immobilising antibody, passing protein antigen 
and then antibody again (i.e. sandwich format) which is biotin-labelled. A vidin is 
then used as a bridge from biotinylated antibody to biotinylated liposome. 198 
Under this format the slope of the calibration curve has been raised to -40,000 
times that of the un-enhanced calibration curve and the detection limit dropped by 
over three orders of magnitude. 198 
Latex particles have also been employed and can be used in one of two ways. 
The first is in the same way as liposomes, as a high mass label of the binding 
interaction and secondly, as a means of increasing chip surface area available for 
immobilisation and thus increasing the binding sites on the chip and thus allowing 
greater binding. In the first case, latex nanoparticles ranging from 40-210 nm 
have been used with a refractometric transducer to give enhancements of five-fold 
over unenhanced sandwich immunoassay for thyroid stimulating hormone and a 
greater than three orders of magnitude reduction in the detection limit.199 In the 
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later case, the molecular capacity of the evanescent field can be increased by 
increasing the effective sensor area.200 This can also be done by use of a hydrogel 
matrix.201 
1ri' I lf antibodies 
0 antigen 
liposome 'filled' 
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Figure 1.32 Liposome-Enhanced SPR Binding198 
Proteins can also be used as high mass labels for binding interactions. Such a 
system was employed to label the binding interactions of progesterone with its 
immobilised antibody by forming a protein conjugate10•15 and indeed this is an 
effective method for detecting small molecules whose binding to immobilised 
antibody would otherwise be undetectable, but is limited by the size that the 
protein can get to before steric crowding prevents approach of the conjugated 
small molecule to the surface and is also limited by the limited ability of proteins 
to increase antigen mass. The enhancement will at best bring the small molecule 
antigen up to the signals obtained for un-labelled protein assays. A better system 
of labelling is to use a protein label as a secondary label that recognises the bound 
complex. This can be done for antibody immobilised on a chip, binding of protein 
antigen, binding of antibody again in a sandwich format and then addition of a 
protein label such as a secondary antibody, or streptavidin to a biotinylated 
antibody. Such a system has been employed for DNA interactions whereby a 
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DNA strand is immobilised on the surface and binds a biotinylated 
complementary strand, which is then labelled with streptavidin to enhance mass 
and signal.202 Here, a four-fold improvement in detection limit is observed. 
Amplification has also been achieved by immobilisation of an enzyme on the 
sensor surface with competitive binding between an inhibitor and a biotinylated 
target and signal amplification by anti-biotin antibody.203 
As well as the attachment of labels, the use of improved transducer 
technologies has also led to an enhancement of signal. These include the use of a 
. 204 . 1 · 205 p h h h d . resonant mirror or a grating coup mg. er aps t e one met o of signal 
enhancement that has received the most attention though is the use of colloidal 
gold nanoparticles as signal enhancement agents. Colloidal gold nanoparticles 
employ surface plasmon resonance effects within the colloid as well as mass 
effects to gain signal enhancement. Some understanding of the physics of this 
process is required. 
1.3.3 Physics of Gold Colloid SPR Signal Enhancement 
The basis for much of the gold enhancement effect lies in surface plasmon 
resonance coupling between the gold nanoparticle and the gold film of the SPR 
chip. Each gold colloid nanoparticle has an enhanced electric field that can be 
many orders of magnitude higher than the incident fields.206 These fields are 
caused by the surface plasmon resonance induced by incident radiation. These 
fields are confined to a small distance out from the nanoparticle surface, typically 
weak beyond 300 nm, and thus produce a very strong field gradient.206 When a 
gold nanoparticle approaches another gold domain such as the gold sensor surf ace 
or another gold nanoparticle these electric fields can overlap and the surf ace 
plasmon modes couple to each other (Figure 1.33). This strong optical coupling 
then produces a large shift in refractive index and thus in plasmon angle that is 
much greater than would be expected from a simple mass increase. These 
changes in the corresponding SPR curve are -25 times larger than those observed 
in binding without the gold colloid.207 Theoretically, if the gold colloid coating is 
such that colloid nanoparticles are close enough to each other to couple then a 
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continuous evanescent wave can move down both gold film and through the gold 
colloid layer. Studies have shown that such coupling produces a large shift in 
plasmon angle, a broadening plasmon resonance and an increase in minimum 
reflectance, all of which results in increased SPR sensitivity.208 
Naturally, this coupling interaction is very much dependent upon the distance 
of the gold colloids from the gold film surface. If the colloids are far away from 
the surface then no coupling of electric fields is possible and so no plasmon 
resonance signal enhancement will be observed. This factor must be considered 
when constructing biosensor formats based around this phenomenon. Research 
has been done on using poly-ion multilayer spacers to calibrate the distance 
dependence of the SPR effect when applied to organic separation layers.ZCl9 The 
coupling distance between the gold film and the labelling nanoparticles can be 
optimised and researchers have utilised this to space the nanoparticles at the 
optimum distance from the chip film by use of a 30 nm Si02 layer immobilised 
upon a gold film surface of 50 nm.29 Another factor that will have a great effect 
on the plasmon angle shift is the size and shape of the gold nanoparticles. It has 
been found that as the colloidal gold diameter increases from 30-59 nm on a 47 
nm thick film, the plasmon angle, minimum reflectance and curve breadth all 
increase with increasing nanoparticle size and coverage until a plateau is reached 
when SPR attenuation is maximised.210 The relationship between colloid size and 
the mean free path (MFP) of the plasmon electrons is also important. Plasmon 
bandwidth will increase as the colloid size decreases below the MFP and increases 
with increasing size above the MFP.211 It has also been found that the extent of the 
sensing distance range out from a gold nanoparticle surface can be tuned by 
adjustment of the composition, shape, in-plane width and out of plane height of 
the nanoparticles.212 As well as gold colloids, silver colloids can also undergo 
SPR but are not as extensively used principally because of the difficulties of 
producing stable silver colloids. Studies have also been done on the effects of 
changing either substrate film or nanoparticle from gold to silver using 2-
aminoethanethiol immobilisation. 213 
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1.3.4 Gold Nanoparticle Enhanced Binding in SPR 
The use of gold nanoparticles for SPR enhancement of binding interactions falls 
into two main areas: 
1. The analysis of oligonucleotide binding interactions and their applications 
to oligonucleotide assays 
2. The analysis of the binding between antibodies and large size antigens, i.e. 




Figure 1.33 Schematic of the gold nanoparticle enhancement effect in SPR 
showing overlapping gold electric fields (which also overlap with the gold 
surface) and the plasmon wave (offset) 
The sensitive detection of oligonucleotides is of great interest for the rapid 
diagnosis of many genetic diseases. SPR has been used to detect DNA for some 
years but it is only comparatively recently that work has been done using gold 
nanoparticles to label the binding interactions between complementary strands for 
the purposes of signal enhancement. He et al. used oligonucleotides linked by 
either a thiol terminus or a biotin / streptavidin linkage to gold colloids of 12 nm 
diameter and obtained signal enhancements of more than 1000-fold over the un-
labelled and a detection limit of -10 pM214 (Figure 1.34). Further work has 
utilised gold "nanoislands" immobilised on glass for hybridisation detection 
through thioether-mediated coupling215 (Figure 1.34). The use of gold labelling of 
DNA interactions has been patented. 216• 29 
Antibody / large antigen interactions with gold enhancement have been studied 
for somewhat longer. Gold amplification is applied to sandwich immunoassay 
formats (Figure 1.35). Studies include detection of immunoglobulin G where a 
25-fold signal enhancement and picomolar detection was observed for binding of 
an -11 nm colloidal gold label.207 lgG Fab' fragments have been immobilised 
upon the gold sensor surface and anti-IgG antibody added labelled with 40 nm 
gold.217 This gave reported sensitivity enhancements of about 300-fold.217 Gold 
labelling of binding proteins has also been applied to high-throughput screening 
applications that exploit the SPR effect of the nanoparticle.218 When the binding 
protein binds to a small molecule target then this results in a shift in the SPR band 
of the gold and has been utilised in simple photometric type experiments in 
association-dissociation assays.218 It has been concluded that clustering of gold 
colloid particles leads to greater signal enhancement in SPR.219 Gold-labelled 
secondary antibodies have been applied extensively in formats such as the 
Nycocard colorimetric system and binding properties have been assessed using 
BIAcore with binding to a capture antibody. 220 Technologies have been patented 
for the use of small gold colloids to amplify the signal when attached to large-size 
antigens binding immobilised antibody in competitive assay.216 Another format 
developed has gold labelling of antibody and binding in a sandwich assay format 
with immobilised antibody.216 These systems use small gold nanoparticles to 
diffuse into the system and then amplify the size by attachment of Ag 
nanoparticles. 216 
To date there have been no reports of gold nanoparticle-enhanced binding 
responses in SPR for small molecule immunoassay. There has only been one 
paper that employs gold labelling of small molecules for SPR studies.221 This 
example uses tiopronin-capped gold nanoparticles to label N-(3-aminopropyl)-N' -
methyl-4,4' -bipyridinium to follow electrochemical deposition of the modified 
gold upon the SPR gold surface and in amplified SPR detection of nicotinamide 
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adenine dinucleotide NAD(+) and NADH cofactors.221 This detection is by 
indirect means through the NAD+ I NADH redox couple with the bipyridinium 
causing changes in bipyridinium oxidation state and thus level of electrochemical 
deposition on the surface. This paper makes no mention of the enhancement 
degrees obtained, and has detection ranges that are quite poor (lxl0-4 - 2x10-3 M) 
and uses an indirect technique for assay by using partial biocatalyzed dissolution 
of the bipyridinium radical cation film in the presence of diaphorase.221 Some 
papers have made allusions to the ability of reported systems to be adapted to 
function for small molecule immunoassay but this has not been followed up by 
reported research.217• 207 There are several possible reasons for this: 
1. Small biomolecules are easily sterically swamped by the larger gold 
colloids and so methods have to be constructed such that the small 
molecule labelled with gold can still bind the antibody to an appreciable 
extent. 
2. The small molecules cannot be immobilised directly upon the sensor 
surface as can proteins and so some linkage needs to be constructed to 
bind them to the surface either via a protein or through some other 
intermediate linker. 
3. The proteins can be bound intimately onto the surface of the gold colloid 
and cover it but the small molecules are constrained to being attached by 
intermediates which could push the gold colloid too far away from the 
gold of the chip and thus spatially prevent enhancement effects. 
4. The small molecules cannot be assayed in a sandwich format and as such 
the gold enhancement will only help in indirectly detecting free antigen / 
antibody binding, forcing the detection to be by inhibition. 
5. Small molecule antigens cannot block the surface of the gold colloids in 
the way that large molecules can and so special blocking and regeneration 
procedures may need to be used if antigen-colloid conjugates are used. 
6. The regeneration of the colloidal gold-small molecule systems may 
introduce problems with the strength and nature of regeneration cocktail 
needed and surface stability under regeneration. 
Another point to note is that the existing gold colloid enhanced immunoassay 
research has not used the BIAcore format except for that of Johne et al. who have 
used it in analysis of their Nyocard conjugate.220 The other studies have rather 
relied upon in-house SPR systems where it is possible that there has not been the 
same degree of system control as is possible with BIAcore. The principle reasons 
for use of in-house systems is that they circumvent patent considerations around 
immobilisation by dextran layer and also the dextran layer can in some cases 
cause problems in enhancement due to its thickness (about 100 nm from the gold 
film) pushing the gold colloid further out from the gold film of the sensor surface. 
Another possible limitation is that specific binding sites on the surface may not be 
accessible to larger molecules such as proteins or larger labels such as gold 
colloids as the dextran forms a three-dimensional array out from the gold film 
surface and thus one can get non-specific binding of proteins to the dextran 
layer.29 A major drawback in not using the dextran layer or some other equivalent 
coupling matrix is that SPR reflectivity changes within uniform substrates, such as 
monolayers of bifunctional organic cross-linkers, are quite often so small as to be 
undetectable. 29 
1.3.5 Immobilisation, Regeneration and Linkage Technologies 
In any consideration of gold labelling of binding interactions for small 
molecules the methods of immobilisation, regeneration and the linkage 
technologies for labelling will be critical. Immobilisation for the protein-based 
nanogold-enhanced systems has employed immobilisation of an alkanethiol layer 
on the naked gold film that is carboxylate-modified, e.g. 3-mercaptopropionic 
acid (MPA), and thus uses carbodiimide coupling to the immobilised protein.207 
Alternatively, modification with a straight chain thiol amine followed by 
treatment with N-succinimidyl-3-(2-pyridyldithio)propionate enables antibody 
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fragments to be attached via a disulfide linkage.217 Immobilisation of small-
molecule antigens would naturaJiy require a specific chemical spacer and 
immobilisation technique to project the antigen from the surface and thus 
eliminate the steric constrictions of the gold film surface, or dextran matrix if 
used. Other linkers used in non-gold-labelled applications include 11-
mercaptoundecanoic acid (MUA) linkers for proteins222 and stable chelating N-(5-
amino-l-carboxypentyl)iminodiacetic acid (NTA) linkers allowing reversible 
immobilisation of oligohistidine tagged proteins.223 Some general immobilisation 
linkers are shown in Figure 1.36. 
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Figure 1.36 Various Thiol -Terminating Linkers used for Spatial Distancing of 
Binding Agents from the Gold Surface224 
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None of these papers include mention of regeneration of the surface after gold 
label binding except that of Johne et al. who used a 100 mM HCI regeneration 
pulse between sandwich assays.220 The reason for lack of reference to 
regeneration methods is unclear, but clearly to develop a biosensor that will be of 
practical use the system must have reliable regeneration steps. The introduction 
of large nanoparticles into the system may conceivably lead to problems of 
surface stability, particularly if the surface is protein-functionalised. This is due to 
non-specific interactions between the gold colloid and the surface removing 
immobilised material or if stronger regeneration conditions (compared to 
unlabelled proteins) are needed then this may lead to chemically induced 
degradation of the immobilised surface. There are a number of regeneration 
cocktails that have been considered with perhaps the most common being 10-100 
mM HCl or 10 mM glycine pH 1.7-2.2.225 It is critically important to ensure 
complete regeneration of the surface or the surface properties will not be constant 
and there will be drift changes from assay to assay. 
There are a number of linkages that can mediate the gold binding interaction. 
These linkages can be constructed before the assay or some biomolecular 
interaction used to mediate the gold colloid attachment in situ. Perhaps the 
simplest technique is to immobilise antibody or protein antigen electrostatically 
on the surface of the colloid by simple pH adjustment of the colloid to mildly 
basic pH and then to add protein and briefly incubate and then block with some 
other protein such as BSA.90 Another possible method is use of the biotin / 
streptavidin linkage to label the antibody or protein. In this case biotinylated 
antibody can be incubated with streptavidin or avidin-coated gold colloid and the 
resulting complex used as the labelled binding unit in the assay. Biotinylation of 
antibodies is a well established technique90 though has the disadvantage that it has 
been known to interfere with antibody recognition in protein / antibody 
interactions using BIAcore.226 The biotin/ streptavidin interaction is the strongest 
non-covalent binding interaction known in nature and has been widely used with 
nanoparticles in a range of formats such as organisation of iron oxide 
nanoparticles in ferritin. 227 Streptavidin-gold labelling of biotinylated antibodies 
has been employed in staining of tissue sections90 (Figure 1.37). Furthermore, the 
streptavidin I biotin interaction can be utilised to immobilise steroidal antigens in 
SPR with the streptavidin functioning as a molecular spacer unit. 228 The use of 







Figure 1.37 Streptavidin-Gold Labelling of Biotinylated Antibody90 
1.3.6 Gold Nanoparticle Production and Modification 
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The production of gold nanoparticles with reproducible mean diameters was 
first made possible with the work of Frens in developing citrate reduction of gold 
colloids.230 By adjustment of the volume of citrate solution added to a solution of 
HAuCl4 one can adjust the mean colloid diameter from 1.6 nm to 147 nm.230 
Colloids of high size are more difficult to reproduce due to the low citrate 
quantities having less control in blocking the aggregation of colloid particles. The 
mean particle diameters can be determined by transmission electron microscopy 
(TEM) through taking microscope pictures and measuring diameters on the 
images compared to reference standards run at the same time. Usually this will 
require at least 100 readings to determine the average. Another possible 
alternative is the use of photon correlation spectroscopy (PCS) that has been 
extensively developed for the measurement of mean particle diameters.23 1 PCS 
obtains particle size data by examining the different velocities of different sized 
particles undergoing Brownian motion. A correlator analyses the variable 
intensity of scattered light with time to determine particle size. This technique has 
been applied in the commercial instrument known as the Malvern Zetasizer™ that 
involves placing the sample in a four-directional cuvette under temperature 
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control and taking a series of readings after having first established a 
correlellogram for the sample.232 These readings give the average particle size, 
and multiple readings on different sub-samples can give an estimation of particle 
size spread. 
Once produced, these nanoparticles then need to be immobilised with the 
binding partner required for the labelled interaction. Immobilisation of functional 
groups has been done via a wide range of methods including modification with 2-
mercaptosuccinic acid to present carboxylic acid functions at the surface.233 
Immobilisation of proteins direct to the surface is probably the most widely used 
system and is adequate in most cases for antibody binding to a gold label. Other 
possibilities as well as the use of ionic interactions include the use of hydrophobic 
interactions and the formation of dative bonds through thiol groups either 
originally present or introduced to the antigen or antibody (Figure 1.38). 
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Figure 1.38 The Methods of Conjugation to Gold Nanoparticles90 
Non-specific binding to gold nanoparticles can be a problem when developing 
gold-labelled complexes for immunosensing and there has been some 
investigation of ways of minimising it.234 Another factor to consider is the need to 
prevent aggregation of the gold colloid particles, which is a particular problem 
when using larger gold nanoparticles. A number of methods have been 
investigated for preventing this. The use of protein coating such as coating with 
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BSA is quite common. Polymers have been shown to prevent aggregation and 
polyethylene glycol is a major example because of its water solubility and the 
ability to terminally functionalise it with such groups as mercapto and acetal 
terminals.235 PEG and protein immobilisation stabilise the gold colloid through 
steric repulsion effects. Varying amounts of PEG added at formation of the 
colloid can vary the size of the colloid produced and PEG terminals have even 
been functionalised with biotin to enable streptavidin-induced aggregation of the 
gold colloids.236 PEG has been used extensively in the surfaces of biomedical 
devices because it increases biocompatibility and reduces thrombogenicity237 and 
has been extensively used for protein modification and is highly suitable for the 
formation of drug carriers or in antibody or receptor binding targets because of its 
suppression of protein binding, low toxicity and because it is non-inimunogenic 
and is very biocompatible.238 PEG has also been used as a linker in the 
modification of antigens for labelling with biotin in streptavidin/biotin systems 
and could potentially be used to label antigens with colloidal gold-streptavidin 
(Figure 1.39). 
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Figure 1.39 Biotinylated Estradiol with PEG linkers228 
It is clear that the development of gold nanoparticle-enhanced immunoassay of 
small molecules by SPR is of great benefit in the development of more sensitive 
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immunoassays for these compounds by SPR. The development of such a system 
clearly poses significant challenges for the chemist in terms of gold colloid 
linkage, assay formats, regeneration and surface immobilisation. 
1.4 Research Aims 
1.4.1 Opportunities 
The field of biosensing technology is a vast and rapidly growing one where 
there is much scope for the development of new and improved assay systems, 
chemical modification of targets and technologies that will enable the production 
of more robust and practical biosensors. In order to improve biosensors and 
develop new ones it is very important to have a fundamental understanding of the 
binding interactions that are taking place and the ways that changing chemistry, 
format and kinetics change the performance of antibody / antigen and receptor / 
target interactions and thus influence biosensing assays. 
Milk progesterone determinations for assessment of reproductive 
endocrinology are widespread, however there is a complete dearth of studies on 
how changing assay format and medium will affect assay performance and 
antibody / progesterone binding behaviour. The production of antigen-
immobilised ELISA for milk progesterone enables assays to be done free of 
enzyme-antigen labels and their inherent problems and so has significant 
advantages over conventional antibody-immobilised formats. The study of 
antibody binding patterns in whole milk with increasing intermediate linker length 
enables comparison to aqueous results to observe media-dependent effects. The 
assay performance can then be assessed with these conjugates to give greater 
understanding of the medium-dependent effect influencing antibody binding 
patterns in whole milk ELISA. 
Estrogens have been traditionally labelled via existing functional groups or via 
epimeric positions on the molecule. There have been no immunoassay or 
antibody binding studies done with regioselective attachment at the 4-position of 
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estradiol and estrone in flow-through formats despite its demonstrated superior 
antibody binding in flow-through formats for progesterone. This gives the 
possibility of novel aromatic substitution chemistry to produce thioether 
conjugates with water-soluble intermediate linkers and then subsequent analysis 
of antibody binding in flow-through SPR formats. 
The catecholamines have been extensively studied for their receptor binding 
properties yet conjugates attached directly to the aromatic ring have not been 
studied for antibody or receptor binding. By thioether bridging to the aromatic 
ring it is possible to form such conjugates without the inherent problems of the 
Mannich reaction. Through ion-exchange chromatography and HPLC analysis it 
should be possible to purify these compounds and then apply them as immobilised 
targets to assess their antibody binding properties by SPR. 
Small-molecule assay by SPR is a burgeoning field and yet whilst there have 
been a number of studies employing nanoparticles in labelling of large-molecule 
binding interactions, there have been no studies for small-molecule I antibody 
binding interactions. There is clearly an opportunity to develop the chemistry 
necessary to produce such gold nanoparticle-enhanced assays with respect to 
assay format, labelling technologies, surface immobilisation and regeneration to 
produce a practical biosensing system. 
1.4.2 The Objectives of the Project 
The objectives of this project can be divided into four separate but interrelated 
areas. All of these areas of research are devoted to the same set of basic research 
aims, which can be summarised as: 
1. To develop fundamental understanding of how changes to parameters in a 
small biomolecule immunosensing system produce changes in the 
performance of this system. The parameters may include sample medium, 
intermediate linker length and/or chemical identity, position of 
modificational attachment to antigens or targets, and the nature of any 
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labels. Performance of the system may be assessed by factors such as 
detection limit, sensitivity and active assay range. 
2. To develop new immunosensing formats for small biomolecule targets that 
utilise innovative chemistries to produce substantial improvements in the 
immunosensing system. 
3. To develop fundamental understanding on how chemical modification of 
targets affects the binding properties of the target to antibodies or 
receptors. 
1.4.2.1 Protein Conjugate-Based ELISA of Whole Milk Progesterone 
Progesterone-ovalbumin conjugates with different length intermediate linkers 
will be applied as coating antigens in ELISA plate immunoassay of cow whole 
milk progesterone. The linker lengths will be four, 11, 18 and 25 atoms long. 
The patterns of binding to antibody and comparison of the assay performances of 
these conjugates will be determined. An ELISA for whole milk progesterone will 
be validated based on this data and compared to existing RIA methods. It is 
envisaged that as well as eliminating antigen-enzyme conjugates this assay will 
require no pre-dilution of milk and will deliver more than adequate accuracy and 
precision for estrus monitoring and pregnancy prediction. 
1.4.2.2 Introduction of Carboxylate Linker Groups by Thioether 
Derivatisation of Bromoestrogens with Mercaptopropionic Acid at 
the Aromatic A-ring - Synthesis and Antibody Binding Studies 
The estrogens, 17~-estradiol and estrone will be conjugated by formation of 
thioether linkages at the 4-position on the aromatic A-ring by substitution of the 
corresponding bromo-compounds to produce 3-mercaptopropionate derivatives, 
which can then be further derivatised by attachment of water-soluble OEG or PEG 
linkers of varying length. These derivatives will then be used as immobilising 
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antigens in SPR studies of their binding interactions relative to hemisuccinate and 
Mannich conjugated controls. 
1.4.2.3 Introduction of Carboxylate linker Groups by Thioether 
Derivatisation of Catecholamines with Mercaptoalkylcarboxylic 
Acids - Synthesis, Purification, HPLC Studies and their Antibody 
Binding Properties 
Thioether derivatives of the catecholamines dopamine, nor-epinephrine and 
epinephrine will be synthesised from the corresponding o-quinones, purified by 
ion-exchange chromatography or conventional silica chromatography as required 
and analysed by HPLC to monitor their purification. The compounds will be 
analysed by nuclear magnetic resonance (NMR) spectroscopy to determine their 
attachment positions and assessed as antibody binding targets in SPR vs the 
equivalent amine-bound control. This work will provide new thioether linked 
carboxylic acid derivatives of catecholamines and yield information on the effect 
of attachment position on antibody binding. This work will be of potential future 
use in raising specific antibodies and designing catecholamine-transported drug 
candidates or biomarker compounds. 
1.4.2.4 Gold-Enhanced SPR lmmunosensing of Small Molecules 
Methods for gold nanoparticle enhancement of small-molecule binding to 
antibody will be developed using progesterone as a model compound. 
Technologies for surface immobilisation, colloid stabilisation and regeneration 
will be developed. Different methods of gold linkage for labelling will be 
developed and the effects of different colloid size, assay format and 
immobilization level will be examined. The levels of signal enhancement will be 
systematically compared and assay performance and antibody binding properties 
will be determined in each case and related to enhancement of signal. The 
fundamental binding effects in this system will be examined for each format. 
Chapter 2 - Protein Conjugate-Based 
Immunoassay of Whole Milk Progesterone 
2.1 Introduction 
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Whole milk progesterone concentration is a well-established indicator of the 
bovine estrous cycle239 and has been used extensively to help diagnose 
pregnancy.66 By establishing a progesterone profile with time across the estrous 
cycle for each cow, the farmer can make decisions about timing of artificial 
insemination to coincide with the estrus phase. At the estrus part of the cycle, the. 
progesterone concentrations are at their lowest, often around 0.5 ng/mL,240 so 
being able to accurately identify these low concentrations is very important for 
successful insemination. Furthermore, by comparing milk progesterone 
concentration at the time of insemination at estrus to the concentration 21 days 
afterwards, the analyst can have a possible early indicator of pregnancy status. If 
the cow is still cycling then progesterone levels can be expected to be low again, 
and if pregnant, the progesterone levels will be high (5 ng/mL is one previously 
used cut-off241 ). 
There have been a large number of immunoassay systems developed for milk 
progesterone, particularly in the enzyme-linked immunosorbent assay (ELISA) 
format. These ELISA systems have relied upon immobilisation of antibody to the 
plate and the use of progesterone-enzyme conjugates to compete with free 
progesterone in milk for binding to limited antibodies on the ELISA plate. Such 
conjugates have been demonstrated to be unreliable in their responses due to their 
multiple antigen bindings to one enzyme molecule, antigens obstructing the active 
site of the enzyme and chemical modification affecting the chemical environment 
and thus the performance of the enzyme.92 This all results in quite variable 
enzyme performance, which is a major problem when using the enzyme to label 
un-bound sites, as for this one requires fixed and repeatable enzyme response per 
unit antibody bound. A further major disadvantage is the difficulty of purifying 
these conjugates, as this requires expensive and time-consuming affinity 
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chromatography that never completely purifies the conjugate. Un-conjugated 
residual enzyme will produce significant non-specific signal in the assay thus 
lowering the signal : noise ratio and reducing the sensitivity of the assay. 
It is thus desirable to eliminate the antigen-enzyme conjugate, and this can be 
done by immobilisation of protein conjugate instead and competition between the 
protein conjugate and sample progesterone for limited monoclonal antibody 
followed by a secondary antibody-enzyme conjugate. This not only eliminates the 
antigen-enzyme conjugate but also improves the specificity of the assay by giving 
a higher "antibody cross-section" by having two specific binding interactions 
involved in labelling. 18 This is particularly important in complex biological media 
such as whole milk where other components may bind non-specifically. 
Furthermore, there is much less inconsistency in conjugation as the enzyme and 
antibody are closer in mass and so could be expected to conjugate in a much 
better defined ratio and the secondary antibody-enzyme conjugate is used in 
excess so all antibody-bound material will be maximally labelled. Removal of 
unconjugated enzyme label is potentially simpler as it could be done by dialysis 
with the smaller enzyme label being passed out through the dialysis membrane. 
Further disadvantages with existing methods are that they usually rely on some 
form of pre-dilution of the whole milk or else some extraction of the milk, e.g. use 
of skim milk, de-fatted milk. These steps are highly labour intensive and 
inevitably result in a reduction in the tested concentration of the progesterone. 
Any attempt to remove fat from the milk may also result in inaccurate results as 
the lipophilic progesterone concentrates in the fat. Dilution is mostly done to gain 
consistent binding results with minimised fat interference. It would be 
advantageous if the development of a new format could largely minimise these 
interferences without the need for prior dilution. 
Currently available ELISA systems also suffer from narrow dynamic ranges, 
i.e. the range of progesterone concentrations that the assay can detect. ELISA for 
milk progesterone have ranges no wider than about 1 to 30 ng/mL.89 These ranges 
often are inadequate for fully profiling the estrous cycles of individual cows. 
Many cows have estrous cycle progesterone peaks of around 50 ng/mL and so 
existing assays tend to truncate the tops of the progesterone cycles. At the low end 
of the cycle, progesterone often drops as low as 0.1 ng/mL and so once again the 
lower parts of the curve are often truncated, making determination of the exact 
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point of estrus difficult. Exact determination of estrus is critical in timing of 
artificial inseminations. 
There has been a great dearth of studies on the effects of fundamental changes 
to ELISA formats particularly in the area of protein conjugate-based 
immunoassay. There has been recent evidence that formation of protein 
conjugates to progesterone through the 4-position and the use of linkers up to 18-
atoms significantly improves antibody binding ability in flow-through formats 10•15 
but this has not been applied to the milk medium of ELISA so any medium-
dependent linker length effects are not known. Caproic acid-based linkers may 
perform better in the high lipid medium of whole milk compared to water as they 
are relatively non-polar and so may orientate into the lipid phase. Protein 
conjugates produced in this way using an NHS-mediated coupling have been 
shown to be very consistent in hapten number and so lend themselves well to 
comparative studies of binding abilities. The protein conjugate structures used in 
this study are given in Figure 2.1 
There have also been no reports of progesterone-protein conjugate-mediated 
ELISA of whole milk progesterone, despite protein conjugates being potentially 
more stable as coating agents for long-term storage relative to sensitive antibody 
and despite the ability of such a system to do away with progesterone-enzyme 
conjugates. 
Reported below are the antibody binding relationships with increasing linker 
length up to 25-atoms in the whole milk medium, of a new protein-conjugate 
based ELISA format. The format uses ovalbumin (OVA) protein conjugated to 
progesterone at the 4-position via E-aminocaproic acid linkers attached end-on-
end via amide linkages to increment the linker length. Also reported are the assay 
standard curves and performance parameters for increasing intermediate linker 
length of protein conjugate in the whole milk medium. From this, the first 
reported protein conjugate-mediated ELISA for whole milk progesterone, one that 
requires no pre-dilution of sample, is developed and validated against an 
established RIA method and used to profile estrous cycles in the dairy cow. The 
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Figure 2.1 Progesterone - Linker - Protein Conjugate Structures 
2.2 Experimental 
2.2.1 Materials and Instruments 
2.2.1.1 General 
ELISA plates were Maxisorp (Nunc, Denmark). The buffers and substrate 
solutions were prepared as described in Appendix 1. All water used was ultra 
high quality (UHQ) deionised water. 3, 3', 5, 5'-Tetramethylbenzidine (TMB) 
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was from Roche (Mannheim, Germany) and hydrogen peroxide was from BDH 
(Poole, UK). The plates were read on an Organon Teknika Reader 230 S and 
washed on an Organon Teknika Microwell System Washer 430. 
The monoclonal antibody from Sigma (St Louis, MO, USA) was raised to 
progesterone-7-BSA and was IgGl Clone no. 2H4 derived from the hybridoma 
produced by the fusion of mouse myeloma cells and splenocytes from immunised 
rats (Sigma P1922). The secondary antibody-HRP conjugate was Anti-Rat IgG 
(whole molecule) Peroxidase (Sigma A5795) developed in rabbit using purified 
rat IgG as immunogen and conjugated to peroxidase by protein cross-linking. 
Statistical analysis was done with the aid of Minitab 14.1 Statistical Software. 
Graphing was done with the aid of Origin 5.0 and Sigma Plot 8.0S. RIA was 
done by Dexcel Ltd. using a Coat a Count Progesterone RIA (Diagnostic Products 
Corp. Los Angeles, USA) validated for milk.242 
2.2.1.2 Milk Samples 
Whole milk samples were taken from New Zealand dairy cows of a variety of 
breeds but principally Friesian Holstein. All whole milk samples were collected 
directly from the cow at milking time in plastic sample vessels and were 
immediately preserved with potassium dichromate preserving tablets and then 
frozen. Once thawed (at 4 °c) the samples were used for measurement within 
three days and were not re-frozen. Blank whole milk was obtained directly from a 
cow 14 days after giving birth and was found by RIA to have negligible 
progesterone concentration. This milk was then spiked with a small volume of 
aqueous progesterone to give a 1 µg/mL stock solution, which was then serially 
diluted with the zero progesterone milk to give all the required standards for the 
assays. Milk standards were frozen until use and never re-frozen. 
2.2.1.3 Progesterone- OVA Conjugates 
Progesterone was conjugated via its A-ring 4-position through 
heterobifunctional caproate linker units linked end-on-end to produce linkers of 4-
, 11-, 18- and 25-atoms. The progesterone-ovalbumin conjugates used in this 
section were synthesised exactly according to the procedures laid out in the 
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author's Masters thesis 10 and the concomitant paper. 15 The hapten numbers for 
these conjugates were exactly the same as those previously reported10• 15 and are 
reproduced here in Table 2.1 as determined by matrix assisted laser desorption 
ionisation mass spectrometry with time of flight detection (MALDI-TOF). The 
protein conjugates will now be referred to by their numbers: C-1-4-atoms, C-2-
11-atoms, C-3- 18-atoms and C-4 - 25-atoms in the intermediate linker. 
Table 2.1 Hapten Numbers of Progesterone Protein Conjugates 
Progesterone-OVA Average MW Hapten Number 
Conjugates 
OVA 44270 0 
C-1 45850 3.9 
C-2 46450 4.1 
C-3 46830 4.1 
C-4 45980 2.3 
The lower number for the 25-atom conjugate occurs because the progesterone-
linker derivative is not very soluble in the polar solvents needed for conjugation. 
2.2.2 Antibody Binding Studies of Progesterone-Protein Conjugates in 
the Whole Milk Medium 
Standard 96-well flat microtitre plates were coated with the progesterone -
OVA conjugates C-1, C-2, C-3 and C-4 at protein concentrations of 0, 0.1, 0.5, 
0.75, 1 and 5 µg/mL in 0.05 M bicarbonate buffer, pH = 9.6 with eight replicates, 
100 µL per well except for the blank wells that had no antibody coated. The 
plates were shaken at 400 rpm for 2 h and then refrigerated overnight. The plates 
were then drained, washed with 3 x 300 µL of phosphate buffered saline with 
Tween-20 pH= 7.4 (PBS/f) and blotted dry. The plates were then blocked with 
OVA (1 %w/v in PBS/f, 200 µL per well) and the plates shaken at 400 rpm for 2 
h. The plates were then drained and washed as before and PBS/f (75 µL/well) 
was added followed by the blank milk (25 µL per well, no prior dilution) added to 
the plates. Monoclonal antibody was added (5 µg/mL in PBS/f, corresponding to 
approximately 1/1600 dilution; 100 µL per well). The plates were then shaken at 
83 
400 rpm for 1 h at room temperature. The plates were then drained and washed as 
before and IgG - horseradish peroxidase (HRP) secondary antibody conjugate 
(1/12500 dilution in PBS/T, 200 µL / well) was added and the plates shaken (400 
rpm, 1 h). The plates were then washed and drained as before and TMB colour 
substrate added (125 µL of 1.5% H202 solution in water and 125 µL of 1 mg/mL 
TMB in dimethyl sulfoxide (DMSO) were added to 12.5 mL of 0.1 M sodium 
acetate buffer pH= 4.0) (100 µU well) and the plates shaken immediately (400 
rpm, 5 min). The plates were developed in the dark before stopping solution was 
added (2 M sulfuric acid, 50 µU well). The plates were then read at 450 nm. 
Four replicates were done of each point. 
2.2.3 Assay Curve Determination for Progesterone-Protein 
Conjugates in Whole Milk 
Protein conjugates C-1, C-2, C-3, and C-4 were immobilised on an ELISA 
plate (1 µg/mL in 0.05 M bicarbonate buffer, pH = 9.6) by shaking for 2 h and 
then refrigerated overnight. The plates were then drained, washed with 3 x 300 
µL of PBS/T and blotted dry. The plate was blocked with OVA (1 %w/v in 
PBS/T) by shaking for 2 h. The plates were then drained and washed as before 
and PBS/T (75 µL / well) was added to the plate followed by milk standards (0, 
0.01, 0.1, 1, 5, 10, 100, 1000 ng/mL progesterone, 25 µUwell). The plate then 
had monoclonal anti-progesterone (5 µg/mL in PBS/T, 100 µL / well) added 
immediately. The plate was shaken for 1 h at room temperature before washing 
(as before but six times) and then adding IgG - HRP (1/12,500, 200 µL / well) 
and shaking for 1 h at room temperature. The plate was then washed (as before 
but six times) and colour development and reading done as above. The standards 
were run in triplicate or quadruplicate. 
2.2.4 Assay Validation 
The ELISA tests for estrous cycling and assay validation were done as for the 
standard curves but with actual milk samples as well as standards. The standards 
used on each plate were 0, 0.1, 1, 2.5, 5, 7.5, 10, 50 ng/mL, and 25 ng/mL where 
needed. Three or four replicates were done of each point for the samples and 
three for the standards. The intra-assay coefficient of variation was calculated as 
the mean of the co-efficient of variation of binding response of triplicates of the 
same sample on the same assay plate (used 22 separate samples across the 
progesterone range of 1.6 to 21 ng/mL). The inter-assay coefficient of variation 
was calculated as the mean of the coefficient of variation for replicates of the 
same sample across different runs (three different assays on separate plates of six 
different samples). The % recovery was defined as the concentration of the 
ELISA determination as a percentage of the actual theoretical progesterone 
concentration from the serial dilution of spiked progesterone standard at five 
concentrations (0, 1, 2.5, 5, 25 ng/mL) with three replicates per concentration. 
The comparison with RIA results was made over 45 samples with the RIA being 
conducted by Dexcel within 24 h of the ELISA being done and assayed in three 
batches, with most assayed as one batch. 
2.2.5 Estrous Profiling and Pregnancy 
Two cows were selected and had their estrous profiles followed by the ELISA 
and RIA for two complete cycles with twice weekly sampling, i.e. sampling 
intervals of three or four days. A set of 12 cows were analysed for pregnancy by 
the ELISA by assessing milk taken within three days of servicing with a bull and 
then again at 17-24 days after servicing using the standard assay validated 
method. Veterinary ultrasound pregnancy tests were conducted 49-88 days after 
service and used as a standard for comparison to the ELISA predictions. 
2.2.6 Statistical Methods 
All determinations were made to the number of replicates stated above. The 
mean, standard deviation and coefficient of variation were taken for all samples. 
Absorbances were taken as outliers where they lay outside two standard 
deviations of the mean of the other replicates. Standards were run with every 
plate and used to formulate a standard curve for every sample plate. To determine 
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the standard errors (SE) and standard deviations (SD) of the blank-corrected 
absorbances the standard errors and standard deviations were combined for 
standard and sample absorbances with the standard deviation or standard error in 
the blank by the method of least-squares. Standard curve data were fitted to a 4-
parameter logistic relationship and errors in the concentration were determined by 
the use of the formulaic approximation given in Figure 1.16. 
The detection limits were calculated as the concentration reading 
corresponding to the absorbance reading that is 2 SD of the absorbance reading of 
the blank below the mean absorbance of blank milk. This value is a value widely 
used in statistical considerations of detection limit.22• 128• 129 As the detection limit 
point is a theoretical point on the curve of best fit there is no actual standard error 
value ready to be used directly in determining detection limit error. It is therefore 
necessary to approximate the error in this point. This may be done by production 
of a standard error vs concentration plot, which is generalised for use in all the 
plots. This method is certainly appropriate if the standard errors are showing a set 
pattern with changing concentration and indeed this is normally the case, with the 
error increasing with increasing binding response. This pattern has however not 
been observed with this ELISA format nor has any other pattern been observed. 
This suggests that the error is more dependent upon the actual sample used and so 
it would be more accurate to use the error in the point on the given standard curve 
closest to the detection limit. It would not be appropriate though to use any point 
that was not in the active region of the curve, i.e. was reading 100% or close to 
0% as these points are out of the dynamic concentration range. This method was 
applied to the calculation of standard errors. 
Binding absorbances were compared using the student t-test (two-tailed unless 
otherwise stated) as were the detection limits of the assay curves to determine if a 
significant difference existed. All error bars represent +/- one SD of the mean. 
Correlation of the ELISA with the RIA was determined by fitting a linear 
correlation and determining the equation and R2 using Origin 5.0 graphing 
software. The coefficient of variation of the slope of the correlation line was 
determined as a measure of spread of the data about the correlation line. Errors 
quoted in the text are standard errors unless otherwise stated. 
2.3 Results and Discussion 
2.3.1 Progesterone-Protein Conjugate Antibody Binding Studies in the 
Whole Milk Medium 
Binding studies were conducted on all four conjugates using the same ELISA 
format that was eventually developed for the whole milk samples. This format is 
illustrated schematically in Figure 1.4, part B. By using blank milk in place of real 
milk samples it was possible to accurately simulate the medium that the protein 
conjugates will operate in under the ELISA conditions. By relating binding 
strength as measured by the enzyme catalysed colour absorbance to the 
concentration of protein conjugate used, a clear picture can be obtained of the 
binding of the antibody to the protein conjugates and the changes in binding that 
occur as the protein conjugate coating concentration is altered. From such studies 
one can determine the optimum coating concentration, that is the concentration 
that gives maximum binding but where the antibody is not in excess, so changing 
the concentration of free antibody available to bind a fixed level of conjugate will 
lead to significant change in signal and hence good sensitivity. In other words, 
high binding signal is preferable but the antibody must not be in excess relative to 
the coating protein conjugate. Figure 2.2 shows the plot of antibody binding 
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Figure 2.2 Plot of Antibody Binding Signal (Absorbance) vs Protein Conjugate 
Concentration (µg/mL) C-1 +, C-2 •. C-3 •. C-4 X. 
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All conjugates showed a sharp rise in binding response from O µg/mL 
conjugate up to maxima at 0.5 µg/mL for all conjugates. This increase in binding 
response is due to increasing conjugate concentration enabling more antibody to 
bind. From this one can conclude that the antibody is in excess up to these 
maxima points, i.e. conjugate binding sites are maximally bound. All conjugates 
then show a sharp decrease in signal by -35% for conjugates C-1, C-2 and C-3 
and by -90% for conjugate C-4. This is most likely due to the conjugates 
crowding together on the plate and preventing antibody binding through steric 
constriction. Clearly the antibody is no longer in excess. The drop is particularly 
pronounced in conjugate C-4 which is possibly due to the longer linker producing 
more substantial steric crowding of the binding sites with more linker-antigen 
folding occurring. From 1 µg/mL to 5 µg/mL there is only a very slight drop in 
binding for conjugates C-1, C-2 and C-3 and no drop for C-4 suggesting that an 
equilibrium has been established at the surface whereby no more conjugate can 
bind as all available spaces are taken and steric constriction of binding is no 
worse. Conjugate C-4 has substantially less binding than all the other conjugates 
and a principal reason for this is that it has a lower hapten number than the others. 
This lower hapten number arose due to the poor solubility of the three-caproic 
acid unit linker derivative in water, making conjugation more difficult. To 
prevent this decrease in progesterone attachment, more polar linkers would need 
to be used, but these will not be so lipophilic and so therefore may not extend into 
the milk medium so well. 
The binding curves have shown that overall antibody binding increased with 
increasing linker length in the whole milk medium up to 18 atoms. 1 µg/mL 
coating concentration appears to be the best concentration to use, as at this 
antibody concentration one has sufficient conjugate coating to bind the available 
antibody, i.e. the antibody is not in excess and small variations in conjugate 
coating concentration are unlikely to cause substantial variations in response 
allowing more consistent plate production. 
At 1 µg/mL coating concentration, increasing the linker from 4 to 11 atoms 
enhanced binding by 32% and incrementing from 11 to 18 atoms produced a 
further increase of 18% at 1 µg/mL. However, extending the linker to 25 atoms 
decreased binding by 96% compared with the 18-atom linker at 1 µg/mL. This 
drop is partly due to the lower hapten number caused by poor linker solubility, but 
cannot be completely explained by this. A further reason may be that the linker is 
folding over the progesterone and preventing approach to the antigen by the 
antibody. 
The un-paired t-test was used to decide upon statistical differences in sets of 
ELISA data. The null hypothesis (Ho) in all cases was Ho µ 1 (mean of data set 1) 
= µ2 (mean of data set 2) and cut-off was a. (significance level) = 0.05. 
Determination of whether the data should be pooled in a pooled t-test, i.e. whether 
variances are equal, cr21 = cr22, was determined by the use of the F-distribution 
table. All results are quoted by using their P-value, taking into account whether 
the t-test is one or two-tailed. The two-tailed t-test is used more commonly here, 
though one-tailed t-test can also be validly used to determine if one value is 
significantly below or above another. The standard error in the antibody binding 
figures was determined by the least-squares combination of the standard errors of 
the blank and individual binding values at 1 µg/mL concentration. The blank was 
set as the same for all curves. A two-tailed, un-paired t-test was used on each of 
the nearest values. More comparisons are not necessary as all these t-test 
comparisons show greatly significant difference and thus all other comparisons 
will also result in significant differences. In all cases the P-values are <0.0001 so 
there can be no doubt that there is a significant difference between all binding 
points compared. The data for 5 µg/mL coating concentration likewise shows all 
significant differences and the same order of conjugate binding as for 1 µg/mL. 
It can be hypothesised that with increasing linker length higher binding is seen 
because of the longer linker enabling better access to the conjugated progesterone 
in whole milk. The linker is lipophilic so speculatively it could be projecting the 
progesterone out into the lipid milk medium quite effectively. These patterns 
were not observed in previous studies for the aqueous medium where all 
conjugates except C-4 showed identical binding pattems.10•15 There is clearly a 
medium effect in operation here and speculatively one could suggest that the 
lipophillic linkers are projected much better by the lipid-laden milk than by the 
polar water medium and so linker length effects in progesterone / antibody 
binding are evident in milk but not in aqueous medium. 
2.3.2 Assay Parameters With Changing Linker Length 
As well as considering the antibody binding patterns it is also important to see 
how these changes are reflected in the performance of the assay constructed 
around these conjugates. The assays were set up exactly as it was intended to run 
the final fully validated assay. The curves were determined over a broad range to 
fully define the active regions and completely cover all physiological ranges. The 
range chosen was 0.01-1000 ng/mL. The assay curves for the conjugates are 
given in Figure 2.3. 
The assay curve plot shows clearly how the assay curves differ as the linker 
length is increased. All the conjugates give full inhibition at 1000 ng/mL. The 
changes come in the limits of detection of the curve. Clearly, conjugate C-3 
reaches saturation surface binding at lower progesterone concentration than 
conjugate C-2 as does conjugate C-2 relative to conjugate C-1. This therefore 
causes the assay curves to slope back more, producing a shallower assay slope and 
thus a broader active range for the assay. This has the effect of changing the 
detection limits of the assays and this is reflected in the assay parameters given in 
Table 2.2. 
One can see a clear pattern of decreasing limit of detection (LOO) with 
increasing linker length up to 18-atoms. Curiously this does not cause the upper 
concentration limit to decrease with the detection limit, and so, as the detection 
limit decreases the assay curve slope also decreases. The inhibitory concentration 
at 50% bound (IC50) figures of the curves showed there has been some shift in the 
curves despite the near identical upper concentration limits, with conjugate C-1 
being much higher than C-2 and C-3, with C-4 even higher again. The IC50 values 
were calculated as a parameter of the curve fitting by four-parameter logistic. 
Conjugate C-4 was not plotted in Figure 2.3 as it does not demonstrate significant 
inhibition until 30 ng/mL and so does not plot well. The antibody binding to this 
conjugate is so low that no practical assay could be constructed around it. The 
detection limit pattern was confirmed by analysis using student's t-test. These 
results showed that the detection limits for C-2 and C-3 were highly significantly 
different (P < 0.001). The high detection limit errors in C-1 and C-4 were caused 
by low curve slope and low antibody binding respectively and made some 
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detection limit comparisons with them statistically difficult, though by one-tailed 
t-test, the 18-atom linker detection limit is lower than both the 4- and 25-atom 
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Figure 2.3 Assay Curves of C-1, C-2 and C-3 as a logistic/ log plot of % Bound 
vs Progesterone Concentration (C-1 R2 = 0.999, C-2 R2 = 0.986, C-3 R2 = 0.991). 
Table 2.2 Assay Parameters 
Conjugate LOD (ng/ml) IC50 (ng/ml) 
C-1 2.7 ± 0.9 25 ± 1.2 
C-2 0.87 ± 0.08 3.5 ± 0.25 
C-3 0.089 ± 0.016 3.4 ± 0.68 
C-4 30 + 10 89 + 0.62 
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This pattern combined with the antibody binding data suggests that the 
detection limit enhancement is probably due to the higher antibody binding 
enabling higher signal: noise ratio and thus increasing the sensitivity of the assay. 
It does not appear that any higher steric preference of the antibody to bind the free 
progesterone over the conjugate has occurred, which might have resulted in a 
greater inhibition of antibody binding and a lower detection limit through moving 
the entire curve to lower concentrations. This is supported by the curves all being 
the same at 1000 ng/mL progesterone. Clearly there are milk medium-dependent 
effects here also as the previous studies done in aqueous medium have shown no 
difference between conjugate assay performance in the ELISA format with 
increasing linker length. 10•15 Once again, the better performance can be attributed 
to the lipophilic nature of the linker allowing better projection of progesterone in 
milk rather than in aqueous medium. These patterns are of great interest in the 
fundamental study of enzyme immunoassay (EIA) formats and dynamics as they 
suggest that tailoring of the linker to the medium in which the assay is conducted 
can allow for higher antibody binding responses and better assay performance. It 
was decided to validate and use the assay based on conjugate C-3 as it had the 
best detection limit, good coefficients of variation and covered the physiological 
range of progesterone in milk. 
2.3.3 ELISA Method Development 
In developing the ELISA format there were several factors that needed to be 
included in the assay. The first of these was that the milk must be delivered direct 
to the plate without pre-dilution. This is a major problem to solve as milk fat is as 
high as 15% w/w in whole milk and the assay must be robust enough to produce 
good results despite high fat levels that have the capacity to interfere with the 
antibody binding. By adding PBS/T first to hydrate the wells, and then the whole 
milk sample followed by antibody, it was possible to effect a final 1/8 dilution in 
the microwells without pre-diluting the milk. This dilution was enough to achieve 
consistent binding results from the milk samples whilst not significantly 
increasing the labour involved in the assay and not diluting the milk so much that 
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detection was not possible. The assay is quite rapid with the binding and 
detection processes being over within three hours from a pre-coated and blocked 
plate. The washing steps in the assay were particularly important as they ensured 
that the high fat milk was completely cleaned from the wells before adding 
secondary antibody to ensure minimal non-specific binding of enzyme label. A 
standard range of 0.1 - 50 ng/mL was decided upon as this covers the whole 
normal physiological range and the use of regular points of l, 2.5, 5, 7.5 and 10 
ng/mL ensures good coverage of the central range of concentrations for estrous 
cycle profiling. 
One of the principal benefits with this assay is that the active region of the 
assay is quite broad with a linear range of 0.1-100 ng/mL (r = 0.99). This allows 
the whole estrous cycle to be plotted from trough to peak in one assay, rather than 
having truncated physiological progesterone plots or needing two assays to cover 
the range. This represents a substantial increase in convenience for the analyst, 
saving time, sample and money. Furthermore, by immobilizing a carrier protein 
conjugated to the antigen, one produces a plate with a much longer lifetime than if 
antibody was immobilised. Antibody-immobilized plates can be quite easily 
destroyed if not stored correctly, and usually have at most a six-month lifetime. 
2.3.4 Assay Validation 
The ELISA then had to be validated to ensure that the results obtained were 
consistent and accurate compared to existing validated methods. The first test 
was the co-efficient of variation for replicates of a single sample within a plate 
and between plates. The within-plate or intra-assay coefficient of variation was 
determined as the average of 22 different samples each with three replicates. This 
gave 5.5%, which compares favourably with other ELISA plate systems for milk 
progesterone22•74 and indicates consistency of determination between wells. The 
lack of pre-dilution has not adversely affected the repeatability between replicates. 
The between-plate or inter-assay coefficient of variation was determined from six 
different samples each repeated for a total of three times. The average coefficient 
of variation (CV) was 12.5%, which also compares well to other existing ELISAs. 
The inter-assay CV is higher than the intra-assay as differences can occur between 
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plates that affect the results and increase the errors. These figures indicate that the 
ELISA is indeed adequately precise in its determinations and that the wide active 
region of the assay has not compromised the precision. 
Validation to determine accuracy was also needed. The first of these was the 
determination of the% recovery, which measures how close the determinations of 
the standards are to the spiked concentrations. This was done for multiple 
concentrations, four replicates each and the results are summarised in Table 2.3. 
Table 2.3 % Recovery Figures for the ELISA 
Actual Progesterone Determined Progesterone Recovery (%) 
Concentration (ng/ml) Concentration (ng/ml) 
1 1.11 111 
2.5 2.78 111 
5 4.91 98 
25 24.9 100 
50 44.7 90 
This range is quite comparable to other milk progesterone ELISA,22•74 with an 
average recovery of 102%. Greater deviations from 100% recovery seem to come 
at points distant from the ICso of the curve as expected when the curve slope 
decreases. The best way of determining accuracy is by comparing the method to 
an already established and validated assay. For milk progesterone this is RIA, 
which is as close to a "gold standard" for milk progesterone determination as is 
possible, having been extensively developed and tested for decades. The RIA 
used in this case has been previously validated for use in milk progesterone 
determinations242 and was conducted by an independent professional commercial 
laboratory (Dexcel). The ELISA was compared to RIA for 45 samples and a 
scatter plot of commercial RIA vs EIA measurements was constructed and a linear 
regression line fitted, which enabled calculation of the coefficient of variation in 
the slope of the line. This plot is given in Figure 2.4. 
The line can be described by the equation: RIA = 0.81EIA + 1.1, so the 
RIA results whilst giving linear fit with the EIA results, are somewhat lower 
overall than those determined by the EIA, differences having been seen in other 
studies also.22•240 The correlation is very good with an r-value of 0.94 and a P-
value of <0.0001. This indicates that the EIA and RIA results have a linear 
relationship, which is an indication of a good level of accuracy. The percentage 
error in the slope of the regression line was 5.6% indicating that the data is quite 
tightly spread about the line of regression, so the relationship between RIA and 
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Figure 2.4 Correlation Scatter Plot of RIA Progesterone Determinations (ng/mL) 
vs ELISA Progesterone Determinations (ng/mL) 
From these four different parameters one can conclude that this ELISA has 
good precision and accuracy and thus is validated for the determination of 
progesterone in whole milk. The assay method may therefore be applied reliably 
to real determinations of endogenous progesterone in bovine whole milk. 
2.3.5 Determination of Estrous Cycles in the Dairy Cow 
Two cows had their milk analysed for progesterone using the ELISA to form a 
hormonal profile through two whole estrous cycles with determinations twice 
weekly, i.e. three or four days between samples. These plots are given in Figure 
2.5. 
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The progesterone cycles are clearly visible in the plots, with cow 1 cycling 
between O and 25 ng/mL and cow 2 between O and 12 ng/mL for ELISA 
determinations. The ELISA shows that the cows are cycling with a 20-21 day 
cycle as expected. For comparison the RIA results are superimposed on the EIA 
results and one can see that there is overall a close agreement between them 
further validating the assay. One can see how variable the amplitudes of the 
progesterone waves are between cows further emphasising the need for individual 
profiles for each cow. Larger error bars on some points reflect that these points are 
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Figure 2.5 Plots of Progesterone Concentration in Whole Milk (ng/mL) vs Time 
(Days) for Two Cows, 1 top, 2 bottom. + ELISA, • RIA (Diagnostic Products 
Corp.) 
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2.3.6 Pregnancy Prediction by ELISA 
It follows that if the estrous cycle progesterone levels can be determined for 
estrus prediction then the assay should also function as an aid in pregnancy 
prediction. To this end a small herd of 12 cows was monitored at time of 
servicing with a bull and then around 21 days later when the progesterone should 
be back down to insemination sample levels if the individual cow has failed to 
conceive or progesterone levels will be high if it has conceived successfully. The 
measured progesterone levels are given in Table 2.4. 
Table 2.4 Pregnancy Assessment Results for 12 cows Using Multiple 
Progesterone Determinations (ng/mL Whole Milk Progesterone) 
Time 1 2 3 4 5 6 7 8 9 10 11 
(days) 
0 1.9 <0.1 <0.1 4.8 <0.1 <0.1 6.1 <0.1 <0.1 <0.1 <0.1 
17 5.5 <0.1 
21 <0.1 16.9 29.4 4.3 4.5 <0.1 
22 3.8 
24 5.2 5.2 6 




Of the 12 cows, nine were inseminated when near estrus as determined by very 
low assayed levels of progesterone ( <0.1 ng/mL). The other three were assayed at 
concentrations between 1.9-6.1 ng/mL, i.e. the lower half of the cycle. As none of 
these cows were fully estrous-profiled these concentrations may be reasonably 
close to the estrus trough. A concentration of 5 ng/mL at around 21 days was 
used as the arbitrary cut-off for pregnancy. Tests done at 17-24 days revealed that 
five of the cows were definitely pregnant using this criterion, three cows were 
definitely not pregnant and the status of four was uncertain though were 
tentatively assigned as pregnant. Further testing at 42 days was done of one 
positive test, one negative test and one uncertain test as determined at 17-24 days. 
These later tests confirmed the positive and negative determinations and 
suggested that the uncertain one was pregnant. Assuming all uncertain results as 
pregnant then the test would have predicted correctly for all the cows studied as 
otherwise determined by veterinary ultrasound. This is a very rough test and by 
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no means a perfect test for pregnancy as progesterone alone cannot be used as a 
complete pregnancy determination, but is a further indication of the efficacy of 
this ELISA technique. 
2.4 Conclusions 
The use of a protein conjugate-based ELISA format for determination of milk 
progesterone has major advantages over progesterone-enzyme conjugate-based 
assays. This format eliminates the need for enzyme-analyte conjugates, which 
have problems of inconsistent enzyme activity and conjugation and difficulties of 
purification. The format also enables two antibody recognition events to be 
employed to further increase specificity. The binding of monoclonal antibody to 
protein-progesterone conjugate increases with increasing linker length up to 18-
atoms in the whole milk medium. The assay detection limits decrease with 
increasing linker length up to 18-atoms. These linker effects are seen in whole 
milk but not in aqueous medium and may be due to the lipophilic nature of the 
linkers. 
A valuable new protein conjugate-based ELISA has been developed around 
conjugate C-3. The ELISA obviates the need for any pre-treatment or predilution 
of the milk and allows a wide dynamic range for clear estrous cycle profiling. 
The ELISA was validated against RIA, and tested for variability and found to be 
acceptable. The ELISA was applied to profiling of estrous cycles in dairy cattle 
and in a rough test to aid early pregnancy diagnosis and showed good correlation 
in both cases against established techniques. 
These results show that there are medium effects in the binding and 
performance of protein conjugate-based immunoassay and indicate the importance 
of a fundamental understanding of the immunoassay format being applied. This 
ELISA system is the first reported protein-conjugate based ELISA in bovine 
whole milk and offers a generic format that may be of great use for other small 
molecules in high-lipid media. 
Chapter 3 - Thioether Derivatives of the 
Estrogens - Synthesis and Antibody Binding 
Studies 
3.1 Introduction 
The estrogens are an extremely important class of steroid hormones and much 
research has been devoted to developing immunoassay systems for these 
compounds. As well as studying estrogen derivatives as immunosensing agents 
through conjugation to enzyme, chemiluminescent or fluorescent labels, and 
conjugation to proteins for raising antibodies, there has been much study of 
estrogens as carriers for drugs directed to specific tissues expressing estrogen 
antibodies or receptors. It is therefore of great importance to develop estrogen 
conjugation technology to ensure that the optimum antibody or receptor binding 
for the estrogen is achieved. In order to do this it is necessary to consider the 
effects that changes to the conjugate structure may have on the ability of the 
antibody or receptor to bind to the target estrogen. 
One of the key conjugate parameters is the position at which a linker is 
attached to the steroidal backbone. If the point of attachment obstructs a major 
functional group or is bonded through an existing functional group, then this may 
greatly interfere with the specificity of the binding and the level of recognition 
and binding to the antibody or receptor. The position of attachment must also be 
considered in relation to the position of attachment used in the conjugate to which 
the antibody is raised. Site heterology, i.e. use of a different position of 
attachment to the one used in raising the antibody, is important for maximising 
recognition. In studies of the non-aromatic steroid progesterone, it has been found 
that in flow-through binding assay formats the A-ring 4-position of the steroid 
offers higher binding than does the ?-position and offers the further advantage of 
providing stereochemical purity due to the 4-5 unsaturation in the A-ring. 10•15 
The estrogens have generally similar structures to the progesterone family with 
the major difference being the presence of an aromatic A-ring phenol instead of 
the non-aromatic 4-5 unsaturated 3-carbonyl ring. Attachment to progesterone at 
the 4-position has been previously done by bromination at the 6-position followed 
by methanolic KOH reflux with 3-mercaptopropionic acid. 117 This method cannot 
be applied exactly to the estrogens but suggests a method by which thioether 
bridging could be achieved. Formation of the bromoestrogens is well established 
including bromination at the 4-position. By formation of the 4-bromo derivatives 
it should be possible to effect an SRNl-type substitution of the bromo derivative to 
produce the corresponding thioether-bridged acid-terminating derivative. 
Thioether bridging by this method has never been attempted before for the 
estrogens. 
Previous studies have attached the linker unit via the Mannich reaction for 
protein conjugation. This is done in a one-step process where there is no control 
over the position of attachment with both 2- and 4-positions being possible. 
Production of the 4-position thioether derivative of estradiol via the 4,5-epoxide 
has been previously reported107 but proceeds through a complex three-step process 
as detailed in Chapter One. Once the thioether linker acid compound is attached 
then one can modify the linker to make it more water-soluble by attachment of 
versatile oligoethylene glycol (OEG) chains of varying lengths, which also 
provide a means of extending the linker length. OEG chains also can be 
connected quite stably via amide linkages and are non-immunogenic, their length 
providing an inert means of distancing the target estrogen from the conjugated 
compound, whether it be a drug, signal label or immunogen carrier protein. 
The conjugated derivatives thus produced, can be studied conveniently by SPR 
through the BIAcore technology, as the flow-through conditions of the BIAcore 
enable controlled studies of the binding interactions in an environment not 
dissimilar to that in the human body, particularly the flow-through nature of the 
environment. Binding in real-time enables the analysis of binding kinetics and 
shows clearly the differences between different conjugation techniques and linker 
types. 
SPR has been used to study binding interactions of estrogen steroids 
conjugated to chemiluminescent labels and in the study of binding interactions 
between steroid derivatives and estrogen receptors. 162•163 There has been a 
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deficiency of studies that systematically use SPR to probe the effects of changing 
conjugation position on the ability of an antibody to bind the hapten. To produce 
effective biosensors and to further understand the ways in which antibodies 
interact with target molecules, one must understand the effect of conjugation 
position and thus modification of the antigen on the levels of antibody binding 
that can be obtained. Higher antibody binding will allow greater signal strength in 
optical assays, which reduces signal: noise ratio and therefore increases the signal 
sensitivity of the assay. In inhibition assays where the antibody is pre-incubated 
with free sample antigen this higher signal should decrease the limit of detection 
(LOO) by enabling better discrimination of low antigen concentrations from the 
blank or otherwise by enabling a lower monoclonal primary antibody 
concentration to be used. 
The development of new sensitive estrogen assays is very important as most 
estrogen assays are restricted to ELISA, which whilst being quite sensitive is 
labour-intensive, laboratory-based and time-consuming. SPR-based assays offer a 
means of determining estrogen concentrations in an automated system, which can 
be potentially adapted for use outside of the laboratory. BIAcore systems provide 
a convenient means of developing such assays. SPR however suffers from inferior 
sensitivity compared to ELISA. 
Studies of antibody binding to conjugated estrogens are not only critical for 
biosensor design, but also for understanding how such conjugates are recognised 
by antibodies in vivo. With the growing development of drug conjugate 
technology for specific delivery to tissues in the human body, an understanding of 
how such conjugates bind to proteins is essential to optimise the conjugate 
production. Conjugation of anti-cancer drugs to estrogens to target estrogen 
receptor bearing cells for the treatment of breast cancer is but one example of the 
emerging applications of estrogenic conjugates to the treatment of disease. 
Clearly, designing conjugates to maximise such binding interactions is of great 
interest. 
Reported below is the synthesis and characterisation of 17~-estradiol and 
estrone thioethers synthesised through aromatic substitution of the corresponding 
bromoestrogens at the 4-position. Also reported is a method for production of 4-
bromoestrone without need of debromination of the 2,4-dibromoestrone 
derivatives. These thioether-linked derivatives are then used to produce OEG 
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chain derivatives of varying chain length, one of which is then applied in SPR 
binding studies by coupling to the sensor chip surface, and compared to 
conjugations via the 3-hemisuccinate and 2-position Mannich reaction as control 
comparisons. 
3.2 Experimental 
3.2.1 Materials and Instruments 
3.2.1.1 General 
17~-Estradiol was purchased from ICN (Aurora, USA, 101656); estrone was 
purchased from Acros Organics (New Jersey, USA, 117840050). Di-t-butyl 
di carbonate and 4, 7, 1 O-trioxa-1, 13-tridecanediamine were purchased from Fluka 
Chemie (Buchs, Germany) and triethylamine from BDH (Poole, UK). All other 
reagents were purchased from Aldrich Chemical Company (Milwaukee, WI, 
USA) and were used without further purification. N-Bromosuccinimide was 
purchased fresh at 99% and used without recrystallisation. Silica gel was Merck 
60A, grade 9385, 230-400 Mesh. Thin layer chromatography (TLC) was run on 
silica gel 60 F2s4 plates, aluminium-backed. All solvents used were of analytical 
grade for synthesis and purification and of Hipersolv chromatography grade for 
HPLC analysis. Molecular sieves were of type 4A 4-8 Mesh. Petroleum spirit 
used was 60-80 °C bp range. 
Melting point determinations were done using a Reichert Thermopan 
instrument and were uncorrected. Proton and carbon-13 NMR spectra were 
acquired using both a 300 MHz Bruker AC300 FT-NMR and a 400 MHz Bruker 
Avance DRX400 FT-NMR and Dept 135 spectra were run also. Chemical shifts 
(6) are reported in parts per million (ppm). Electrospray mass spectra were 
acquired using a VG Platform II Electrospray Mass Spectrometer (ES-MS) 
instrument in either positive or negative ion mode as appropriate. Analytical 
reverse phase high performance liquid chromatography (RP-HPLC) was done 
using a Sphereclone C8 3 µm column ( 100 x 4.60 mm) on a Shimadzu instrument. 
High resolution fast atom bombardment mass spectrometry (FAB-MS) and high 
resolution electron impact mass spectrometry (El-MS) was done by Michael 
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Walker of Auckland University using a VG 70-SE mass spectrometer with 
MASPEC 2 data analysis software. BIAcore SPR analysis was done using a 
BIAcore 3000 instrument at the School of Science and Technology, Waikato 
University with CMS sensor chips (research grade). Monoclonal anti-17Ji-
estradiol antibody was from US Biologicals (E3550-29) and was raised to 
estradiol-6-CMO-BSA conjugate as mouse anti-human. It had a calculated affinity 
constant of -1 x 1010 UM. The whole antiserum polyclonal anti-estradiol 
antibody was from Sigma (E2885) and raised using l 7Ji-estradiol-6-BSA 
conjugate from rabbit and stored in lyophilised form. The whole antiserum 
polyclonal estrone antibody was from Sigma (E3135) and raised using estrone-6-
thyroglobulin from rabbit and stored in lyophilised form. Secondary antibody was 
anti-mouse IgG (whole molecule) raised in rabbit as the IgG fraction of the 
antiserum in aqueous solution (Sigma, M7023). Immobilisation amine coupling 
kit was from BIAcore (BR-1000-50) consisting of 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and NHS solutions. 
BIAcore experiments were run using HEPES buffered saline with EDTA and P-
20 (HBS-EP) as running buffer, see Appendix 1. For full details of the statistical 
methods and graphical fittings used, see Chapter 5. All error bars on graphs are 
+/- 1 SD and all errors given in the text are standard errors. 
3.2.1.2 HPLC Methods/or Determination of Compound Purity 
All HPLC analysis was performed by injection of the sample of the compound 
in question run according to the conditions detailed in each experimental section. 
The injection volume was the maximum that the column could withstand without 
overloading. The product peak was collected entirely to give the pure standard, 
which was then dried in vacuo. The pure standard and dried raw sample were 
then both made to 1 mg/mL concentration and three or four replicate injections of 
10 µL each of both standard and raw sample were made. The peak integrals were 
calculated using the computer program and averaged. The percentage purity was 
determined by: % Purity= mean raw sample area x 100 
mean standard area 
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3.2.2 Synthesis of Estrogen Thioethers1 
3.2.2.1 4-Bromo-17P.estradiol (1) 
This was adapted from a previous method156 that did not itself stipulate molar 
ratios of reactants or volume of solvent. 17{3-Estradiol (800 mg, 2.94 mmol) was 
dissolved in dry EtOH (40 mL, dried over molecular sieves) and N-
bromosuccinimide (522 mg, 2.94 mmol in 15 mL of dry EtOH) was added drop-
wise to the vigorously stirring solution. A white solid formed within 1 h of 
reaction and the mixture was stirred for a further 24 h. The solid was removed 
and recrystalised from CHCh to yield 1 as a white crystalline solid. Yield: 55% 
(572 mg, 1.63 mmol). Mp 203-205 °C (lit. 148 207-208 °C). TLC retention factor 
(Rr) = 0.89 (15:1 CHCh: MeOH). IR (KBr disc): 1053 (aromatic vibration), 1437 
(CH2/CH3 deformation), 2926 (CH2 asymmetric u), 3242 (OH u), 3504 cm·' (OH 
u). 1H NMR (CDCh + CD30D) 6: 0.80 (3H, s, 18-CH3), 1.98 (2H, d of d, J = 2.7 
Hz, J = 12 Hz, 12-H), 2.16 (2H, m, 11-H), 2.72 (lH, m, 9-H), 2.93 (lH, d of d, J= 
5.6 Hz, J = 11.9 Hz, 17-H), 3.75 (2H, q, J = 1.0 Hz, 6-H), 5.59 (lH, s, OH), 6.88 
(lH, d, J = 8.5 Hz, 2-H), 7.21 (lH, d, J = 8.3 Hz, 1-H). 13C NMR (CDCh) 6: 11.1 
(18-CH3) 23.2 (C-6), 26.7 (C-15), 27.4 (C-7), 27.6 (C-11), 30.0 (C-16), 31.3 (C-
12), 36.8 (C-8), 38.2 (C-9), 43.3 (C-13), 44.3 (C-14), 81.6 (C-17), 113.1 (C-4), 
113.5 (C-2), 125.2 (C-1), 134.1 (C-5), 137.2 (C-10), 151.2 (C-3). ES-MS mlz 
(MeOH-45 V) 349.1, 351.1 [M-Hr. 
3.2.2.2 2,4-Dibromoestrone (2) 
Estrone (400 mg, 1.48 mmol) was dissolved in dry ethanol (25 mL) with 
warming. N-Bromosuccinimide (790 mg) was added and the mixture stirred 
vigorously for 24 h in the dark. The solvent was removed from the deep purple 
solution and the solid separated on a silica gel column using in succession, 
petroleum spirit, 4: 1 petroleum spirit: ethyl acetate eluant to yield 2 as an off-
white solid. Yield: 53% (336 mg, 0.784 mmol). Mp 230 °C (lit. 151 235-236 °C). 
1 Seep. 120 for reaction scheme of 4-position derivatives and p. 121 for 3- and 2-position 
derivatives. Full bromination reaction scheme is given on p.123. 
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TLC Rr = 0.41 (4:1 petroleum spirit: ethyl acetate). IR (KBr disc): 1462 (CH2 
deformation), 1720 (C=O u), 2925 (CH2 asymmetric u), 3337 cm·1 (OH u). 1H 
NMR (CDCh) 6: 0.93 (3H, s, 18-CH3), 1.27-2.98 (m), 5.90 (lH, s, OH), 7.43 (lH, 
s, 1-H). 13C NMR (CDCh) 6: 14.1 {18-CH3), 21.9 (C-15), 26.5 (C-6), 26.8 (C-7), 
30.1 (C-11), 31.3 (C-12), 31.8 (C-16), 36.2 (C-8), 37.7 (C-9), 44.3 (C-13), 48.1 
(C-14), 106.9 (C-2), 113.6 (C-4), 128.9 (C-1), 135.4 (C-5), 137 (C-10), 147.7 (C-
3), 220.6 (C-17). ES-MS m/z (MeOH-20 V) 425 -429 isotope pattern [M-Hr. 
3.2.2.3 4-Bromoestrone (3A)from 2,4-dibromoestrone (2) 
2,4-Dibromoestrone (300 mg, 0.70 mmol) was dissolved in 
dimethylformamide (DMF) (10 mL) and 3%w/w palladium on carbon (333 mg) 
was added followed by formic acid (270 µL). The mixture was then refluxed for 
105 min, cooled to room temperature and the catalyst filtered off and washed with 
ethyl acetate (2 x 4 mL). The combined filtrate and ethyl acetate washings were 
further diluted in ethyl acetate and washed with aqueous saturated sodium 
bicarbonate solution (twice) and distilled water (twice). The organic phase was 
then dried over magnesium sulfate and the rose pink solution was separated on a 
silica column (using in succession, petroleum spirit, 4 : 1 petroleum spirit : ethyl 
acetate, 3:1 petroleum spirit: ethyl acetate, 2:1 petroleum spirit: ethyl acetate) to 
yield 4-bromoestrone as a white solid. Yield 30% (74 mg, 0.21 mmol). Mp 258-
259 °C (lit. 150 264-265 °C). TLC Rr = 0.23 (4: 1 petroleum spirit: ethyl acetate). 1H 
NMR (CDC13) 6: 0.90 (3H, s, 18-CH3), 0.90 (lH, s), 1.26 - 2.96 (m), 5.37 {lH, s), 
6.86 (lH, d, J = 8.6 Hz, 2-H), 7.18 (lH, d, J = 8.6 Hz, 1-H). 13C NMR (CDCh) 6: 
14.1 (18-CH3), 21.9 (C-15), 26.3 (C-6), 27.0 (C-7), 30.1 (C-11), 31.4 (C-12), 31.9 
(C-16), 36.2 (C-8), 37.9 (C-9), 44.5 (C-13), 50.7 (C-14), 113.3 (C-4), 115.6 (2-C), 
125.9 (C-1), 134.0 (5-C), 136.5 (10-C), 150.6 (3-C), 221.1 (17-C=O). ES-MS m/z 
(-40V MeOH) 346.7 and 348.7 [M-Hr. 
3.2.2.4 4-Bromoestrone (3B)/rom estrone 
Estrone (400 mg, 1.48 mmol) was dissolved in dry EtOH (10 mL) and acetone 
(10 mL). N-Bromosuccinimide (263 mg, 1.48 mmol) was added to the vigorously 
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stirring solution and the stirring continued at room temperature for 24 h. The 
white solid formed was filtered off and washed with ethanol. The filtrate solvent 
was removed and the resultant solid from the filtrate was recrystallised from 
chloroform to increase yield and then added to the filtered solid yielding 38. 
Yield 43% (221 mg, 0.63 mmol). Mp 264-265 °C (lit. 150 264-265 °C). TLC Rr = 
0.23 (4: 1 petroleum spirit 60-80°C : ethyl acetate). IR (KBr disc): 1472 (CH2 
deformation), 1731 (17 C=O u), 3420 cm·' (OH u). 1H NMR (CDCh) 6: 0.90 
(3H, s, l8-CH3), 0.90 (lH, s), 1.26 - 2.96 (m), 5.37 {lH, s, OH), 6.86 (lH, d, J = 
8.6 Hz, 2-H), 7.18 {lH, d, J = 8.6 Hz, 1-H). 13C NMR (CDCh) 6: 14.0 (18-CH3), 
21.8 (C-15), 26.3 (C-6), 26.9 (C-7), 31.2 (C-11), 31.7 (C-12), 36.2 (C-16), 37.8 
(C-8), 44.4 (C-9), 49.1 (C-13), 50.5 (C-14), 113.2 (4-C), 118.9 (2-C), 125.3 (1-C), 
133.3 (5-C), 137.0 (10-C), 151.4 (3-C), 222.6 (17-C). ES-MS m/z (-40V MeOH) 
346.7 and 348.7 [M-H]"; High resolution (HiRes) Electron impact-MS: 
Calculated: 348.0725 and 350.0705, Found: 348.0727 and 350.0708 (M+). 
3.2.2.5 3-(3,17 P.Dihydroxyestra-1,3,5(1 O)-trien-4-yl)thiopropanoic acid ( 4) 
1 (200 mg, 0.57 mmol) was dissolved in dry MeOH (20 mL). Methanolic 
potassium hydroxide (20 mL, 7.8 mg/mL) was added followed by 3-
mercaptopropionic acid (550 µL). The solution was refluxed under dry conditions 
(oven-dried glassware, drying tube and solvent dried over molecular sieves) for 24 
h in the dark. The solvent was removed and the sample reconstituted in distilled 
water (50 mL). The aqueous phase was washed with EtOAc (2 x 25 mL, 1 x 50 
mL). The EtOAc phase was then back washed with distilled water (50 mL in 
total). TLC analysis revealed that the Rr of the product was too close to that of 3-
mercaptopropionic acid to allow column separation and so the solvent was 
removed in vacuo and the product was reacted directly through to the next stage. 
TLC Rr = 0.52 (5:1 CHCh: MeOH). 1H NMR (CDCIJ) 6: 0.81 (3H, s, l8-CH3), 
1.38-2.3 (m, steroidal backbone), 2.75 (3H, t, J = 4.6 Hz, 17-CH), 2.81 (2H, m, S-
CH2), 6.89 (lH, d, J = 6.3 Hz, 2-H), 7.22 (lH, d, J = 6.1 Hz, 1-H); incomplete 
assignment as the spectrum was obtained overlaid with 3-mercaptopropionic acid 
(MPA) peaks. 13C NMR (CDCIJ) 6: 14.2 (18-CH3), 21.2 (C-15), 21.4 (C-6), 22.8 
(C-7), 23.1 (C-11), 24.0, 25.4, 26.8, 29.1 (S-CH2), 29.8, 30.2, 31.0 (C-12), 33.8 
106 
(CH2-COOH), 34.2 (C-16), 37.1 (C-8), 50.9 (C-14), 74.6 (C-17), 90.5, 171.5 
(COOH), 194.0; ES-MS mlz (+ve ion mode, MeOH) 399.1 [M+Na]+, (-ve ion 
mode, MeOH) 406.8 [M+OMer. 
3.2.2.6 3-(3-Hydroxyestra-1,3,5(10)-trien-17-on-4-yl)thiopropanoic acid (5) 
3 (150 mg, 0.43 mmol) was dissolved in dry MeOH (20 mL, dried over 
molecular sieves) and potassium hydroxide (15 mL, 23 mg/mL in dry MeOH) was 
added whilst stirring, followed by 3-mercaptopropionic acid (425 µL) and the 
solution heated under reflux with oven dried glassware and a drying tube for 24 h. 
The sample was then cooled and the solvent removed. The sample was 
reconstituted in distilled water (25 mL) and washed with EtOAc (2 x 12.5 mL, 1 x 
25 mL). The water was removed in vacuo and the sample column separated using 
1:1 CHCh: MeOH eluant to yield 5 as a white solid. Yield 27% (43 mg, 0.11 
mmol). Mp 108-112 °C. TLC Rr = 0.65 (10:1 CHCh: MeOH). IR (KBr disc): 
1241 (CH2-S u), 1400 (CH3 deformation), 1698 (acid C=O u), 1735 (17 C=O u), 
3429 cm-1 (OH u). 1H NMR (CDCh + CD30D) 6: 0.93 (3H, s, CH3-18), 2.54 (2H, 
t, J = 9.4 Hz, CH2-COOH), 2.88 (2H, t, J = 8.8 Hz, CH2-S), 6.81 (lH, d, J = 11 
Hz, H-2), 7.22 (lH, d, J = 11 Hz, H-1). 13C NMR (CDCh + CD30D) 6: 13.8 (18-
CH3), 21.6 (C-15), 26.2 (C-6), 26.7 (C-7), 29.5 (S-CH2), 31.0 (C-11), 31.5 (C-12), 
35.9 (CH2-COOH), 37.4 (C-16), 38.5 (C-13), 44.0 (C-9), 48.0 (C-13), 50.3 (C-
14), 113.0 (C-2), 125.4 (C-1), 133.6 (C-5), 136.5 (C-10), 150.6 (C-4), 156.2 (C-
3), 175.4 (COOH), 223.0 (CO). ES-MS mlz (MeOH) 397.4 [M+Nat, 373.4 [M-
Hr. 
3.2.3 Synthesis of Polyethylene Glycol Derivatives of the Estrogens 
3.2.3.1 2,5-Dioxo-l-py"olidinyl 3-(3,17ft-dihydroxyestra-1,3,5(10)-trien-4-
yl)thiopropionate (6) 
The entire semi-solid from the ethyl acetate phase of the 4 reaction was 
dissolved in dry DMF (1 mL) and dicyclohexylcarbodiimide (DCC) (176 mg in 1 
mL of dry DMF) was added drop-wise followed by NHS (98 mg in 1 mL of dry 
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DMF). A white solid precipitated out within 1 h and the mixture was left sealed 
stirring in the dark overnight. The solvent was removed in vacuo and the sample 
separated by silica column using in succession, CHCh, 15:1 CHCh: MeOH, 10:1 
CHCl3: MeOH and then 2: 1 CHCh: MeOH as eluant to yield 6 as a white solid. 
Yield 52% (141 mg, 0.297 mmol) from 1. Mp 194-196 °C. TLC Rr = 0.48 (10:1 
CHCl3: MeOH). IR (KBr disc): 1242 (CH2-S u), 1576 (aromatic u), 1626 
(aromatic u), 1736 (NHS C=O out of phase u, C=O u active ester), 1783 (NHS 
C=O in-phase u), 2851 (CH2 symmetric u), 2929 (CH2 asymmetric u), 3327 cm-1 
(OH u). 1H NMR (CDCh +CD30D) 8: 0.79 (3H, s, 18-CH3), 2.97 (4H, s, NHS), 
3.05 (t, J = 6.7 Hz, CH2-S, overlaid with H-9 1H to make 3H group), 3.75 (lH, t, J 
= 10.9 Hz, H-17), 6.87 (lH, d, J = 11.3 Hz, H-2), 7.20 (lH, d, J = 11.4 Hz, H-1). 
13C NMR (CDCh + CD30D) 8: 11.1 (18-CH3), 23.1 (C-6), 24.7 (C-15), 25.0 
(NHS ring CH2), 25.5 (NHS ring CH2), 26.6 (C-7), 27.4 (C-11), 30.7 (CH2-COO). 
31.2 (S-CH2), 32.4 (C-16), 32.9 (C-12), 38.1 (C-8), 43.2 (C-9), 44.2 (C-13), 52.9 
(14-C), 81.9 (C-17), 112.8 (C-2), 113.8 (C-5), 125.6 (C-1), 134.4 (C-10), 136.5 
(C-4), 150.2 (C-3), 162.6 (ester C=O), 169.0 (NHS C=O), 179.3 (NHS C=O). 
ES-MS m/z (40 V, MeCN) 515.5 [M+MeCN+Ht. 
3.2.3.2 2,5-Dioxo-1-py"olidinyl-3-(3-hydroxyestra-1,3,5( 1 O)-trien-3-ol-17-on-4-
yl)thiopropionate (7) 
5 (100 mg, 0.268 mmol) was dissolved in dry DMF (1 mL) and DCC (72 mg, 
0.348 mmol, in 0.5 mL dry DMF) was added to the rapidly stirring solution drop-
wise. This was followed by NHS (40 mg, 0.348 mmol, in 0.5 mL of dry DMF). 
The solution was left stirring at room temperature overnight in the dark. The 
solvent was removed in vacuo and the resulting semi-solid separated on a silica 
column using 15: 1 CHCh : MeOH eluant to yield 7 as a white solid. Yield 32% 
(40 mg, 0.085 mmol). Mp 193-197 °C. TLC Rr = 0.96 (15:1 CHCh: MeOH). IR 
(KBr disc): 1576 (aromatic u), 1627 (aromatic u), 1736 (NHS C=O out of phase 
u, 17 C=O u), 1780 (NHS C=O in-phase u), 2851 (CH2 symmetric u), 2929 (CH2 
asymmetric u), 3328 (OH u) cm- 1• 1H NMR (CDCI3 + CD30D) 8: 0.90 (3H, s, 18-
CH3), 2.89 (4H, s, NHS), 4.31 (lH, d, J = 9.4 Hz), 6.85 (lH, J = 11.4 Hz, H-2), 
7.16 (lH, J = 11.4 Hz, H-1). 13C NMR (CDCl3 + CD30D) 8: 13.9 (18-CH3), 21.6 
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(C-15), 24.8 (NHS CH2), 25.0 (NHS CH2), 25.5 (C-6), 25.7 (C-7), 26.2 (C-11), 
26.7 (CH2COO), 31.1 (CH2-S), 32.9 (12-C), 34.0, 36.6 (C-16), 37.6 (C-8), 44.2 
(C-9), 48.0 (C-13), 52.8 (C-14), 113.0 (C-2), 125.5 (C-1), 133.6 (C-5), 136.4 (C-
10), 150.6 (C-4), 157.1 (C-3), 162.7 (ester C=O), 179.3 (NHS C=O), 220.9 (17 
C=O). ES-MS m/z (MeOH 40 V) 471.6 [M+Ht. 
3.2.3.3 N-(t-Butoxycarbonyl)-4,7,10-trioxa-l,13-tridecanediamine (8) 
Adapted from the method of Wilbur et al.243 4,7,10-Trioxa-1,13-
tridecanediamine (OEG) (1.9 g, 8.60 mmol) was dissolved in 20 mL of molecular 
sieves-dried methanol in a round bottom flask (50 mL). Di-tert-butyl dicarbonate 
(DBDC) (1 g) was dissolved in dry methanol (10 mL). Triethylamine (1 mL) was 
added to the vigorously stirred OEG solution under a septum. The DBDC 
solution was then added drop-wise under a septum to the vigorously stirred 
solution via syringe. The solution was stirred overnight. The solvent was 
removed and the sample dried in vacuo. The resultant oil was then column 
separated by flash chromatography using successively 4: 1 CH2Ch: MeOH, 32:8: 
1 CH2Ch: MeOH: AcOH, 16:4:1 CH2Ch: MeOH: AcOH to yield 8 as a clear, 
colourless oil. To return to free amine form 8 can be washed with aqueous 
sodium bicarbonate solution. Yield: 69% (1.925 g, 5.93 mmol). TLC Rr = 0.85 
(16: 4: 1 CH2Ch: MeOH: AcOH). IR (film): 1113 (CH2-0 u), 1555 (Boe amide), 
1694 (Boe amide C=O u), 2874 (-NHt u, CH2 symmetric u), 2931 cm·1 (CH2 
asymmetric u). 1H NMR (CDCh, 8 as acetate salt) o: 1.43 {s, 9H, t-butoxy 
carbonyl (Boe) methyl), 1.77 (quin, 2H, J = 6.3 Hz, CH2-CH2-NHt), 1.94 (quin, 
2H, J = 5.8 Hz, CH2-CH2-NH-CO), 3.09 (2H, t, 6.1 Hz, CH2-NHt), 3.19 (2H, d 
of t, Jd = 5.9 Hz, CH2-NH-CO), 3.53 (2H, t, J = 6.0 Hz, CH2-0), 3.58 (2H, t, J = 
3.3 Hz, CH2-0), 3.62 (6H, m, CH2-0), 3.66 (2H, t, J = 5.6 Hz CH2-0). 13C NMR 
(CDC13) o: 28.4 (Boe Me), 29.7 (CH2-CH2-CH2), 33.4 (CH2-CH2-CH2), 38.4 
(CH2-NH), 39.6 (CH2-NH2), 69.4 (CH2-0), 70.19 (CH2-0), 70.22 (CH2-0), 70.57 
(CH2-0), 70.60 (CH2-0), 156.1 (C=O). ES-MS mlz (MeOH): 321.1 [M+Ht. 
Purity: 97% (HPLC, retention time (Rt) = 1.34 min, 60:40 MeOH: H20, Amax = 
201 nm). 
3.2. 3. 4 N-(13-(t-Butoxycarbonylamino )-4, 7,1 O-trioxatridecanyl)-3-(3,17 P. 
dihydroxyestra-1,3,5( 10 )-trien-4-yl)thiopropanamide (9) 
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6 (50 mg, 0.075 mmol) was dissolved in dry DMF (1 mL). 8 (Na2C03 washed, 
21 mg, 0.064 mmol in 0.5 mL of CHCh) was added drop-wise with vigorous 
stirring followed by triethylamine (100 µL, dried over molecular sieves). The 
solution was stirred in the dark at room temperature over 60 h. Solvent was then 
removed and the product separated on a silica column using successively 15: 1 
CHCh: MeOH, 10:1 CHCh: MeOH, 5:1 CHCh: MeOH, 1:1 CHCh: MeOH and 
then MeOH as eluant to yield 9 as a clear, colourless oil. Yield: 86% (44 mg, 
0.064 mmol). TLC Rr 0.50 (15:1 CHCh:MeOH). IR (film): 1542 (Boe amide), 
1655 (amide C=O u), 1695 (Boe amide C=O u), 2919 (CH2 asymmetric u), 3410 
cm-1 (OH u). 1H NMR (CDCh) 6: 0.77 (3H, s, CH3-18), 1.44 (9H, s, Boe CH3), 
2.56 (2H, t, J = 7.1 Hz CH2COO-), 2.99 (2H, t, J = 7.1 Hz Ar-S-CH2), 3.6 (12H, 
m, PEG CH2-0), 3.73 (lH, t, J = 8.5 Hz, H-17), 6.85 (lH, d, J = 8.5 Hz, H-2), 
7.17 (lH, d, J= 8.5 Hz, H-1). 13C NMR (CDCh) 6: 11.0 (CH3-18), 23.2 (15-C, C-
6), 27.2 (C-7), 28.1 (C-11), 28.4 (Boe CH3), 28.5 (Boe Me), 28.9 (Boe Me), 29.2 
(OEG chain), 29.5 (OEG chain), 29.7 (CH2S), 31.1 (C-16), 34.2 (C-12), 35.9 
(CH2CO), 36.5 (CH2NH steroid end), 37.9 (CH2NH Boe end), 38.1 (C-8), 43.2 
(C-9), 44.2 (C-13), 49.9 (C-14), 69.5 (OEG CH20), 69.9 (OEG CH20), 70.1 
(OEG CH20), 70.2 (OEG CH20), 70.5 (OEG CH20), 81.8 (Boe C-0), 82.3 (C-
17), 112.8 (C-2), 113.7 (C-4), 125.4 (C-1), 134.2 (C-10), 136.5 (C-5), 150.3 (C-
3), 156.1 (ester), 170.9 (ester). ES-MS mlz (H20, 60 V) 718.9 [M+H20+Nat. 
3.2.3.5 0-( N-(t-Butoxycarbonyl)-2-aminopropyl),0'-(2-aminopropyl) 
polypropylene glycol-block-polyethylene glycol-block polypropylene glycol (10) 
Polyethylene glycol 800 (0, O' -Bis-(2-aminopropyl)polypropylene glycol-
block-polyethylene glycol-block polypropylene glycol, Fluka 14527) (2 g, approx. 
2.22 mmol as exact chain length varies) was dissolved in dry MeOH (20 mL) and 
dry triethylamine (1 mL) was then added. Di-tert-butyl dicarbonate (Boe) (0.486 
g, 2.22 mmol) was dissolved in dry MeOH (10 mL) and added drop-wise to the 
rapidly stirring PEG solution over 20 min using a syringe and septum. The 
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solution was then left to rapidly stir overnight at room temperature. The solvent 
was then removed and the sample separated on a silica column using successively 
32: 1: 1, 32:2: 1, 32:4: 1, 16:4: 1 CH2Ch : MeOH : AcOH as eluant to yield 10 as a 
clear colourless semi-solid. Yield: 41 % (911 mg, approx. 0.91 mmol). TLC Rr = 
0.53 (32:2:1 CH2Ch : MeOH: AcOH). IR (film): 1105 (CH2-0 u), 1699 (Boe 
amide C=O u), 2875 (CH2 symmetric u), 3411 cm-• (-NH2 u). 1H NMR (CDCh) 
6: 1.13 (s, 8H), 1.27 (s, 3H), 1.44 (s, 9H, Boe CH3), 2.00 (s, 6H), 3.45 (s, 7H), 
3.65 (s, 65H, ethylene protons); 13C NMR (CDCh) 6: 15.0, 15.3, 15.4, 16.1, 16.8, 
16.9, 17.0, 17.9, 18.8, 22.5, 28.4 (Boe CH3), 46.6, 47.1, 47.2, 48.4, 70.3 (cluster, 
OCH2), 72.5, 72.6, 74.4, 74.9, 75.2, 75.5, 76.2, 155.5, 176.1 (Boe carbonyl). ES-
MS (MeOH 40V) multiple peaks corresponding to different n-values of the PEG 
chain. Note: the PEG chain varies slightly in length so this is not one discrete 
compound but rather a mixture with a narrow distribution of chain lengths. 
3.2.3.6 0-2-[3-[(3,17P.Dihydroxyestra-l,3,5(10)-trien-4-
yl)thiopropanoyl]aminopropyl), 0'-2-(N-(t-butoxycarbonyl)-2-aminopropyl) 
polypropylene glycol-block-polyethylene glycol-block polypropylene glycol ( 11) 
6 (50 mg, 0.106 mmol) was dissolved in dry DMF (1 mL) and stirred rapidly 
whilst 8 (372 mg, approx. 0.372 mmol (as exact Mr is variable), dissolved in 5:1 
CHCI3: MeOH, 3 mL) was added drop-wise followed by triethylamine (0.5 mL). 
The solution was stirred at room temperature for 60 h in the dark. The solvent 
was then removed and the resulting orange oil separated on a silica column using 
successively 15: 1 CHCh: MeOH, 10: 1 CHCh: MeOH, 5: 1 CHCh: MeOH as 
eluant to yield 11 as a clear, colourless oil. Yield 27% (40 mg, 0.029 mmol). TLC 
Rr= 0.52 (5:1 CHCh: MeOH). IR (film): 1106 (CH2-0 u), 1659 (amide C=O u), 
1711 (Boe amide C=O u), 2873 (CH2 symmetric u), 3340 (OH u) cm-•. 1H NMR 
(CDCh) 6: 1.14 (14H, m), 1.44 (9H, s, Boe CH3), 2.58 (2H, t, J = 7.1 Hz, CH2-
COO-), 2.73 (2H, t, J = 1.0 Hz, S-CH2-, H-9 overlapping to give 3H total), 2.97 
(6H, m), 3.47 (m), 4.91 (lH, s), 6.75 (lH, t of d, J = 34.9 Hz, J = 1.9 Hz); 13C 
NMR (CDCh) 6: 16.7, 17.1, 17.6, 18.0, 28.5 (Boe CH3), 29.7 (CH2S), 34.1 
(CH2CO), 34.3, 36.2 (17-CH), 45.1 (C-9), 45.5 (C-13), 70.6 (PEG C-0), 71.9 
(PEG C-0), 72.1 (PEG C-0), 72.4, 72.6, 73.4, 74.0, 74.5, 75.1, 75.3, 75.6, 75.9, 
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118.8 (2-C), 126 (1-C), 128 (4-C), 130 (5-C), 155.7 (3-C), 170.8 (C=O), 174.4 
(C=O). ES-MS (MeOH, 40 V) multiple peaks from range of PEG chain n-values. 
Note: as for 10 this is a mixture of estradiol derivatives with slightly different 
PEG chain lengths. The large PEG component of the derivatives has made 
discrimination of some estradiol NMR peaks difficult. 
3.2.3. 7 N-(13-(t-Butoxycarbonylamino)-4,7,10-trioxatridecanyl)-3-(3-
hydroxyestra-1,3,5(10)-trien-17-on-4-yl)thiopropanamide (12) 
7 (37 mg, 0.079 mmol) was dissolved in dry DMF (1 mL). A solution of 8 (51 
mg, 0.159 mmol, in 750 µL of dry CHCh) was added drop-wise to the stirring 
steroid solution. Triethylamine (dry, 250 µL) was then added and the reaction 
stirred in the dark at room temperature for 2.5 days. After the second day another 
250 µL of dry CHCh was added to aid solubility. The solvent was removed under 
vacuum and the sample separated on a silica column using successively CHCh 
and 15: 1 CHCh: MeOH as eluant to yield 12 as a waxy white solid. Yield: 50% 
(27 mg, 0.040 mmol). IR (film): 1626 (aromatic u), 1655 (amide C=O u) 1702 
(Boe amide C=O u), 1736 (estrone C=O u), 2850 (CH2 symmetric u), 2928 (CH2 
asymmetric u), 3327 (OH u) cm·1• 1H NMR (CDCh) 6: 0.91 (3H, s, 18-CH3), 1.44 
(9H, s, Boe CH3), 3.63 (13H, m, OEG), 4.62 (lH, d, J = 10.0 Hz), 6.83 (lH, d, J = 
11.3 Hz, 2-H), 7.15 (lH, d, J = 11.7 Hz, 1-H). 13C NMR (CDCh) 6: 13.8 (18-
CH3), 21.6 (C-15), 25.0 (C-6), 25.6 (C-7), 26.2 (C-11), 28.4 (Boe Methyl), 29.6 
(CH2 chain), 31.1 (CH2 chain), 31.5 (CH2-S), 33.8 (C-12), 36.0 (CH2CO), 37.6 
(C-16), 38.2 (CH2-NH), 39.3 (C-8), 44.1 (CH2-NH), 48.9 (C-9), 49.0 (C-13), 50.3 
(C-14), 69.4 (CH2-0), 69.9 (CH2-0), 70.2 (CH2-0), 70.5 (CH2-0), 79.2 (0-C-
(Meh), 113.0 (C-2), 117.5 (C-5), 125.3 (C-1), 133.3 (C-10), 136.6 (C-4), 157.5 
(C-3), 161.9 (C=O), 178.7 (C=O), 221.8 (17 C=O). ES-MS mlz (MeOH 40V): 
695.6 [M+H20+Ht. Purity: 96% (HPLC, 203 nm, R1 = 12.76 min, 65% MeOH). 
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3.2.3.8 N-(13-Amino-4,7,JO-trioxatridecanyl)-(3,17P.dihydroxyestra-1,3,5(10)-
trien-4-yl)thiopropanamide ( 13) 
9 (28 mg, 0.041 mmol) was dissolved in formic acid (4 mL) and stirred at room 
temperature for 4 h before removal of acid under vacuum. The compound 13 
could not be column separated on normal phase silica due to its high polarity and 
so was used as is (though shown to be quite pure by TLC apart from the Boe unit). 
TLC Rr = 0.12 (5:1 MeOH: acetic acid). ES-MS m/z (MeOH) 615.2 
[M+2H20+H]\ 637.3 [M+2H20+Nat. 
3.2.3.9 N-(13-Amino-4,7,10-trioxatridecanyl)-(3-hydroxyestra-1,3,5(10)-trien-
17-on-4-yl)thiopropanamide (14) 
12 (15 mg, 0.022 mmol) was dissolved in formic acid (2 mL) and stirred at 
room temperature for 5 h before removal of solvent under vacuum. The 
compound 14 could not be column separated on normal phase silica due to its 
high polarity and so was used as is (though shown to be quite pure by TLC apart 
from the cleaved Boe). TLC Rr= 0.28 (1:1 methanol: acetic acid). ES-MS m/z (20 
V, MeOH): 577.5 [M+Ht. 
3.2.3.1017P.Hydroxyestra-1,3,5(10)-trien-3-yl hemisuccinate (15) 
17~-Estradiol (100 mg, 0.367 mmol) was dissolved in pyridine (9 mL). 
Succinic anhydride (37 mg, 0.367 mmol in 1 mL of pyridine) was added drop-
wise to the rapidly stirring solution. The reaction was then stirred at 45 °C for 24 
h. The pyridine was then dried off in vacuo and the resultant sample purified by 
flash chromatography using successively CHCh, 15: 1 CHCh: MeOH, 10: 1 
CHCh: MeOH as eluant to yield 15 as a semi-solid. Yield: 24% (33 mg, 0.088 
mmol). IR (film): 1588 (COO- u), 1739 (C=O u ester), 3584 (OH u) cm-1• 1H 
NMR (CDCh + CD30D) 6: 0.77 (3H, s, l8-CH3), 2.74 (2H, t, J = 8.9 Hz, CH2-
ester), 2.84 (2H, t, J = 7.3 Hz, CH2-acid), 6.55 (lH, m, 4-H), 6.84 (lH, m, 1-H), 
7.28 (lH, m, 2-H); 13C NMR (CDCh + CD30D) 6: 11.1 (18-CH3), 23.1 (C-15), 
26.2 (C-7), 27.1 (C-11), 27.3 (CH2CO), 29.1 (C-6), 29.5 (CH2COOH), 36.7 (C-
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12), 38.6 (C-16), 43.2 (C-8), 44.2 (C-9), 49.8 (C-13), 50.1 (C-14), 81.6 (17-C), 
118.5 (2-C), 121.4 (4-C), 126.4 (1-C), 131.7 (5-C), 138.0 (10-C), 148.4 (3-C), 
171.6 (C=O), 174.9 (COOH). ES-MS m/z (MeOH, 40 V) 395.3 [M+Nat. 
3.2.3.11 N-(13-(t-Butoxycarbonylamino )-4, 7,1 O-trioxatridecanyl)-3-(17 p. 
hydroxyestra-1,3,5(10 )-trien-3-yl)oxycarbonylpropanamide (16) 
15 (72 mg, 0.194 mmol) was dissolved in 1: 1 DMF: CHCh (2.5 mL, dried over 
molecular sieves). This solution was stirred whilst DCC (60 mg, 0.292 mmol, in 
500 µL of DMF dried over molecular sieves) was added drop-wise followed by 
NHS (34 mg, 0.292 mmol, in 500 µL of DMF dried over molecular sieves) also 
drop-wise. The solution was stirred in the dark overnight. White solid was 
filtered from the solution and washed with CHCh and DMF before removing all 
solvent in the filtrate under vacuum. The resultant white semi-solid was 
reconstituted in 1: 1 DMF: CHCh (2 mL, dried over molecular sieves) and 8 was 
added (94 mg in 3.25 mL of 2:1 DMF: CHCh dried over molecular sieves) drop-
wise to the stirring solution. Triethylamine (1 mL, dried over molecular sieves) 
was added and the reaction stirred in the dark overnight. The solvent was 
removed and the sample dried under vacuum. The sample was then column 
separated using CHCh, 15:1 CHCh: MeOH and 10:1 CHCh: MeOH as eluant to 
yield 16 as a white semi-solid. Yield: 49% (64 mg, 0.095 mmol). IR (film): 1627 
(aromatic u), 1654 (amide C=O u), 1702 (Boe C=O u), 1736 (ester C=O u), 2850 
(CH2 symmetric u), 2926 (CH2 asymmetric u), 3326 (OH u) cm-1• 1H NMR 
(CDCh + CD30D) o: 0.77 (3H, s, l8-CH3), 1.44 (9H, s, Boe methyls), 2.47 (2H, t, 
J = 9.3 Hz, hemisuccinate CH2-amide), 2.65 (2H, t, J = 9.4 Hz, hemisuccinate 
CH2-ester), 6.62 (lH, m, 2-H), 6.79 (lH, m, 4-H), 7.12 (lH, m, 1-H); 13C NMR 
(CDCh + CD30D) o: 11.1 (18-CH3), 23.2 (C-15), 25.7 (C-7), 26.5 (11-C), 27.4 
(CH2CO), 28.5 (Boe Me), 28.9 (Boe Me), 29.5 (Boe Me), 29.6 (CH2 OEG chain), 
29.8 (CH2 OEG chain), 30.1 (C-6), 30.8 (C-16), 33.9 (C-CO), 36.8 (C-12), 37.5 
(CH2-NH steroid end), 39.1 (CH2-NH Boe end), 44.1 (C-8), 48.8 (C-9), 48.9 (C-
13), 50.2 (C-14), 69.6 (CH20), 70.2 (CH20), 70.2 (CH20), 70.6 (CH20), 70.6 
(CH20), 81.7 (C-17) 83.3 (OCMe3), 118.6 (2-C), 121.5 (4-C), 126.4 (1-C), 131.8 
(5-C), 138.0 (10-C), 148.5 (3-C), 158.0 (C=O), 172.1 (C=O), 173.8 (C=O). ES-
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MS mlz (MeOH, 40 V) 697.5 [M+Nat. HiRes FAB-MS: Calculated 675.4202, 
Found 675.4202 (Mfr). 
3.2.3.12 Estra-1,3,5(10)-trien-17-on-3-yl hemisuccinate (17) 
Estrone (200 mg, 0.740 mmol) was dissolved in THF (5 mL). Succinic 
anhydride (140 mg, 1.39 mmol, in lmL of THF) was added to the stirring estrone 
solution. Triethylamine was added (240 µL) and then 4-(dimethylamino)pyridine 
(DMAP) (90 mg) and the reaction solution was stirred at 60 °c for 24 h. The 
solvent was then removed and the sample purified by flash chromatography using 
CHCh and 10:1 CHCh: MeOH eluant to yield 17 as a white powder. Yield: 25% 
(69 mg, 0.185 mmol). TLC Rr = 0.39 (15:1 CHCh: MeOH). Mp 211-212 °C 
(lit.245 215-217 °C). IR (film): 1711 (acid C=O u), 1735 (estrone 17- C=O u), 
1755 (ester C=O u) cm-1• 1H NMR (CDCh) 6: 0.91 (3H, s, 18-CH3), 2.74 (2H, t, J 
= 6.9 Hz, CH2-amide), 2.85 (2H, t, J = 6.9 Hz, CH2-acid), 6.81 (lH, s, 4-H), 6.85 
(lH, d, J = 9.3 Hz, 1-H), 7.26 (lH, d, J = 8.5 Hz, 2-H). 13C NMR (CDCh) 6: 13.9 
(13-CH3), 21.6 (15-CH2), 25.8 (7-CH2), 26.4 (1 l-CH2), 29.0 (CH2-ester), 29.4 (6-
CH2), 31.6 (CH2-COOH), 35.9 (C-12), 38.1 (C-16 and C-8), 44.2 (C-9), 48.1 (C-
13), 50.5 (C-14), 118.7 (2-C), 121.5 (4-C), 126.4 (1-C), 137.5 (5-C), 138.1 (10-
C), 148.6 (3-C), 171.5 (ester), 174.8 (COOH), 221.8 (17 C=O). ES-MS m/z 
(MeOH, 60 V) 392.6 [M+Nat. 
3.2.3.13 N-(13-(t-Butoxycarbonylamino)-4,7,10-trioxatridecanyl)-3-(estra-
1,3,5(10)-trien-17-on-3-yl)oxycarbonylpropanamide. (18) 
17 (64 mg, 0.173 mmol) was dissolved in dry DMF (1 mL). DCC (47 mg in 
500 µL of dry DMF) was added dropwise to the rapidly stirring solution. This 
was followed by NHS (26 mg in 500 µL of dry DMF) and the reaction was stirred 
overnight in the dark. The reaction sample was filtered to remove 1,3-
dicyclohexylurea (DCU) and the filtrate was dried under vacuum. The sample 
was reconstituted in dry DMF (1 mL) and 8 (79 mg, 0.260 mmol in 2: 1 DMF: 
CHCh (dry, 3 mL)) was added drop-wise to the rapidly stirring solution. This was 
followed by triethylamine (1 mL) and the solution was stirred overnight in the 
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dark. The solvent was removed and the dried sample purified by flash 
chromatography using in succession CHCh, 15: 1 CHCh: MeOH, 10: 1 CHCh: 
MeOH, 2: 1 CHCh: MeOH to yield 18 as a waxy white solid. Yield: 91% (106 
mg, 0.157 mmol). TLC Rr = 0.55 (15:1 CHCh: MeOH). IR (film): 1141 (CH20 
u), 1649 (C=O u amide), 1710 (Boe amide C=O u), 1738 (estrone 17- C=O u, 
ester C=O u), 2858 (CH2 symmetric u), 2929 (CH2 asymmetric u) cm-1• 1H NMR 
(CDCl3 + CD30D) 6: 0.92 (3H, s, l8-CH3), 1.44 (9H, s, Boe CH3), 2.85 (2H, m, 
CH2-hemisuccinate amide, OEG end), 2.88 (2H, m, CH2- hemisuccinate ester, 
aromatic end), 3.53-3.73 (lOH, m, OEG CH2-0), 6.62 (lH, m, 4-H), 6.83 (lH, m, 
2-H), 7.19 (lH, m, 1-H). 13C NMR (CDCh + CD30D) 6: 13.9 (18-CH3), 21.7 (C-
15), 25.1 (C-7), 25.8 (C-11), 25.9 (C-6), 26.5 (Boe CH3), 28.5 (Boe CH3), 29.0 
(Boe CH3), 29.5 (CH2CO), 29.6 (CH2 OEG chain), 31.6 (CH2CO), 31.7 (C-12), 
33.9 (C-16), 36.1 (CH2NH), 38.2 (CH2NH), 44.1 (C-8), 44.3 (C-9), 48.7 (C-13), 
50.6 (C-14), 69.4 (CH20), 69.5 (CH20), 70.2 (CH20), 70.2 (CH20), 70.6 (CH20), 
79.3 (CMe3), 118.8 (2-C), 121.6 (4-C), 126.4 (1-C), 131.0 (5-C), 137.8 (10-C), 
148.7 (3-C), 156.8 (C=O), 163.3 (C=O), 172.1 (C=O), 222.3 (17 C=O). ES-MS 
m/z (MeOH, 40 V): 695.5 [M+Nat. 
3.2.3.14 2-(N-(13-(t-Butoxycarbonylamino)-4,7,10-trioxa-1,13-tridecanyl)-
(aminomethyl)-3,17P.dihydroxyestra-1,3,5(10)-triene) (19). 
Estradiol (100 mg, 0.367 mmol) was dissolved in absolute EtOH (10 mL). 8 
(236 mg, 0.734 mmol in 4:1 EtOH:water (5 mL)) was added gradually to the 
solution whilst stirring. This was followed by 37% v/v formaldehyde solution 
(222 µL, 8.06 mmol) and the solution was heated under reflux with stirring for 6 
h. The solvent was removed under vacuum and the sample reconstituted in 
chloroform before column separation with CHCh, 15: 1 CHCh: MeOH, 10: 1 
CHCh: MeOH as successive eluants to yield 19 as a clear colourless oil. Yield: 
13% (30 mg, 0.048 mmol). IR (film): 1692 (C=O u Boe amide), 3584 (OH u) cm-
1. 1H NMR (CDCh +CD30D) 6: 0.77 (3H, s, 18-CH3), 1.43 (9H, s, Boe methyl), 
2.80 (2H, m, CH2-Ar), 3.60 (14H, m, OEG CH2-0), 6.51 (lH, s, 4-H), 6.88 (lH, s, 
1-H). 13C NMR (CDCh + CD30D) 6: 11.1 (l8-CH3), 23.2 (C-15), 26.5 (7-C), 
27.3 (C-11), 28.2 (Boe Me), 28.4 (Boe Me), 28.5 (Boe Me), 29.4 (CH2 OEG 
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chain), 29.6 (C-6), 30.1 (16-C and 5-C), 36.8 (12-C), 38.2 (CH2NH Boe end), 
39.0 (8-C), 43.3 (9-C), 44.1 (CH2NH), 48.3 (CH2NH), 48.9 (13-C), 49.5 (14-C), 
69.1 (CH20), 69.3 (CH20), 69.5 (CH20), 70.2 (CH20), 70.6 (CH20), 72.1 
(CH20), 81.6 (Boe CMe3), 82.4 (17-C), 116.0 (4-C), 117.3 (2-C), 124.4 (1-C), 
133.0 (5-C), 136.5 (10-C), 151.8 (3-C), 155.1 (amide C=O). COSY NMR 
(CDCh) showed no coupling of aromatic protons. ES-MS m/z (MeOH, 40 V) 
605.5 [M+Ht. 
3.2.3.15 2-(N-(13-(t-Butoxycarbonylamino )-4, 7,10-trioxatridecanyl)-
( aminomethyl)-3-hydroxyestra-1,3,5(10 )-trien-17-one) (20 ). 
Estrone (100 mg, 0.37 mmol) was dissolved in absolute ethanol (10 mL). 8 
(238 mg, 0.74 mmol in 4:1 ethanol: water, 5 mL) was added gradually to the 
solution whilst stirring, followed by formaldehyde, (37%, 224 µL, 8.13 mmol). 
The solution was heated under reflux with stirring for 6 h. The solvent was 
removed in vacuo and the compound purified on a silica column using CHCh, 
15:1 CHCh: MeOH, 10:1 CHCh: MeOH, 5:1 CHCh: MeOH, 2:1 CHCh: MeOH 
as successive eluants to yield a clear, colourless oil. Yield: 15% (33 mg, 0.054 
mmol). IR (film): 1114 (CH20 u), 1691 (Boe C=O u), 1736 (17 C=O uestrone) 
2868 (CH2 symmetric u), 2929 (CH2 asymmetric u), 3403 (OH u) cm-1• 1H NMR 
(CDCh + CD30D) o: 0.90 (3H, s, I8-CH3), 1.43 (9H, s, Boe CH3), 2.83 (2H, m, 
C-6), 3.60 (14H, m, OEG CH2-0), 6.70 (lH, d, J = 9.1 Hz, C-4), 7.03 (lH, s, C-
l). 13C NMR (CDCh + CD30D) o: 13.9 (18-CH3), 21.6 (15-C), 26.0 (7-C), 26.6 
(11-C), 28.4 (Boe Me), 28.5 (Boe Me), 29.2 (C-CH2-C Boe end of OEG), 29.3 (6-
C, C-CH2-C steroid end of OEG), 29.7 (16-C), 31.6 (12-C), 35.9 (CH2-N), 38.3 
(8-C), 43.9 (9-C), 44.0 (CH2-Ar), 46.2 (CH2-NH estrone end), 48.0 (13-C), 50.1 
(14-C), 69.0 (CH2-0), 69.1 (CH2-0), 69.4 (CH2-0), 70.2 (CH2-0), 70.4 (CH2-0), 
70.6 (CH2-0), 78.9 (Boe CMe3), 116.1 (C-4), 124.3 (C-2), 131.2 (C-1), 132.1 (C-
5), 136.1 (C-10), 152.1 (C-3), 156.1 (Boe C=O), 220.8 (17 C=O). ES-MS m/z 
(MeOH, 40 V) 603.5 [M+Ht. COSY NMR: No coupling between aromatic 
signals. 
3.2.3.16 (13-Amino-4,7,IO-trioxatridecanyl)-3-(17P.hydroxyestra-l,3,5(10)-
trien-3-yl)oxycarbonylpropanamide (21 ). 
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16 (48 mg, 0.071 mmol) was dissolved in formic acid (4 mL) and stirred at 
room temperature for 2.5 h before adding chloroform (1 mL) to improve 
solubility. Stirring was continued for an additional 1.5 h. Solvent was removed in 
vacuo and the compound column separated using 10:1 MeOH: AcOH eluant to 
yield 21 as a semi-solid after drying in vacuo. IR (film): 1414 (CH2 or CH3 
deformation), 1561 (-NH/), 1638 (amide C=O u), 3434 (OH u) cm-1• 1H NMR 
(CDCh) 8: 2.52 (2H, t, J = 6.0 Hz, CH2-amide), 2.65 (2H, t, J = 1.2 Hz, CH2-
ester), 2.81 (2H, d, J = 12.0 Hz), 3.09 (2H, t, J = 1.4 Hz), 3.23 (2H, m), 3.55 (3H, 
m, OEG CH2-0), 3.66 (llH, m, OEG CH2-0). 13C NMR (CDCl3) 8: 21.1 (6-C), 
23.3 (15-C), 29.8 (CH2-ester), 38.8 (CH2-NH2), 70.1 (CH2-0), 70.4 (CH2-0), 83.4 
(17-C), 174.8 (C=O amide). Note: NMR weak due to low solubility. ES-MS m/z 
(MeOH) 575.2 [M+Ht. 
3.2.3.17 2-(13-Amino-4,7,10-trioxa-l,13-tridecanyl)-(aminomethyl)-3,17P. 
dihydroxyestra-1,3,5( IO )-triene) (22 ). 
19 (21 mg, 0.034 mmol) was dissolved in formic acid (3 mL) and stirred for 4 
h at room temperature before removal of acid in vacuo. The product was column 
purified using 2: 1 methanol: acetic acid to elute the product. TLC Rr = 0.33 (10: 1 
methanol: acetic acid). IR (film): 1134 (CH20 u), 1421 (CH2-S/CH2 or CH3 
deformation), 2981 (-NH/ u or CH2 u), 3438 (OH u) cm- 1• 1H NMR (CD30D) 8: 
0.89 (3H, s, 18-CH3), 2.83 (2H, m, C-7), 3.64 (m, OEG CH2-0). ES-MS m/z 
(MeOH) 505.3 [M+Ht. 
3.2.3.18 (13-Amino-4,7,10-trioxa-tridecanyl)-3-(estra-1,3,5(10)-trien-17-on-3-
yl)oxycarbonylpropanamide (23 ). 
18 (55 mg, 0.081 mmol) was dissolved in formic acid (3 mL) and stirred for 4 
hat room temperature before removal of solvent in vacuo. The compound was too 
polar to be column separated on normal phase silica and so was used as is. TLC Rr 
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20 (18 mg, 0.030 mmol) was dissolved in formic acid (2 mL) and stirred for 4 
hat room temperature before removal of solvent in vacuo. The compound was too 
polar to be column separated on normal phase silica and so was used as is. TLC Rr 
= 0.19 (1:1 methanol: acetic acid, very streaky). ES-MS m/z (MeOH 40 V) 503.5 
[M+Ht. 
3.2.4 B/Acore Binding Analysis Studies 
3.2.4.1 Immobilisation of Estradiol Derivatives 
A carboxymethyl 5 (CM5) sensor chip was docked in the BIAcore instrument 
and primed x 2 with running buffer. The surface was activated with 1:1 EDC: 
NHS (50 µL, 5 µUmin). An -1 mg/mL solution of the estrogen derivative to be 
immobilized (in 1 %v/v DMF in PBS/T buffer, pH = 9.7) was injected after 
centrifugation to remove any insoluble material (1 x 20 µL, 1 x 80 µL, 1 x 100 
µL, 1 x 200 µL, 5 µUmin). This was immediately followed by injections of 
estrogen derivative (-1 mg/mL, 1 %v/v DMF in PBS/T buffer, pH = 11.7, 1 x 200 
µL, 2 x 100 µL) and then deactivation with 1.0 M ethanolamine (50 µL, 5 
µUmin). 21 was immobilized in flow cell 2, 22 in flow cell 3 and 13 in flow cell 
4. Flow cell 1 was activated with EDC/NHS as for the others and then 
immediately deactivated with ethanolamine (50 µL, 5µUmin) without 
immobilisation of estrogens to serve as a reference flow cell. 
3.2.4.2 17P,.Estradiol Antibody Binding Studies 
Plots of response vs primary antibody concentration with no secondary 
antibody enhancement were prepared using a wizard program by injecting 
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primary monoclonal antibody (60 µL, at 0, 0.25, 0.5, 1, 2, 5, 10 and 25 µg/mL, 5 
replicates of each, 20 µUmin) and waiting 120 s before regeneration with two 
pulses of 50 mM NaOH, 10% v/v MeCN (20 µLeach, 20 µUmin). 
Plots of response vs secondary antibody concentration for secondary antibody 
signal enhancement were prepared by injecting monoclonal primary antibody (60 
µL, 20 µUmin, 0.5 µg/mL) followed immediately by secondary antibody (60 µL, 
0, 10, 20, 50, 100, 200, 300 µg/mL, 10 µUmin) and then a 120 s wait before 
regeneration as above. 
Plots of response vs monoclonal antibody concentration with secondary 
antibody enhancement were prepared by injecting monoclonal primary antibody 
(60 µL, 0, 10, 25, 50, 100, 200, 350, 500 ng/mL, 20 µUmin) immediately 
followed by secondary antibody (60 µL, 200 µg/mL, 10 µUmin), a 120 s wait and 
then regeneration as above. 
3.2.4.3 SPR 17 P-Estradiol Assays. 
Assay curves for 17~-estradiol assay without secondary antibody enhancement 
were prepared by mixing monoclonal primary antibody (70 µL, 1 µg/mL) with 
17~-estradiol solutions (70 µL, 0, 1, 5, 10, 50, 100, 500 pg/mL, 1, 5, 10 ng/mL, 
five replicates each, in HBS-EP pH=7.4 serially diluted from a 10 mg/mL stock in 
DMF) in a microwell plate, mixing using the automatic mixing function, 
incubating for 5 min at 25 °C and then injecting (60 µL, 20 µUmin) and then after 
a 120 s wait regenerating as above. 
Assay curves for 17~-estradiol assay with secondary antibody enhancement 
were prepared by mixing monoclonal primary antibody (50 ng/mL, 70 µL) with 
17~-estradiol solutions (70 µL, 0, 0.5, 1, 5, 10, 50, 100, 500 pg/mL, 1, 5 ng/mL, 
five replicates each, in HBS-EP pH=7.4) in a microwell plate, mixing and 
incubating and injecting as above. This injection was then immediately followed 
by injection of secondary antibody (60 µL, 200 µg/mL, 10 µUmin), a wait of 120 
s and then regeneration as above. Assay curve data was fitted to four parameter 
logistic curves as described in Chapters 1 and 5. All CVs mentioned in the text are 
of the binding responses and the errors mentioned in the text are standard errors. 
Error bars on the curves are one standard deviation of the mean. 
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3.3 Results and Discussion 
The complete reaction schemes for all the thio-bridged compounds are given in 
Figure 3.1 and the reference compounds in Figure 3.2. Each part of the synthesis 
is described in detail below. 
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Figure 3.1. Synthesis of 4-position thiopropionate derivatives of 17~-estradiol 
and estrone and the attachment of oligoethylene glycol (OEG) chains. 
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Figure 3.2. Synthesis of reference compounds. Synthesis of 3-hemisuccinate 
derivative of estradiol and estrone and attachment of an oligoethylene glycol 
(OEG) chain (top) and synthesis of 2-position Mannich reaction derivatives and 
attachment of OEG chain (bottom). 
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3.3.1 Synthesis of Estrogen Thioethers 
The synthesis of 4-bromo-1713-estradiol (1) was achieved using an adaptation 
of the method of Lovely et al. 156 In their paper, they give no explicit directions on 
the experimental procedure and so the exact conditions used were determined by 
experimentation. The volume of ethanol used is critical for the successful 
precipitation of the brominated product from solution. TLC indicates that there is 
clearly some 4-bromo-17~-estradiol left in the solution, which can be recovered 
by column separation to further improve the 55% yield. The quality of the 
crystallised product was good with only one recrystalisation necessary to purify 
the compound, see Appendix 4. The NBS was used in a 1:1 molar ratio244 to 
minimize any production of the 2,4-dibromoestradiol, and the 4-bromoestradiol is 
less soluble than any 2-bromo and so was precipitated out of the ethanol pure. 
NMR analysis showed no sign of 2-bromo or dibromo and so any such 
contaminant could be envisaged to be less than 1 %. The same applies to the 
bromination of estrone. 
The synthesis of the 4-bromoestrone (3) gave somewhat more synthetic 
challenge. It has been previously asserted that this product should be made via 
the 2,4-dibromoestrone in order to get pure product uncontaminated by 2-
bromoestrone.151·152 In this thesis this method was applied successfully to produce 
the 4-bromoestrone (3A) by regioselective debromination of the 2,4-
dibromoestrone (2) using palladium on carbon and formic acid in DMF. The 
overall yields involved in this two-step process were 16%, which is far too low for 
the production of a precursor compound at the beginning of a multi-step synthetic 
sequence. The original one-step method was successfully adapted to produce 4-
bromoestrone (38) in acceptably pure form and reasonable yield from simple 
reaction with N-bromosuccinimide (NBS). The key to this reaction was the use of 
a solvent combination of ethanol / acetone 1: 1. This enabled the product to 
precipitate out of solution in the same way as for the 17~-estradiol bromination. 
The melting point was quite sharp and the NMR spectrum showed only the 4-
bromoestrone. FAB-MS revealed a weak dibromo peak but this was not 
detectable under electrospray. The bromoestrogen products gave very distinctive 
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ES-MS spectra with the 1: 1 bromo isotope pattern being very clearly visible, 
Figure 3.3. The brominations are shown in Figure 3.4. 
Estrone Bromide 40V MeOH 
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Figure 3.3 Electrospray mass spectrum of 4-bromoestrone 3B. 
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Figure 3.4 Bromination of estradiol and estrone to obtain 4-bromoestrogens. 
The next step in the reaction sequence was to perform the aromatic substitution 
of the bromoestrogens with 3-mercaptopropionic acid (MPA). This unit is very 
0 
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useful for conjugations as it can fonn the thioether linkage without interference 
from the carboxylic acid function. The thioether linkage is very stable, and the 
carboxylic acid enables attachment either directly to a protein or to an amine-
tenninating intennediate linker by N-hydroxysuccinimide (NHS) activation with 
dicyclohexylcarbodiimide (DCC) as dehydrating agent. Such conjugations have 
been demonstrated to be very repeatable as they are not very sensitive to changes 
in reaction conditions. 10• 15 
The aromatic A-ring of the estrogens does not lend itself to nucleophilic 
substitution because of the presence of the electron donating hydroxyl moiety, 
which will deactivate nucleophilic substitution at the ortho position. However, 
radical-mediated substitutions of halogens on aromatic rings by thiol compounds 
is widely known and usually proceeds via an SRNl mechanism.174 
By regioselectively synthesising the 4-monobromo product it is possible to 
directly substitute to the 4-position exclusively. This exclusive attachment at the 
4-position is not possible when using the Mannich reaction, which produces a 
mixture of products at the 4- and 2-positions that is seldom purified but rather 
reacted straight through to protein conjugation in one step. The use of a 4-bromo 
derivative provides a labile leaving group for the substitution whilst the 4-bromo 
derivative is quite stable when stored at room temperature in the dark. To effect 
the substitution, base is used to abstract the proton from the -SH group of the 3-
mercaptopropionic acid (MPA) to produce R-s-. 
The reflux is done under dry conditions to minimise risk of hydrolysis of the 
bromo derivative. The substitution was perfonned in both cases by reflux with 
the MP A in methanolic KOH. The reaction scheme for the thioether fonnation is 
given in Figure 3.1. 
For estradiol, the reflux was for 24 h, in the dark to ensure no photolytic 
degradation of the 4-bromoestradiol reactant. The product (4) was extracted into 
the ethyl acetate phase from water and the organic phase washed to remove as 
much MPA as possible (product and MPA were found in both phases). Upon 
TLC analysis, it was seen that the product spot was overlapping with that of the 
MPA and this was confinned by NMR which showed strong MPA peaks 
overlaying the estradiol-thioether structure whose CH2-S and CH2-COOH peaks 
could be seen offset slightly from those of the unreacted MPA. The NMR overall 
corresponds to the literature data but the coupling constants for the propionic acid 
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chain are somewhat distorted by the MP A though they are much clearer for the 
later pure compounds 6 and 9 at around 7 .1 Hz, which is the coupling constant 
observed for the acid propionate chain in the literature. 107 Presence of the product 
was further confirmed by mass spectrometry with a clear [M+Nat peak. There 
was no presence of 4-bromoestradiol signals and their characteristic double peak. 
In order to completely remove the MPA and obtain a pure sample it was necessary 
to proceed directly to the next step without further purification. Attempts were 
also made to purify the product by precipitation from the aqueous phase by pH 
adjustment to acid. This method proved to be unreliable. 
The only previous synthesis of 4 was done through the 4,5-epoxide in three 
steps from nandrolone. 107 This reaction is rather complex and starts from a 
restricted drug making it a less desirable method to use. 
For production of the estrone MPA derivative (5) the same reaction method 
was employed. The sample was worked up by reconstituting the raw reaction 
mixture in water and then washing it with ethyl acetate to remove unreacted 4-
bromoestrone. The aqueous phase was then separated by flash chromatography. 
The lower polarity of the estrone MPA compared with the estradiol MPA product 
allowed complete column purification at this stage so NMR could be obtained of 
the pure sample, Figure 3.5. Once again further conclusive mass spectra were 
obtained and there was once again no sign of unreacted bromo-derivative in the 
final pure sample. In both samples the risk of hydrolysis of the bromo-estrogen 
was minimised by using thoroughly dried solvents. In both steroid derivatives 
attachment at the 4-position was verified by the aromatic proton substitution 
pattern, which showed two doublets at 6.89 and 7.22 ppm for estradiol and 6.81 
and 7.22 ppm for estrone. This is consistent with two single aromatic protons 
coupling to each other ortho, which can only occur for the protons 1 and 2. There 
are no other aromatic proton signals, so this emphatically shows 4-substitution. 
The same sorts of pattern can of course be seen in the corresponding 
bromoestrogens, with 6.88 and 7.21 ppm and J = 8.5 and 8.3 Hz respectively for 
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3.3.2 Synthesis of Polyethylene Glycol Derivatives 
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The NHS active ester of 4 was synthesised by simply dissolving the steroid 
derivative in dry DMF and adding DCC and NHS. As the compound was 
somewhat impure with MPA, a large excess of NHS was used to produce the 
active ester. The DCC acts as a dehydrating agent in the reaction, removing water 
released upon active ester formation to produce dicyclohexylurea (DCU) and so 
push the reaction further forward. The active ester product (6) could be purified 
well by flash chromatography, as the polarity was now much lower and was quite 
different from that of any contaminating MPA or MPA ester. There was no sign 
of the MPA or MPA ester in the NMR or TLC analyses indicating that 
purification at the ester stage has been successful. 
The Dept 135 spectrum (Figure 3.6) shows that there are only two CH aromatic 
carbons in the structure, showing that 4-position attachment of the propionate unit 
has been retained under the reaction conditions. The chemical shifts are consistent 
with those expected for the 1-H and 2-H protons. The estradiol steroid peaks for 
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the non-aromatic rings are clearly visible up-field and the CH2-S signal is seen at 
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The formation of the estrone-NHS ester (7) occurred as expected. The expected 
electrospray peak was clearly observed and the NHS proton peak at 2.89 ppm was 
seen at the expected 4H intensity. Throughout these reactions the aromatic proton 
peaks at 1- and 2-positions have been retained as expected. The 13C NMR 
spectrum is given in Figure 3.7. 
The next step in the reaction sequence was to produce oligoethylene glycol 
derivatives of the steroids. To do this one uses amine-terminating OEG chains. 
To prevent dimerisation of the steroid it was necessary to protect one of the amine 
terminals and react the other with the NHS active ester of the steroid. The most 
effective way of doing this is to attach a tert-butoxy carbonyl moiety (Boe) to one 
of the terminal amine groups through reaction with di-tert-butyl dicarbonate 
(DBDC). Boe is a very common protecting group and can be easily attached to 
amine groups. When it needs to be removed this can be done by treatment with 
formic acid, Figure 3.1. The production of the mono-Boe protected OEG (8)243 
proceeds simply by adding the DBDC to a stirring solution of the OEG under 
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septum, drop-wise with vigorous stirring to ensure that the minimum of di-Boe 
product is formed, after adding triethylamine as a weak base. The reaction can be 
clearly visualised by ninhydrin treatment of the TLC plate, with the di-Boe 
producing only a very weak signal and the mono-Boe and starting material 
producing much stronger colour. The column separation is quite effective and the 
yields are quite good at 69%. The reaction can clearly be confirmed by ESMS, 
which gives a very strong product peak. The same reaction can be applied to the 
longer PEG-900 chain (10) with a yield of 41 %. The electrospray mass 
spectrometry of this sample produces a large number of peaks arising from 
multiple charging of the polymer chain whereas the shorter OEG chain produces 
one discrete [M+Ht peak only. The short OEG chain has three ethylene glycol 
monomeric units whereas the longer PEG chain has on average n = 15-19 
ethylene glycol and/or propylene glycol units. 
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The mono-Boe protected OEG (8) was then reacted with the activated acid unit 
of the steroid to attach the OEG chain through the 4-position of the steroid. This 
could be achieved simply by addition of the mono-Boe OEG to the steroid active 
ester under dry conditions and addition of some triethylamine as mild base. The 
active ester is very reactive with the amine under these conditions and the amide 
linkage is formed to the OEG chain. For estradiol this was done by reaction of the 
active ester derivative and purification by simple flash chromatography to produce 
the amide (9) in 86% yield. The oil-nature of the OEG chain means that the 
product is also an oil. The compound in this Boe-protected form is quite stable 
for extended periods with no highly reactive functional groups. When it is ready 
to use it is a simple matter of removing the Boe protecting group of the compound 
to expose the terminal amine and proceed as required either with further reaction 
or immobilisation. The various characteristic groups of the estradiol derivative 
can be seen quite clearly in the NMR spectrum with the CH2-S at 2.99 ppm J = 
7.1 Hz, and CH2-CO-N at 2.56 ppm J = 7.1 Hz. The Boe trimethyl protons are 
very characteristic at 1.44 ppm as a 9H singlet. The repeating ethylene glycol 
units can also be seen at 3.6 ppm for the CH2-0 and 12H intensity (six CH2-0 in 
the chain). The 1H NMR spectrum for the estradiol short OEG derivative (9) is 
given in Figure 3.8. 
The same general procedure was applied for the long PEG-900 derivative 
synthesis, though the yield was somewhat lower at 27%, compared with 86% for 
the shorter chain. This could possibly be due to approach to the amine terminal 
being sterically hindered by the much longer PEG chain folding over its amine 
terminals in solution. TLC analysis shows that the longer chain derivative (11) is 
noticeably more polar than the shorter chain derivative indicating that the longer 
the PEG chain the more polar the end steroid derivative becomes. This is as 
expected as the estrogens are not very polar whilst the PEG chain is. Once again 
the characteristic peaks are present in the NMR of the Boe 9H at 1.44 ppm and the 
CH2-COO- at 2.58 ppm, J = 7.1 Hz and the CH2-S- at 2.73 ppm, J = 7.0 Hz. In 
the ESMS there is a multiple charging pattern as expected. 
For estrone, the analogous short OEG compound (12) was synthesised 
successfully in good yield (50%) and gave consistent NMR (very similar to the 
estradiol compound) and appropriate mass spectral data. 
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The active esters of the propionic acid derivatives are quite versatile in as much 
as any of a number of different amine bearing linkers may be attached. In previous 
studies we have attached caproate linkers through these esters to form 
progesterone-protein conjugates. 10•15 The ethylene glycol-based linkers have been 
selected as they are highly water-soluble and so make the estrogen derivatives 
much more water-soluble. These derivatives when conjugated to a sensor surface 
should thus project themselves well in the aqueous medium, particularly in flow-
through biosensing formats such as SPR. The oligo- and polyethylene glycol 
chains have the further advantage that they are non-immunogenic and so they are 
not recognised by the antibody, thus avoiding problems of bridge recognition by 
the antibody. Such linkers have potential use as biocompatible linkers for drug 
conjugates of the estrogens and so these derivatives have other potential uses 
outside of biosensing. 
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3.3.3 Synthesis of Reference Compounds 
To provide conjugates for comparison to the thioether-linked conjugates, it was 
necessary to attach the OEG linker chain through different positions on the 
steroid, in this case using the common conjugation techniques of hemisuccinate 
linkage through the existing 3-position hydroxyl moiety; and Mannich reaction 
direct to the aromatic A-ring, which produces a mixture of products at the 2- and 
4-positions. 
The hemisuccinate of estradiol (15) was synthesised by adapting established 
methods through reflux in pyridine with succinic anhydride.245 With the estrone, 
the same procedure could not be adopted as it was not soluble enough in the 
pyridine and so THF was used as the polar aprotic solvent and a combination of 
triethylamine and DMAP were used as the bases instead to produce the 
hemisuccinate product (17) by adapting the method of Won et al. 246 DMAP is 
commonly used as a base in hemisuccinate-linked protein conjugations. The 
hemisuccinates with their exposed carboxylic acid groups could now be activated 
with NHS in the presence of DCC and reacted with the free amine terminal of the 
mono-Boe protected OEG chain (8). This reaction was done without purification 
of the active ester. The 1H NMR spectrum for the estradiol-hemisuccinate-OEG-
Boc derivative (16) is given in Figure 3.9. 13C NMR showed that some of the 
hemisuccinates would hydrolyse slightly with time (as shown by the development 
of peaks at 113 and 115 ppm and sometimes 154 ppm corresponding to the parent 
steroid). Any hydrolysis products were purified away at each step and final 
products checked by mass spectrometry and / or NMR immediately before use in 
BIAcore experiments to ensure the hemisuccinate linkages were intact. 
Conjugation via the Mannich reaction is widely used for protein conjugations 
in immunology, where the reaction is done in one step with hapten and protein 
both present. This means that the exact position of attachment, 2- or 4-, cannot be 
precisely determined. Attempts have been made with reference compounds to 
simulate this process and it is widely acknowledged that the reaction gives rise to 
a mixture of conjugates. In this thesis, the reaction was used to conjugate the 
steroid to the amine-bearing linker, not a protein, and so this allowed the 
possibility of isolating a Mannich product to one position only on the aromatic 
132 
nng. The conjugation was done much as it would be for a protein, with 
formaldehyde solution providing the methylene spacer between aromatic ring and 
amine. TLC analysis showed that the reaction mixture was quite complex and 
careful column chromatography was needed to purify out the main product. For 
estradiol (19), the position of attachment in the purified Mannich product was 
found to be the 2-position. This was seen in the lack of coupling between the two 
aromatic protons and in their matching the expected chemical shifts. In 4-
conjugated systems the coupling of the 1- and 2-protons is quite clear and this was 
not seen for the Mannich product. The position was further confirmed for the 
estradiol product by 2-D homonuclear correlated spectroscopy (COSY), which 
definitely showed no significant coupling between the two aromatic protons. The 
COSY spectrum is given in Figure 3.10. 
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The yield for the Mannich reaction is quite low (13%) and this is consistent 
with previous observations.90 In the case of estrone (20), the position of 
attachment was the 2-position as there was no aromatic coupling in the COSY. 





Figure 3.10 COSY of 19 showing the aromatic proton signals with no cross-
peaks, indicating 2-position conjugation 
3.3.4 Removal of Protecting Groups 
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Removal of the Boe protecting groups was easily achieved in all cases through 
simply stirring in formic acid. TLC analysis of the products showed that most 
were far too polar to give separation on a normal phase silica flash 
chromatography column and so would need a reversed phase column. As such 
columns are very expensive and the only remaining impurity of note would be the 
Boe protecting group, most of the compounds were used without further 
purification. The Boe-protected compounds were fully purified. It was possible to 
purify the estradiol-hemisuccinate derivative (21) and the estradiol Mannich 
derivative (22) but the thioether (13) was too polar to purify. The hemisuccinate, 
being conjugated through the 3-hydroxyl moiety, was of sufficiently low polarity 
to be columned. All these free amine compounds were analysed by mass 
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spectrometry and appropriate peaks found in each case. The electrospray mass 
spectrum for (13) is given in Figure 3.11. The yields of all the reactions in this 
reaction series are summarised in Table 3.1. 
Estd PEG·NH2 raw 20V MeOH 
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Figure 3.11 Electrospray Mass Spectrum of 13 615.2 = [M+2H20+H]+, 637.3 = 
[M+2H20+Nat. 
In summary, it has been shown how linkage to the 4-position of estrogens can 
be achieved with complete regioselectivity and by a simple series of reactions 
starting from the parent steroid. No complex reaction procedures are needed and 
one does not need to begin with a controlled drug such as nandrolone. The 4-
position carboxylic acid derivative enables attachment of any of a range of 
different linkers tailored to the individual requirements of the chemist. Such 
derivatives can be used as drug carriers, in the attachment of fluorescent or 
chemiluminescent labels or in the formation of enzyme conjugates. 
One of the most important potential applications of these derivatives is their 
use as coating antigens in the production of stable and highly sensitive biosensors 
by conjugation via their free amine terminal. It is this application that is explored 
below in the BIAcore SPR flow-through biosensor. 
Table 3.1 % Yields for Estrogen Derivatives 
Comeound 1 2 3A 38 4 5 6 7 8 
%Yield 55 53 30 43 * 27 52* 32 69 
Comeound 10 11 12 15 16 17 18 19 20 
%Yield 41 27 50 24 49 25 91 13 15 




3.3.5 Immobilisation of Free Amine Derivatives of Estrogens on the 
B/Acore Dextran Chip 
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The BIAcore biosensor has a range of sensor chips that can be used in its 
system. One of the most widely used is the CM5 carboxymethylated dextran chip, 
which presents carboxylic acid units to the surface and enables conjugation of 
primary amine-bearing compounds. Such compounds are usually antibodies or 
receptors immobilised through their amino acids. In a converse format, it is 
possible to immobilise a coating antigen on the surface to form a surface-bound 
conjugate and to use the high mass of the antibody in detection of the binding 
events. This is particularly important for small molecules that lack the mass to 
label the binding interaction themselves. Immobilisation by this method will result 
in the formation of stable covalent amide linkages. 
It is possible to immobilise primary amine containing compounds directly onto 
the carboxymethylated dextran surface of the BIAcore CM5 chip. This can be 
done by first activating the chip with EDC and NHS coupling reagents. This was 
done at a slow flow rate (5 µUmin) and with a high loading of EDC and NHS to 
ensure that the maximum number of carboxylic acid sites had been activated. The 
primary amine containing estradiol derivatives were then immobilised under 
alkaline pH in situ also at the slow flow rate (5 µUmin). In order to ensure 
saturation of all binding sites on the chip, the amines were immobilised at very 
high concentration (1 mg/mL) and at very slow flow rate (5 µUmin). The 
compounds were injected at two different pH. The first, pH 9.7, is below the 
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estimated pKa for the free amine but is still quite basic and so should result in a 
significant proportion of the primary amines being in the -NH2 form whilst not 
risking any damage to the active ester before reaction. The second pH was 11.7 
and is significantly above the projected pKa of the free amine and so can ensure 
any unreacted surface sites are bound to the free amine and saturation of the 
surface has been attained. Under both pH conditions the volumes used for 
immobilisation were very high (400 µL per flow cell for each pH). Flow cell one 
was activated with the EDC / NHS and then deactivated with the ethanolamine to 
serve as a blank reference flow cell. Flow cell two was immobilised with the 3-
hemisuccinate linked derivative (21) and flow cell three with the 2-Mannich 
linked derivative (22) and flow cell four with the 4-thioether linked derivative 
(13). All derivatives were immobilised under identical conditions. These thorough 
immobilization conditions will ensure that the surfaces are in each case 
immobilised to saturation and so comparisons between flow cells will be valid and 
not subject simply to differences in the amounts immobilised. 
After initial immobilisation, the surfaces were extensively flushed with running 
buffer (HBS-EP) until stable baseline was obtained. This flushing enabled loosely 
bound material to be removed from the sensor surface. Binding to the surface was 
then examined for both polyclonal anti-estradiol and monoclonal anti-estradiol 
antibodies. The polyclonal antibody showed no binding whatsoever to the 
immobilised surface. The possible reasons for this include firstly, that the 
polyclonal antibody is not directed specifically to the epitope of the estradiol 
molecule and so only a sub-set of the polyclonal anti-serum will bind to the 
surface thus resulting in lower binding compared to a monoclonal antibody. Also, 
the affinity constant of the polyclonal antibody is 7.3 x 109 UM compared to 1 x 
1010 UM for the monoclonal antibody and it was supplied as a somewhat dilute 
solution, though it was used here undiluted and still gave no binding. Monoclonal 
antibody binding on the other hand was found to be very strong indeed and so 
once the baseline had stabilised the surface was used in antibody binding studies. 
A BIAcore sensor chip was similarly immobilised with the corresponding 
estrone conjugates on another chip, and polyclonal anti-estrone antibody binding 
was tested. As for the estradiol, no antibody binding was seen. Monoclonal 
antibody binding could not be done as we lack a reliable commercial source of 
monoclonal anti-estrone, with most antibodies being directed to estrone-3-sulfate 
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or estrone-3-glucuronide. If we find such a source then comparable studies could 
be done on estrone. 
3.3.6 Antibody Binding Studies of the Estradiol Conjugated Surface 
Monoclonal antibody (mAb) bindings were studied for a range of mAb 
concentrations on all three flow cells to assess the level of antibody binding that 
could be achieved with each different method of conjugation. Plots of response 
















0 5 10 15 20 25 30 
mAb Concentration (µg/ml) 
Figure 3.12 Plot of Response (RU) vs Monoclonal Antibody (mAb) 
Concentration (µg/mL) for Hemisuccinate ( + ), Thioether ( • ), Manni ch ( • ) (Error 
bars are too small to see) 
From this plot, one can clearly see that the hernisuccinate conjugate has given 
very little binding at all, whereas the conjugations that have not compromised an 
existing functional group on the A-ring give much higher binding despite being 
attached at very similar points on the A-ring (2-, 3- and 4-). Saturation binding is 
shown by the curve flattening off to horizontal and occurs at around 25 µg/mL 
mAb concentration. At saturation, the binding to the 3-position hemisuccinate is 
only 2% that of the 2-position conjugate, which in tum gives binding that is 19% 
higher than that of the 4-position conjugate. The low binding of the hemisuccinate 
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in a flow-through fonnat can be explained by the conjugate modifying the 3-
hydroxyl moiety of the estradiol and so removing one of the key functional groups 
that the antibody recognises. This low binding has important ramifications for the 
use of 3-position conjugates, as it suggests that such conjugates will give much 
lower antibody binding than those that are not conjugated through the hydroxyl, 
and so give much lower signal in flow-through SPR biosensing. 3-position 
hemisuccinate conjugates are widely used as enzyme conjugates in ELISA, and 
for the attachment of chemiluminescent labels, but they are clearly of no use in a 
flow-through format such as SPR for estradiol. The low hemisuccinate binding is 
unlikely to be due to alkaline hydrolysis of the ester linkage as the hemisuccinate 
was immobilised on another SPR chip at pH .=. 4.2 for comparison and still 
showed the same low antibody binding compared to strong binding for a Mannich 
linked surface (hemisuccinate gave - 4% of the Mannich binding). 
Another important result from this data is that the Mannich 2-position 
conjugate is giving significantly more antibody binding than the 4-position 
thioether. The mAb has been raised to a conjugate at the six position and so one 
would expect that modification of the opposite side of the estradiol molecule to 
that of the immunogen conjugate attachment would result in significantly lower 
antibody binding response. It appears that the 2-position is not so far round the 
other side of the estradiol as to result in diminished binding. Mannich reaction 
conjugation at the 2-position has the same advantages as the 4-position, i.e. no 
epimerisation, and no functional group conjugation, but gives a slightly better 
mAb binding response. 
These results differ from those previously reported for fluorescent conjugates 
in non-flow-through fluoroimmunoassay where conjugates through the 2-position 
(carboxypentyloxime linkage) were found to give no binding to an antibody raised 
to a 6- position CMO conjugate, whereas thioether conjugation of the fluorescent 
label through the 4-position showed binding to the antibody. 107 The differences 
observed for the 2-position are due to the different binding formats used (flow-
through and non-flow-through) and / or the conjugation method employed. This 
shows how important the format and / or conjugation linkage of the assay or 
binding test are in determining the amount of antibody binding. Speculatively, the 
linker may be covering over the side of the steroid opposite the 6-position in the 
plate-based fluoroimmunoassay whereas in a flow-through format the linker is 
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held out from the steroid by the fluid flow with the linker end anchored to a solid 
surface so potentially allowing much better access by the antibody. 
3.3.7 17~Estradiol Assay 
With this antibody binding data in mind, it is wise to consider the ways thjs 
mjght affect the performance of an inhibition assay of estradiol. An assay was 
constructed using the antibody concentration of 1 µg/rnL (diluted to 0.5 µg/rnL 
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Figure 3.13 Assay Standard Curves for 4-Position Thioether (• ) and 2-Position 
Manni ch ( +) (Error bars are too small to see) 
One can see once again that the Mannich conjugated surface is giving higher 
binding response than the thioether surface. An assay could not be run for the 
hemisuccinate surface, as the binding responses were too low. The limits of 
detection (LOD) are 96 ± 32 pg/rnL and 111 ± 33 pg/rnL for 2- and 4-position 
conjugation respectively. The higher signal has not significantly improved the 
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LOD of the 2-position conjugate assay over the 4-position. The high standard 
errors are due to the low curve slope around the LOD. The coefficients of 
variation (CV) of the responses for these assays are quite low (1.4% and 2.6% for 
2-position and 4-position respectively). The inhibitory concentration at 50% 
bound (ICso) values are also very similar, suggesting no significant curve position 
difference. It is of interest to try and lower the detection limit by use of signal 
enhancement techniques. Such techniques are detailed fully in Chapter 5. One 
such technique developed in Chapter 5 is the use of a secondary antibody that 
binds the bound primary antibody to enhance the signal of the binding interaction 
and so hopefully produce a more sensitive assay. 
3.3.8 Secondary Antibody Signal Enhancement 
Binding of anti-mouse IgG secondary antibody to the bound primary mAb 
raised in mouse should result in a significant signal enhancement due to the 
additional large mass of the secondary antibody. This was studied at a primary 
mAb concentration of 0.5 µg/mL and a plot prepared of the response vs secondary 
antibody concentration, Figure 3.14. The binding is achieved by first injecting 
primary mAb over the surface and then immediately injecting the secondary 
antibody. In this way binding attributed to the primary mAb and the total binding 
with secondary antibody labelling can be determined. The time between primary 
mAb injection and secondary antibody injection is very short and so there is 
minimal dissociation of primary mAb before injection of the labelling secondary 
antibody. 
One can see that the final binding response has increased greatly from that of 
the primary mAb alone. Saturation binding of the bound primary mAb is 
occurring by 200 µg/mL, with only a 4% increase in signal from 200 to 300 
µg/mL. As the higher secondary antibody concentration will possibly produce 
more non-specific binding, it was deemed best to use the 200 µg/mL secondary 
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Figure 3.14 Plot of Total Response (RU) vs Secondary Antibody Concentration 
(µg/mL) for 4-Position Thioether (• ) and 2-Position Mannich (+) (Error bars too 
small to see) 
To determine the effect of changing primary mAb concentration on the total 
signal, a plot of response vs primary mAb concentration was prepared at fixed 
secondary antibody concentration (200 µg/mL), Figure 3.15. 
This plot shows the high level of signal enhancement obtained with secondary 
antibody labelling. With higher primary mAb levels, the enhanced signal is 
levelling off, suggesting that maximum secondary antibody binding has been 
achieved at the high mAb concentrations. A higher secondary antibody 
concentration would keep the binding line linear by having enough to fully label 
the primary mAb at higher concentrations, but would also potentially increase 
non-specific binding. The 4-position thioether surface gives very similar curves to 
this but at slightly lower signal. The linear range of these curves for the 2-position 
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Figure 3.15 Plot of Response (RU) vs Primary mAb Concentration (ng/mL) for 
Primary mAb only (+) and Secondary Antibody Enhanced Response (• ) for 2-
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Figure 3.16 Linear Plot of Response (RU) vs Primary mAb Concentration 
(ng/mL) for Primary mAb only (+)and Secondary Antibody Enhanced Response 
(• ) for the 2-Conjugate Surface (Error bars too small to see) 
From the slopes of the linear plots one can determine the degree of signal 
enhancement obtained. These plots show signal enhancements of 9.5-fold for the 
2-position and 8.9-fold for the 4-position. This is much larger than would be 
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expected for simple 1: 1 mAb to secondary antibody binding on the basis of mass 
alone. For a fuller discussion of this phenomenon see Chapter 5. The plots are 
very linear (R2 near 1) and the error bars are too small to see on the plot. The 
intercepts of these lines give the non-specific binding of the primary mAb (4.0 
RU) and the secondary antibody enhancement (93 RU). Enhancements obtained 
here are slightly better than those obtained with secondary antibody alone in 
Chapter 5. The difference is likely simply due to differences in binding affinity 
between the two antibodies. About 100 RU of specific binding response is all that 
is needed for a reliable inhibition assay and this was obtained at a primary mAb 
concentration of about 25 ng/mL. The CVs for the entire antibody binding studies 
have been very low, resulting in small error bars on the plots and demonstrating 
the excellent stability of the coated surface. 
An assay was then constructed for estradiol using the 25 ng/mL final primary 
mAb concentration and secondary antibody signal enhancement at a loading of 
200 µg/mL. The assay standard curve is plotted in Figure 3.17 with the 4-
parameter logistic regression line shown. 
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Figure 3.17 Assay Standard Curve for Secondary Antibody Enhanced Inhibition 
Assay of Estradiol Using 2-position Conjugated Surface Using a 4-Parameter 
Logistic Curve Fitting 
144 
The parameters for all the assays mentioned in this chapter are summarised in 
Table 3.2. All the assay curve data has been fitted to 4-parameter logistic 
relationships as mentioned in Chapter 1. This fitting gave good R2 values with the 
data and is in line with standard methods for immunoassay curve data fitting. 
The LOD for the primary mAb only part of the assay, appear to have decreased 
somewhat for 2-position Mannich conjugate but not for the 4-position, however it 
is very difficult to draw firm conclusions as the standard errors in the WD are too 
large, caused by shallow curve slope and slightly higher CV. The WD for the 
enhanced assay is significantly lower for the 2-conjugate but not the 4-conjugate 
and in any event has not lowered anywhere near as much as one would expect 
with this level of primary mAb concentration reduction. The primary mAb 
concentration has been reduced to 1120th of what it was originally and so one 
would expect an LOD of around 5 pg/mL; instead the best LOD is 5-times that. 
The reason for this is unclear. 
Table 3.2 Assay Parameters For Estradiol SPR Assays 
PrimarymAb LOO IC50 Sensitivity 
Enhancement 
Assa:z: Format Conjugation Position Concentration !nS,!mq !eS,!mq !eS,!mq !RU.ml/ngl 
mAbOnly 2 500 96±32 1457 ±9.6 22 
mAbOnly 4 500 111 ±33 1432 ± 14 16 
mAbOnly 2 25 66±27 414.9±5.9 6.9 
mAbOnly 4 25 95.2±32 351 ± 14 4.1 
Secondary Antibody 2 25 25±22 324±21 65 
Secondary Antibody 4 25 61 ±39 396±28 41 
•Au errors quoted are 
standard errors 
The IC50 values show a drop to about l/3ro of their original value when the 
primary mAb concentration is dropped, and this is seen in both enhanced and non-
enhanced assays and so is due to the lowering of the primary mAb only, as 
expected. This drop in IC50 has not been in direct proportion to the lowering of 
primary mAb concentration and in fact has dropped less than the LOD. The slope 
sensitivity of the assay is significantly improved with enhancement, changing 
from 16-22 RU.mUng to 41-65 RU.mUng. This occurs more because the assay 









because the primary mAb concentration has been dropped. The standard curve in 
Figure 3.17 has been corrected for non-specific binding from the secondary 
antibody, though this non-specific binding does not appear to in any way affect 
the performance of the assay. The absorbance CVs for the assay, at an average of 
4.6% and 6.1 % for the 2- and 4-position assays respectively, showed good 
precision for the assays. 
These estradiol assays represent the most sensitive reported SPR 
immunoassays of estradiol. The only previous report of estradiol SPR 
immunoassay relies upon unstable estradiol-BSA surface coatings and 
demonstrates an LOD of 200 pg/mL, i.e. 8-fold higher than is reported here.247 
Furthermore, they require manual mixing and manual injections of solutions and 1 
h incubations at 4 °C making the assay unsuitable for rapid, automated testing and 
do not use site or bridge heterology.247 Previous SPR studies have also used 
receptor binding assay for estradiol. 163•248 One system163 uses amine-mediated 
immobilisation of estradiol through the 17-hemisuccinate and estradiol assayed 
through competition assay with human estradiol receptor-a.. This assay gave a 
very poor LOD for estradiol (5 nM corresponding to 1.4 µg/mL, i.e. about 5 
orders of magnitude higher than the assay reported here). Another study 
demonstrated inhibition of receptor binding to an estradiol-BSA functionalised 
surface by estradiol but did not fully develop an estradiol assay.248 Estradiol is a 
very important marker of ovarian function in women. Monitoring of estradiol 
levels is needed for in vitro fertilisation monitoring as well as in environmental 
sampling of estrogen levels. Many biological fluids, such as saliva, have only very 
low levels of estradiol present, i.e. high fg/mL or low pg/mL concentrations. The 
assay results presented here represent a significant improvement in the ability of 
optical biosensors to detect low (pg/mL) quantities of estradiol. The results show 
how optical biosensors could be used as replacements of ELISA technology for 
routine analysis of estradiol samples thus greatly improving sensory technology in 
this area. 
There has been a dearth of studies in the area of estrogen binding interactions 
with antibodies studied using SPR technology, particularly with a view to 
producing optical biosensors. Estrone-3-glucuronide has been detected with 
Texas-instruments-based SPR technology, but this has only produced LOD of 10 
ng/mL.249 
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The use of the estrogen - OEG compounds, as coating antigens has been vital 
to ensuring the long-term stability of the surface. The surfaces produced here have 
shown stable binding responses over more than 200 cycles and are likely to be 
stable for over 1000 cycles in light of the success achieved with comparable 
progesterone surfaces, see Chapter 5. If an antibody had been coated or a protein 
conjugate produced and then coated on the surface, the stability would certainly 
be much poorer than the covalently immobilized surface used. Lack of surface 
stability in biosensors is a major problem limiting their widespread use. 
Production of such surf aces using the covalent attachment method and non-
immunogenic OEG chains has been shown to go a long way to overcoming these 
problems. The use of the OEG bridge minimises bridge recognition. It does this 
by being non-immunogenic and also because it is a different linker to that 
employed in the conjugate used to raise the antibody and so introduces bridge 
heterology. If binding to the bridge were to occur, this would reduce the 
specificity of the binding interaction and potentially its binding to the bridge could 
be stronger than that to free estradiol and so reduce the levels of inhibition 
attained and increase the LOD of the assay. 
Throughout all of the binding studies and assays, the regeneration cocktail used 
has been a combination of sodium hydroxide and the chaotrophic reagent 
acetonitrile. This combination regenerated the OEG-linked surfaces quite well 
with no deterioration in the surface detectable. The surfaces seem quite stable and 
there is no decline in binding capacity from cycle to cycle. In the early cycles over 
the surface, the regeneration pulses removed loosely bound material from the 
surface. All surfaces were fully stabilised before antibody binding studies and 
assays were commenced. Less alkaline regeneration solutions such as sodium 
carbonate or bicarbonate and lower concentrations of sodium hydroxide proved 
ineffective in regenerating the surface, as did solutions without acetonitrile. This 
combination has been used to good effect in the studies in Chapter 5 for 
progesterone and seems equally as effective with estradiol. For a more thorough 
discussion of these factors, see Chapter 5. 
These results show how important it is to have a thorough knowledge of the 
factors affecting assay antibody binding before developing immunoassays of 
small molecules. The widely used hemisuccinate method of linkage is clearly not 
appropriate for use in flow-through immunoassay of estradiol, giving very poor 
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antibody binding. Binding at either 2- or 4-positions is much better. Surprisingly it 
has been seen in these results that if the antibody is raised to the 6-position, then 
conjugation to the 2-position is still close enough to the same side of the antigen 
as to result in high antibody binding, even better than the 4-position. Conjugation 
on the opposite side of the molecule to that used for antibody generation could be 
expected to result in loss of shape recognition and so greatly diminished binding. 
The Mannich reaction still has major limitations when used as a one-step method 
for protein conjugation but if it is used to attach linkers to the steroid structure, 
then it can give excellent binding results when such a linker derivative is used as a 
coating antigen. The 4-position thioether method still gives strong antibody 
binding, and in these studies has similar assay performance to the 2-position 
Mannich conjugation. 
3.4 Conclusions 
Thioether bridging can be applied to estrogens where there is an aromatic A-
ring. This has been done through substitution of the corresponding estrogen 
brominated at the 4-position. By using 3-mercaptopropionic acid as the thiol, one 
can introduce a carboxylic acid group to the compound and thus allow attachment 
of a wide range of linkers through amide coupling. OEG linkers of varying length 
have been attached to estradiol and estrone through the 4-propionate using NHS 
activation of the carboxylic acid and protection of one of the linker terminal amine 
functions. Once attached, the Boe protecting group may be removed by formic 
acid exposure when the compound is ready for use. 
Estrogen-OEG-amine derivatives can be conjugated to the surface of an 
activated carboxymethylated dextran surface in situ using high loadings of 
estrogen derivatives and slow flow rates and varied pH to ensure saturation of the 
surface. The thioether-conjugated surface was then compared to reference 
compounds also with the same OEG linkage attached to the steroid through the 3-
hemisuccinate or the 2-position Mannich reaction. Antibody binding studies 
showed that the 2-position Mannich conjugation was best for flow-through 
binding formats, followed by the 4-position, and the 3-position giving very little 
antibody binding at all. 
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Assays for estradiol were constructed with and without secondary antibody 
signal enhancement and showed LOD of 96-111 pg/mL without enhancement and 
25-61 pg/mL with enhancement. Secondary antibody enhancement ratios varied 
from 8.9-9.5. The surface was completely stable throughout all binding studies 
and assays (over 200 cycles). This represents the most convenient, sensitive and 
robust reported SPR immunoassay of estradiol. 
These results have clearly indicated that conjugation of the estrogens through 
an existing functional group (3-0H) is highly inferior to conjugation through 
other aromatic A-ring positions not bearing functional groups (2- or 4-position) 
for flow-through immunoassays. Although the 2-position conjugation has given 
slightly better antibody binding than conjugation at the 4-position, synthesis of 4-
thioethers offers a better synthetic method of conjugation for the estrogens in that 
attachment is specific to one position and does not require difficult column 
purification of isomers. The thioether synthetic route is straightforward and allows 
for a range of different intermediate linkers to be attached to the parent steroid. 
This study opens a wide range of possible assay formats for small molecules 
including new conjugation techniques and new biosensor surface modifications. 
This assay system could easily be modified to detect the estrogen mimics, which 
are one potential group of analytes of great interest for their environmental and 
health impacts. This research demonstrates how biosensors and small-molecule 
conjugates may be significantly improved by an understanding of the underlying 
organic chemistry involved in antibody epitope recognition and contributes to on-
going studies in the development of more sensitive, stable and rapid 
immunobiosensors. 
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Chapter 4 - Catecholamine Thioether-Linked 
Derivatives - Synthesis, Purification and 
Antibody Binding Studies 
4.1 Introduction 
The catecholamine neurotransmitters and hormones are another class of 
aromatic small biomolecules that are of great interest for quantification in 
biosensors, particularly at the often-low concentrations prevalent in many 
samples, including vertebrate brain dialysates. The catecholamines can be 
chemically modified to produce conjugates that are of great interest and have 
various applications. One can attach linkers to them to produce protein 
conjugates that can be used to raise antibodies250• 251 or as immobilisation agents 
in immunosensing. There is potential also to attach linkers to them to produce 
drug conjugates that can be targeted to particular tissues expressing receptors for 
the target compound, or to also produce conjugates with chemiluminescent, 
enzyme or fluorescent labels for applications in immunosensing or high-
throughput screening. 
There has been a dearth of studies into the synthetic routes that can be 
employed to synthesise these conjugates and in systematic studies of their 
antibody or receptor binding properties. It is of much interest to consider how the 
position of attachment, whether to the aromatic ring directly or not, and the 
method of attachment may affect the ability of an antibody or receptor to 
recognise the target conjugate. The only studies of conjugates of the 
catecholamines have employed either conjugation directly through an existing 
functional group such as the amine terminal, the amine being crucial for receptor 
or antibody recognition; or through use of the Mannich reaction, 172• 173• 175• 176 
which produces conjugates attaching ortho to a phenol moiety. 
Conjugation through the primary amine has been effected by the 
glutaraldehyde method,252• 253• 250• 254 which links the primary amine of the 
catecholamine to amines present in the carrier protein. Naturally such a reaction 
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will modify the primary amine and so remove a major part of the set of functional 
groups needed to recognise the catecholamine target. This is of particular concern 
with very small molecule targets like the catecholamines where there are few 
functional groups to begin with and little uniqueness in the shape of the target. 
Carbodiimide linkage through the amine has the same problems,251 · 255 as would 
any conjugation through the hydroxyl moieties. It has been shown that 
conjugation by glutaraldehyde and carbodiimide results in changes of charge in 
the hapten and a sterically different hapten structure.255 Further studies with 
protein conjugates of the catecholamines linked through the glutaraldehyde 
method and used to raise antisera, show that these antisera will bind the original 
protein conjugate well in ELISA but bind very poorly to the free catecholamines, 
thus further reinforcing the inadequacy of this method.250 The glutaraldehyde 
method of conjugation is widely used in immunocytochemistry for a range of 
catecholamine neurotransmitters. 256 
The problem with the Mannich reaction is that the reaction does not direct to a 
single position of attachment, and gives mixtures of conjugates with different 
positions of attachment when the conjugation reaction is performed in the 
preferred one-step process. In order to achieve attachment direct to the aromatic 
ring by the Mannich reaction,256 any primary amine of the catecholamine has to be 
protected before the conjugation otherwise the reaction will occur through free 
amines as well as direct to the aromatic ring and may produce dimers. Whilst the 
Mannich reaction can be used for conjugation to the aromatic ring if adequate 
protection can be used and position of attachment identified, it is possible to have 
an alternative that can be easily synthesised and also allows direct attachment to 
the aromatic ring by production of a thioether derivative. The problems with the 
Mannich reaction have been outlined in previous work, with conjugates of 
serotonin linked in this way to generate antibodies, resulting in the antibody 
binding the conjugated serotonin strongly but the free serotonin very weakly.251 
Thioether linkages offer significant potential for conjugation to the aromatic 
ring without the problems inherent in use of the Mannich reaction. Thioether 
· J h' d · h b d251 25s 259 d' . conJugates to g utat 1one an cysteme ave een reporte · · procee mg via 
production of the o-quinone and subsequent addition of a thiol-containing 
compound, a route possible only through ortho-dihydroxylated aromatics and so 
unavailable for use with 17~-estradiol and estrone. These cysteine and 
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glutathione conjugates have also been synthesised by enzyme-catalysed routes.260• 
261 Such thioether derivatives are well known metabolites of the 
catecholamines.262' 263' 264' 265 • 266 6-Mercaptodopamine has been synthesised by 
thiocyanation.267 Thioether bridging would produce stable compounds that could 
be easily reacted further with other intermediate linkers to produce conjugates. 
The ultra-polar nature of these compounds would make purification in reasonable 
quantities a significant challenge, though any purification could be observed 
clearly by UV-Visible detection by HPLC. If mercaptoalkanoic acids are used as 
the reacting thiol, then linkers can be attached that will terminate in a carboxylic 
acid, thus enabling activation with NHS / DCC and subsequent conjugation to 
amines in a carrier protein or label, which is a reliable and repeatable method. 
These novel compounds would be of much interest in antibody and receptor 
binding studies to systematically assess how changes to target structure in the 
formation of conjugates affects the antibody or receptor binding abilities of those 
conjugates. Antibodies and receptors recognise their targets according to shape 
and functionality and these conjugations should provide the minimum of 
disruption to the antibody or receptor binding abilities as attachment does not 
compromise existing functional groups and linkers provide adequate projection of 
bound label, protein or surface out from the target to allow full binding around 
virtually the whole hapten. With a wide range of catecholamines available, it 
would be anticipated that the synthetic techniques could be applied broadly to all 
catecholamines with a-hydroxyl groups. 
Reported below is the synthesis of thioether-bridged catecholamine derivatives 
for dopamine, nor-epinephrine and epinephrine using 3-mercaptopropionic acid 
(MPA) and 11-mercaptoundecanoic acid (MUA) as the intermediate attaching 
linkers, which attach directly to the aromatic ring. These compounds are purified 
using ion-exchange chromatography techniques or normal-phase silica 
chromatography and their purification is profiled by their characteristic HPLC 
absorbance patterns. The purified compounds are characterised and their 
positions of attachment determined with the aid of 2-dimensional NMR 
spectroscopy. The dopamine mercaptopropionate derivative is then immobilised 
onto an SPR chip surface specially modified with amine-bearing functional 
terminals and the bindings to a monoclonal antibody are studied using BIAcore 
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and compared to immobilisation via existing functional groups and different 
linker types. 
4.2 Experimental 
4.2.1 Materials and Instruments 
4.2.1.1 General 
Dopamine HCI and nor-epinephrine bitartrate were purchased from Sigma 
(dopamine as the racemate and nor-epinephrine as the R-isomer) and epinephrine 
was purchased from Aldrich (R-isomer). All other chemicals were from Aldrich. 
All solvents used were analytical grade except for the HPLC solvents that were 
HPLC reagent grade ACS. Solvents used were from Scharlau (Barcelona, Spain). 
The silica gel used in column chromatography and the TLC plates were as for 
Chapter 3. Melting point determinations, NMR analysis and electrospray mass 
spectrometry and high resolution mass spectrometry were all done as for Chapter 
3. All products synthesised and isolated using the electrochemical methods were 
purified to one significant HPLC peak. 
4.2.1.2 HPLC and Antibody Studies 
HPLC was performed on a Shimaclzu instrument composed of the following 
modules: Autoinjector (SIL-lOAD VP), pumps (LC-lOAD VP), UV/visible 
detector (SPD-MlO A VP), thermostatted oven (CTO-lOAC VP) and a system 
controller (SCL-lOA VP). The UV-visible chromatograms and spectra plots were 
analysed using Class-VP software 5.032 1999. The column used was a Prodigy, 3 
µm ODS 100 x 4.6 mm, OOD-4243-EO, 111274-4 from Phenomenex (Milford, 
Auckland, New Zealand). All mobile phases used were mixed, pH adjusted, 
filtered through a Nylon 47 mm diameter, 0.45 µm filter and degassed before use. 
The HPLC had a degasser also. 
BIAcore analysis was done using the same instrument specifications as in 
Chapter 3 and using a CMS sensor chip (research grade). The monoclonal 
antibody used was mouse anti-human dopamine (US Biological, Swampscott, 
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USA, D9000) raised to dopamine-BSA conjugate conjugated through the primary 
amine using the glutaraldehyde method, and with an affinity of -1 x 107 UM. 
The ion-exchange column was a Dowex-50W strongly acidic cation exchange 
resin column (10 g of dry resin slurry packed in deionised water into a glass 
column to give a bed of dimensions 15 mm x 150 mm). The resin had been 
thoroughly washed with deionised water, acetone, methanol and deionised water, 
2 M HCl and deionised water again, dried down with diethyl ether and vacuum 
drying and re-hydration in deionised water before use. 
4.2.2 Dopamine Thioether Derivatisation by Aromatic Substitution1 
4.2.2.1 5-(2-Aminoethyl)-x-bromobenzene-1,2-diol (1) 
Dopamine (400 mg, 2.12 mmol) was dissolved in dry methanol (30 mL) and N-
bromosuccinimide (NBS) (375 mg, 2.12 mmol) was added and the solution stirred 
at room temperature in the dark for 24 h. The solution then had the solvent 
removed and was reconstituted in distilled water (50 mL) and washed with 
chloroform (2 x 25 mL, 1 x 50 mL) and the solvent removed from the aqueous 
phase. The sample was reconstituted in methanol and decoloured thoroughly with 
activated charcoal. The solvent was then removed to yield 1 as a brown oil. 
Yield: 71% (347 mg, 1.51 mmol). TLC Rr = 0.62 (40:1 MeOH: acetic acid). IR 
(KBr disc): 1189 (phenol C-C-0 out of phase u), 3410 (OH u) cm-1• 1H NMR 
(D20) 6: 2.94 (2H, t, J = 7.2 Hz, Ar-CH2), 3.17 (2H, t, J = 6.9 Hz, +NH3-CH2), 
6.74 (lH, m, 2-CH), 6.92 (lH, m, 6-CH); 13C NMR 6: 31.0 (Ar-C) 39.4 (C-NH/), 
115.7 (2-C), 116.5 (5-C), 116.6 (6-C), 117.0 (1-C), 118.0 (4-C), 124.2 (3-C); ES-
MS m/z (MeOH, 20 V) 230.7 and 232.7 [M+Ht. HiRes FAB-MS: Calculated: 
230.9895, 232.9874, Found: 230.9902, 232.9893 (MW). 
4.2.2.2 3-(5-(2-Aminoethyl)-2,3-dihydroxyphenylthio)propanoic acid (2A) 
1 (338 mg, 1.46 mmol) was dissolved in dry methanol (5 mL) and 3-
mercaptopropionic acid (380 µL, 4.37 mmol) was added and the solution stirred 
1 For reaction scheme seep. 166 
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vigorously. Methanolic KOH (200 mg in 5 mL of dry methanol) was added with 
vigorous stining. The solution was then refluxed for 24 h in the dark in oven-
dried glassware and with a drying tube. The solvent was removed and the sample 
constituted in distilled water (25 mL) and washed with ethyl acetate (2 x 12.5 mL, 
1 x 25 mL). The aqueous phase then had its pH adjusted to 1 with 2 M HCI 
solution and then to 10 with 2 M NaOH solution which produced a cream 
coloured solid flock, which was then separated from the supernatant by a 
combination of gravity settling and centrifugation to yield 2A. Yield: 9% (35 mg, 
0.135 mmol). IR (KBr disc): 1200 (phenol C-C-0 out of phase u), 1401 (CH2 
deformation), 1561 (COO-), 3449 (OH u) cm-1• 1H NMR (D20) o: 2.53 (2H, t, J = 
9.4 Hz, CH2-COO-), 2.6-2.75 (2H, m, CH2-Ar), 2.86 (2H, t, J = 9.4 Hz, S-CH2), 
3.06 (2H, q, J = 9.1 Hz, CH2-N), 6.39-6.62 (2H, m, aromatic protons). 13C NMR 
(D20) o: 30.0 (CH2-S), 34.7 (CH2-COO-), 36.9 (CH2-Ar), 40.7 (CH2-NHt), 116 
(C-2), 119 (C-5), 124 (C-6), 127 (C-1), 172 (COO); ES-MS m/z (-20 V, H20) 
253.9 [M-Hr. Mass peak corresponds to the o-quinone form, see section 4.3.1. 
4.2.3 Catecholamine-Thioether Synthesis by Electrolysis2 
4.2.3.1 3-(5-(2-Amino-ethyl)-2,3-dihydroxyphenylthio)propanoic acid (2B) 
Dopamine (30 mg, 0.158 mmol) was dissolved in 0.1 M HCI (80 mL). The 
solution had a voltage of 2 V applied across it between two pressed graphite bar 
electrodes and was vigorously stirred to prevent air bubble formation. The 
electrolysis was conducted over 2.5-3 h and the initially colourless solution soon 
turned bright yellow and then bright orange. The formation of the coloured o-
quinone was monitored by HPLC. Once maximum o-quinone formation had 
occurred, 10%v/v 3-mercaptopropionic acid solution (413 µL, 0.473 mmol in 
O. lM HCI) was added rapidly with vigorous stining. The reaction was monitored 
and was left overnight as a precaution to ensure maximum product formation. The 
raw reaction mixture was pH adjusted to 5 with 2 M and 0.1 M NaOH with 
vigorous stining to prevent isolated pockets of base destroying the compound. 
2 For reaction scheme see p. 167 
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The solution was then poured onto a Dowex-50W strongly acidic cation 
exchange resin column. The solution was eluted straight through the column and 
the column thoroughly flushed with deionised water until no more 3-
mercaptopropionic acid was observed eluting from the column. The 3-
mercaptopropionic acid could be seen in the eluant by HPLC, Figure 4.10, with no 
other compounds eluting straight through. The column was then flushed with HCl 
(1 M), ethanol (10%v/v) and fractions collected (10-20 mL). Fractions were 
analysed at regular intervals by HPLC to determine their content. Yield: 34% (14 
mg, 0.0545 mmol). Mp: decomposes. IR (K.Br disc): 1241 (phenol C-C-0 u), 
1400 (CH2 deformation or COO- u), 1638 (Coo- u), 3434 (OH u) cm-1• 1H NMR 
(D20) 6: 2.49 (2H, t, J = 1.9 Hz, CH2-COO-), 2.72 (2H, t, J = 9.2 Hz, CH2-Ar), 
2.95 (2H, t, J = 1.0 Hz, CH2-S), 3.07 (2H, t, J = 9.2 Hz, CH2-N), 6.68 (lH, s, 2-
H), 6.77 (lH, s, 6-H). 13C NMR (D20) 6: 28.6 (CH2-S), 32.0 (CH2-COO-), 34.1 
(CH2-Ar), 40.6 (CH2-NHt), 116.5 (2-C), 120.5 (5-C), 125.3 (6-C), 129.3 (1-C), 
144 (4-C), 144.5 (3-C). ES-MS mlz (MeCN: H20 1:1 5 V) 258.9 [M+Ht. 
4.2.3.2 11-(5-(2-Aminoethyl)-2,3-dihydroxyphenylthio )undecanoic acid (3) 
Dopamine (30 mg, 0.158 mmol) was dissolved in HCl solution (80 mL, 0.2 M 
in 1:1 MeCN: H20) and electrolysed at 2 V with vigorous stirring for 2.5 h. The 
ortho-quinone formation was followed by HPLC and the current was observed to 
drop from 20 mA to 9 mA within 30 min. 11-Mercaptoundecanoic acid (104 mg, 
0.475 mmol, in 6 mL of 50%v/v MeCN, 0.2 M HCl total) was added rapidly to 
the vigorously stirring solution. Colour was observed to fade gradually until by 
30 min there was no significant colour left. The raw reaction solution after 
running for 1 h (no further changes detected by HPLC) was pH adjusted to 5 
carefully with 2 M NaOH and then 0.1 M NaOH. The solution was run into a 
Dowex strongly acid cation exchange column as before (10 g) with the column 
first regenerated by washing with 100 mL of 2 M HCl and then deionised water 
until washings were stable at pH 3.5. The column was then washed extensively 
with 50%v/v MeCN to remove all 11-mercaptoundecanoic acid. HPLC analysis 
revealed that MUA · alone eluted through the column and all other compounds 
were retained. 
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The column was then eluted with the following elution scheme to 
chromatographically separate the products and reactant: 
1020 mL eluted at 10%v/v EtOH IM HCI total (2 x 20 mL, 18 x 10 mL, 40x20 
mL) 
100 mL eluted at 20%v/v EtOH IM HCI total (5 x 20 mL) 
100 mL eluted at 30%v/v EtOH IM HCI total (5 x 20 mL) 
400 mL eluted at 40%v/v EtOH IM HCI total (20x20 mL) 
100 mL eluted at 50%v/v EtOH IM HCI total (5 x 20 mL) 
100 mL eluted at 20%v/v EtOH 2M HCI total (5 x 20 mL) 
Fractions were combined and solvent removed (in vacuo) and sample dried 
(vacuum line) extensively. Yield: 16% (9.2 mg, 0.025 mmol). IR (film): 1413 
(Coo- u), 1638 (COO- u), 2855 (-NH/ u, CH2 symmetric u), 2929 (CH2 
asymmetric u), 3437 (OH u) cm-1• 1H NMR (D20) 8: 1.21 (IOH, main chain CH2 
of MUA), 1.36 (2H, MUA), 1.56 (4H, MUA), 2.36 (2H, CH2-COO-), 2.87 (2H, 
CH2-S), 2.88 (2H, CH2-Ar), 3.22 (2H, CH2-N), 6.78 (IH, m, 2-H), 6.88 (IH, m, 6-
H). 13C NMR (D20) 8: 24.3 (MUA chain), 28.3 (MUA chain), 32.1 (CH2-COO-), 
33.3 (CH2-S), 33.9 (CH2-Ar), 40.6 (CH2-NH3 +), 115.5 (2-C), 122.6 (5-C), 123.8 
(6-C), 129.3(1-C), 143.0 (4-C), 144.4 (3-C), 179.1 (COOH). ES-MS m/z 
(CH3CN: H20 1:1) 370.6 [M+Ht. Hi-Res FAB-MS: Calculated: 370.2052, 
Found: 370.2047 MW. 
4.2.3.3 3-(2-(2-Amino-l-hydroxyethyl)-4,5-dihydroxyphenylthio )propanoic acid 
(4) 
Nor-epinephrine bitartrate (40 mg, 0.125 mmol) was dissolved in HCI solution 
(80 mL; 0.1 M) and electrolysed at 2 V until maximum conversion to ortho-
quinone was observed (usually 2 h). 3-Mercaptopropionic acid (328 µL of 1/10 
solution in 0.1 M HCI, 0.375 mmol) was added with rapid stirring and the bright 
orange colour left the solution immediately. The reaction was stirred vigorously 
overnight. The reaction mixture was adjusted to pH 5 with 2 M NaOH and 0.1 M 
NaOH before eluting into a regenerated Dowex column (as before) and then being 
flushed with deionised water until no more MPA was visible eluting from the 
column. The column was then eluted using the following eluant scheme: 
100 mL 0.01 M HCI 
100 mL 0.1 M HCI 
100 mL 0.1 M HCI 10%v/v EtOH 
100 mL 0.2 M HCI 
460 mL 0.4 M HCI 
100 mL 0.3 M HCI 10%v/v EtOH 
100 mL 0.3 M HCI 
700 mL 0.4 M HCI 
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Yield 41 % (14 mg, 0.0512 mmol). IR (film): 1193 (CH2 wag), 1470 (CH2 
deformation), 1633 (COO- u), 3450 (OH u) cm-1• 1H NMR (D20) 6: 2.67 (2H, t, J 
= 7.2 Hz, CH2-COO-), 3.15 (2H, m, CH2-S), 3.27 (2H, m, CH2-N), 4.55 (lH, s, 
CH-OH), 6.91 (lH, s, 2-H), 7.07 (lH, s, 5-H). 13C NMR (D20) 6: 40.5 (CH2-
COO-), 41.0 (CH-NH/), 123 (6-C), 129 (1-C), 139 (3-C or 4-C). ES-MS m/z 
(MeCN: H20 1:1, 20 V) 274.3 [M+Ht. 
4.2.3.4 11-(2-(2-Amino-1-hydroxyethyl)-4,5-dihydroxyphenylthio )undecanoic 
acid (5) 
Nor-epinephrine bitartate (40 mg, 0.125 mmol) was dissolved in HCI solution 
(80 mL; 0.2 M in 1:1 MeCN: H20) and electrolysed at 2 V until maximum 
conversion to ortho-quinone was observed (2 h). 11-Mercaptoundecanoic acid 
(82 mg, 0.375 mmol in 5 mL of 0.2 M HCI in 1:1 MeCN: H20) was added 
quickly to the rapidly stirring solution. After 1 h the colour had almost 
completely disappeared though colour loss was a lot slower than the 
corresponding 3-mercaptopropionate derivative, with distinct strong colour still 
persisting at 20 min. The solution was left stirring overnight at a reduced speed. 
The reaction mixture was pH adjusted to 5 with 2 M NaOH and 0.1 M NaOH as 
before and then eluted into the column and the column flushed with 50%v/v 
acetonitrile in deionised water until all the MUA had eluted according to the 
HPLC analysis. The column was then eluted using the following elution scheme: 
700 mL 0.4 M HCI 
600 mL 0.6 M HCI 
200 mL 0.6 M HCI total 10%v/v EtOH 
200 mL 0.6 M HCI total 20%v/v EtOH 
100 mL 0.8 M HCI total 10%v/v EtOH 
100 mL 1 M HCI total 10%v/v EtOH 
100 mL 1 M HCI total 20%v/v EtOH 
100 mL 1 M HCI total 30%v/v EtOH 
300 mL 1 M HCI total 20%v/v EtOH 
300mL IM HCI total 30%v/v EtOH 
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Yield 28% (14 mg, 0.0353 mmol). IR (film): 1456 (CH2 deformation), 1616 
(COO- u), 3394 (OH u), 3429 (OH u) cm·1• 1H NMR (020) 6: 1.15 (12H, m, 
MUA chain CH2), 1.44 (4H, m, MUA CH2), 2.26 (2H, m, CH2-Coo·), 2.62 (2H, 
m, CH2-S), 3.10 (2H, m, CH2-NHt), 6.92 (lH, m, 2-H), 7.07 (lH, m, 5-H). 13C 
NMR (020) 6: 24.3 (MUA chain CH2), 28.7 (CH2-S), 115.8 (2-C). ES-MS mlz 
(MeCN/H20, 20 V): 386.5 [M+Ht. HiRes FAB-MS: Calculated 386.2001, Found 
386.2010 (MW). 
4.2.3.5 3-( 4,5-dihydroxy-2-( 1-hydroxy-2-
(methylamino )ethyl)phenylthio )propanoic acid (6) 
Epinephrine (30 mg, 0.164 mmol) was dissolved in aqueous HCI (0.1 M; 80 
mL) and electrolysed at 2 V until maximum ortho-quinone formation was 
observed by HPLC. 3-Mercaptopropionic acid (428 µL, 0.491 mmol diluted 1/10 
in 0.1 M HCI) was then added quickly to the rapidly stirring solution. The 
solution changed from bright orange through green to a very deep green, almost 
black after 30 min. At 30 min reaction the columning process was begun. Rather 
than using an ion-exchange column, the epinephrine derivatives were purified 
using conventional phase chromatography on silica gel, Merck 60 A, grade 9385, 
230-400 mesh. For compound 6 the elution was MeCN, 5%v/v H20 in MeCN, 
10%v/v H20 in MeCN, 20%v/v H20 in MeCN, 10% 0.01 M HCI in MeCN, 10% 
0.1 M HCI in MeCN, 20% 0.1 M HCI in MeCN, 10% 1 M HCI in MeCN, 20% 2 
M HCI in MeCN and 2 M HCI. Yield 21% (10 mg, 0.035 mmol) Mp: 
decomposes. IR (KBr disc): 1123 (CH-OH u), 1638 (Coo· u), 3447 (OH u) cm· 
1• 1H NMR (D20) 6: 2.75 (3H, s, NH-CH3), 2.86 (2H, t, J = 6.7 Hz, CH2-COO-), 
3.01 (2H, t, J = 7.1 Hz, CH2-S), 6.91-7.09 (2H, m, aromatics). 13C NMR (D20) 6: 
16.7 (CH3-N), 28.7 (CH2-S), 42 (CH2-COO-), 57.4 (CH2-N), 115 (2-C), 117 (5-
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C), 126 (6-C), 130 (1-C), 138 (4-C), 140 (3-C), 167 (COOH) (low resolution for 
peaks at 42 and 115-167 ppm). ES-MS m/z (CH3CN: H20 1:1, 30 V) 288.5 
[M+Ht. (H20, 5 V): 214.5 [M-amine side chain+ H]+, 306.3 [M+H20+Ht. 
4.2.3.611-(4,5-dihydroxy-2-(l-hydroxy-2-
(methylamino)ethyl)phenylthio)undecanoic acid (7) 
Epinephrine (30 mg, 0.164 mmol) was dissolved in HCl solution (80 mL; 0.2 
M in 1:1 MeCN: H20) and electrolysed at 2 V until maximum ortho-quinone 
formation was observed by HPLC. 11-Mercaptoundecanoic acid (107 mg, 0.491 
mmol, in 9 mL 0.2 M HCl in 1:1 MeCN: H20) was added to the rapidly stirring 
solution. The colour changed from bright orange to colourless slowly but did not 
go black. The reaction was allowed to proceed overnight before columning. This 
compound was also purified using conventional phase silica and using an elution 
sequence of MeCN, 5% H20 in MeCN, 10% H20 in MeCN, 20% H20 in MeCN 
and 10% 0.1 M HCI in MeCN. Yield 36% (24 mg 0.0596 mmol), Mp: 
decomposes. IR (KBr disc): 1120 (CH-OH u), 1638 (Coo- u), 3437 (OH u) cm-
1. 1H NMR (D20) 6: 1.24 (lOH, s, MUA chain CH2), 1.33 (2H, m, MUA chain 
CH2), 1.51 (2H, m, MUA chain CH2 13 to COOH), 1.66 (2H, m, MUA chain CH2 
13 to S), 2.23 (2H, t, J = 9.8 Hz, CH2-COOH), 2.71 (3H, m, N-CH3), 2.84 (2H, m, 
CH2-S), 3.13 (lH, m, CH-NH), 3.21 (lH, m, CH-NH), 6.87 (2H, m, aromatic). 
13C NMR (D20 + CD30D) 6: 24.0, 27.8, 28.3, 28.5, 28.5 (24-28.5 CH2 chain), 
33.1 (N-CH3), 54.6 (CH2-N), 68.4 (CH-OH), 113.9 (C-2), 114.5 (C-5), 116.4 (C-
6), 118.7 (C-1), 132.2 (C-4). ES-MS mlz (MeCN: H20 1:1, 40 V): 454.6 
[M+MeOH+Nat. 
4.2.3.7 Optimisation of the Electrolysis Method 
Optimisation of the electrolysis method was done to three parameters. The 
first was electrode type with dopamine-o-quinone formation being monitored 
using stainless steel _gauze, platinum wire, silver foil and pressed graphite 
electrodes. The graphite electrodes were the carbon electrodes from D-size cells 
that were cut out of the casing and soaked in nitric acid and organic solvents and 
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regularly sonicated until all loose material had been cleaned away and a clean 
graphite surface was exposed. 
4.2.4 HPLC Analysis of Catecholamine Derivatives 
4.2.4.1 General 
All the thioether reactions carried out by electrolysis were monitored by HPLC 
using UV/visible detection. All were analysed using the same reverse-phase 
Prodigy column and all employed an oven temperature of 40 °C and a total flow 
rate of l mUmin. Analysis injections were 10 µL and were done through an 
autoinjector. The wavelength range employed in the scans was 190 nm-400 nm. 
A photodiode array detector was used with deuterium and tungsten lamps. All 
plumbing was in stainless steel. Three-dimensional plots of absorbance vs time vs 
wavelength were obtained and these signature peaks used in identification of the 
products. 
4.2.4.2 Elution, Pump and Mobile Phase Sequences 
Compounds 2B, 4, 6 
Mobile Phases: A: 50%v/v MeCN pH adjusted to 2.15 with trifluoroacetic acid 
(TFA) 
8: 5%v/v MeCN pH adjusted to 2.15 with TFA 
Gradient: 100% 8 for 6.5 min then linear gradient to 50%8 until 11 min. 
Compounds 3, 5, 7 
Mobile Phases: A: 50% MeCN, pH 2.15 with TFA 
8: 5% MeCN pH 2.15 with TFA 
1. 0-6.5 min 100%8 
6.5-14.5 min 100%8 - 0%8 
14.5-20 min 0%8 
or 2. 0-4 min 100%8-50%8 
4-8 min 50%8-0%8 
13.5 min 0% 8 
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4.2.5 Determination of Position of Attachment 
The positions of attachment of the thioethers to the aromatic ring were 
determined by use of Nuclear Overhauser Enhancement Spectroscopy (NOESY) 
NMR spectroscopy combined with close examination of the chemical shifts of the 
aromatic carbons compared to the chemical shifts expected for the various 
positions of attachment by addition of the appropriate chemical shift increments 
around the aromatic ring. NOESY determination was used to assess whether the 
two aromatic protons were within 5 A. of each other. This could be assessed by 
running a thorough NOESY over many scans and seeing if there was a cross-peak 
between the two protons in the 2-D spectrum. If there was a cross-peak and no 
cross peak in the COSY then attachment was very likely to be at the 5-position 
and if no cross-peaks, then it was very likely to be at the 6-position, and if there 
was no NOESY cross-peak but one in the COSY then it was very likely to be at 
the 2-position. 
4.2.6 Antibody Binding Studies 
4.2. 6.1 2,5-Dioxo-1-pyrrolidinyl-3-(5-(2-amino-1-hydroxyethyl)-2,3-
dihydroxyphenylthio )propionate ( 8) 
28 (5 mg, 0.019 mmol) was dissolved in DMF (1 mL, DMF pH adjusted to 4.2 
with HCI) and DCC (96 mg, 0.465 mmol in 125 µL of DMF pH = 4.2) and NHS 
(54 mg, 0.465 mmol in 125 µL of DMF pH = 4.2) were then added drop-wise to 
the stirring solution of catecholamine. The reaction was stirred at room 
temperature in the dark for 3 h. The production of the ester was confirmed by ES-
MS and the raw reaction mixture used as is immediately to minimise risk of 
internal cyclisation. ES-MS: (MeOH, 40 V): 354.4 [M+Ht. 
4.2.6.2 Immobilisation of SPR Flow Cells 
A new CM5 chip was docked and primed x2 with HBS-EP running buffer and 
flow cell two activated with 100 µL of EDC/NHS 1: 1 (5 µUmin) (150 µL of EDC 
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coupling solution mixed with 150 µL of NHS solution and take 100 µL to inject). 
To the flow cell 4,7,10-trioxa-1,13-tridecanediamine was injected (2 x 200 µL, 
quick inject, 5 µUmin, 1 % w/v, pH = 9.7 aqueous) and then immediately 
followed by more 4,7,10-trioxa-1,13-tridecanediamine (2 x 200 µL, quick inject, 5 
µUmin, 1 % w/v, pH = 11.3 aqueous). The flow cell was then deactivated with 
ethanolamine (50 µL, 5 µUmin). Flow cell three was then activated as above and 
injected with 1,6-hexanediamine exactly as for the 4,7,10-trioxa-1,13-
tridecanediamine and was then deactivated as above. Flow cell one was activated 
and then deactivated as above to serve as the blank flow cell. 
The chip was primed with deionised water and flow cell two was washed with 
50 mM NaOH (4 x 20 µL, 5 µUmin), 100 mM Na2C03 (100 µL, 5 µUmin) and 
then 50 mM NaOH (2 x 20 µL, 5 µUmin) before quick injecting the raw 8 
reaction solution (1/4 dilution in deionised water centrifuged at 14k x g for 8 min, 
1 x 200 µL, 4 x 50 µL injected at 5 µUmin). Flow cell 3 was then treated in the 
exact same way. The reaction solution of 8 (1/.a dilution in deionised water and pH 
adjusted to 7.0 using 50 mM NaOH, freshly prepared) was then injected over flow 
cell 2 (8 x 50 µL at 5 µUmin) after centrifugation as before, before and after pH 
adjustment. Flow cell 3 was then treated exactly as for flow cell 2. 
Flow cell 4 was equilibrated to HBS-EP running buffer and activated with 
EDC/NHS as above. This was immediately followed by E-aminocaproic acid 
(1 %w/v, pH= 9.7 aqueous, 2 x 200 µL injections at 5 µUmin) and then the same 
at pH= 11.3. The surface was then deactivated with ethanolamine (as above). The 
flow cell was then equilibrated in deionised water and activated with EDC/NHS 
(as above but 200 µL injected). The flow cell was then immediately injected with 
dopamine (1 % w/v, pH= 5.5 aqueous, 1 x 200 µL, 4 x 50 µL, 5 µUmin) and then 
dopamine (1 %w/v pH= 7.0 aqueous, 8 x 50 µL). The chip was then deactivated 
with ethanolamine (50 µL, 5 µUmin). 
4.2.6.3 Antibody Binding Tests 
The flow cells were primed with 0.15 M NaCl, 0.01 M phosphate buffer pH= 
5.2 (used as running buffer) and monoclonal anti-dopamine injected (100 µg/mL 
and 50 µg/mL, 60 µL, 20 µUmin). The surface was regenerated with HCl solution 
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(pH = 3.5 in 20%v/v MeCN). An antibody binding study was then set up. mAb (0, 
5, 10, 25, 50, 100, 150 µg/mL in PBS (phosphate buffered saline) pH= 5.2) was 
injected (60 µL 20 µUmin). The surface was then regenerated as above. Five 
replicates of each antibody concentration were run. The running buffer was PBS 
pH = 5.2. Another binding study was set up as for the first, using mAb 
concentrations of 0, 2.5, 5, 10, 25, 50, 75, 150, 225, 300 µg/mL with five or four 
replicates of each concentration prepared in PBS pH= 7.0. This was then mixed 
1 :2 with PBS pH = 5.2 in microwells and injected immediately (60 µL, 5 
µUmin). Regeneration was as above. mAb injection was also done using the 
buffer PBS pH = 6.2 by direct injection (60 µL) for 100 µg/mL mAb and blank 
injections. 
4.3 Results and Discussion 
4.3.1 Synthesis of the Dopamine-Thioether Derivative by Aromatic 
Substitution 
When developing the aromatic substitution chemistry for the estrogens at their 
aromatic A-ring, it was thought that this principle should be applicable to other 
important biomolecules with an aromatic ring. This would thus allow direct ring 
attachment without compromising the exisiting functional groups and continuing 
use of a thioether linkage that has proven to be so stable and to demonstrate such 
good antibody binding properties as an immunoassay linkage in the past. 10• 15 The 
obvious choice for such a new class of aromatic biomolecules are the 
catecholamines. 
Like the estrogens, the catecholamines have free aromatic ring positions for 
conjugation thus enabling the aromatic substitution of a halo derivative, e.g. 
bromo, in the same way as for the estrogens. Once again, like the estrogens 
studied in Chapter 3, the aromatic ring positions are deactivated with respect to 
nucleophilic aromatic substitution by the presence of hydroxyl moieties but 
substitution could be envisaged to proceed via a radical SRN 1 mechanism. To this 
end bromodopamine was synthesised through reaction with N-bromosuccinimide 
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(NBS). Chemical synthesis of bromodopamine has not been previously reported, 
with only one report of 6-bromodopamine having been synthesised biochemically 
by enzymatic cleavage of bromo-L-DOPA.268 
Simple treatment of a dopamine solution with a solution of NBS resulted in 
intense colour changes ranging from blue, green, and red to dark crimson. The 
product could be isolated by washing the aqueous phase with chloroform to 
remove the unreacted NBS and the succimide side product and then treating it 
with activated charcoal to decolourise. The compound had strong electrospray 
twin peaks at 231 and 233 m/z corresponding to the twin isotopes of bromine, 
Figure 4.1. The proton NMR spectrum showed clearly monobromo product but 
the carbon-13 spectrum indicated more than one positional isomer was present. 






0 "-v--- . -- .. , ·> 







225 - 130 





The next step in the synthesis would then be the aromatic substitution of the 
bromodopamine with a thiol to form a thioether linkage to the aromatic ring. This 
was done for the estrogens by heating under reflux in methanolic KOH with 3-, 
mercaptopropionic acid. The problem with such a reaction for the catecholamines 
is that it is well documented that in alkaline conditions the catecholamines 
undergo superoxide-mediated radical oxidation to produce a number of oxidation 
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products including the ortho-quinone. 17° From these products polymerisation can 
occur to produce black melanin-type polymers that are insoluble tars. Basic 
conditions however, are needed in this reaction, as the thiol must be present in the 
-s-R form. 
This reaction was attempted from the bromodopamine and through careful 
purification, the product was able to be isolated this way but in quite low yield, as 
one would expect (9% ). The overall reaction scheme is given in Figure 4.2. The 
numbering given in the scheme is given to minimise confusion and has been used 
in discussions of attachment positions of thioethers. The numbering may differ 
from that used for the systematic names. The purification was effected by 
constituting the raw reaction in water and then washing with ethyl acetate to 
remove excess 3-mercaptopropionic acid (MPA) and then pH adjustment to 
precipitate the product as the less soluble sodium salt. The electrospray mass 
spectrum gives a peak consistent with the o-quinone form and most probably 
reflects simply the conditions prevalent in the ESMS instrument, as ring ketone 
signals are not visible in the NMR spectrum. The NMR spectrum of the 
propionate derivative suggests that attachment has occurred at the 5-position 
judging from the lack of coupling between the aromatic protons and from the 
chemical shifts of the carbons. The purification of these catecholamine products is 
made more difficult by not being able to see them very clearly in TLC analyses. 
The catecholamines have a UV-visible absorbance that can be seen quite clearly 
on HPLC but is somewhat weak on TLC, and ninhydrin staining of the plates had 
only limited success in further enhancing the spots. Furthermore, the amine group 
tends to produce spots that are smeared and thus hard to discriminate. A further 
obvious disadvantage is that the compounds are extremely hard to move from the 
baseline using conventional phase silica plates and the reversed phase plates seem 
to be of limited use in visualisation of the spots. 
4.3.2 Electrolysis to Produce Catecholamine Ortho-Quinones 
Whilst this substitution approach to production of the thioether derivatives of 
catecholamines has been shown to work for dopamine, it is clearly not an ideal 
method. It would be far simpler and would produce better yields if the reaction 
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were to be done in such a way that no oxidised by-products are produced. The 
work of groups such as Dryhurst et al. suggest a way of doing this. 167• 168 
Thioethers can be formed from the ortho-quinone of the catecholamine in a 
reaction mimicking the body's natural metabolism of catecholamines. To produce 
the ortho-quinones in a controlled way it is necessary to apply a potential 
difference through an electrolyte. As the catecholamines are quite stable in 








Figure 4.2 Reaction Scheme for Aromatic Substitution to Produce Dopamine-
Thioether 
Here the methods of previous papers for glutathione and cysteine conjugates of 
dopamine have been adapted to produce 3-mercaptopropionic acid (MP A) and 11-
mercaptoundecanoic acid (MUA) derivatives of three different catecholamines -
dopamine, nor-epinephrine and epinephrine. The reaction scheme is given in 
Figure 4.3. Before proceeding with these reactions it was necessary to optimise 
the conditions for electrolysis by considering the types of electrode that would 
work best and the concentration of electrolyte and the potential difference that can 
be safely applied without electrolytic degradation. Several different types of 
electrode were tried, these being stainless steel mesh, platinum wire, silver foil 
and pressed graphite electrodes. The stainless steel meshes were used in different 
sizes and were able to deliver effective currents that were shown to produce the 
ortho-quinone products, however they leached metal ions into the solutions 
producing a green colour that masked the formation of the ortho-quinone and 
were not the most effective electrodes. The platinum wire, whilst being inert, 
presented too small a surface area to the solution and the levels of dopamine-o-
quinone formation were not adequate. The silver foil tarnished and oxidised and 
once again did not produce enough current. Pressed graphite electrodes were 
eventually decided upon as they were inert, leaching nothing into the electrolyte, 
OH 
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had comparatively large surface area and produced good levels of current and the 
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Figure 4.3 Reaction Scheme for the Production of Catecholamine Thioethers via 
the Corresponding a-Quinones 
The electrolyte concentration was altered to above 0.1 M HCl but no 
improvement in o-quinone formation was seen. The electrode potential was 
altered and o-quinone formation traced relative to the change. It was found that 
above 2 V potential difference there was a clear electrolytic degradation of the 
product and dopamine into a mass of product peaks in the HPLC, and that lesser 
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voltages led to a reduction in rate of formation of the o-quinone and in final 
product levels. The reaction apparatus is shown in Figure 4.4. 
Figure 4.4 Electrolysis Reaction Apparatus 
The reactions were done at around 30 mg scale successfully, making them of 
sufficient scale to not require very many multiple runs but still being low enough 
to ensure efficient production of the o-quinone under electrolysis. In all cases, 
upon electrolysis there was a clear change in colour from a colourless solution 
through to a bright orange colour with colour change beginning almost 
immediately, Figure 4.5. The colour arises from o-quinone formation. Another 
phenomenon observed in all the o-quinone reactions is that the current begins high 
and immediately drops rapidly and eventually evens out at a stable value. This 
suggests speculatively that at first there is a lot of charged dopamine present but 
as the reaction proceeds to o-quinone these levels drop down until equilibrium is 
achieved between dopamine and o-quinone product. 
-
The formation of the o-quinones can be traced clearly by reverse-phase HPLC 
with the catecholamine and its corresponding o-quinone producing characteristic 
HPLC peaks. To take the example of dopamine, the o-quinone peak comes at R1 
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= 1.7 min whilst the dopamine comes at an Rt= 1.95 min. The two peaks have 
signature absorbances that are different across the wavelength scale, Figure 4.6. 
Dopamine has a characteristic double peaking at 204 nm and 279 nm, the 
dopamine-a-quinone has a single peak at 202 nm, and the dopamine-propionic 
acid product has peaks at 204 nm and 291 nm. 
Figure 4.5 Illustration of the Colour Change in Solution Upon Formation of the a-
Quinone Using Dopamine as an Example 
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In the case of preparing the o-quinones for production of the MUA thioether 
derivatives, it is necessary to adjust the electrolyte so as to have an acetonitrile 
component to ensure solubility of the MUA. In order to compensate for the 
50%v/v acetonitrile loadings in the electrolyte, it was necessary to increase the 
electrolyte concentration up to 0.2 M HCl in total. 
3.0 300 
Figure 4.6 3-D Profiles of the Dopamine o-quinone and Dopamine Peaks by 
HPLC 
4.3.3 Production of the Catecholamine Thioethers 
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Production of the thioether from the o-quinone involves simply adding the thiol 
under a fast rate of stirring. This, in the case of the MPA derivatives of dopamine 
and nor-epinephrine, results in an immediate change back to colourless solution as 
all the o-quinone is reacted through to product. In the case of the MUA reactions, 
the colour change is somewhat more gradual, probably due to the presence of the 
acetonitrile. The epinephrine MPA reaction had a slightly different colour change 
with changes from orange to green to deep green to black within 30 min of 
addition. The reasons for this difference are unclear. 
The addition of the MPA produced several products in each case, 
corresponding most probably to the different positional isomers. The products, 
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like the original catecholamines had a main peak in the UV with lesser peaks and 
shoulders at higher wavelength. A typical example would be the dopamine 
mercaptopropionate, which is shown in Figure 4.7 with peaks at 204 nm and 291 
nm. The original catecholamines themselves have one main UV peak at around 
205 nm and then one associated peak usually around 280 nm, rather than a 
shoulder. Use of water / acetonitrile combinations has enabled the fine 
adjustment of polarity conditions necessary to achieve chromatographic resolution 




Figure 4.7 3-D HPLC Plot of the Dopamine-Propionate Peak 
For each reaction the mam product was the one that was the focus of 
purification efforts. Whilst other positional isomers have clearly been produced in 
each case, no attempt was made at purifying them out as they were present in 
lesser quantities and thus were of lesser interest. The MPA peak in each of the 
MPA reactions was found at Rt = 5.2 min and consisted of just one UV 
absorbance peak. The MUA was correspondingly seen as two peaks at Rt= 5.7 
and 6.5 min. The MUA was observed to persist in the HPLC column for a time, 
leaching out slowly, which had to be allowed for in assessment of purification. 
172 
4.3.4 Ion Exchange Chromatography of the Catecholamine Thioethers 
4.3.4.1 General Considerations 
The purification of such complex reaction mixtures posed special problems. 
The foremost of these was that the compounds were so polar that they could not 
be expected to be separated on conventional phase silica. The use of reversed 
phase silica should work but this has been complicated by the inability to visualise 
the compounds on reversed phase silica TLC plates and is not a cost-effective 
method as reversed phase silica costs approximately NZ$ 400 per 50 g. Previous 
researchers have relied upon the use of analytical reversed phase HPLC columns 
for purification and whilst these can be anticipated to work, the columns are very 
expensive (of the order of NZ$ 4000) and only provide quite small amounts of 
pure product, with several runs usually needing to be done. The use of ion-
exchange resin columns offers an alternative to these techniques. The columns 
can be used to uptake the desired compound from solution by charge interactions 
and then release the compounds in a chromatographic fashion upon application of 
carefully chosen eluants. Small ion-exchange columns have been used in work-up 
of biological samples containing multiple catecholamines181 but have previously 
tended to use small volumes and low concentrations of catecholamines. 
Ion-exchange columns were used here to purify the derivatives of dopamine 
and nor-epinephrine. Weakly acidic cation exchange resins have been used for 
the catecholamines previously269• 180 but did not retain the catecholamines strongly 
enough in this case. A strongly acidic cation exchanger, Dowex 50W, was used. 
This resin presents carboxylic acid residues on the surface of the beads. Before 
use, the resin had to be washed to ensure that all loosely held material was washed 
away and then had to be fully converted to its Ir form, Figure 4.8. Once this was 
done, excess acid needed to be washed away so that the compounds being eluted 
through the column would not be excluded from attaching to the resin due to high 
competition for binding sites from free Ir ions in the column. The 
catecholamines can be purified from the MPA or MUA by attaching the basic 
amine group to the acid groups of the resin. The MPA and MUA do not possess 
basic groups capable of binding and so would be expected to flow straight 
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through. In order for this to work, the catecholamines should be predominantly in 
the -NH2 form, rather than the -NH3 + form so the amine group can be protonated 
by the acid group of the resin. To do this it is necessary to pH adjust the solution 
to more basic pH. The problem is however, that the catecholamines cannot be 
adjusted to alkaline pH without some degradation and are not completely stable 
even at neutral pH. Consequently, the pH was adjusted to 5 very carefully with 
NaOH solutions and very vigorous stirring to prevent localised alkalinity. The 
solutions were then eluted into the column as is shown. 
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Figure 4.8 Schematic Representation of the Ion-Exchange Separation and 
Chromatography 
The column used in these purifications was gravity fed. Flow was controlled 
simply by a tap and fractions collected as required. All of the reaction solution 
was eluted into the one column. Experiments were done using smaller volumes 
but these resulted in no improvement in chromatographic resolution. In the case 
of the MPA derivatives, it could be seen that as the sample was eluted into the 
column and then flushed with deionised water that the MPA flowed straight 
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through the column whilst all other compounds, i.e. the catecholamines, remained 
adsorbed to the resin. Equivalent results were obtained for the MUA derivatives. 
By carefully tuning the acid concentration it is possible to elute the adsorbed 
compounds chromatographically from the column. It has been previously 
reported that one may use organic solvents with the acid to elute the compounds 
in a compressed volume 181 and this has been employed here using ethanol 
combinations. 
Between runs the resin must be regenerated. This is done by flushing 
concentrated HCl solutions through the column to remove any remaining counter 
ion material and restore all sites to the protonated form. This regeneration must 
be followed by flushing with deionised water to ensure that all residual acid is 
gone from the column. 
Ion-exchange purification using two resins was attempted. Under this format, 
the first resin was the same as above and adsorbed the catecholamines. The 
second was an Amberlite anion-exchange resin, which was supposed to adsorb the 
carboxylic acid containing products and elute out the un-modified catecholamine. 
This method failed as the Amberlite resin liberated OH- ions upon product 
adsorption and blackened the column with oxidised catecholamines. 
4.3.4. 2 3-( 5-(2-Amino-l-hydroxyethyl)-2,3-dihydroxyphenylthio )propanoic acid 
(2B) 
The dopamine product and unreacted dopamine were eluted from the column 
using acid solutions with ethanol content. The fractions were analysed at regular 
intervals by HPLC to determine their content. The dopamine was seen to elute 
first appearing at 50 mL total eluant. Practically all of the dopamine had gone by 
645 mL. The product first appeared at 210 mL as a small peak and this small 
peak was seen throughout the rest of the dopamine elution and beyond until 765 
mL. The product appears to be somewhat more concentrated in the later fractions 
that are devoid of unreacted dopamine and it was these that were combined. 
Without the use of ethanol to compress elution volume, separation is still possible 
with about the same efficiency but this requires more than twice the eluant 
volume and requires the use of 2 M HCl to get the compounds to elute. It is far 
better for the purposes of purification to use less acid and less volume as this 
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allows for easier product recovery. Attempts were made at using 50%v/v ethanol 
instead of 10%v/v ethanol but whilst this compressed the elution volume much 
more again, in doing so it completely compromised all separation. The ion-
exchange resin elution order reflects the order in which the products elute from 
the HPLC column, i.e. in order of decreasing hydrophilicity with dopamine first 
and then the dopamine thioether product. 
The mass spectrum gave an [M+Ht ion peak when run in 1: 1 H20: 
acetonitrile. The NMR could be run in D20. These results demonstrate how ion-
exchange chromatography may be used to effectively purify a catecholamine 
derivative in good yield and to a good level of purity. 
4.3.4.3 11-( 5-(2-Amino-l-hydroxyethyl)-2,3-dihydroxyphenylthio )undecanoic 
acid (3) 
For this compound, reaction only needed to proceed for 1 h before HPLC 
showed that maximum product formation had been achieved. In the raw reaction 
chromatogram one could clearly see the dopamine peak at 1.5 min and the 
principal product peak at 14.8 min and a secondary product peak at 17.6 min, 
Figure 4.9. The ion exchange chromatography proceeded successfully by again 
using 1 M HCl solutions with varying amounts of ethanol to achieve separation. 
The separation can be followed by plotting peak integral vs elution volume and 
this plot is given in Figure 4.10. One can see how the dopamine has eluted well 
before the product and how the product and dopamine elutions do not overlap. 
The pure product exhibits one principal peak and two lesser peaks in the UV-
Visible spectrum characteristic of such compounds. 
The yield for this reaction was not as good as that for the dopamine-MPA 
thioether at only 16%. This is perhaps due to the introduction of acetonitrile to 
the reaction mixture reducing formation of the o-quinone. The mass spectrum 
shows a clear [M+Ht signal in H20 / acetonitrile, Figure 4.11. The NMR 
spectrum shows the characteristic undecanoic acid chain signals including the S-
CH2 signal of the thioether. 
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Figure 4.9 Raw reaction using HPLC method 1 (Top) and purified chromatogram 
using HPLC method 2 (Bottom)-Dopamine-MUA Thioether at 218 nm 
4.3.4. 4 3-(2-(2-Amino-1-hydroxyethyl)-4,5-dihydroxyphenylthio )propanoic acid 
(4) 
The purification was much the same as for the dopamine-MPA. Once 
again there was substantial overlap of nor-epinephrine and MPA thioether as the 
compounds eluted and this can be seen in Figure 4.12. The greater polarity of the 
catecholamine starting compound and the thioether products meant that more 
dilute acid was needed to elute the compounds from the column and finer control 
of acid concentration was needed. Clear purification of the 3.31 min peak could 
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be seen, the other peaks being too close to nor-epinephrine to resolve. There was 
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Figure 4.10 Plot of Peak Integral vs Elution Volume for Dopamine-
mercaptoundecanoate Purification, • (dopamine), • (3). 
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Figure 4.12 Plot of Peak Integral vs Eluent Volume for Nor-epinephrine-MPA 
Column: + Nor-epinephrine, * Nor-epinephrine-propionate. 
The yield was quite good at 41 % and 1H NMR showed all the required signals 
including those for the CH-OH moiety. The ultra-polar nature of the nor-
epinephrine acid compound means that NMR spectra are correspondingly much 
weaker as they are less soluble in D20 . The proton spectra are very clear but some 
of the aromatic carbon signals are hard to detect. 
4. 3. 4.5 11-(2-(2-Amino-1-hydroxyethyl)-4,5-dihydroxyphenylthio )undecanoic 
acid (5) 
This compound was done in the same manner as for the dopamine derivative 
but once again finer acid control was needed as the compound was more polar. 
The pure chromatogram is given in Figure 4.13. One can see that the product is 
eluting much sooner under these HPLC conditions, as one would expect for these 
more polar compounds. The 5.79 min peak was isolated and was quite pure. 
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Figure 4.13 Purified Chromatogram for 5 Reaction 
4.3.5 Epinephrine Thioether Purification 
The epinephrine thioether compounds were originally chromatographed by ion-
exchange chromatography like the other catecholamine thioethers. The column 
still retained the catecholamines even though they now contained only a 
secondary amine, indicating that the resin was sufficiently strongly acidic to 
adsorb even weaker basic groups. Purification of epinephrine-MPA was 
attempted but was only partially successful with there still being significant 
contamination with epinephrine and other products. Whilst the purified sample 
was mostly the 4.69 min product there was still a significant amount of both 
epinephrine and another product. Purification of the epinephrine-MUA thioether 
was completely unsuccessful despite quite fine gradations in acid concentration. 
It was clear that another approach was needed to ensure properly purified product. 
The epinephrine compounds are significantly less polar than the other 
catecholamines studied as the amino group is a secondary amine not a primary 
one. It made sense then to try conventional phase chromatography to achieve 
purification. Methods were developed using eluants composed of acetonitrile and 
HCl solutions of increasing polarity. 
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For the epinephrine-MPA reaction the silica column purification gave a single 
peak upon HPLC examination and so is clearly an efficient way of purifying the 
sample. Likewise for the epinephrine-MU A reaction there was a clear single peak 
upon HPLC examination. The retention times for all the purified products are 
given in Table 4.1. 
Table 4.1 Retention Times for the Thioether-Linked Products 







4.3.6 Determination of Positions of Attachment 
Thioether groups could attach at any of the 2-, 5- or 6-position of the aromatic 
ring. The 5- and 6-positions would be favoured over the 2-position on steric 
grounds. Position can be determined by a combination of 2-D NMR spectroscopy 
and studying carbon chemical shift increments. COSY NMR can be used to show 
cross-peaks between protons that are one C-C bond apart and so should only show 
an aromatic cross-peak for the 2-position of substitution. Nuclear Overhauser 
Enhancement Spectroscopy (NOESY) gives cross-peaks between protons that are 
less than - 5 A apart where the intensity of the cross peak signals is inversely 
proportional to the sixth power of the distance between the protons. In the case of 
the aromatic protons of the thioether derivatives, one would expect to see the 
cross-peak between the 6- and 2-protons if the compound is the 5-thioether and no 
cross-peak if the compound is the 6-thioether (too far away). Combining these 
methods with an assessment of the carbon chemical shifts, one can determine with 
good certainty the position of attachment. 
For the dopamine-MPA, the 1H NMR spectrum is given in Figure 4.14 and the 
NOESY spectrum is given in Figure 4.15. This shows a clear cross-peak between 
the aromatic protons and as COSY shows no cross-peak, this indicates attachment 
at the 5-position. This is further supported by the incremental carbon chemical 
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shifts that can be tabulated as in Table 4.2. One can see from the table that the 
signals for the carbons on the opposite side of the ring to the 5/6 position are very 
little altered from dopamine to the product as one would expect for attachment at 
the 5 or 6 position and both peaks in the aromatic region of the proton spectrum 
are singlets providing evidence that there is no 2-substitution. Considering the C-
5 signal, it is seen that the product closely matches the signal of the 5-derivative, 
with the signal of the 6-derivative matching that of dopamine. Furthermore, the 
C-5 signal has no peak in the Dept 135 which is completely inconsistent with the 
6-derivative and dopamine but wholly consistent with the 5-derivative. When 
considering C-6 it is seen that the product peak matches that predicted for the 5-
derivative closely and has the correct phase. This is good evidence of attachment 
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Figure 4.14 1H NMR Spectrum of Dopamine-MP A Thioether 
The dopamine-MUA 3 NOESY spectrum once again showed proton cross-
peak but no cross-peak in the COSY, and thus supported 5-position attachment. 
The analysis of the chemical shifts is shown in Table 4.3. This shows clearly that 
the 5-position attachment best supports the chemical shift data. For the nor-
epinephrine-MPA 4 there was no cross-peak visible in the NOESY or COSY and 
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the NMR data was consistent with the 6-position also. For the nor-epinephrine-
MUA 5 there were no cross-peaks in the NOESY or COSY thus supporting 6-
position attachment. In the case of the epinephrine-MFA 6, the NOESY shows no 
cross-peak and neither does the COSY and the carbon signals are consistent with 
6-position attachment. The epinephrine-MUA 7 has no cross-peak in the NOESY 
and no cross-peak in the COSY and shows carbon chemical shifts consistent with 
6-position attachment. The catecholamine derivatives were found to decompose at 
high temperatures and so clear melting points could not be obtained. The 
catecholamine thioethers when in the solid state or protic solvents will be in the 
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Figure 4.15 NOESY Spectrum of Dopamine-Mercaptopropionate Showing the 
Aromatic Region 
Table 4.2 Chemical Shift Data for Dopamine - MPA Thioether Aromatic Region 
(ppm) with Dept 135 Phase in Brackets (0 = No Peak) 
Assianment Doeamine 5-Derivative 6-Derivative Product 
C-2 116(+) 1·13(+) 117 (+) 117 (+) 
C-5 116(+) 120 (0) 117 (+) 121 (0) 
C-6 119 (+) 123 (+) 126 (0) 125 (+) 
C-1 128 (0) 138 (0) 138 (0) 129(0) 
C-3 144 (O) 143 (O) 139 (0) 144 (0) 
C-4 147 {0~ 143 {0~ 141 {0~ 145 {0~ 
Table 4.3 Chemical Shift Data - Dopamine-MU A Thioether Aromatic Region 
(ppm) with Dept 135 Phase in Brackets (0 = No Peak) 
Assignment Doeamine 5-derivative 6-derivative Product 
C-2 116(+) 113(+) 117(+) 116(+) 
C-5 116(+) 120(0) 117(+) 123 (0) 
C-6 119(+) 123(+) 126(0) 124(+) 
C-1 128(0) 138(0) 138(0) 129(0) 
C-3 144(0) 143(0) 139(0) 143(0) 
C-4 147!0} 143!0} 141 !0} 144!0} 
4.3. 7 Antibody Binding Studies - Monoclonal Anti-Dopamine 
4.3.7.1 Formation of the Dopamine-Mercaptopropionate Active Ester (8) 
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The production of active esters to the thioether-bridged derivatives of the 
steroids has been done in DMF successfully with simple room temperature 
stirring overnight. There are two factors that prevent use of this method with the 
dopamine-mercaptopropionate. The first is that the alkaline conditions of the 
DMF may result in oxidation of the product, the second is that if the active ester is 
left for many hours then it will probably internally cyclise with the primary amine. 
The reaction was thus conducted under acid conditions at pH = 4.2 and the 
reaction was restricted to 3 h to minimise internal cyclisation. The reaction was 
analysed by mass spectrometry and showed a strong [M+Ht peak for the ester 
and no sign of any peaks corresponding to the internally cyclised product. Any 
such product will of course just pass straight over the surface without being 
immobilised; and should have no effect on the immobilisation provided plenty of 
the active ester is still present as indicated by the electrospray. The reaction 
mixture had to be used without purification, as rapid conjugation was needed to 
minimise cyclisation. The structure of 8 is given in Figure 4.16. 
4.3. 7.2 Immobilisation of Dopamine Derivatives Onto the Flow Cells 
To construct flow cells that contain the small molecule antigen immobilised on 
the surface, it is necessary to introduce intermediate linkers to space the antigen 
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from the surface and thus minimise steric obstruction to binding. The best way to 
introduce such linkers is to assemble them in situ on the sensor chip itself. This 
can be done by first activating the carboxylic acid bearing dextran surface with 
EDC I NHS to produce the active ester. This was done with large excess in each 
flow cell to ensure saturation of the surface. The next step was to pass the 
intermediate linker over the surface. The linker must contain a primary amine 
group to couple covalently to the surface. The linkers were attached first at pH = 
9.7 which was just below the pKa of the linkers and was not so alkaline as to risk 
degradation of the active esters on the surface. Once a large excess of the linkers 
had been passed to ensure saturation at this pH, the linkers were then passed at pH 
= 11.3, which was above the pKa of the amines and thus ensured maximum -NH2 
form and so maximum attachment. The use of these two pHs and large excess in 
both volume and concentration of linker compounds coupled with a slow flow rate 
should ensure that saturation immobilisation takes place. Three different linkers 
were used here. The first was the oligoethylene glycol (OEG) linker used in the 
SPR experiments in Chapters 3 and 5, the second was 1,6-hexanediamine, a 
somewhat shorter and less water-soluble linker and the third was the 
heterobifunctional linker E-aminocaproic acid which is of nearly identical length 
to the hexanediamine. The first two linkers had two terminal primary amines and 
the pHs were selected to maximise coupling to one of the amines only. There may 
be some immobilization at both amine terminals, but the selection of pH and the 
short length of the linkers should minimise this effect. The caproic acid linker has 
only one primary amine and is otherwise very similar to the 1,6-hexanediamine. 
Figure 4.16 Structure of Dopamine-Mercaptopropionate Active Ester 8. 
The next step was to attach the dopamine-mercaptopropionate to the first two 
linkers in situ on the surface. The active ester reaction mixture had to first be 
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diluted in deionised water as the integrated microfluidics cartridge (IFC) of the 
BIAcore instrument could be damaged if straight DMF was used. The addition of 
the water precipitated unreacted NHS and DCC and DCU on top of that which 
had already precipitated. This solid was removed by centrifugation before 
injection. The running buffer used could no longer be HBS-EP (pH= 7.4) as this 
may have oxidised the dopamine derivative. Instead, deionised water was used as 
the dopamine could withstand this for short periods without significant oxidation. 
An acidic buffer could not be used as it would convert much of the amine to the -
NH3 + form and thus diminish reaction. To ensure that the amines were in their -
NH2 form, the linker surface was flushed with base before addition of the ester. 
Once again, a large excess of the ester was used to ensure saturation of the 
surface. The ester was first passed at pH = 5.2 (the pH resulting from deionised 
water dilution) and then at pH= 7.0. This treatment was applied to the OEG and 
hexanediamine linkers. 
For the caproate linker, the carboxylic acid unit now needed to be activated 
with EDC/NHS and this was done in excess to ensure maximum activation of the 
linker ends. Dopamine was then passed over the surface at pH = 5.5 in excess and 
was then followed by dopamine again at pH= 7.0 to ensure saturation conjugation 
through the primary amine of the dopamine. These immobilisations are 
summarised in Figure 4.17. 
4.3. 7.3 Antibody Binding Studies 
To conduct the antibody binding studies, the running buffer had to be specially 
modified to ensure that the pH was acidic so as to minimise any risk of oxidation 
of the immobilised dopamine hapten. The running buffer selected was 0.15 M 
NaCl 0.01 M phosphate buffer (pH = 5.2). The surface was primed and flushed 
with this running buffer and stable baseline obtained before injecting monoclonal 
antibody that had been raised to a BSA conjugate through the primary amine by 
the glutaraldehyde method. _The binding was tested at both 100 µg/mL and 50 
µg/mL antibody concentrations. All three flow cells showed very high antibody 
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Figure 4.17. Immobilisation of Dopamine to the SPR Chip 
One can see from these sensorgrams that the highest antibody binding response 
was to the caproate-linked dopamine. This makes sense as the antibody has been 
raised to a conjugate through the amine of the catecholamine and so would be 
expected to recognise best an antigen immobilised in the same way. The next best 
binding response in this binding event comes from the OEG-linked surface, which 
could be explained by the water-soluble OEG linker projecting the dopamine 
better into the aqueous phase than the less water-soluble hexanediamine. 
Furthermore, since all the sensorgrams are blank corrected, the significant binding 
observed with all three linkages suggests that the antibody binding is specific on 
each surf ace. 
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Figure 4.18. Overlay Plot of the Sensorgrams for mAb (100 µg/mL) Binding to 
the Dopamine Chip. + Flow Cell Two (OEG-Linked), • Flow Cell Three 
(Hexanediamine-Linked), • Flow Cell Four (Caproate-Linked). 
Whilst there is strong initial binding, these surfaces suffered from quite rapid 
degradation, with the binding responses regularly declining in all three flow cells 
from one cycle to the next. This decline in response was not due to degradation of 
the antibody, as making solutions of antibody fresh did not have any effect on the 
decline. It was also not due to poor regeneration, as the responses obtained bore 
no relationship to any residual baseline rise. The absolute response of the surfaces 
was seen to decline with time and successive cycles and to decline between 
docking and undocking of the chip. The surfaces were clearly not stable long-term 
and this precluded the production of a full antibody binding curve across many 
concentrations or the construction of an assay using the surfaces. This decline 
eventually seemed to stop but the CVs of the binding responses were too high to 
enable any reasonable assay to be done. 
The surfaces were stable enough however to determjne triplicates of antibody 
binding at 100 µg/mL and 50 µg/mL antibody concentrations. The CVs were 
somewhat larger because of the declining responses however the results were still 
clear and are given in Table 4.4. 








580 + 100 
Hexanediamine 
(RU) 
135 ± 43 
650 + 140 




1670 + 210 
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Analysis of these values by one-tailed t-test showed that the caproate-linked 
flow cell definitely had higher antibody binding than the other two at both 50 and 
100 µg/mL (P < 0.05) though the OEG and hexanediamine values cannot be 
regarded as statistically different from each other. The higher binding observed 
for the caproate-amine-immobilised conjugate was very likely due to the position 
of attachment and not to the linker type as the caproate linker is very similar to the 
hexanediamine linker. 
Antibody binding tests were attempted by setting up a "wizard" program to run 
mAb injections in phosphate buffer pH = 5.2, but the binding responses declined 
rapidly with time, due either to the deteriorating surface or gradual destruction of 
the antibody at this pH. The assay was then repeated using injections of the mAb 
at pH= 7.0 mixed 1:2 with phosphate buffer pH= 5.2 to generate a final solution 
pH of 6.25. The binding responses here had very high CVs and very low 
magnitude, largely swamped out by a phase change effect caused by the buffer as 
it was injected. Injections of mAb in pH= 5.2 buffer were made fresh each time 
but gave erratic binding. The regeneration buffer used in all cases was HCl 
solution (pH = 3.5, in 20%v/v MeCN) that regenerated the surface well. 
To develop a biosensor assay using this surface, it will be necessary to 
extensively investigate the conditions under which the surface will be stable. The 
inherent instability of the catecholamines makes biosensing of them using an 
antigen-immobilized surface very challenging, and beyond the scope of this 
investigation. The experiments presented here demonstrate that the surfaces 
constructed all bind strongly to the monoclonal dopamine antibody and that the 
immobilization through the primary amine via a caproate linker, gives the 
strongest antibody binding due to the manner in which the antibody has been 
raised. 
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The catecholamine derivatives produced can clearly be used to produce protein 
conjugates and then be used to raise antibodies. Such antibodies should, regarding 
the SPR results obtained, show superior binding to the mercaptoalkanoate-
modified SPR surfaces. As this conjugation does not compromise existing 
functional groups on the catecholamine, it could be anticipated that antibodies 
raised to these conjugates will be better able to recognise the free catecholamine 
than would the existing antibody raised to conjugates through the primary amine. 
Clearly such immunogenic protein conjugate studies would be a very interesting 
area of further research in this field. 
4.4 Conclusions 
The catecholamines are of great interest as analytical targets for the 
development of sensitive immunoassay. Conjugation of the catecholamines for 
immunoassay has previously relied upon the use of conjugation through the 
primary amine group (glutaraldehyde and carbodiimide methods) or through the 
unreliable Mannich reaction. Production of thioether-bridged conjugates offers an 
excellent alternative to these traditional conjugations by allowing attachment 
directly to the aromatic ring, without compromising existing functional groups, 
through a simple and rapid reaction, purification to a single positional isomer and 
no significant undesirable side reactions. 
The synthesis of mercaptopropionate and mercaptoundecanoate derivatives of 
the catecholamines dopamine, norepinephrine and epinephrine by electrochemical 
production of the corresponding o-quinones and then addition of the appropriate 
linker has been reported. The products have been purified by ion-exchange 
chromatography for dopamine and norepinephrine using a simple procedure with 
only one ion-exchange resin. Reactions and purifications have been monitored by 
HPLC. The positions of attachment have been established with the aid of 2-D 
NMR spectroscopy in each case. 
An SPR sensor chip· has been immobilized with the dopamine-
mercaptopropionate compound using OEG and hexanediamine linkers assembled 
in situ on the chip. Dopamine was also immobilized through the primary amine 
using a caproate linker. The antibody binding to these conjugated surfaces was 
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assessed and the primary amine-immobilised dopamine gave highest binding by 
virtue of the antibody being raised to an amine conjugated protein conjugate. All 
flow cells gave strong antibody binding. 
These results demonstrate how a new generation of catecholamine-linker 
derivatives may be synthesised and applied in conjugations. These derivatives 
have important potential applications in the raising of antibodies and as coating 
antigens for antibody binding. In order for antibodies to specifically recognise 
small molecules that lack a large number of functional groups or specific shapes, 
it is important that existing functional groups are kept intact when those 
antibodies are raised. Thioether-linked conjugations provide a simple means of 
producing specific conjugations direct to the aromatic ring and so open up the 
possibility of developing a new generation of specific antibodies to the 
catecholamines and the production of biosensors based around these. This is 
another illustration of how organic chemistry can help to improve 
immunosensing. 
Chapter 5 - Signal Enhancement of SPR 
Immunosensing of Small Biomolecules 
5.1 Introduction 
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The lack of sensitivity of SPR-based immunoassays has been a major factor 
preventing their more widespread implementation as practical biosensing systems. 
To perform adequately for many applications, the SPR biosensor must 
demonstrate comparable sensitivity to corresponding ELISA. Sensitivity may be 
expressed in one of two interrelated ways: first, as the limit of detection of the 
assay, which is affected by the concentration range of the standard curve and the 
errors in the concentration determinations; second, as the slope of the active 
region of the immunoassay curve, and is affected by the signal change per unit 
concentration change. One of the most critical factors determining the sensitivity 
of SPR is the level of refractive index change obtained per unit concentration 
change in the assay. This can be increased by the use of high mass labels of 
which colloidal gold is the most widespread because of its high mass, its ability to 
undergo surface plasmon resonance and its ease of production. Nanoparticle 
labels have been employed in the assay of large size biomolecules such as 
proteins and oligonucleotides and have achieved immunoassay signal 
enhancements of around 25-fold207 and improvements in detection limit of around 
three-orders of magnitude, 199 but no successful attempt had yet been made to 
apply these concepts to SPR immunoassay of small biomolecules. 
The development of such formats for the small molecule has many great 
challenges not found for the larger molecules. The principal challenge is how to 
preserve antibody binding to the small molecule in the face of the steric 
constraints that a large label produces. Another challenge is how to space the 
small molecule out from the ·label to allow antibody binding whilst preserving the 
gold colloid enhancement effect, bearing in mind that the SPR signal 
reinforcement will operate only within about 300 nm of the surface. There are 
further challenges in developing regeneration cocktails strong enough to remove 
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the bound gold from the surface and still have a surface stable enough to 
withstand the repeated regeneration cycles needed for a practical system. Further 
problems can be anticipated to arise by the need to attach the small molecule to 
the colloidal label via some kind of intermediate compound, thus losing the 
intimate contact seen in immobilisation of say a protein on the gold label surface, 
which would be expected to provide more enhancement of the signal. 
Furthermore, there are potential problems associated with the propensity of gold 
to bind to surfaces and proteins non-specifically. 
In spite of all these potential challenges, the possible benefits of signal 
enhancement of antibody / antigen binding interactions for small molecules are 
great, and include the much improved ability to distinguish low target 
concentrations from the zero response, higher signal/noise ratios, steeper active 
regions of the assay standard curves and the ability to lower the primary antibody 
concentration and still have sufficient binding response for an accurate assay. 
Progesterone is an ideal model compound for studying small-molecule 
immunosensing formats as it is the first target to be detected by enzyme 
immunoassay, and hence its antibody binding interactions have been extensively 
studied. Monoclonal antibody to progesterone has been fully developed and 
widely used and is commercially available. Furthermore, progesterone is similar 
in structure to a range of other biologically important steroids. Progesterone is 
also of great physiological interest for its role as a female sex steroid hormone, 
which means that it acts as a biomarker for a range of physiological processes 
including mammalian estrous cycles. Previous work has established linker 
attachment chemistries via the 4-position and shown this to provide superior 
antibody binding in the BIAcore SPR format. 10• 15 
There has been a great dearth of studies on the effect of new immunosensing 
formats on antigen / antibody binding performance and on how novel labelling 
technologies and formats might affect immunosensor performance. The 
principles developed here for progesterone should extend in a generic sense to 
other small biomolecules, and the formats developed could be easily transferred to 
other targets. 
Reported below is the first successful study of nanoparticle signal enhancement 
of SPR-based immunoassay for small molecules. Surface immobilisation 
chemistries, regeneration cocktails and non-specific binding treatments necessary 
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to achieve a high level of repeatable assay performance are developed along with 
the use of gold colloids of varying sizes to label antibody binding interactions in 
SPR, for use in immunoassay, through a range of labelling techniques, including 
biotin / streptavidin coupling and secondary antibody coupling, and in different 
label delivery formats, both pre-labelling and sequential binding. All the binding 
curve and assay standard curve data for all these formats are presented, as are the 
levels of signal enhancement and the effects on assay detection limits and 
sensitivities. 
5.2 Experimental 
5.2.1 Materials and Instruments 
5.2.1.1 General 
Progesterone for synthetic work was purchased from Applichem (Darmstadt, 
Germany A06770025) and for preparation of standards was from Sigma (Cell 
culture tested, P8783, ~ 99%). Di-tert-butyl dicarbonate and 4,7,10-trioxa-1,13-
tridecanediamine were purchased from Fluka Chemie (Buchs, Germany). DMF 
was from Aldrich (anhydrous under septum 99.8%, 227056). PEG-400 was from 
Prolabo (26 602-290), HAuCJ4.3H20 from Acros (ACS reagent 411070010), 
trisodium citrate from Aldrich (99% pure, 855782). Biotin N-hydroxysuccinimide 
ester was from Sigma (Hl 759) as was biotinamidohexanoic acid N-
hydroxysuccinimide ester (B2643) and OVA (A5503) and BSA (A 7030). All 
other chemicals were from Aldrich. All solvents used were analytical grade 
except for the HPLC solvents that were HPLC reagent grade ACS. The primary 
anti-progesterone antibody (monoclonal antibody) was from Sigma (P1922) raised 
in rat to the ?-position conjugate as for Chapter 2. The secondary antibody was 
anti-rat IgG (whole molecule) raised in rabbit (Sigma, R5128). 
Melting point determinations, NMR spectroscopy and electrospray mass 
spectrometry were all run as for Chapter 3. Analytical RP-HPLC was done as for 
Chapter 2 but using a Sphereclone ODS 3 µm column (150 x 4.60 mm) on a 
Shimadzu instrument using PDA detection. 
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5.2.1.2 Gold Conjugates 
Streptavidin-gold 10 nm conjugate was purchased from Sigma (S-9059, 
monodisperse 8-12 nm) and was supplied in 0.01 M phosphate buffered saline, 
pH=7.2, containing 1 % BSA, 20% glycerol and 15 mM sodium azide. The 
concentration of the 10 nm colloid corresponded to an absorbance, A520 = 2.5, 
which was verified by additional UV-Visible spectroscopic examination. The 
streptavidin-gold 20 nm conjugates were purchased from Sigma (S-6514 
monodisperse 17-23 nm) supplied in DMSO. The colloid was dialyzed against 
several changes of PBS/T at 4 °C and was then analysed by UV-Visible 
spectroscopy and gave an absorbance at Amax at 523 nm of 1.577 ± 0.001. To 
ensure that the colloid had preserved streptavidin function during dialysis it was 
tested in a strip assay with immobilised progesterone - OVA conjugate. The strip 
was dipped into a microwell with 15 µL of Tween-20 1 %v/v in PBS/T, 15 µL of 
polyvinylpyrrolidone (PVP) 2%v/v in PBS/T, 10 µL of undiluted biotin-mAb in 
PBS/T and 10 µL of streptavidin gold undiluted. A clear red band was seen, 
indicative of preservation of streptavidin function. 
5.2.1.3 BIAcore Instrumentation and Zetasizer 
BIAcore analysis was done using a BIAcore 2000 instrument from the Fraser 
Group, Department of Molecular Medicine, University of Auckland. The running 
buffer used was HBS-EP pH= 7.4 (see Appendix 1 for details). All samples were 
diluted in HBS-EP unless otherwise stated, except for the regeneration buffers, 
which were prepared using deionised water. All experiments were done at an 
incubation temperature of 25 °C and a flow rate of 20 µL/min unless otherwise 
stated. Between injections the flow cells were returned to running buffer as for all 
SPR experiments in this thesis. Flow rates quoted with the injections refer to the 
injection period unless otherwise stated. The term "quickinjection" refers to a 
BIAcore command that injects sample with only a 10 µL pre-injection plug. 
"Extraclean" refers to another BIAcore function that includes extra cleaning of the 
needle in the injection. A "wizard" is a computer program for running BIAcore 
applications. All mixing for assays and binding studies was done in microtitre 
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plates and the samples were run in random order. The chips used were BIAcore 
CM5 chips (research grade). The gold colloid particles were sized using a 
Malvern Zetasizer™ 3000HS with temperature set at 25 °C, a count rate of 260 
kCps in a capillary cell with a detector angle of 90° and a wavelength of 633 nm. 
UV-visible spectra were obtained on a Shimadzu UV-1601 instrument and data 
processed using UV Probe 1.01 software. 
5.2.1.4 Statistical Analysis 
All error bars shown on graphs represent one standard deviation of the mean. 
All assay standard curve data has been fitted to a four-parameter logistic 
relationship using Sigma Plot 8.02 (SPSS Inc.). All limits of detection have been 
computed as the concentration corresponding to the blank or curve maximum less 
two standard deviations of the blank determination. The ICso values have been 
computed as a parameter of the curve fitting. Standard deviations (SD) in the 
LOD and IC5o have been computed by inputting the standard deviation of a 
neighbouring standard point into the rearranged four-parameter logistic equation, 
calculating from the SD in the response. Sensitivities represent the slope of the 
linear portion of the assay curve. The enhancement ratios are calculated by 
dividing the slope of the enhanced antibody-binding concentration plot by the 
slope of the primary antibody concentration plot, or dividing the slope of the 
active range of the enhanced assay by that of the primary antibody-only assay 
where the two determinations are greatly different. Errors quoted in the text, 
including tables, are the standard error of the determination. Outliers have been 
rejected where they are more than three standard deviations from the mean of the 
remaining values. All difference comparisons of LOD and IC5o mentioned in the 
text have been examined by two-tailed unpaired t-test (or one-tailed where stated) 
and differences have been found to be statistically significant (P 5 0.04). CVs 
mentioned in the text are the CVs of the binding responses. 
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5.2.2 Biotinylation of Antibody 
Biotinamidocaproate-N-hydroxysuccinimide ester (BcapNHS) (Sigma Aldrich 
B-2643) was dissolved in dry DMF to make a 5 mg/mL solution. Monoclonal 
anti-progesterone (100 µL) was added to 0.1 M sodium bicarbonate solution (900 
µL) and the BcapNHS solution was added (25 µL in 1 mL of 0.1 M sodium 
bicarbonate) dropwise to the stirring antibody solution. The solution was stirred 
for 5 min before leaving without stirring at room temperature for 2 h. The 
solution was then dialysed against 0.15 M NaCl at 4 °C for four changes including 
one overnight and then four changes of PBS/T including one overnight. The 
solution was then passed through a PD-10 column and protein concentration 
determined by assumption of negligible loss of antibody, as the 2-bincinchonic 
acid (BCA) method of protein concentration determination was found to be 
unreliable due to the effects of modifying the antibody with biotin and thus 
changing the numbers of free lysine residues used in the determination. Antibody 
was stored frozen until use and once thawed was not refrozen. 
5.2.3 Progesterone-Protein Conjugates as Coating Antigens in Biotin-
Streptavidin Mediated Gold Labelled SPR 
5.2.3.1 lmmobilisanon 
pH scouting was done to determine the best pH for immobilisation of the C-2 
and C-4 conjugates to the sensor chip. The conjugates are as described in Chapter 
2 (11 and 25-atom linkers for C-2 and C-4 respectively). The conjugates were 
prepared at 500 µg/mL and 1.125 mg/mL respectively. For C-2, pH of 4, 4.5 and 
3.5 10 mM sodium formate were trialed. Flow-rates were 5 µUmin for 2 min. 
Immobilisation was done manually aiming for a minimum immobilisation of 
2000 RU. C-2 was immobilised at pH 3.5 and C-4 at pH 4.0. Flow rates were 5 
µUmin and final immobilisations obtained were 2523.9 RU for C-2 and 2207.7 
RU for C-4. The chip had a solution of OVA (5 µg/mL in running buffer) passed 
over the surface to help to stabilise it (10 min at 25 µUmin). 
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5.2.3.2 Antibody Binding Tests 
Monoclonal anti-progesterone (un-modified) was passed over the surface to 
assess its binding (100 µg/mL in running buffer, 3 min injection, 20 µUmin) and 
the surface then regenerated with 50 mM glycine pH = 1.5 (2 x 75 µL, 50 
µUmin). Biotinylated monoclonal anti-progesterone was then passed over the 
surface (100 µg/mL in running buffer, 3 min injection at 20 µUmin) and 
regenerated. Biotinylated monoclonal antibody (100 µg/mL in running buffer, 
100 µL) was mixed 1: 1 with undiluted 10 nm colloidal gold - streptavidin 
conjugate and vortex mixed and then incubated at room temperature for 10 min 
before injection (120 µL, 20 µUmin). The same regeneration conditions were 
used for all protein conjugate binding work. 
To determine the best antibody / gold volume ratio to use for assay 
development, various ratios were employed and their binding values determined. 
The biotinylated monoclonal anti-progesterone was set at a concentration of 100 
µg/mL. The total mix volume was set at 160 µL to allow for the 120 µL injection 
plus the 30 µL dead volume. The 10 nm gold colloid - streptavidin was used 
without prior dilution and the incubation was for 35 min at room temperature with 
one 5 s vortex mix at the start. The ratios tested were 1: 1 (80 µL mAb: 80 µL 
gold), 1.67:1 (100 µL: 60µL), 3:1 (120 µL: 40 µL), 7:1 (140 µL: 20µL) and 15:1 
(150 µL: 10 µL). The same testing was then done but with running buffer instead 
of gold colloid to determine the degree of gold signal enhancement at each ratio. 
5.2.3.3 Progesterone Assay Curves 
The progesterone assay curve was determined by mixing 100 µL of 
progesterone stock solution in running buffer with 100 µL of 7:1 mAb (100 
µg/mL): 10 nm gold colloid - streptavidin, incubating at room temperature for 5 
min and then injecting at 10 µUmin, 120 µL, with regeneration as above. The 
antibody gold mixture was incubated at room temperature for 3 h before the assay 
began to ensure complete biotin-streptavidin binding. Progesterone 
concentrations of 0, 100 fg/mL, 1 pg/mL, 10 pg/mL, 100 pg/mL, 1 ng/mL, 10 
ng/mL, 100 ng/mL and 1 µg/mL were used (in running buffer). Assay curves 
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were determined for both C-2 and C-4 conjugates and each point was done in 
triplicate. 
5.2.3.4 20 nm Gold Colloid 
Biotinylated monoclonal antibody (100 µL, 100 µg/mL in running buffer) was 
mixed with 20 nm gold - streptavidin colloid (undiluted, 100 µL) and vortex 
mixed and then incubated at room temperature for 10 min before injection (120 
µL, 20 µUmin). The incubation time was then extended to 35 min and the 
experiment repeated. 
Monoclonal antibody - biotin was passed over the surface (100 µg/mL, 20 
µUmin for 3 min) immediately followed (in co-injection mode) by the 20 nm 
gold-streptavidin (20 µUmin, 3 min). 
To determine the most appropriate antibody/ gold ratio to use for development 
of the assay, different ratios were trialed. The ratios were 2: 1 antibody: gold, 1: 1 
antibody: gold, 1 :2 antibody: gold and 5: 1 antibody: gold. These were done by 
co-injecting 80, 60, 40 and 100 µL of biotinylated antibody with 40, 60, 80 and 20 
µL of gold colloid respectively (20 µUmin, 6 min) in a sequential format. It was 
not necessary to run separate antibody blanks as the antibody binding could be 
clearly seen in the sensorgrams separate from the gold enhancement. 
5.2.4 Progesterone-DEG-Biotin and Immobilised Antibody1 
5. 2. 4.1 N-(13-(t-butoxycarbonylamino )-4, 7,1 O-trioxatridecanyl)-3-(pregn-4-ene-
3,20-dione-4-yl)thiopropanamide (1) 
2,5-Dioxo-1-pyrrolidinyl-3-(pregn-4-ene-3,20-dione-4-yl)thiopropanoate 
(1.106 g, 2.14 mmol)10•15 was dissolved in DMF (dry, 5 mL) and N-(t-
butoxycarbonyl)-4,7,10-trioxa-1,13-tridecanediamine (1.371 g, 4.27 mmol) was 
added drop-wise to the stirring steroid solution. Triethylamine (2 mL) was then 
added and the solution stirred for 60 h in the dark. The solvent was removed in 
vacuo and the mixture column-separated on silica gel using 15:1 CHCh: MeOH 
1 See p. 222 for reaction scheme 
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eluant to yield 3 as a yellow oil. Yield: 63% (967 mg, 1.341 mmol). TLC Rr = 
0.36 (15:1 CHCh: MeOH). IR (film): 2932 (CH2 anti-symmetric u), 1699 (Boe 
amide C=O u), 1532 (Boe amide), 1117 (CH2-0 u) cm-1• 1H NMR (CDCh) 6: 
0.65 (s, 3H, l8-CH3), 1.13 (s, 3H, 19-CH3), 1.41 (s, 9H, Boe CH3), 2.09 (s, 3H, 
21-CH3), 2.89 (m, 6H, OEG), 3.57 (m, 14H, OEG, CH2-0). 13C NMR (CDCh + 
CD30D) 6: 13.7 (18-CH3), 18.4 (19-CH3), 21.5 (11-CH2), 23.2 (16-CH2), 24.6 
(15-CH2), 28.8 (Boe CH3), 29.4 (21-CH3), 29.6 (C-6), 30.0 (CH2 OEG chain), 
30.9 (CH2 OEG chain), 31.0 (C-2), 31.7 (C-7), 34.3 (CH2-S), 34.7 (CH2-CO), 
34.9 (C-1), 35.6 (C-8), 37.0 (CH2N steroid end, C-12), 39.1 (CH2-NH Boe end), 
41.7 (C-10), 44.2 (C-13), 54.5 (C-9), 56.3 (C-14), 63.7 (C-17), 69.8 (OEG CH2-
0), 70.0 (OEG CH2-0), 70.5 (OEG CH2-0), 70.9 (OEG CH2-0), 79 (CMe3) 
129.0 (4-C), 156.3 (ester C=O), 171.4 (5-C), 176.2 (C=O), 195.7 (3-C), 209.5 (20-
C). ES-MS mlz (MeOH) 721.6 [M+H]+, 743.6 [M+Nat. HiRes FAB-MS: 
Calculated: 721.4462, Found: 721.4473 (Mir). 
5.2. 4.2 (13-Amino-4, 7,1 O-trioxatridecanyl)-3-(pregn-4-ene-3,20-dione-4-
yl)thiopropanamide (2) 
1 (140 mg, 0.193 mmol) was dissolved in formic acid (8 mL) and stirred in the 
dark for 3 h. Formic acid was removed in vacuo to leave an oil, which was then 
column separated on silica gel using 15: 1 CHCh: MeOH. Yield: 73% (94 mg, 
0.152 mmol). TLC Rr= 0.29 (5:1 CHCh: MeOH). IR (film) 2960 (-NH/u), 2920 
(CH2 anti-symmetric u), 1670 (progesterone C=O u), 1640 (progesterone C=O u), 
1116 (CH20 u) cm-1• 1H NMR (CDCl3) 6: 0.68 (s, 3H, 18-CH3), 1.26 (s, 3H, 19-
CH3), 2.12 (s, 3H, 21-CH3), 2.48 (t, 2H, CH2-CO, J = 6.1 Hz), 2.52 (3H, m, 
OEG), 2.85 (t, 2H, CH2-S, J = 6.8 Hz), 3.26 (2H, t, J = 5.0 Hz), 3.35 (2H, t, J = 
6.1 Hz), 3.48-3.66 (llH, m, OEG CH2-0), 3.71 (lH, m, 6a.-H), 3.73 (2H, t, OEG, 
J = 5.2 Hz). 13C NMR (CDCh) 6: 13.4 (18-CH3), 18.1 (19-CH3), 21.2 (11-C), 
23.0 (16-C), 24.3 (15-C), 26.2 (C-6), 29.3 (21-CH3), 29.7 (CH2 OEG chain), 31.0 
(CH2 OEG chain), 31.5 (2-C), 32.1 (7-C), 34.4 (CH2-S), 34.5 (CH2CO, C-1), 35.3 
(C-8), 36.6 (CH2-NH steroid end, C-12), 38.7 (CH2-NH2), 40.3 (10-C), 43.9 (13-
C), 54.1 (9-C), 55.9 (14-C), 63.5 (17-C), 68.8 (OEG CH2-0), 69.7 (OEG CH2-0), 
70.5 (OEG CH2-0), 171.9 (amide C=O), 176.9 (5-C), 196.4 (3-C), 209.2 (20-C). 
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ES-MS mlz (MeOH) 621.8 [M+Ht. Purity: 97% (R1 = 1.20 min, 60: 40 MeOH: 
H20, Amax = 248 nm). 
5.2.4.3 1-(3-(Pregn-4-ene-3,20-dione-4-yl)thiopropanoyl)amino) 4, 7, JO-trioxa-
13-tridecane-13-amino-biotinylate (3) 
2 (160 mg, 0.258 mmol) was dissolved in chloroform (1.5 mL, dried over 
molecular sieves 4A). Biotin-N-hydroxysuccinimide (114 mg, in 1 mL of dry 
DMF with warming) was added drop-wise to the stirring progesterone - OEG -
NH2 solution. The solution was stirred in the dark for 2 h before addition of 
triethylamine (0.5 mL) after which it was left stirring for 60 h. A solid initially 
formed but by the end of the reaction it had gone. The solvent was removed in 
vacuo and then column-separated using 10 : 1 CHCh : MeOH then 5 : 1 CHCh : 
MeOH eluant. Yield: 44% (96 mg, 0.113 mmol). TLC Rr = 0.70 (5: 1 CHCh : 
MeOH). IR (film): 1120 (CH20 u), 1672 (amide C=O u), 2929 (CH2 anti-
symmetric u) cm·1• 1H NMR (CDCh) 6: 0.70 (s, 3H, 18-CH3), 1.25 (s, 3H, 19-
CH3), 1.72 (m, caproate chain), 1.80 (m, caproate chain), 2.14 (s, 3H, 21-CH3), 
2.95 (m, 5H, OEG), 3.20 (d, lH, biotin HCH-S), 3.37 (m, 2H, OEG), 3.62 (m, 
13H, OEG), 4.36 and 4.54 (d oft, 2H, biotin, CH-NH), 5.16 and 5.23 (d, lH, 
biotin). 13C NMR (CDCh) 6: 13.7 (18-CH3), 18.5 (19-CH3), 21.5 (C-11), 23.3 
(15-CH2), 24.6 (16-CH2), 25.3 (CH2 biotin chain), 25.7 (CH2 biotin chain), 25.9 
(C-6), 28.4 (OEG chain CH2), 29.3 (OEG chain CH2), 29.5 (C-2), 31.1 (C-7), 31.8 
(S-CH2), 34.3 (CH2CO), 35.7 (C-8), 36.3 (l-CH2, CH2CO), 37.1 (C-10), 38.3 
(CH2-NH), 39.0 (CH2-NH), 40.9 (12-CH2), 41.7 (CH2-S biotin), 44.3 (C-13), 54.5 
(9-CH/ biotin), 56.3 (14-CH), 60.5 (biotin-ring C-N), 63.8 (17-CH), 70.4 (OEG-
CH2-0), 70.9 (OEG CH2-0), 129.1 (4-C), 163.7 (biotin C=O), 172 (C=ON biotin 
end), 173.4 (C=ON steroid end), 176 (5-C), 196 (3 C=O), 209.6 (18 C=O). ES-
MS mlz (MeOH 80 V): 848.1 [M+H]+, 870.1 [M+Nat. 
5.2.4.4 Format Developmentjor Progesterone-DEG-Biotin 
Monoclonal anti-progesterone was immobilised onto flow cell two of a fresh 
chip with activation as before and using a 35 µL injection of monoclonal antibody 
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(100 µg/mL) at 5 µUmin flow rate followed by de-activation as before. The 
immobilisation buffer used was determined by preconcentration using a 2 min 
injection of 40 µL of monoclonal antibody (100 µg/mL in 10 mM sodium acetate 
pH= 5.5). Immobilisation of 7475 RU was achieved at the pH 5.5. Flow cell one 
was used as the blank control flow cell as before. 
Rather than use a 100 µg/mL solution which would contain 1 %v/v DMF and 
thus may damage the antibody, 3 was made up to 5 mg/mL in deionised water and 
diluted one fifth to make a 1 mg/mL solution which was then used to incubate 
with the gold as above (35 min incubation at room temperature and using a 1:1 
volume ratio) and was then injected (120 µL, 10 µUmin). The volume ratio was 
then changed to 7: 1 and all other conditions kept the same. Regeneration was 
attempted with one pulse of 10 mM glycine (pH 2). 
An alternative format was then trialed where the progesterone-biotin (1 
mg/mL) was injected (240 µL at 20 µUmin). This was then immediately 
followed by a quickinjection of the 10 nm gold (60 µL at 10 µUmin). 
Regeneration was then attempted with two pulses of 75 µL of 10 mM glycine pH 
= 2 to regenerate the surface. This process was repeated again to test the 
repeatability of the binding response. 
Flow cell 3 was then immobilised with antibody as before giving a final 
immobilisation value of 3375.5 RU. The following tests were then conducted: 
1. 10 nm gold colloid was pre-mixed with 100 µg/mL progesterone-DEG-biotin 
for 35 min in a 7: 1 progesterone-DEG-biotin: gold volume ratio. 60 µL was 
then injected at 10 µUmin. 
2. As for 1 but using 20 nm colloid. The binding response was 10.9 RU 
indicating that some binding is occurring. Regeneration with 2x 10 mM 
glycine (pH 2) as before. 
3. Sequential injection of progesterone-DEG-biotin (250 µg/mL, 60 µL) gave 0.3 
RU bound (10 µUmin) followed immediately by 20 nm gold (30 µL, 10 
µUmin). Regeneration as for 2. 
4. Premixed 500 µg/mL progesterone-DEG-biotin and 20 nm gold at a 7: 1 
progesterone-DEG-biotin: gold volume ratio for 35 min and then injected 60 
µL at 10 µUmin. 
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5. Premixed 500 µg/mL progesterone-OEG-biotin and 10 nm gold 7:1 
progesterone-OEG-biotin: gold volume ratio, 35 min incubation and then 
injected 60 µL. 
Flow cell four was immobilised with antibody as before to a final 
immobilisation figure of 6605 RU and the following injections performed: 
1. 10 nm gold and 500 µg/mL progesterone-biotin in 7: 1 ratio as before - 60 µL 
injection as before. No binding response was observed. No regeneration 
attempted. 
2. 20 nm gold and 500 µg/mL progesterone-biotin in 7: 1 - 60 µL injection. 
Flow cell 4 (Fc4) = 460.9 RU, flow cell 3 (Fc3) = 70.1 RU, flow cell 2 (Fc2) = 
76.1 RU. Regeneration as above. 
3. An exact repeat of 2 but with a fresh batch of mixture. The bindings were: 
Fc4 = 248.9 RU, Fc3 = 30.6 RU, Fc2= 40.1 RU. Regeneration as above. 
5.2.5 Progesterone-OEG-NH2 Mediated Assay -An Ultra-Stable 
Surface 
5.2.5.1 Immobilisation 
A solution of 2 was made up in DMF (100 mg/mL). The stock was diluted in 
PBS/f pH = 9.0 to make a 1 mg/mL solution (1 %v/v DMF). A new CM5 chip 
had flow cell two (Fc2) activated with EDC and NHS (150 µL of each transferred 
to a vial and then 200 µL mixed and 50 µL injected at 5 µUmin). The 2 solution 
was then quickinjected (5 µUmin, 100 µL). The surface was then deactivated 
with ethanolamine (50 µL, 5 µUmin). Flow cell one (Pel) was activated and 
deactivated without injection of 2, as a blank flow cell. The surfaces were then 
washed with three pulses of 50 mM NaOH (15 µL at 5 µUmin). The washes 
removed surface material that was not covalently bound. The first pulse removed 
211.7 RU, the second 53.1 RU and the third 26.8 RU in Fc2. Flow cell three (Fc3) 
was also later immobilised as for Fc2 but with about l.5x the immobilised RU 
value, and used with Fc2 from section 5.2.6 onwards. 
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5.2.5.2 Antibody I Gold Ratio Testing 
These data were obtained by using the given volume ratio of antibody (100 
µg/mL): gold and mixing 1: 1 with blank buffer as for the progesterone assay in 
5.2.5.3 (using the same wizard). The same applied for the gold only injections 
mentioned in Section 5.3.4.2. The zero point of the ratio curve was obtained by 
injecting straight buffer. 
5.2.5.3 Aqueous Progesterone Assay Using Biotin I Streptavidin-Mediated 10 
nm Gold Labelling 
An assay for aqueous progesterone was set up using a wizard which mixed 
progesterone standard solutions with a pre-incubated (2 h) mixture of 7: 1 
biotinylated antibody (100 µg/mL): 10 nm gold - streptavidin, in a 1: 1 ratio. The 
components were mixed, incubated for 5 min and then injected (60 µL at 20 
µUmin). A 60 s wait was introduced before regeneration with two pulses of 20 
µL of l0%v/v MeCN in 50 mM NaOH. The flow rate throughout was 20 µUmin. 
Five replicates were done of each point. The wizard file is in Appendix 3. 
5.2.5.4 Antibody-Only Assay Using The Progesterone - OEG - NH2 Surface 
The program was exactly as for the pre-incubation assay in 5.2.5.3 with 
biotinylated antibody at a final injection concentration of 43.75 µg/mL (no gold 
label). Standards of 0, 1 pg/mL, 10 pg/mL, 100 pg/mL, 200 pg/mL, 1 ng/mL, 2 
ng/mL, 10 ng/mL, 100 ng/mL and 1 µg/mL were used. Five replicates of each 
were run. 
5.2.5.5 20 nm Pre-incubation Assay 
Assay conditions were exactly as for the 10 nm pre-incubation assay in 5.2.5.3 
but with 20 nm colloid and 0.84 M ethylene glycol used in the antibody diluent to 
give a final ethylene glycol concentration of 0.2 M. 
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5.2.6 Sequential Binding Assay Format 
5.2.6.1 Gold Dilution Binding Test 
The method for the determination of the relationship between total gold 
enhanced response and 10 nm gold colloid dilution factor was as follows. Buffer 
was run at 20 µUmin (same flow rate throughout), and monoclonal anti-
progesterone-biotin labelled was quickinjected (50 µg/mL, 60 µL) and binding 
response determined. The baseline was taken 60 s before antibody injection and 
the antibody bound point was taken 10 s before quickinjection of gold-
streptavidin colloid (30 µL). There was no wait time between quickinjections. 
The gold quickinjection was finished with an extraclean and a wait of 180 s before 
quickinjection of three pulses of 20 µL of 20%v/v MeCN 200 mM NaOH total 
concentration. The final quickinjection had an extraclean and the cycle was then 
repeated. These conditions of injection are the same as in the corresponding assay 
(Section 5.2.6.3). This process was repeated for a total of five replicates of each 
of 0.25, 0.15, 0.10, 0.05, 0.02, 0.01 dilution of gold in HBS-EP (0.2 Methylene 
glycol, 10%w/v BSA). 
5.2.6.2 Antibody Binding Curve Determination 
The antibody binding curve wizard program was set up as follows. Flow rate 
set at 20 µUmin throughout. The antibody solution (60 µL) was quickinjected 
followed immediately by the gold (0.15 dilution, 10%w/v BSA total 
concentration, 0.2 M ethylene glycol total concentration, 30 µL) also 
quickinjected. There was a wait of 180 s then injection of three 20 µL pulses of 
20%v/v MeCN 200 mM NaOH total concentration, one after the other. Antibody 
concentrations of 0, 5, 10, 15, 25, 35 and 50 µg/mL were used with five replicates 
per point. 
5.2.6.3 Progesterone Sequential Assay 
An assay for aqueous progesterone was established that used the following 
format. 70 µL of biotinylated antibody (30 µg/mL) was transferred to an empty 
205 
microtitre plate well. 70 µL of progesterone standard was then transferred to the 
same well, and the contents mixed (105 µL). The contents were then incubated at 
25 °C for 5 min before injecting 60 µL at 20 µUmin flow rate (flow rate the same 
throughout). Immediately after this injection, 30 µL of gold colloid (0.15 dilution, 
10%w/v BSA total concentration, 0.2 M ethylene glycol total concentration) was 
quickinjected. There was then a wait of 3 min before regeneration by three pulses 
of 20 µL of 20%v/v MeCN, 200 mM NaOH total concentration. There was then a 
further wait of 1 min before the next cycle. Ten progesterone concentrations were 
used: 0, 10 fg/mL, 1 pg/mL, 10 pg/mL, 100 pg/mL, 500 pg/mL, 1 ng/mL, 10 
ng/mL, 100 ng/mL and 1 µg/mL. Each point was done with five replicates. The 
mixings were done in a microtitre plate as for the pre-incubated assay format. 
For Section 5.2.6 all injections were quickinjects except for the 
antibody/progesterone mixes used in the final assay format. The delay between 
antibody and gold injections when both were quickinjects is 70 s compared to 80 s 
if the antibody was injected normally and the gold in a quickinject. Quickinject 
was used to save valuable material but a normal inject was used for all the assay 
progesterone / antibody injections as this was likely to produce more repeatable 
antibody bindings and thus lower CV than quickinject. 
5.2.6.4 A New Progesterone Sequential Assay 
A new assay was set up exactly as before except for these changes: 
I. Monoclonal antibody concentration was reduced to 15 µg/mL (diluted 1:1 
with progesterone solution to give a final concentration of 7.5 µg/mL) 
2. The 60 s wait after regeneration was removed to speed up the assay 
3. The progesterone concentrations used were 0, 100 fg/mL, 1, 10, 20, 100, 
200 pg/mL, 1, 10, 100 ng/mL. 
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5.2. 7 Antibody Binding Tests and Non-specific Binding Treatments for 
the Sequential Injection Format 
5.2.7.1 Optimisation of the Non-Specific Binding Treatment 
In order to determine whether reduction of the gold labelling flow rate would 
produce additional gold label binding, a test was set up with the same format as 
for the sequential antibody binding assay but with the gold flow rate set to 10 
µUmin rather than 20 µUmin and the antibody was set at 50 µg/mL and blank 
running buffer used in the place of progesterone solution. The gold was 0.15 
dilution in HBS-EP with 5%v/v total PEG-400 and 0.2 M total ethylene glycol. 
30 µL of the gold alone was injected over the surface at 10 µUmin flow rate 
(treatment as above) and the surface was regenerated as before. The gold 
injection was repeated but at 20 µUmin flow rate. The gold was prepared as 
above but with 10%v/v PEG-400 and 30 µL injected. Gold with 1 %v/v PEG-400 
treatment was injected (30 µL) after regeneration as before. Regeneration was 
followed by injection of the gold with a 0.1 %v/v PEG-400 loading. After 
regeneration, a 0.5%v/v loading was tried. 
To test to see if the slope of the antibody curve would be improved by reducing 
the PEG-400 loading, the biotinylated antibody (50 µg/mL) was used in an assay 
using the blank with gold at a 0.15 dilution in 1 %v/v PEG-400, 0.2 M total EG. 
This was also then repeated for a 0.5%v/v total PEG-400 loading using 
regenerations as above. 
5.2.7.2 Antibody Binding Test with Reduced Non-Specific Binding 
A new antibody-binding test was then set up to determine the binding response 
vs antibody concentration relationship using the new non-specific binding 
minimisation treatment. The format was exactly the same as for the previous 
study (5.2.6.2) but with use of a 1 %v/v PEG-400, 0.2 M EG treatment for the gold 
colloid and a 60 s wait at the end of the assay cycle to ensure return to baseline. 
Five replicates were done at concentrations of 0, 1, 5, 15, 25, 35, 50 µg/mL. 
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5.2. 7.3 Gold Loading - Is it Optimal? 
30 µL of 0.25 dilution gold with the same 1 %v/v PEG-400 treatment and 0.2 
M total EG was injected. An antibody-binding test was run using the same 
antibody-binding wizard as in 5.2.7.2 with 50 µg/mL antibody and 0.25 dilution 
of gold. 
To assess whether simply increasing the volume of gold label used would 
improve the binding enhancement, an antibody gold-enhanced assay was 
attempted using a 60 µL injection of the 0.15 dilution with all other factors the 
same as 5.2.7.2 with 50 µg/mL mAb-biotin concentration, flow rate 20 µUmin 
throughout. 
To see if increasing the incubation time of progesterone solution with antibody 
would improve the ability of the assay to discriminate low progesterone 
concentrations, 100 pg/mL determinations were set up using 0.15 dilution gold 
(1 %v/v PEG-400, 0.2 MEG total) 30 µL, all 20 µUmin, but one with a 600 s wait 
and one with a 300 s wait, antibody at 15 µg/mL. 
5.2.7.4 Gold-Enhanced Assay-Low Antibody 
A new progesterone assay was set up using the 0.15 dilution gold with the new 
treatment, other conditions the same as the previous assay (Section 5.2.6.4) but 
using a biotinylated antibody concentration of 5 µg/mL (diluted by progesterone 
solution to 2.5 µg/mL). Five replicates were run of each of 0, 0.1, 1, 5, 10, 50, 
100 pg/mL, 1, 10, 100 ng/mL progesterone. 
5.2.7.5 ls the Gold Enhancement MediaJed Through the Biotin I Streptavidin 
Couple? 
Five replicate injections of the monoclonal un-modified antibody in the 
antibody-binding wizard of 5.2.7.2 were done vs five replicates of the biotinylated 
antibody, both at 50 µg/mL concentration. 
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5.2.7.6 Gold Level I Response Relationship with Use of PEG-400 
This was repeated exactly as before (Section 5.2.6.1) except using the 1 %v/v 
PEG-400, 0.2 MEG gold treatment and with 15 µg/mL of mAb-biotin (60 µL). 
5.2.7.7 Attempts to Remove Non-specific Binding of the Antibody 
In an attempt to remove mAb non-specific binding from the surface, the mAb-
biotin was made up at 5 µg/mL using HBS-EP but with 1 %v/v total PEG-400. 
This was then incubated with the 100 ng/mL progesterone solution as before (5 
min) and then injected (60 µL at 20 µL /min). The process was repeated with 
1 %w/v BSA total instead of 1 %v/v PEG-400. The surface was regenerated as 
before and then the process repeated with 5%v/v PEG-400. The process was 
repeated with 1 %v/v PEG-400 and 1 µg/mL progesterone. The injection was 
repeated using 100 ng/mL progesterone and no PEG agent. 
To check to see if the non-specific binding may be due to progesterone binding 
or simply driftings in the baseline, progesterone (1 µg/mL, 30 µL) was injected. 
All regenerations were done as before. 
5.2. 7.8 Another Low Monoclonal Antibody Assay 
The assay was repeated using 15 µg/mL mAb-biotin 1: 1 with progesterone 
using a narrower range of concentrations (0, 5, 20, 50, 100, 200, 500 pg/mL, 1, 5, 
50 ng/mL) to allow better determination of the standard curve. The gold used was 
prepared at 0.15 dilution using 1 %v/v PEG-400 and 0.2 MEG. 
5.2.7.9 20 nm Colloid Sequential Binding- Will the larger colloid substantially 
improve enhancement? 
The antibody binding test wizard from 5.2.7.2 was run as before with 1 x 50 
µg/mL biotinylated antibody and 20 nm gold at a 0.5 dilution with 1 %v/v PEG-
400 total and 0.2 M EG total. Regeneration was attempted (3 pulses of 20 µL of 
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20%v/v MeCN, 200 mM NaOH). Then 10%v/v MeCN, 50 mM NaOH (70 µL, 
50 µUmin) was used. This injection was repeated. An injection of 75 µL (50 
µUmin) of 50 mM glycine pH = 3 was made. This was followed by injection of 
20%v/v MeCN, 200 mM NaOH total (75 µL, 50 µUmin). 
The antibody injection wizard was repeated with a 60 µL injection of 20 nm 
colloid, all other factors the same as above. The surface was then injected with 20 
nm colloid, (1 %v/v PEG-400 total, 0.2 M EG total, 30 µL, 0.5 dilution). The first 
30 µL gold-antibody injection was repeated after first regenerating the surface 
with 20%v/v MeCN, 200 mM NaOH (3 x 20 µL) as before using 20 nm gold from 
a different vial. 
To see if steric hindrance could be minimised by lowering the binding 
concentration of colloid, the dilution was changed to 0.25 (1 %v/v PEG-400 total, 
0.2 M EG total, 120 µL instead of 60 µL, 20 µUmin). A 15 µL injection of un-
diluted 20 nm gold was used as label (20 µUmin), all the rest being the same as 
the previous test. This was then followed by a check for non-specific binding 
whereby un-diluted 20 nm colloid was injected (15 µL, 20 µUmin). This process 
was repeated with 10 nm colloid (0.30 dilution, 1 %v/v PEG-400 total, 0.2 M EG 
total). 
5.2.8 Secondary Antibody Labelling 
5.2.8.1 The Secondary Antibody Labelling Effect 
Secondary antibody enhancement curves were prepared by quickinjecting 
monoclonal primary antibody (25 µg/mL, 60 µL, 20 µUmin) immediately 
followed by quickinject of anti-rat IgG secondary antibody (60 µL, 10 µUmin) 
and then regeneration with one pulse of 20%v/v MeCN, 200 mM NaOH (20 µL, 
20 µUmin). Secondary antibody concentrations of 0, 50, 100, 200, 400, 600, 800 
µg/mL were used, five replicates each. 
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5.2.8.2 Secondary Antibody Signal Enhancement of Primary Antibody Binding 
Primary antibody binding curves were produced as for section 5.2.8.1 but with 
secondary antibody concentration held constant at 800 µg/mL and varying the 
primary antibody concentration using 0, 0.75, 1.5, 3, 6.25, 12.5, 18.75, 25 µg/mL 
concentrations. 
5.2.8.3 Progesterone Assay Using Secondary Antibody Signal Enhancement 
The assay was set up using the normal 70 + 70 µL and mix and 5 min 
incubation method. The primary antibody/ progesterone mixture was injected as 
before (60 µL, 20 µUmin) and then immediately injected anti-rat IgG (60 µL, 10 
µUmin, 800 µg/mL) then a 30 s wait and regeneration as for all the above tests 
(20 µL of 20%v/v MeCN, 200 mM NaOH, 20 µUmin). The progesterone 
concentrations used were: 0, 0.1, 1, 5, 10, 50, 100 pg/mL, 1, 10, 50 ng/mL. The 
final primary antibody concentration after 1: 1 dilution with progesterone sample 
was 25 µg/mL. The wizard program is given in Appendix 3. 
Another assay was set up as for the preceding assay but with primary antibody 
at 3 µg/mL final concentration and anti-rat IgG at 400 µg/mL and using 
progesterone standards prepared by serial dilution at 0, 1, 10, 25, 50, 100 pg/mL, 
1, 2.5, 10 ng/mL. 
5.2.9 Secondary Antibody-Gold Signal Enhancement 
5.2.9.1 Colloid Production and Sizi,ng 
Gold colloids were produced by an adaptation of the citrate reduction method 
of Frens.266 Specifically, the colloids were prepared as follows: 
25 nm: A 0.01 %w/v solution of HAuCl4 was prepared (50 mL) and brought to 
the boil under reflux with no stirring. A 1 %w/v tri-sodium citrate solution was 
added (900 µL) and the colour monitored. Boiling was sustained for 10 min 
before cooling. 
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43 nm: Prepared by citrate reduction as for 25 nm at the same scale but with 
600 µL of the 1 %w/w trisodium citrate and 10 min boiling. 
56 nm: A 0.01 %w/v solution of HAuCl4.3H20 was prepared (50 mL) and 
brought to the boil with no stirring. A 1 %w/v tri-sodium citrate solution was 
added (500 µL) and the colour monitored. After -40 s the solution went blue and 
then a further 1 min to tum red. The boiling was sustained for a total of 10 min 
before cooling. 
70 nm: As for the 41 nm method but using stirring (vigorous, maximum 
setting) and adding 300 µL of 1 %w/v tri-sodium citrate solution. The solution 
turned black after 49 s and went red at 170 s. The boiling was sustained for 14 
min total before cooling. It was found for this colloid that not stirring the solution 
resulted in too broad a particle distribution. 
120 nm: As for the 56 nm method but using reflux conditions and using a 
0.01 %w/v solution of HAuCl4 (50 mL) and then adding 250 µL of 1 %w/v tri-
sodium citrate solution and refluxing for 17 min only. 
The exact citrate volumes often had to be adjusted slightly based on sizing 
results. Once cooled to room temperature, the volumes of each were determined 
and from this the total gold concentration could be calculated. All glassware was 
washed with aqua regia before use. 
Each colloid was examined by the Malvern Zetasizer to determine the average 
colloid diameter and the diameter distribution by photon correlation spectroscopy. 
Five runs, each of 10 sub-runs, were completed for each colloid and the Zavg 
(cumulant mean diameter) parameter used to determine colloid diameter for 
colloids below 30 nm and the intensity function used to determine colloid 
diameter for larger colloids. All colloids were either used as is or were 
centrifugally concentrated as indicated for each experiment. Centrifugal 
concentration was done with PEG-400 (3%v/v) to prevent aggregation. 
5.2.9.2 Optimisation of Gold-Secondary Antibody Conjugate Production 
Each of the colloid parameters mentioned in the results section was 
systematically studied to determine the effects on secondary antibody-gold 
binding to the surface. Regeneration was as before. Decisions on parameters to 
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use for colloid-conjugate production were made on the basis of the binding 
responses obtained and any non-specific bindings obtained. The large number of 
individual binding tests makes full experimental details space prohibitive. 
5.2.9.3 Signal Enhancement with Secondary Antibody-Gold Conjugate by 
Removing Un-Bound Secondary Antibody 
The 25 nm gold-secondary antibody conjugate was prepared as follows. 25 nm 
gold sol was prepared according to the directions in Section 5.2.9.1 and sized 
accordingly. The pH of the colloid was adjusted to 8.6, and 10 mL vortex shaken 
and 1 mL of 900 µg/ mL anti-rat IgG was injected with vortex shaking for 60 s 
and then shaking at 400 rpm for 10 min. The colloid was then stored at 4 °C for 
18.5 hand then BSA (10%w/v, 3.66 mL) was injected while vortex shaking. The 
sample was vortex shaken for 60 s and then shaken at 400 rpm for 10 min and the 
sample stored at 4 °C for 3.5 h before centrifuging at 13,000xg for 30 min. The 
supernatant was removed (Pasteur pipette) and the sample constituted in 'h the 
volume and sonicated and centrifuged again before supernatant removal and re-
constitution to give a 3x concentrated sample relative to the raw reaction mixture. 
The binding procedure was done by injection of mAb (60 µL, 20 µUmin), 
followed immediately by anti-rat IgG-gold 25 nm (60 µL, 10 µUmin, 0.5 dilution, 
10%v/v PEG-400), 180 s wait, then regeneration by 1x pulse (20%v/v MeCN, 0.2 
M NaOH 20 µLat 20 µUmin). The mAb concentrations used were 0, 0.25, 0.5, 1, 
2, and 3 µg/mL, five replicates of each. 
5.2.9.4 Signal Enhancement by Secondary Antibody - Gold Conjugate Without 
Removing Un-bound Secondary Antibody 
Gold colloids were produced according to the methods detailed in Section 
5.2.9.1 and sized accordingly. Five-fold concentrated gold sols were prepared and 
conjugated by altering the pH of the sol to 8.5 with dilute NaOH and adding anti-
rat IgG secondary antibody (8 mg/mL) in deionised water (pH = 8.5), at 10%v/v 
to the colloid with vortex agitation. The colloid was then shaken for 5 min at 400 
rpm before storage at 4 °C for 18.5 h and then blocking with 20%w/v bovine 
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serum albumin (BSA) (1 %v/v of BSA solution in the colloid making 0.2%w/v 
final BSA) using the same conditions as for the antibody. 
All the colloid sizes produced at both concentrated and non-concentrated levels 
were run (injected primary antibody 25 µg/mL, 60 µL, 20 µUmin and then 
immediately gold conjugate undiluted, 60 µL, 10 µUmin) for a minimum of three 
replicates to determine if there was any difference between colloid sizes and if 
concentration of the colloid produced a change in binding enhancement. 
Regeneration was as before. 
Primary antibody binding plots were prepared by injecting primary antibody 
(60 µL, 20 µUmin) and then immediately injecting 25 nm gold-secondary 
antibody conjugate (0.5 dilution in deionised water l0%v/v PEG-400, 60 µL, 10 
µUmin), 180 s wait and then regeneration as above with one pulse. All points 
were in triplicate and primary antibody concentrations used were 0, 1, 2, 5, 10, 15, 
25 µg/mL. 
5.2.9.5 Assay Using 25nm Sol-Secondary Antibody Without Centrifugal 
Purification 
The assay was constructed by mixing of primary antibody (3 µg/mL) 1:1 with 
progesterone solutions in microwells, 5 min incubation at 25 °C and then injection 
(60 µL, 20 µUmin) immediately followed by secondary antibody - gold 25 nm 
conjugate (0.5 dilution in deionised water 1 %v/v PEG-400, 60 µL, 20 µUmin) 
and then regeneration with two pulses as above. The progesterone concentrations 
used were 0, 10, 50, 100 pg/mL, 1, 10 ng/mL. All points were in triplicate. 
5.3 Results and Discussion 
5.3.1 Biotinylation of Monoclonal Anti-Progesterone 
To attach signal-enhancing gold nanoparticle labels to the primary antibody, 
two different coupling methods were investigated. The first involved the binding 
of streptavidin-conjugated gold to biotinylated primary antibody. The 
streptavidin/biotin interaction is very strong and so this linkage should be quite 
stable, allow good capture binding in flow-through formats, and through the bulk 
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of the streptavidin and the introduction of a linker between the biotin and the 
antibody, allow sufficient steric spacing of the antibody from the gold 
nanoparticle surface. 
The biotinylation of the anti-progesterone monoclonal antibody proceeded by 
an established method that allows for attachment of the biotin via the NHS active 
ester technique. The biotin was spaced from the antibody by a short 6-carbon 
caproate chain that ultimately links to the lysine residues of the antibody. Binding 
tests of this antibody compared to un-modified monoclonal antibody in the 
BIAcore format revealed that the biotinylated antibody retained ~ 85% of the 
original antibody binding capacity. The concentration of the biotinylated 
antibody must be determined by assuming no loss of material upon purification, 
which is a reasonable approximation as the antibody was handled carefully 
throughout. Bincinchonic acid (BCA) assay cannot be used as the biotinylation 
alters the structure of the protein substantially, changing the number of free lysine 
residues and resulting in unreliable BCA assay determinations. Dialysis would 
have removed all unbound biotin-caproate and so helped to ensure minimal non-
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Figure 5.1 Biontinylation of Monoclonal Anti-Progesterone 
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5.3.2 Progesterone-Protein Conjugates As Coating Antigens in Biotin-
Streptavidin-Mediated Gold-Labelled SPR 
The first experiments with biotin-streptavidin-mediated gold labelling of 
primary antibody were done using progesterone-protein conjugate immobilised on 
SPR sensor chip surfaces. 
5.3.2.1 Antibody Binding Tests 
An SPR CMS chip was immobilised with protein conjugates C-2 and C-4 to 
the levels as described in 5.2.3.1. The structures of these conjugates are given in 
Figure 2.1. Monoclonal anti-progesterone Cun-modified) was passed over the 
surface to assess its binding. This gave positive binding for both conjugates with 
little non-specific binding. Regeneration was effected with 50 rnM glycine pH= 
1.5 buffer. Glycine buffers of pHs 2, 1.5 and 1 were tried, but 1.5 gave the best 
results. Biotinylated monoclonal anti-progesterone was then passed over the 
surface and gave positive binding for both conjugates. The biotinylated antibody 
binding sensorgrams are given in Figure 5.2. 
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To determine the best mixing ratio of biotinylated antibody to streptavidin -
gold, a series of ratios was examined for its binding enhancement effects. 
Monoclonal antibody only blanks were run as comparison. The results of the 
antibody I gold ratio testing are given in Tables 5.1 and 5.2. 
Table 5.1. Conjugate C-2 Ratio data 
Volume Ratio 1 1.67 
mAb/gold 
mAb Only (RU) 497.9 
mAb Gold (RU) 796.3 890.5 
Enhancement 298.4 
(RU) 
% Enhancement 60 
Table 5.2. Conjugate C-4 Ratio data 
Volume Ratio 
mAb/gold 
mAb Only (RU) 




























Based on the signals obtained from the ratios above, the ratio giving largest 
overall signal considering both conjugates (7: 1 antibody: gold) was selected for 
use in development of a progesterone assay curve. 
5.3.2.2 Progesterone Assay 
Plots of % bound (relative to the blank) vs progesterone concentration were 
prepared, Figure 5.3. The assays for both C-2 and C-4 demonstrated preliminary 
detection limits of< 1 pg/mL progesterone and had a broad active region from 1 
µg/mL to < 1 pg/mL, Table 5.3. The ICso values are given below and are taken as 









0 50 m 





1 10 100 1000 1 0000 1 00000 1000000 
Progesterone Concentration (pg/ml.) 
Figure 5.3 Plot of % Bound vs Progesterone Concentration (pg/mL) for C-2 
Table 5.3 Preliminary Assay Data for the C-2 and C-4 Conjugates in the Aqueous 
Progesterone Assay 








These detection limits seem to be very good, but there was significant drift 
downwards in the binding values and this was magnifying the errors of each point. 
It would seem that each regeneration cycle was removing some of the 
immobilised conjugate from the surface and this resulted in poor assay data. 
Indeed, eventually the entire antibody binding signal was lost and the baseline 
seen to decline significantly. This is no doubt due to the regeneration of the bound 
gold removing protein conjugate from the surface, and so protein conjugate coated 
surfaces for gold-enhanced progesterone assay seem to not be adequately stable 
despite promising preliminary assay LOD. 
5.3.2.3 20 nm Gold Colloid 
Having investigated the use of 10 nm colloids to label pnmary antibody 
binding to protein conjugates, it was then advisable to examine a larger colloid 
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size to see if more enhancement could be obtained. The 20 nm streptavidin-gold 
conjugate was also commercially available. Incubating the 20 nm streptavidin-
gold with primary antibody for 10 min resulted in no binding at all. It was 
thought that the cause might have been inadequate binding time for the 
streptavidin-gold to bind the biotin-antibody due to the larger size of the colloid 
sterically impeding binding. The incubation time was then extended to 35 min 
and the experiment repeated. This also resulted in no binding. This suggests that 
speculatively, the streptavidin - gold may be binding the biotinylated antibody but 
that the larger colloid size may be blocking any binding of the complex to 
immobilised progesterone. Bearing these observations in mind, it was decided to 
pass the antibody over the surface first, followed by the streptavidin - gold in a 
co-injection, i.e. a sequential format rather then a pre-incubated format. This 
resulted in an antibody binding curve similar to those observed above followed by 
a much stronger binding curve corresponding to the gold conjugate binding to the 
modified antibody. The curve produced when biotinylated antibody and then 20 
nm gold were co-injected is shown in Figure 5.4. It was found that with two 
pulses of 50 mM glycine pH 12.9 (75 µL, 50 µUmin) complete regeneration 
could be achieved initially. The results of preliminary antibody/ gold ratio testing 
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Figure 5.4 Sensorgram Overlay for Various Ratios of mAb to Gold 20 nm for C-
2. 
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Table 5.4. C-2 Antibody/Gold Ratio Data 
Volume Ratio 0.5 1 2 5 
mAb:gold 
mAb Only (RU) 41.1 52.8 134.7 52.4 
mAb Gold (RU) 88.8 67.9 334.8 54.3 
Enhancement 
(RU) 47.7 15.1 200.1 1.9 
Enhancement 
Ratio 2.2 1.3 2.5 1.0 
Table 5.5. C-4 Antibody/Gold Ratio Data 
Volume Ratio 0.5 1 2 5 
mAb:gold 
mAb Only (RU) 31.8 39.4 38.1 36.6 
mAb Gold (RU) 33.6 35 17.3 35.2 
Enhancement 
(RU) 1.8 -4.4 -20.8 -1.4 
Enhancement 
Ratio 1.1 0.88 0.45 0.96 
Based on the results above, a ratio of 0.5 monoclonal antibody-biotin to gold 
20 nm would give the best enhancement ratio over both conjugates and thus 
would be most appropriate for use in an assay. 
After this data was obtained, regeneration of the surface became very difficult, 
and though a large range of regeneration cocktails were used to try and regenerate 
the surface, none was really effective. The 2: 1 antibody: gold ratio was repeated 
under the exact same conditions and an antibody binding of 59.0 RU and a total 
binding of 75.6 RU were obtained indicating that the flow cell binding capacity 
had dropped substantially. To use the 20 nm gold colloids in this way, a longer 
linker may need to be employed between the antibody and the gold colloid to try 
and ensure that adequate regeneration can be achieved. If this is achieved, then 
the 20 nm colloid shows promise to give either comparable or better signal 
enhancements than the 10 nm and possibly even lower detection limit in this 
conjugate-based format. 
Subsequent tests showed that the regeneration of the conjugate immobilised 
surface produced declines in the· binding capacity of the surface even when 
exposed to weaker regeneration solutions. The 20 nm colloid could not 
eventually be fully regenerated. This suggests that practical biosensors cannot be 
constructed around a conjugate- immobilised surface in these formats due to 
surface instability. The gold seems to be causing the removal of the protein 
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conjugates from the surface perhaps through strong non-specific interactions. 
Clearly, another format and/ or surface immobilisation technique was required. 
5.3.3 Progesterone - OEG - Biotin Format 
Another alternative format for gold labelling of the antibody binding in the 
SPR immunosensor is the labelling of the antigen, progesterone, with the gold 
through a biotin / streptavidin couple and competing the biotinylated progesterone 
with free sample progesterone; and then passing over streptavidin-gold to label it. 
This format would involve immobilising antibody rather than protein conjugate, 




Figure 5.5 Schematic of the Binding of Biotinylated Progesterone to Immobilised 
Antibody Followed by Streptavidin-Gold 
The best method for biotinylating progesterone would be to attach an 
oligoethylene glycol (OEG) linker at the 4-position and terminate this chain with 
biotin. This would provide the spatial separation of biotin and progesterone 
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needed for streptavidin binding at one end and antibody binding at the other, and 
the water-soluble nature of the DEG chain should help to improve solubility. To 
do this, the progesterone - DEG derivative must be synthesised first. This can be 
done by reacting the previously reported progesterone-4-thiopropionate117· 122 with 
mono-Boe protected 4,7,10-trioxa-1,13-tridecanediamine. This reaction was 
effected simply with mild base (triethylamine). The yield was reasonable at 63% 
and the NMR spectra showed clear S-CH2 and ethylene glycol signals as well as 
the characteristic progesterone peaks and the 9H Boe methyl peak at 1.41 ppm in 
the 1H-NMR. Production of the biotinylated final product can then be achieved 
by first removing the Boe protecting group simply by stirring in formic acid, and 
then reacting the free amine with biotin-N-hydroxysuccinimide active ester under 
dry conditions. The NMR spectra showed the peaks characteristic for 
progesterone, the ethylene glycol units and biotin with no sign of any residual Boe 
signal. The synthesis scheme is shown in Figure 5.6. 
The use of a 1 mg/mL solution of progesterone-DEG-biotin did not produce 
any binding response to the immobilised antibody when a 35 min pre-incubation 
at the volume ratio of 1: 1 with 10 nm streptavidin-gold was used. Changing the 
volume ratio to 7:1 progesterone-DEG-biotin: gold led to a response of 68.7 RU. 
Regeneration was attempted with one pulse of 10 mM glycine pH= 2 and this 
totally regenerated the surface. An alternative format was then tried where the 
progesterone-DEG-biotin (1 mg/mL) was injected (240 µL at 20 µUmin) giving a 
binding of 55.5 RU. This was then immediately followed by a quickinjection of 
the 10 nm gold (60 µL at 10 µUmin). This produced a binding of 933.6 RU. 
Regeneration was then attempted with two pulses of 75 µL of 10 mM glycine pH 
= 2 which seemed to have completely regenerated the surface. This process was 
repeated again to test the repeatability of the binding response. The second test 
gave 179.0 RU response for the progesterone-biotin binding but gave 914.8 RU 
for the gold response (a variation of only 2%). This seemed to offer promise as an 
alternative assay technique, which could potentially be used for the 20 nm gold 
colloid. However, flow cell 2 began to exhibit no binding response to 
progesterone-DEG-Biotin, and testing by passing progesterone protein conjugate 














Figure 5.6 Synthesis Scheme for Production of Biotinylated Progesterone 
The antibody appeared to be de-natured. This was possibly caused by the 
DMF content of the progesterone-OEG-biotin solution. It should be noted that it 
was found to be impossible to dissolve a 10 mg/mL solution of progesterone-
biotin in aqueous DMF less concentrated than 10%. 
From the series of tests done on surface stability, as detailed in the 
experimental section (5.2.4.4), there were a number of conclusions that could be 
made from the binding responses obtained. 
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• The sequential injection method was shown to be ineffective when using 
the progesterone-OEG-biotin 
• The 10 nm colloid size did not produce significant binding even after 
overnight incubation 
• Overnight incubation with the 20 nm colloid was necessary to obtain 
responses of reasonable size 
• Preliminary binding test data indicated that total response would change in 
accordance with changing progesterone-OEG-Biotin concentration. 
The sequential injection method likely failed as there were too few biotin units 
projecting from the surface (only one per bound progesterone) for the 
streptavidin-gold to bind when it was being flowed over the surface. Likewise 
this low abundance of biotin units was possibly the cause of short time 
incubations producing low binding, long incubation times being necessary for the 
streptavidin to bind the biotin. To get higher response one may need a larger 
colloid size to increase the degree of SPR signal enhancement. 
The low responses obtained mean that an assay in this format is probably not 
advisable. The high progesterone - biotin concentration needed for binding 
response means that it is unlikely to compete suitably with free progesterone as it 
would require too high a concentration of free progesterone to inhibit binding of 
the progesterone-biotin. Furthermore, the regeneration solutions used to remove 
the gold will damage the antibody irreparably after only a few cycles. The best 
way to develop a reliable assay seemed to be to develop a very stable immobilised 
chip surface that will not be stripped by gold colloid or damaged by the 
regeneration solutions. The covalent attachment of progesterone to the surface, 
mediated by an OEG linkage, offered the best chance for a stable surface coating. 




From the above results, it had become apparent that BIAcore chip surfaces that 
have proteins immobilised, whether they be protein conjugate or antibody, would 
not be stable under the regeneration conditions needed to remove the gold labels 
from the surface. In some cases this had been probably due to the strength of the 
regeneration solutions destroying the surface, and in others likely due to the gold 
binding non-specifically to the protein and stripping it from the surface. Having a 
stable biosensor surface that is capable of withstanding many binding and 
regeneration cycles is an important part of a viable biosensor. Covalent bond 
attachment of a target to the surface offers a potential means by which the stability 
of the surface can be improved. Proteins are immobilised to the surface 
covalently but their linkages to the surface have not been very stable and they 
have been easily stripped by gold labels or through exposure to extreme 
regeneration conditions. As a further advantage, immobilisation of a non-antibody 
target means that harsher regeneration conditions can be used without needing to 
worry about loss of immunochemical function. 
Small molecules will need to be projected out from the surface so as to provide 
room for antibody binding, however they cannot be too far from the surface as 
this will potentially compromise the surface plasmon enhancement of gold labels. 
The use of short OEG chains gives the ability to project the antigen out into the 
fluid stream whilst keeping it close enough to the surface for enhancement. A 15-
atom chain would be about the right length in such a compromise. OEG has the 
further advantages of not being immunogenic; making the progesterone-linker 
compound water soluble and thus aiding projection in the aqueous phase; and 
being quite inert to potential regeneration cocktails. 
Immobilisation can be achieved by passing pure compound 2 (Figure 5.6) over 
the surface. Once the dextran surface has been activated by formation of NHS 
esters, one can simply flow 2 over the surface at high concentration and low flow 
rate for immobilisation, Figure 5.7. The immobilisation curve for attachment of 
225 
the progesterone-OEG-NH2 is given below in Figure 5.8. One can therefore 
actually see the compound being immobilised despite its small size of 623 g/mol. 
The immobilisation value was 638.9 RU after de-activation. This suggests that 
the progesterone-OEG-NH2 was immobilised to quite high surface concentrations 
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5.3.4.2 Antibody I Gold Ratio Testing 
To understand how binding response varies with varying ratios of antibody-
biotin / streptavidin-gold, a plot of response vs antibody / gold volume ratio was 
produced, Figure 5.9. This plot shows how the amount of binding response 
obtained increases with increasing antibody / gold ratio up to about 5: 1 where it 
levels off. It seems from this that the quantity of antibody present is the limiting 
factor in the amount of binding obtained. The ratio of 7: 1 was chosen as this 
gives comparable binding to 5:1 but with lower consumption of the gold label 
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Figure 5.9 Plot of Response (RU) vs Antibody/ Gold Volume Ratio for the 10 
nm Gold Colloid Streptavidin / Biotin Pre-incubation Method 
An important point to note is that injection of gold over the surface without the 
presence of antibody resulted in large (-380 RU) non-specific binding, which was 
not observed in the presence of antibody even down to an antibody / gold ratio of 
0.30. The magnitude of this non-specific gold binding was unaffected by dilution 
of the gold in buffer. Using both undiluted gold and 7: 1 buffer: gold the same 
final response was obtained. This suggests that the antibody was preventing non-
specific binding that would otherwise be very significant. As will be seen later in 
this chapter, the binding of antibody to gold was specific to the biotin / 
streptavidin interaction. 
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It should be noted that this data was obtained by using the given volume ratio 
of antibody (100 µg/mL): gold and mixing 1:1 with blank buffer as for the 
progesterone assay in 5.3.4.3 (using the same wizard). The same applied for the 
gold only injections above. The zero point of the ratio curve was obtained by 
injecting straight buffer. 
5.3.4.3 Aqueous Progesterone Assay Using Biotin I Streptavidin Mediated JO 
nm Gold Labelling 
An assay was then developed for progesterone using the 10 nm gold-
streptavidin conjugate pre-incubated with the biotinylated antibody mixed 1: 1 
with the free progesterone standard solutions in a 5 min incubation, and then 
injected over the progesterone-OEG surface. 
The progesterone assay standard curve was established using the new surface 
and this is shown in Figure 5.10. The assay curve had good shape and CVs were 
all acceptable and no outliers were present. All CVs except one were below 10% 
and five of the CVs were on or below 5%. All standard deviations were less than 
10 RU. The assay parameters are detailed below in Table 5.6. Our previous SPR 
assays of progesterone using immobilised protein conjugate10• 15 have given very 
high errors for progesterone determinations below 1 ng/mL, due to shallow assay 
curve slope, limiting detection to concentrations above 1 ng/mL. The IC5o for our 
earlier assay was 4.441 ± 0.019 ng/mL, which whilst being comparable to many 
ELISA, was still far larger than the IC5o of the gold-labelled assay. This gold-
labelled assay also has a broader linear range caused by the lowering of the 
detection limit (0.1 - 10 ng/mL compared with 2.0-7.3 ng/mL previously10). As 
well as demonstrating better detection capabilities than the previous progesterone 
aqueous assays, this method gave a far lower LOD than that previously reported 
for milk progesterone determination by SPR (3.56 ng/mL).86 
5.3.4.4 Baseline Stability 
A plot of the baseline response with each cycle is given in Figure 5.11. The 
baseline is quite steady, with gradual declines being corrected by later rises, often 
these rises occur when the chip is undocked and then re-docked and primed and 
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may be due to salt deposition but does not affect antibody binding at all. Such 
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Figure 5.10 Assay Standard Curve Using lOnm-Streptavidin / Biotinylated 
Antibody Pre-Incubation (43.75 µg/mL final mAb concentration) 
Table 5.6 Assay Parameters for the 10 nm Pre-incubation Method 
mAb Concentration LOD IC50 
(µg/ml) (pg/ml) (pg/ml) 






Such good surface stability did not stop with this assay. The same chip was 
used successfully throughout all of the gold enhancement work of this thesis and, 
at the time of writing this thesis, was still functioning well without any 
appreciable loss in antibody binding capacity. This meant that the chip could 
withstand more than 1100 binding and regeneration cycles intact without 
significant loss of binding capacity over a period of about 14 months. This 
surface treatment is clearly far more stable than that used for most sensor chips 
where the chip is limited to about 100 cycles. Gillis et al.86 have reported a sensor 
surface that could withstand 3600 cycles before losing binding response. Their 
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surface was prepared by removing the gold chip from the cartridge and manually 
pipetting EDC and NHS solutions onto the chip and then contacting progesterone-
3-CMO with the surface, also manually. The method used in this thesis is to 
immobilise in situ which is clearly much more convenient than stripping apart the 
CMS cartridge. The progesterone-3-CMO method used would not work as well 
as the 4-0EG attachment as the linker used would not be long enough to provide 
the necessary spatial separation from the surface and attachment at the 3-position 
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Figure 5.11 Plot of Baseline Absolute Response vs Cycle Number for 153 
Binding Cycles 
5.3.4.5 Antibody Only Assay Using The Progesterone - OEG - NH2 Surface 
To determine the effect that the gold labelling was having on the curve position 
and limit of detection in the pre-incubation method, it was necessary to determine 
the assay curve for the biotinylated antibody only, using the new surface at the 
same concentrations of antibody applied in the pre-incubation format above. 
The standard curve for the biotinylated mAb only is plotted below in Figure 
5.12. The assay data is summarised in Table 5.7. 
The assay constructed on the OEG-linked surface using biotinylated antibody 
without gold, at the same concentration, gave an LOD of 387 ± 67 pg/mL, so 
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clearly the gold nanoparticle labelling was improving the detection limit. 
However, comparing biotinylated antibody response to the gold-labelled response, 
it was found that there had been no significant signal enhancement. Speculatively, 
this could be caused by the steric bulk of the nanoparticle hindering approach of 
the antigen to the antibody binding site and so reducing binding and counteracting 
the signal enhancement effects of the nanoparticle. The steric bulk of the 
nanoparticle would then make approach easier for the free antigen than for the 
bound antigen and so inhibition of surface binding by the free antigen would be 
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Figure 5.12 Assay Standard Curve for Biotinylated mAb Binding Only 












5.3.4.6 The Pre-Incubation Method With 20 nm Gold Colloid 
10000 
To compare the signal enhancements possible with a larger colloid size to those 
obtained with 10 nm colloid, the colloid diameter was increased to 20 nm and the 
pre-incubation format repeated at the same primary antibody concentration. The 
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20 nm gold sol was dialysed into PBSff from the DMSO solution it was stored in, 
ensuring minimal dilution upon dialysis by allowing no air pocket in the dialysis 
tube. The UV-Visible spectroscopic analysis showed an A1..max = 1.577 (Amax= 523 
nm) compared to 2.5 for the 10 nm colloid. The absorbance did not necessarily 
indicate lower gold loading than for the 10 nm. This was because if the same gold 
loading was used then doubling of the diameter would drop the particle 
concentration by 1/8 (assuming spherical particles and homogeneous density) and 
this could cause an absorbance drop. As the colloid was a commercial preparation, 
it was decided to use the colloid as is and apply it in the same assay format as for 
the pre-incubated 10 nm label. The assay standard curve is given below in Figure 
5.13. 
One can see from the assay results that the 20 nm colloid has, under these 
conditions, failed to produce any more enhancement of signal than was observed 
for the 10 nm colloid. The LOO was no different from that of the 10 nm pre-
incubation format and the IC5o was also fairly similar, Table 5.8. The 20 nm 
colloid seemed to be performing in the same way as the 10 nm colloid did. 
Speculatively, it may be sterically restricting binding of the antibody to the 
surface whilst at the same time enhancing the signal of what has bound in such a 
way that the two effects largely cancel each other out. 
Addition of ethylene glycol was needed to minimise settling of the larger 
colloid with time, which initially caused drifting binding responses. With ethylene 
glycol added, the binding responses were fairly constant throughout, even over 
more than 30 h. 
The pre-incubation labelling format had shown no overall enhancement of the 
binding signal relative to the same concentration of biotinylated antibody alone. 
However, the detection limits of the assays were substantially better than those 
previously reported for SPR of progesterone. 10• 86 The steric inhibition arising 
from having the large gold label attached to the antibody upon binding to 
progesterone may have reduced the amount of binding signal enhancement that 
was possible. Speculatively, it may have done this by reducing the amount of 
antibody that bound to the surface to such an extent that no overall enhancement 
was observed. The steric impedance of binding to the antibody would be more 
severe for the surface confined progesterone than for the free progesterone, and 
this may mean that the inhibition conditions of the assay were weighted in favour 
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of free progesterone, which would result in an assay capable of detecting lower 
progesterone levels. In other words, if the antibody could bind free progesterone 
better than surf ace bound progesterone then smaller amounts of free progesterone 
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Figure 5.13 Assay Standard Curve for 20 nm Pre-incubation Format 
The assay parameters are summarised in Table 5.8. 




LOO IC50 Sensitivity Enhancement Ratio 
(pg/ml) (pg/ml) (RU.mUng) 
198 + 57 1910 + 150 28 1 
5.3.5 Sequential Binding Assay Format 
5.3.5.1 Gold Dilution Binding Test 
It is of interest to consider another inhibition assay format whereby the 
antibody is introduced with the free progesterone and passed over the surface-
bound progesterone first, and then a gold-streptavidin label is passed over the 
surface to label what biotinylated antibody has now bound to the surface. In such 
a format there would be none of the steric inhibition of binding to the antibody 
possible in the previous pre-incubation format, but rather the gold would serve to 
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enhance the antibody binding response already present. This format is shown 











Figure 5.14 Schematic Diagram of the Sequential Binding Format for Gold-
Labelling of Biotinylated Primary Antibody 
The first step in developing such a format is to determine the best 10 nm gold 
dilution for use in labelling by formation of a gold dilution binding curve. The 
results are presented in Figure 5.15 as a plot of total gold enhanced response vs 
gold colloid dilution factor for flow cell two. The plot clearly shows that as the 
gold dilution ratio is reduced, the binding response is also reduced at an increasing 
rate down to the antibody-biotin only binding response of about 250 RU. Further 
testing has shown only slight additional increases in total binding response when 
increasing the dilution ratio beyond 0.25. Such points have not been included in 
this curve due to the large wastage of gold this produces for very little further 
benefit. The CVs of all the points are quite low(< 3%). 
The flow cell three curve (about 1.5 times the immobilisation value of flow cell 
two) completely mirrors that of flow cell two but with higher overall binding 
responses and slightly higher CVs ( < 7% ). It is interesting to see how much 
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enhancement of response is provided at each gold dilution. This can be measured 
by taking the ratio of the total response over the antibody only response. A plot of 
the enhancement ratio with different dilutions of the colloid is given in Figure 
5.16 for flow cell two. The plot showed an ever-sharpening decline in 
enhancement as the gold dilution ratio was decreased until finally the ratio 
reached 1, i.e. no enhancement. This was as one would expect given that lower 
gold dilution ratios produce greater shortages of gold and thus greater restrictions 
on the degree of gold enhancement. As one approaches and goes above 0.25 
dilution, the gold came into excess and no further enhancement was possible for 
that antibody binding. This mirrored the total response data, as the antibody 
binding each time was constant. The enhancement ratios in this plot are clearly 
not corrected for non-specific binding. 
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Figure 5.15 Plot of Gold Enhanced Response vs Gold Dilution Ratio 
Based on this data, it was necessary to select a gold dilution to use for the assay 
and antibody binding studies. The best dilution to use was 0.15 as this gave high 
enhancement of signal (2.8 compared to 3.2 for 0.25 dilution) whilst not 
consuming excessive amounts of gold colloid, which would increase the price of 
assays, and be more likely to clog the fluidics system. 
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Figure 5.16 Plot of Gold Enhancement Ratio vs Gold Dilution Ratio 
5.3.5.2 Antibody Binding Curve Determination 
A plot of binding response vs antibody concentration is given below in Figure 
5.17 for flow cell two, showing both total binding response and antibody only 
binding response. One can see that the responses obtained, both total and 
antibody only, were directly proportional to the antibody concentration in a linear 
relationship over the whole range of antibody concentrations considered (R2 > 
0.99). The lines were highly divergent showing that the actual gold enhancement 
portion of the signal was increasing with increasing antibody concentration. 
Signals for the pre-incubation method reached a maximum of 150 RU, so one can 
see from this curve that the antibody concentration can be reduced to at least 15 
µg/mL and still retain good levels of binding response. It probably would not be 
wise to reduce the concentration much further as the gold is demonstrating about 
100 RU of non-specific binding making the target gold enhanced signal around 
250-300 RU, i. e. about 15 µg/mL biotinylated antibody. 
From this data, one can compute . the signal enhancement ratio by taking the 
ratio of the slope of the total signal line over the antibody only binding line. This 
gave a signal enhancement of 2.2. Clearly, gold labelling in a sequential binding 
format is giving signal enhancement, speculatively due to the gold not sterically 
reducing binding of the primary antibody. The same enhancement is seen in flow 
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cell three. All discussion will now be directed to flow cell two unless otherwise 
stated as flow cell three overall showed worse or equivalent assay performance 
compared to flow cell two. 
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Figure 5.17 Antibody Dilution Plot. • Primary Antibody Only, + Gold Enhanced 
Signal 
Based on this data, one can now produce an assay for progesterone. It was 
hoped that the reduction in the concentration of antibody would mean that 
substantially smaller amounts of progesterone would produce significant 
inhibition of binding thus pushing the LOD to lower concentrations. 
5.3.5.3 Progesterone Sequential Assay 
The assay results were analysed in a number of ways. Firstly the monoclonal 
antibody only (15 µg/mL injected concentration) responses were plotted to give a 
calibration curve. This curve is shown below in Figure 5.18. 
The curve for the total response was then plotted and is given in Figure 5.19. 
The CVs were a little better than those of the antibody only curves and the curve 
gave blank binding of 181 RU. The data for these curves are summarised below 
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Figure 5.18 Antibody Only Assay Standard Curve, 15 µg/mL Primary mAb 
(Injected Concentration) 
One can see that the antibody-only detection limits are substantially lower than 
those obtained by antibody alone at a final concentration of 43.75 µg/mL (see 
Section 5.3.4.5). Dropping the antibody concentration has enabled detection of 
lower levels of progesterone as expected. This level of non-specific binding was 
actually less than that anticipated (antibody binding curve data suggested non-
specific binding of -100 RU but it was 5 40 RU for flow cell 2). This may mean 
that the presence of progesterone was further diminishing non-specific binding. 
The CVs were slightly high for a practical assay using the un-labelled antibody, 
but were significantly better with labelled antibody. The LOO of the assay using 
antibody only seemed quite low but had high standard error. 
Comparing the IC50 values, it could be seen that there was no great difference 
between the unlabelled and labelled binding curve positions, indicating that the 
gold label was scaling up the binding response without shifting the curve position. 
This is wholly expected, as the gold is not present during incubation with free 
progesterone and so will not shift the overall curve position. The slope sensitivity 
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Figure 5.19 Assay Curve with Gold Enhancement, 15 µg/mL Primary mAb 







mAb Only Total 
32 ± 53 150 ± 49 




The only way that one can further reduce the detection limit of this assay 
format is to reduce the concentration of the antibody still further. If the final 
antibody level is halved to 7.5 µg/mL, then one would expect maximum antibody 
binding of -27 RU which would be expected to translate to total maximum 
binding of -83 RU based on the assay curves. Based on the drop experienced in 
the detection limit so far, a detection limit then of 25-50 pg/mL would be 
expected. The question would then remain as to whether the CVs would be low 
enough. It has been seen that the gold enhancement is capable of improving the 
CV somewhat. 
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5.3.5.4 A New Progesterone Sequential Assay 
The standard curves for antibody only binding (7.5 µg/mL after dilution with 
progesterone solutions) and total gold enhanced binding are given in Figure 5.20. 
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Figure 5.20 Assay Standard Curves with Primary Antibody Only (Top), Gold-
Enhanced Signal (Bottom) - 7.5 µg/mL Primary mAb (Injected Concentration) 
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Table 5.10 Assay Data - New Sequential Assay 
mAb Only Gold Total 
LOO (pg/ml) 28 ± 21 23.1 ± 4.4 
ICso (pg/ml) 455 ± 30 460 ± 16 
Average CV 4.4 3.3 
Dynamic Range 0.01-1 ng/ml 0.01-1 ng/ml 
Sensitivity (RU.mUng) 14 40 
Further reduction of the antibody concentration has significantly reduced the 
LOD of the enhanced assay to 23.1 ± 4.4 pg/mL. The CV for this assay was quite 
good and this has probably contributed to the low LOD. The gold has enhanced 
the signal by a factor of 2 as before. Once again, there is no real shift in the IC50 
from unlabelled to labelled. It was a little surprising that the antibody bindings 
have retained good CVs down to such low binding levels (maximum binding 
response of 30 RU) and indicated the robustness of this surface treatment down to 
such very low levels of binding. The overall CVs were all acceptable, though the 
CVs for the gold responses were in practical terms almost double this because of 
the non-specific binding. It was clear that to further reduce the antibody 
concentration it would be necessary to largely eliminate the non-specific binding 
still being exhibited by the gold colloid. 
5.3.6 Antibody Binding Tests and Non-specific Binding Treatments for 
the Sequential Format 
5.3.6.1 Optimisation of the Non-Specific Binding Treatment 
Slower flow rates for passing of the labelling compounds could possibly have 
resulted in higher enhancements, so a 10 µUmin flow rate was tried. The 
enhancement ratios obtained were no better than those for the 20 µUmin flow 
rate. The biotinylated antibody (50 µg/mL) was injected in the assay format with 
a blank and with gold at a 0.15 dilution in 1 %v/v PEG-400, 0.2 MEG. This was 
also then repeated for a 0.5%v/v total PEG-400 loading. Preliminary tests 
indicated that 1 %v/v PEG-400 would reduce non-specific binding without 
reducing the response slope. As the 1 %v/v PEG-400 was not decreasing the slope 
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of the binding curve, it was decided that it be used at this level for use in new 
binding studies and assays. 
5.3.6.2 Antibody Binding Test with Reduced Non-Specific Binding 
Using the new treatment to further reduce non-specific binding, the antibody-
binding plot was re-done. The plot is given below in Figure 5.21. It was clear that 
these plots have very good correlation lines and that the non-specific binding is 
down to 14 RU. The slope of the gold enhanced line as a ratio to the monoclonal 
antibody line was 2.1. This is an indication that the level of non-specific binding 
up to at least about 100 RU did not affect the degree of signal enhancement. 
Clearly this slightly different gold label treatment had significantly reduced non-
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Figure 5.21 Antibody Binding Plot With New Non-Specific Binding Treatment. + 
Primary Antibody Only, • Gold Enhanced Signal 
5.3.6.3 Gold Loading - Is it Optimal? 
To test whether raising the gold loading in the labelling step had any effect on 
the enhancement with the new PEG treatment, higher gold loadings of 0.25 
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dilution were tried. This produced an enhancement of 2.3. One can see that the 
enhancement was not greatly different from the 0.15 loading (enhancements 
calculated after correction for non-specific binding). 
To assess whether simply increasing the volume of gold label used would 
improve the binding enhancement, an antibody gold-enhanced binding was done 
using a 60 µL injection of the 0.15 dilution and 50 µg/mL antibody and flow rate 
at 20 µUmin. The binding results showed enhancements of 2.3-2.4. Enhancement 
was not much greater than that achieved previously. Certainly for the 0.15-0.2 
extra ratio signal enhancement a lot of gold was wasted (now using twice as 
much) and the extra benefits were minimal - no better than for the 0.25 dilution. 
0.15 dilution and 30 µL injection volume certainly seemed to be the optimal 
condition for gold labelling. 
To see if increasing the incubation time of progesterone solution with antibody 
would improve the ability of the assay to discriminate low progesterone 
concentrations, a 100 pg/mL progesterone standard was run using the assay 
program with 0.15 gold (1 %v/v PEG-400, 0.2 MEG total) at 20 µUmin but one 
with a 10 min incubation and one with a 5 min incubation. The antibody was at 
15 µg/mL. This test showed clearly that the increased incubation time was not 
having any effect whatever on the binding and thus no effect on the discrimination 
of lower concentrations of progesterone. The 5 min incubation was therefore 
retained. 
5.3.6.4 Gold Enhanced Assay - Low Antibody 
Having further minimised the non-specific binding seen on the surface, a new 
progesterone assay could be constructed using even lower primary antibody 
concentration. The concentration was thus reduced to 2.5 µg/mL (injected 
concentration). The assay curves are given below in Figure 5.22. The assay 
parameters are summarised in Table 5.11. 
It can be seen from the LOD that there was no real benefit obtained from 
reducing the final antibody concentration from 7.5 to 2.5 µg/mL, indeed the LOD 
was worse than that for the 7 .5 µg/mL case. The worsening LOD was caused by 
the signal dropping too low (sensitivity of only 9.1 RU.mUng compared to 40 
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RU.mIJng for the 7.5 µg/mL case) causing the CVs to rise and push the LOO to 
higher concentrations as low concentrations cannot be discriminated from the 
blank so well. The ICso had continued to drop however, as the lower antibody 
concentration pushed the curve further to the left. This drop was not as large as 
might be expected from the reduction in antibody concentration. The linear ranges 
were the same before and after enhancement, and extended to 50 pg/mL compared 
with 10 pg/mL for the 7.5 µg/mL antibody concentration. 
Clearly, in order to further reduce the LOO at this concentration of antibody, 
the degree of signal enhancement would need to be increased to much more then 
2x, i.e. at least around 4x. To achieve this, it may have been necessary to increase 
the size of the colloid particle employed. The next logical step was to proceed 
with use of a 20 nm colloid. It is useful to compare the assay plots and linear 
ranges of the three different antibody concentrations used thus far. These are 
shown in Figure 5.23. 
It was clear that, with decreasing antibody concentration the maximum 
response declined as expected. Also as expected, the curve flattened substantially 
at higher progesterone concentration with significant binding response not 
occurring until lower than 1 ng/mL for the 2.5 µg/mL curve, 10 ng/mL for the 7 .5 
µg/mL curve and 100 ng/mL for the 15 µg/mL curve. It was of interest to note 
that the non-enhanced curves did not reach zero response but rather levelled out at 
between 5-8 RU. This was caused in part by non-specific binding of the antibody 
to the OEG-progesterone surface. 
If lower antibody concentrations were to be used in this format, then this non-
specific binding would likely need to be removed, probably by adding an agent to 
the diluent of the antibody solution. Gold enhancement alone would not solve this 
problem as the gold enhances the antibody that is present on the surface (see 
Section 5.3.6.7). The linear regions of the assay curves had improved from 0.1-10 
ng/mL for 15 µg/mL to 0.01-0.2 ng/mL for 7.5 µg/mL but for 2.5 µg/mL the 
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Figure 5.22 Assay Standard Curves With Primary Antibody Only (Top) and With 
Gold-Enhanced Signal (Bottom) - 2.5 µg/mL Primary mAb (Injected 
Concentration) 
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Figure 5.23 Comparison Plot of Gold Enhanced Assay Curves. T 2.5 µg/mL, o 
7.5 µg/mL, • 15 µg/mL Primary Antibody 
5.3.6.5 ls the Gold Enhancement Mediated Through the Biotin I Streptavidin 
Couple? 
To prove that the gold labelling of the biotinylated antibody was due to 
coupling via the biotin / streptavidin linkage alone, it was necessary to test any 
enhancement of the monoclonal antibody unmodified vs the enhancements 
already gained from this data for the biotinylated antibody. The results are 
summarised in Table 5.12. 




Flow Cell 2 1.05 2.2 
Flow Cell 3 1.02 2.18 
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The very small enhancement in the monoclonal un-modified antibody was due 
to a very small amount of non-specific binding. One can therefore conclude that 
practically all labelling binding was mediated by the biotin-streptavidin 
interaction and there was negligible non-specific binding between primary 
antibody and gold. 
5.3.6.6 Gold Level I Response Relationship with Use of PEG-400 
Now that the PEG-400 treatment had been successfully employed to reduce 
non-specific binding, a new gold dilution response curve could be produced. The 
total response curve is given below in Figure 5.24. When checked against the 
new antibody concentration curve plot (Figure 5.21), the 0.15 point compared 
very closely to that predicted by the equations. A more pronounced drop could be 
seen in the curve at lower gold dilutions here than previously, and once again the 
0.15 dilution was revealed as the best dilution as 0.25 was producing little extra 
enhancement despite using nearly twice as much gold. 
5.3.6.7 Attempts to Remove Non-specific Binding of the Antibody 
Results have indicated that there was some non-specific binding of the primary 
antibody to the surface. To construct assays with still lower primary antibody 
concentrations using the sequential binding format and the biotin/streptavidin 
couple, this non-specific binding may need to be removed. Attempts were made to 
remove this by adding in PEG to the antibody solution but this appears to have 
had no real effect. The progesterone itself at high concentrations seemed to 
produce some non-specific binding but this does not account for all the non-
specific binding observed. 
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Figure 5.24 Plot of Response (RU) vs Gold Dilution Ratio with New Non-
Specific Binding Treatment 
5.3.6.8 Another Low Monoclonal Antibody Progesterone Assay 
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0.3 
The 7.5 µg/mL primary antibody assay method was repeated using the PEG-
400 treatment to reduce non-specific binding to see if this would improve the 
assay results. This method produced good progesterone assay standard curves 
with almost all CVs equal to or less then 5%. The assay curves are given in 
Figure 5.25. 
Whilst the IC50 for this format was somewhat lower than that above, the LOD 
was not statistically any different from that achieved without the PEG-400 
treatment. From the graph, it can be seen that the non-specific binding was no 
more than 16 RU. 
The parameters for this assay are given below in Table 5.13. 
5.3.6.9 20 nm Colloid Sequential Binding - Will the Larger Colloid 
Substantially Improve Enhancement? 
It was of interest to examine the effects of increasing the colloid size used for 
labelling to see if this would greatly improve the binding enhancement under the 
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sequential injection format. To this end injections of 30 and 60 µL of streptavidin-
gold 20 nm were made. The binding results showed that increasing the gold 
volume had no effect on the enhancement obtained and that these enhancements 
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Figure 5.25 Assay Standard Curves. Primary Antibody Only (Top), Gold Signal-
Enhanced (Bottom) 
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The surface was then injected with 0.5 dilution 20 nm colloid (1 %v/v PEG-400 
total, 0.2 M EG total, 30 µL) and this gave next to no non-specific binding (0.4 
RU in flow cell 2 and 1.1 RU in flow cell 3) so the enhancement was antibody-
streptavidin gold mediated. Non-specific binding actually appears to be less of a 
problem than for 10 nm. 
So, there has been some improvement in the enhancement ratio but there was 
still not much more than the 0.15 dilution gives for the 10 nm colloid. The 
increase in enhancement for a doubling of the injection volume (0.25 dilution) 
was quite small so further increases in the injection volume are not likely to 
improve the 20 nm gold enhancement and will only waste gold. 
The reason for the lower than expected 20 nm colloid enhancement is possibly 
that the larger size of the colloid is sterically blocking binding more than for the 
10 nm colloid, and so fewer colloid particles are bound, but those that are bound 
give higher signal enhancement. To see if such steric hindrance could be 
minimised by lowering the binding concentration of colloid, the dilution was 
changed to 0.25 (1 %v/v PEG-400 total, 0.2 M EG total, 120 µL, 20 µUmin, 
instead of 60 µL) but this made no difference. 
It was thought that putting very concentrated gold in a shorter injection over 
the surface may improve response enhancement. To this end, a 15 µL injection of 
un-diluted 20 nm gold was used as label at a flow rate of 20 µUmin. This was 
then followed by a check for non-specific binding with un-diluted 20 nm colloid 
(15 µL, 20 µUmin) and gave non-specific binding of around 11 RU. There was a 
slight increase in the enhancement to 2.42 (correcting for non-specific binding). 
This was still only a little higher (-0.3) than the 10 nm colloid and the sensorgram 
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showed binding had just about reached equilibrium so minimal further 
enhancement could be expected by increasing the injected volume. 
It is possible that further increasing the colloid size beyond 20 nm may produce 
further enhancement, as the larger colloids have been demonstrated in previous 
studies with large molecules to produce more enhancement. The results with 20 
nm are not promising though and there are potential problems with larger sizes as 
they may result in regeneration or non-specific binding problems or sterically 
crowd each other around the surf ace. 
5.3.7 Secondary Antibody Labelling 
5.3.7.1 The Secondary Antibody Labelling Effect 
The biotin/ streptavidin couple has demonstrated enhancement of the binding 
signal of primary antibody when applied in a sequential format. It is of interest to 
consider how use of a different binding couple to label the primary antibody 
binding interaction with the surface may be used to achieve signal enhancement. 
Another method of labelling is to use secondary antibody directed to the primary 
antibody. This secondary antibody can increase the bound mass on the surface by 
binding the primary antibody. In this case, one would use anti-rat IgG, as the 
primary antibody has been raised in rat. The secondary antibody has mass 
comparable to the primary antibody, and so one would expect an approximately 
two-fold enhancement of signal upon secondary antibody binding, assuming a 1: 1 
binding interaction. 
This method of labelling was employed in the progesterone system by injecting 
secondary antibody solution at high concentration immediately after the primary 
antibody in the same fashion as for the sequential binding format detailed above. 
A sensorgram of the binding interactions is given in Figure 5.26. 
It can be seen that the secondary antibody binding was very high relative to the 
primary antibody binding and had achieved maximum binding of the primary 
antibody as evidenced by the levelling off of the binding response. The secondary 
antibody had been injected at a flow rate of 10 µUmin to maximise the labelling, 
as it was found in testing that 20 µUmin resulted in a much lower enhancement. 
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This was probably because the primary/ secondary antibody binding interaction is 
weaker than the biotin/ streptavidin binding interaction, and so in the flow-
through format more exposure time to the surface was needed to effect good 
binding enhancement. Regeneration of the binding was easily achieved using the 
same regeneration cocktail as was used for the gold experiments. Regeneration, as 
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Figure 5.26 Sensorgram of the Binding of Primary mAb (25 µg/mL) Followed by 
Secondary Antibody (800 µg/mL) and then Regeneration 
To determine the effect of secondary antibody concentration on the level of 
signal obtained, a plot was prepared at varying concentrations of secondary 
antibody with fixed primary antibody (25 µg/mL). This plot is given in Figure 
5.27. 
It can be seen that both total binding signal and enhancement ratio increase 
rapidly with increasing secondary antibody concentration until they level off at 
high secondary antibody concentrations corresponding to saturation binding of the 
primary antibody on the surface. Some testing was done at concentrations above 
800 µg/mL but showed no significant further increases in signal. One can see 
clearly from this plot that the enhancement ratios rise up much higher than 2, 
indicating that there is far more enhancement of signal than would be expected 
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from a simple 1: 1 binding of secondary antibody to the primary antibody. The 
reason for such a high signal enhancement is not clear and has not to the author's 
knowledge been reported before, but it may be caused by several secondary 
antibody molecules binding one primary antibody molecule. Enhancements of 7-
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Figure 5.27 Plot of Total Binding Signal vs Secondary Antibody Concentration 
(µg/mL) (Top) and Enhancement Ratio vs Secondary Antibody Concentration 
(Bottom) 
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5.3. 7.2 Secondary Antibody Signal Enhancement of Primary Antibody Binding 
To determine the exact enhancement ratio at fixed secondary antibody 
concentration, and to show the relationship between primary antibody 
concentration and total response, a plot of response vs primary antibody 
concentration was prepared, Figure 5.28. 
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Figure 5.28 Antibody Binding Plot of Response (RU) vs Primary Antibody 
Concentration (µg/mL). • Primary Antibody Response, • Total Response 
From this plot, it can be seen that the primary antibody only and secondary 
antibody enhanced binding responses were linear with increasing primary 
antibody concentration up to 25 µg/mL (R2 > 0.99). The slope of the secondary 
antibody enhanced plot was 7.7 times that of the primary antibody plot, indicating 
7.7-fold signal enhancement and further confirming the results in Figure 5.27. The 
non-specific binding of the secondary antibody enhanced signal was only 6.5 RU, 
very small relative to the total signal. On the basis of these data, one could now 
proceed to constructing assays for progesterone using secondary antibody signal 
enhancement. 
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5.3.7.3 Progesterone Assay Using Secondary Antibody Signal Enhancement 
Progesterone assays were performed at two concentrations of primary antibody 
(3 and 25 µg/mL final injected concentration). The assay curves for these two 
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Figure 5.29 Progesterone Assay Standard Curves for 25 µg/mL Primary Antibody 
(Top) and 3 µg/mL Primary Antibody (Bottom). + Primary Antibody, o 
Secondary Antibody-Enhanced 
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The 25 µg/mL assay had a high slope sensitivity caused by high binding 
responses over a relatively narrow dynamic range. The LOO of the assay (246 ± 
41 pg/mL) was indistinguishable from the corresponding un-labelled assay (197 ± 
18 pg/mL) as the CVs for the unlabelled assay were adequate to get good LOO 
and the labelling was only increasing the slope sensitivity. The 3 µg/mL assay was 
another situation altogether. In this case, the LOO (20.1 ± 4.0 pg/mL) was 
significantly lower than the corresponding un-labelled assay (46 ± 10 pg/mL) 
(one-tailed t-test P value of 0.04). This arises as the higher signal brings about 
better CV and thus lower LOO. 
The LOO drops from the 25 to the 3 µg/mL assay in rough proportion to the 
drop in primary antibody concentration, but the IC50 does not drop as much. The 
slope sensitivity of the 3 µg/mL assay was roughly 2.5 times that of the 10 nm 
sequential binding biotin/streptavidin assay at 2.5 µg/mL. Theoretically, if gold 
labels are applied to the secondary antibody then one should observe further 
signal enhancement from the SPR-active nanoparticle. The secondary antibody 
concentration was dropped to 400 µg/mL for the assay using 3 µg/mL primary 
antibody. 
5.3.7.4 Non-Specific Binding and Regeneration 
The secondary antibody has bound the surfaces with very little non-specific 
binding. No additives were needed to minimise non-specific binding. The 
secondary antibody format developed here was a quick and simple assay format 
that generated substantial signal enhancement without needing the use of gold 
nanoparticles. The format was generically applicable to other small molecule 
systems such as that detailed in Chapter 3 for estradiol. Regeneration could be 
very effectively achieved with the same regeneration cocktail as used previously 
with the gold, and the surface continued to demonstrate excellent stability and 
consistent antibody binding responses. The CVs for these bindings were all quite 
low, averaging about 5%. 
The assay parameters are given in Table 5.14. 





LOD IC50 Sensitivity Enhancement Ratio 
(pg/ml) (pg/ml) (RU.mUng) 
20.1 ± 4.0 242.8 ± 5.1 99 8 
246 + 41 865 + 63 226 8 
5.3.8 Secondary Antibody-Gold Signal Enhancement 
5.3.8.1 Colloid Production and Sizi.ng 
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To produce even higher signal enhancement than that obtained with the 
secondary antibody alone, gold labels were attached to the secondary antibody to 
examine the level of signal enhancement that could be obtained. The first step in 
doing this was to produce gold sols of well-defined size. 
The citrate reduction method of Frens230 is an excellent method of producing 
gold sols in the size range of 20-70 nm. By simply adjusting the volume of citrate 
solution added to a fixed amount of gold, the colloid size can be altered using a 
reflux method. To ensure against aggregation, and that a consistent colloid size 
can be obtained, it was necessary to wash all glassware used with aqua regia to 
remove all traces of metals on the surface of the glassware. Glassware used in 
these experiments was washed between every colloid batch produced. All 
colloids were made to the same gold concentration (0.01 %w/v of the HAuC14, 
compensating for water of hydration). 
The colloids, once cooled, were adjusted for any water losses due to 
evaporation and were then analysed by the Malvern Zetasizer™. The Zetasizer 
results could, for all colloids, be done without prior centrifugation or filtering and 
there were very few large particles formed in the colloids. The sizings matched 
the Frens method determinations quite closely but tended to suggest that the 
colloids were on the whole larger than the desired size thus requiring slight 
changes to the citrate loadings used to ensure the correct size colloids were 
produced. 
As a validating comparison, commercially produced 20 nm gold conjugates 
that had been sized by TEM were analysed in the Zetasizer. This showed that for 
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colloid sized by TEM as 19 ± 2.1 nm, the Zetasizer gave 23.0 ± 1.0 nm n = 30, i.e. 
the sizings were statistically indistinguishable (values are mean ± SD). This 
demonstrates the robustness of using the Zetasizer to size the gold sols. 
Attempts to produce colloids larger than 70 nm were fraught with problems, as 
they very easily aggregated under the reaction conditions and also were very hard 
to produce repeatably, as very small variations in the citrate quantity could 
produce very large variations in colloid size at low citrate loadings. 
The changing sizes could be easily distinguished by the naked eye and a 
photograph indicating some of the different colloid sizes is given in Figure 5.30. 
Figure 5.30 Gold Colloid Sizes, Left to Right: Approximately 25, 50, 70, 120 nm 
5.3.8.2 Optimisation of Gold-Secondary Antibody Conjugate Production 
To produce gold nanoparticle-secondary antibody conjugates which would 
perform optimally as signal enhancement agents, and to develop the conditions for 
their use, a large number of parameters had to be optimised. These parameters are 
listed below. 
1. colloid nanoparticle diameter 
11. binding flow rate 
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iii. gold dilution factor 
iv. additives needed to minimise non-specific binding 
v. regeneration conditions 
vi. concentration of the original colloid 
vii. antibody coating concentration 
viii. pH used for conjugation 
ix. level of BSA blocking agent 
x. use of centrifugation 
xi. use of sonication 
xii. use of azide preservative 
xiii. time of contact of antibody to sol before blocking 
Each of these parameters was investigated in tum by conducting binding 
studies of the sols over the SPR chip surface after injection of primary antibody. 
The number of tests performed makes discussion of each and every one overlong, 
so the results of the binding investigations are summarised for each parameter. 
Colloid size was altered by use of the appropriate conditions in the citrate 
reduction method. Overall, it was concluded that the 25 nm colloid was the best to 
use in this case. Sizes of approximately 25, 40, 50, 70 and 120 nm were all 
examined. The flow rate was optimised at 10 µUmin with higher flow rates 
reducing amount bound and even lower flow rates taking too much time. The 
lower flow rate was needed as the secondary antibody I primary antibody 
interaction is not as strong as the streptavidin I biotin interaction and the gold sol 
may have been slightly sterically hindering approach of the labelling antibody. It 
was found that either not diluting the gold at all, or using a 0.5 dilution was best 
for maximum binding response (see Sections 5.2.9.3-5.2.9.5). The agent used to 
minimise non-specific binding was 10% v/v PEG-400 for experiments with 
centrifugal purification and 1 %v/v PEG-400 without purification, added straight 
to the gold-antibody with loadings optimised by binding tests. Other agents tried 
but not used included 1-octanthiol, PEG-600 diacid, and PEG-4000. Regeneration 
was achieved with the same regeneration cocktail as used previously (200 mM 
NaOH, 20%v/v MeCN). Sols were used both as produced and 5x concentrated 
from their original citrate reduction concentration (concentrated by centrifugation 
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with PEG-400, 3%v/v) and the 5x concentrated method was found to give slightly 
higher binding though it did not raise the binding by 5-fold; see Section 5.3.8.4. 
The optimal antibody coating concentration for the sols was found to be 900 
µg/mL for the purified sol and 8 mg/mL was used for the non-purified sol 
(concentrations before adding to gold). These concentrations were sufficient to 
prevent aggregation by NaCl addition. The pH used for the sol on conjugation was 
pH 8.6 for the purified sol and pH 8.5 for the non-purified. The pH of the 
antibody solution was 7.2 for the purified sol and 8.5 for the non-purified. In order 
to optimise the binding of the protein to the sol, the pH should be above the pl of 
the protein. The typical pl range for lgG is 5.8-7.3. The bovine serum albumin 
which was used to block the un-bound sites on the sol and so reduce non-specific 
binding, was applied at 2.5%w/v final concentration for the purified sample and 
0.2%w/v final concentration for the un-purified sample. 
Centrifugation up to 13k x g was found to have no effect on the integrity of the 
antibody being conjugated. Sonication also seemed to have minimal effect, as did 
addition of azide. The amount of time in which the antibody was exposed to the 
sol before blocking, was found to have a strong effect on the binding intensity of 
the gold-antibody conjugate. Long, i.e. 18 h, binding times at 4 °C were needed to 
ensure that the antibody was optimally bound to the colloid surface. Only then 
could BSA blocking agent be applied and the colloid centrifuged if necessary. 
Attempts to use shorter times before blocking resulted in much lower signal 
enhancement, due most probably to lower antibody adsorption on the sol. 
5.3.8.3 Signal Enhancement with Purification of Un-Bound Secondary 
Antibody 
At first, the secondary antibody-gold conjugate was formed with a step to 
centrifugally remove any un-bound anti-rat lgG. This enabled the binding 
enhancement possible with anti-rat lgG-gold alone to be determined. The 
colloid's signal enhancement was then plotted, Figure 5.31. 
This plot shows that the level of enhancement obtained with secondary 
antibody-gold with removal of unbound antibody is 3.5-fold. This is far less than 
that obtained by the secondary antibody at 800 µg/mL. The reason for this lower 
enhancement was that the gold colloid cannot adsorb the entire secondary 
260 
antibody that was mixed with it, and so a significant proportion of the antibody 
was washed away during the centrifugal purification. The only way to further 
improve the signal enhancement is to either increase the size of the sol at the same 
particle concentration, or increase the particle concentration of the sol. Both these 
methods can lead to aggregation of the colloid, which will affect the binding 
responses obtained and may clog the integrated microfluidics cartridge (IFC) of 
the BIAcore. It seems that the surface area of the gold sol is a limiting factor in 
the level of adsorption of the antibody and thus in the level of signal enhancement 
that can be obtained. 
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Figure 5.31 Antibody Binding Plot. + Primary Monoclonal Antibody Only, • 
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The non-specific binding of this colloid, whilst being only 10 RU, was 
significant relative to the amount of signal response obtained, though this may not 
necessarily affect an assay. There is no point in doing an assay using these 
conditions as the level of enhancement is not superior to that of secondary 
antibody alone and so it cannot be expected that the LOD will be any better as the 
primary antibody concentration cannot be lowered any further with this 
enhancement. 
5.3.8.4 Signal Enhancement Without Purification of Secondary Antibody -
Colloid Sizes 
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To determine the actual level of enhancement a gold colloid will give to the 
secondary antibody, it was necessary to compare the gold-secondary antibody 
labelling to secondary antibody alone at the same final concentration. To do this, 
one cannot purify out unbound secondary antibody, but rather must leave all the 
antibody in place. 
In such a format, one should fi rst consider the best colloid size to use in the 
labelling. Previous reports have suggested that larger colloid sizes can allow better 
SPR signal enhancement increasing from 30-59 nm on a 47 nm gold film.210 To 
determine if colloid size was important, a plot was prepared to compare colloid 
size to signal obtained for five different colloid sizes. They were compared at both 
the concentrations produced by the citrate method and 5-fold concentrated (by 
centrifugation with 3%v/v PEG-400 to prevent aggregation). Naturally, as the 
gold loading was the same for all colloids produced, the particle concentration 
will be lower for larger colloids, however not so large as to not be compensated 
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One can see from this plot that the five-fold concentration has made very little 
difference to the enhancement obtained and furthermore, there is no statistically 
significant difference between the sizes. This effect may be produced by the sol 
being a larger distance out from the surface than was previously reported for 
protein work. As the larger sols are much more prone to aggregation, it was 
decided to keep using the 25 nm sol, which was comparatively stable. 
5.3.8.5 Assay Using 25 nm Sol-Secondary Antibody Without Centrifugal 
Purification 
Having decided on the colloid size to use, it was then necessary to determine 
the level of enhancement that could be obtained with the conjugate. The antibody 
binding plot is given in Figure 5.33. 
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Figure 5.33 Antibody Binding Plot for 25 nm Gold-Secondary Antibody 
Enhancement 
The signal enhancement observed here is 8.5-fold, much better than that 
obtained for the purified gold-secondary antibody conjugate, but seemingly not 
much better than the secondary antibody alone. The gold sol gives some 
significant non-specific binding (about 200 RU) and this may affect low-level 
antibody assays. To get a true picture of the enhancement ratio it was wise to 
perform the assay and assess the actual enhancement of the active region of the 
30 
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curve, which up until now has been the same as that computed from the antibody 
binding plot. 
A progesterone assay was then constructed using the 25 nm gold-secondary 
antibody conjugate at the same secondary antibody loading as the original 
secondary antibody-only assays. The primary antibody concentration used was 1.5 
µg/mL (final injected concentration). The assay standard curve for flow cell 3 is 
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Figure 5.34 Assay Standard Curve for 25 nm Gold-Secondary Antibody-
Enhanced Assay 
The enhancement ratio of this assay is 13-fold, much higher than the antibody 
binding plot suggested, and the highest signal enhancement ratio yet attained in 
these studies. The LOD was 8.6 ± 3.2 pg/mL, which was the lowest LOD yet 
attained, and shows very clearly that higher signal enhancement can lead to better 
LOD through reduction in primary antibody concentration. This LOD was about 
what one would expect given that the assay uses half the primary antibody 
concentration of the 3 µg/mL secondary antibody enhanced assay, and that gave 
an LOD of 20.1 ± 4.0 RU. The IC50 had also decreased with the decreasing 
primary antibody concentration. This lower curve position, coupled with the 
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sustained binding signal has led to the highest assay slope sensitivity of this study 
(308 RU.mUng). Clearly this assay format has given the best performance overall 
and shows that addition of the gold label to the secondary antibody can enhance 
the signal obtained to about 1.6-times that of the secondary antibody alone. Flow 
cell 3 gave slightly better assay performance than flow cell 2 for this assay only. 
This assay does have some non-specific binding to the surface (-150 RU), but 
this does not appear to have affected the assay performance in any way and can 
just be subtracted out as has been done in Figure 5.34. It may be of interest in 
future to try and reduce this non-specific binding component. 





LOD IC50 Sensitivity Enhancement Ratio 
(pg/ml) (pg/mL) (RU.mUng) 
8.6+3.2 151.7+2.1 308 13 
5.3.9 Overall Results Summary 
To enable easier comparison of the assay data obtained, a table of the assay 
parameters for all the main assay formats is given in Table 5.16. The primary 
antibody concentrations given are the final concentrations after 1:1 mixing with 
progesterone solutions. 
5.3.10 Regeneration Solutions 
The successful regeneration of the biosensor surface was critical to maintaining 
repeatable antibody binding responses. The regeneration cocktail used in this 
study is a combination of strong base (200 mM NaOH) and the chaotrophic 
reagent acetonitrile. Acidic pH and weaker base have proven to be ineffective in 
regenerating the surface, and acetonitrile was also needed to achieve complete 
regeneration. This cocktail did not damage the surface to any appreciable extent 
and yet was very effective in removing bound gold label. 
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Table 5.16 Summary of the Assay Parameters for Each of the Progesterone Assay 
Formats 
Primary Antibody 
Concentration LOD ICso Sensitivity 
Assa:t Format (1:!:9/mq <egtmq (egtmq (RU.mUng) Enhancement Ratio 
Primary Antibody 
Only 43.75 387± 67 1060 ± 290 9.4 
Pre-incubation 
10nm 43.75 143± 35 1670 ± 100 57 
Pre-incubation 
20nm 43.75 198 ± 57 1910 ± 150 28 
Sequential 10nm 15 150 ± 49 1000 ± 145 32 
Sequential 10nm 7.5 23.1 ± 4.4 460± 16 40 
Sequential 10nm 2.5 104 ± 40 314 ±21 9.1 
Secondary Antibody 3 20.1 ± 4.0 242.8± 5.1 99 
Secondary Antibody 25 246± 41 865±63 226 
Secondary 
Antibody- Gold 
25nm 1.5 8.6±3.2 151.7±2.1 308 
a All errors quoted are standard errors 
5.3.11 Statistics Discussion 
A thorough statistical analysis of immunoassay data is important in drawing valid 
conclusions about the assay data and to make valid comparisons between different 
assay formats. It is necessary therefore to discuss the statistical methods employed 
in this study. The limit of detection (LOD) was computed as the concentration 
corresponding to the response value that is two standard deviations below the 
blank response value. This definition is one that is widely used for 
immunoassay22• 128• 129 and ensures that the figure quoted is the minimum value the 
assay can distinguish from the blank. As the value is dependent upon the standard 
deviation of the blank, assays with better blank CV can give better LOD as can 
assays with steeper slopes in the assay curve close to the blank value. Limit of 
detection therefore is a combination of precision of the assay's concentration 
determination at low levels and the position of the assay curve. The errors in the 
LOD needed to be computed to give accurate comparisons of LOD. These were 
computed by translating the error in the response of a point nearest the LOD on 
the assay curve into error in the concentration by use of the 4-parameter logistic 
fitting equation. All the curve data have been fitted to 4-parameter logistic 











concentration at 50% bound (ICso) is determined as a parameter of the curve 
fitting and so was not affected by non-specific binding. The errors in this 
parameter were computed in the same fashion as for the LOO. Sensitivity is a 
measure of the slope of the assay curve's linear region and shows how much 
signal response can be obtained per unit concentration change. It is affected by 
both the signal strength and the assay curve position. This means that if the active 
concentration region of the curve is lower then the sensitivity will be higher, and 
if the response is higher then the sensitivity will be higher. In comparison, the 
enhancement ratio is simply the ratio of enhanced signal over non-enhanced 
signal calculated by taking the ratio of the slopes of the antibody binding response 
plots or the assay response ranges. The active or dynamic region of the curve is 
the concentration band between 10-90% bound that in these studies has been 
referenced to the nearest standard at either end. 
All comparisons of assay curves are validated by use of t-test. In most cases 
this was two-tailed, but in some cases as mentioned they are one-tailed (i.e. show 
that one average is higher than the other). In this chapter all the P-values 5 0.04, 
i.e. they meet the requirements for a statistically significant difference. All the 
errors quoted in the tables were standard errors. 
5.4 Conclusions 
SPR biosensors for small molecules have long suffered from poorer detection 
capability compared with more traditional ELISA techniques. Such biosensors 
exhibit limits of detection often many orders of magnitude higher than ELISA and 
have low signal strength due to their reliance on the primary antibody to produce 
signal through its mass. Whilst there have been extensive investigations of signal 
enhancement of large molecules through use of nanoparticle and other high mass 
labels, there has been a complete absence of successful studies directed to small 
molecule immunoassay. The importance of immunosensing of small molecules 
cannot be overlooked and so it is of clear interest to develop more sensitive SPR 
biosensor assays through the use of signal-enhancing labels. 
In this study, a robust SPR chip surface has been constructed by covalently 
immobilising progesterone through an OEG linker to the chip surface in situ. This 
easily produced surface has proven to be stable for in excess of 1100 binding and 
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regeneration cycles without appreciable loss of antibody binding capacity. The 
biotin / streptavidin linkage has been used to attach gold nanoparticle labels to 
primary antibody. This was done firstly in a pre-incubation format where the LOD 
was significantly improved over non-labelled antibody but there was no overall 
signal enhancement. Both 10 nm and 20 nm colloids were used and showed no 
difference in enhancement. When applied in a sequential binding format, the gold 
labelling gave 2-fold signal enhancement and enabled substantial reduction in the 
concentrations of primary antibody used. This enabled the LOD to be reduced to 
as low as 23.1 ± 4.4 pg/mL. 
Secondary antibody can also be used to label bound primary antibody and was 
used as a binding label giving an 8-fold signal enhancement. This enabled 
reduction of primary antibody sufficient to achieve LOD of 20.1 ± 4.0 pg/mL and 
slope sensitivities much higher than those for streptavidin-bound gold. Use of 
secondary antibody-gold conjugates with purification of the conjugates to remove 
unbound secondary antibody, resulted in enhancements of about 3-fold due to the 
limited ability of the colloid to adsorb antibody. When the secondary antibody-
gold conjugate is used without purification at the same loadings as for the 
secondary antibody alone, the enhancement is improved to 13-fold and the LOD 
drops still further to 8.6 ± 3.2 pg/mL. 
Conditions of regeneration, and additives to reduce non-specific binding have 
been developed and discussed. Full antibody binding studies have been conducted 
for each format and the effects of labelling concentrations have been examined. 
This study represents the first successful report of gold nanoparticle signal 
enhancement of small molecule immunoassay using SPR and shows how 
technologies that until now have been limited to large molecules can be applied to 
small molecules. Such enhancements have been successfully achieved through use 
of a "double-linker" system whereby the antigen is projected from the sensor 
surface by one linker and the labelling particle has been spaced from the antibody 
by use of another linker or spacer. The major problems of surface stability, 
reliable regeneration, steric obstruction from labelling particles and reduction of 
non-specific binding have all been successfully addressed. 
The formats developed here for progesterone are very generic in nature and can 
be applied to a whole range of different small molecule antigens through 
appropriate conjugation chemistries, and examples of this are clearly shown in 
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Chapters 3 and 4. High mass label signal enhancement of small molecule binding 
interactions has enormous future potential for the development of sensitive SPR 
immunosensors for small molecules. The limits of detection achieved in this study 
are comparable to or better than most ELISA for progesterone11 •15•74 and now 
enable SPR technology to compete on a more equal footing with ELISA in 
detection capability. 
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Chapter 6 - The Chemistry of Immunosensing 
6.1 Chemistry and the Immunoassay 
The development of biosensors that utilise immunochemical binding 
interactions has been greatly hindered by a number of fundamental problems. 
These include unstable sensor surfaces, poor signal on antibody binding, the ease 
with which antibodies can be destroyed, and difficulties with adapting to new 
biological media. ELISA continues to be the mainstay of the immunochemical 
diagnostics market as they demonstrate limits of detection and sensitivities 
superior to most biosensors. This is despite the major limitations of ELISA, i.e. 
that they are laboratory-based, labour intensive and can give unreliable signal 
responses. 
If the immunosensor is to truly compete with ELISA then new technologies 
need to be developed to address the outstanding problems. The chemist is in a 
unique position to apply knowledge of organic and physical chemistry to solving 
some of these problems. It has been the principal objective of this thesis to 
logically develop new immunosensory systems that demonstrate clear advantages 
over existing technology through the application of organic chemistry and 
nanotechnology. All the parts of this thesis contribute to this, and taken together 
they demonstrate, in a wide range of applications, how new chemical architectures 
can improve immunosensing. 
6.2 Protein Conjugate-Based Immunoassay of Whole Milk 
Progesterone 
The development of protein conjugate-based ELISA has many advantages over 
enzyme-antigen conjugate-based systems. Progesterone-protein conjugates have 
been applied as coating antigens in ELISA of whole milk progesterone. Studies 
have been conducted that show a clear pattern of increasing antibody binding with 
increasing linker length of the conjugate in the whole milk medium up to 18-
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atoms in linker length, in contrast with results previously reported in the aqueous 
medium. The detection limit of the immunoassay is considerably improved when 
the linker length is increased up to 18-atoms in length. An ELISA format was 
developed that requires no pre-dilution of milk samples and is rapid and does not 
require enzyme-antigen conjugates. The assay was validated against existing 
RIA, and variability and recovery values assessed. The immunoassay was applied 
to the detection of progesterone in bovine whole milk samples to form a profile of 
the estrous cycle of the cow. 
This study demonstrates how re-designing the assay format can lead to 
improvement in the ELISA through elimination of the enzyme-antigen conjugate, 
production of a potentially more stable assay surface, generation of an assay with 
a broad detection range for full profiling of bovine estrous cycles and no pre-
treatment of the milk samples. The assay system gives significant additional 
benefit to the farmer by making routine whole milk ELISA testing for 
progesterone much easier. 
6.3 Thioether Derivatives of the Estrogens - Synthesis and Antibody 
Binding Studies 
Attachment of linkers directly to the ring structure of a steroid enables 
immunogenic conjugates to be produced that do not modify existing functional 
groups and so closely resemble the free antigen. This enables production of 
immunogenic conjugates that can raise antibodies that are highly specific to the 
small molecule target. It also enables immobilisation of binding antigens on 
biosensor surfaces that demonstrate high binding strength to specific antibodies. 
Thioether derivatives at the 4-position of estradiol and estrone were synthesised 
through substitution of their corresponding bromo-derivatives. These compounds 
were then used to link to OEG linkers through NHS activation. 
An SPR chip was immobilised with the estradiol derivative and compared to 
reference compounds conjugated through the 2-position by Mannich reaction and 
the 3-position by hemisuccinate conjugation through the 3-0H, also attached to 
the surface via OEG linkers. Antibody binding studies showed that conjugation at 
the 2-position by Mannich reaction gave 19% more binding than the thioether but 
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the hemisuccinate gave very little binding at all. This supports the theory that 
conjugation through functional groups will greatly reduce specific antibody 
binding in the flow-through format, and interestingly shows that binding to the 2-
conjugate using an antibody produced to a 6-position conjugate still gives strong 
antibody binding. Sensitive estradiol assays could then be constructed from this 
surface. 
This study shows how a rational consideration of the position of attachment 
can optimise the antibody binding strength in flow-through assays and gives 
important information on antibody binding properties to different conjugates. A 
sensitive SPR immunoassay of estradiol has been developed and through the use 
of secondary antibody labelling technology has an LOD of 25 pg/mL. 
6.4 Catecholamine Thioether Linked Derivatives - Synthesis, 
Purification and Antibody Binding Studies 
Attachment of linkers to the aromatic ring by formation of thioether bridges 
has been demonstrated for the catecholamines dopamine, nor-epinephrine and 
epinephrine. The use of electrolysis methods proved to be an efficient means of 
producing the thioether conjugates without degradation of the catecholamine. 
This was done through formation of the o-quinone followed by addition of the 
thiol. This was demonstrated for both three and 11-carbon thiol chains. 
Convenient purification was developed by ion-exchange chromatography, and 
reactions and separations monitored by HPLC. These compounds were then 
analysed by 2-dimensional NMR spectroscopy to help determine the position of 
attachment in each case. The dopamine-propionate derivative was used as coating 
antigen in the in situ immobilisation of the neurotransmitter using OEG and 
hexanediamine linkers and in comparing to conjugation through the amine. As the 
antibody was raised to glutaraldehyde-conjugated dopamine it exhibited highest 
binding to the amine-conjugated surface. 
This study has demonstrated the synthesis of a new group of catecholamine-
thioether derivatives tailored for use in bioconjugates that do not compromise 
existing functional groups on the catecholamine and may be used to raise specific 
antibodies, to construct enzyme or protein conjugates or immobilize onto the 
biosensor surface as coating antigens for better immunoassays in future. 
6.5 Signal Enhancement of SPR lmmunosensing of Small 
Biomolecules 
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The use of gold colloids to enhance the binding signal in SPR-based 
immunosensing of small biomolecules was examined in detail. Protein conjugates 
were initially used as coating antigens, but whilst they produced promising 
preliminary assay results, they were found to be unstable when exposed to gold 
colloids and the regeneration solutions needed. Similarly, progesterone-OEG-
biotin used as a competitive agent with free progesterone for limited bound 
antibody and with signal enhancement via streptavidin-gold, was found to be 
unreliable because of denaturing of the immobilised antibody. 
A novel covalent immobilisation system was developed for progesterone using 
attachment of an OEG linker at the 4-position and in situ immobilisation of the 
amine terminus of the chain on the dextran surface by NHS mediated coupling. 
This produced a surface capable of withstanding more than 1100 binding and 
regeneration cycles without loss of binding capacity. The surface was employed 
in two labelling formats. In the first, biotinylated monoclonal antibody was pre-
incubated with streptavidin-gold and the labelled antibody used in an assay of 
progesterone. This produced no signal enhancement but enabled reduction of the 
detection limit to as low as 143 pg/mL. In the second format, free progesterone 
competed with bound progesterone for binding to biotinylated antibody and the 
bound biotinylated antibody was labelled by passing over streptavidin-gold. This 
resulted in a two-fold signal enhancement and enabled the detection limit to be 
reduced to 23.1 pg/mL through reduction of primary antibody concentration. 
Enhancement of the binding interaction of eight-fold was achieved with use of 
secondary antibody as the label in a sequential binding format. The use of 
secondary antibody-labelled gold sols resulted in a four-fold enhancement of 
signal when the excess secondary antibody was removed and a 13-fold signal 
enhancement when the secondary antibody total concentration was set the same as 
for the assay with secondary antibody alone. In none of the formats, except the 
protein conjugate or progesterone-biotin conjugate work, was increasing colloid 
size from 10 nm for streptavidin-biotin labelling or 25 nm for secondary antibody 
labelling seen to improve the degree of enhancement. 
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Treatments for regeneration of the surface and the minimisation of non-specific 
binding were examined in full, as was confirmation of the nature of the labelling 
interactions, and optimisation of antibody coating in secondary antibody-mediated 
gold coupling. 
This study represents the first successful nanoparticle signal enhancement of 
small molecule SPR-based immunoassay and demonstrates how careful chemical 
design of the assay system through use of a double-linker format can allow the use 
of nanoparticle enhancement for small molecules causing large-scale signal 
enhancement and improvements in assay performance including a reduction in 
limit of detection of about two orders of magnitude. 
6.6 Future Work 
There is a large number of different possibilities for future research building on 
the work of this thesis. In the area of milk progesterone immunoassay, the 
development of SPR-based biosensors around 4-position attachment to the steroid 
offers great promise in the development of sensitive and stable biosensing 
systems, particularly through the OEG intermediate linkage system. The protein-
conjugate method of ELISA immobilisation has been much underused and there is 
great potential for expanding ELISA technologies based on this system to a range 
of other targets and media. 
In the field of estrogen A-ring-linked conjugates, there is the possibility of 
forming drug conjugates to the estrogens using this attachment and linker 
technology and to direct them to estrogen receptors in vivo for the purposes of 
treating diseases where these receptors proliferate, e.g. breast cancer. The OEG 
linker offers much promise here because of its low immunogenicity and its 
inertness and water solubility. 
In the field of catecholamine thioethers there is also the possibility of 
developing drug conjugates analogously to the estrogens or attaching 
chemiluminescent agents for the study of brain tissues in vitro. 
The field of gold-labelled SPR interactions of small biomolecules for 
immunoassay is completely new as this work represents the first SPR 
immunosensing system to demonstrate this nanoparticle signal enhancement for 
274 
small biomolecules, a significant challenge in terms of binding, surface stability 
and labelling techniques. The possibilities for future research stemming from this 
are large. The generic in situ chemical immobilization techniques developed open 
up the possibility of adapting this technology for other small molecule targets. 
The adaptation of these systems to a non-BIAcore format will be a major future 
step in developing this technology for practical on-site biosensors. 
The diagnostics market for small biomolecules is huge and encompasses a 
wide range of technologies. This thesis has concentrated on addressing some 
fundamental questions about the design of small molecule immunoassays and has 
shown how currently used formats and methods may be substantially improved by 
the rational application of chemical knowledge to the study and development of 
immunosensing systems. It is anticipated that the ability of the chemist to further 
augment and improve immunodiagnostics is immense, with this thesis providing 
just a small example of what can be gained by rational engineering and 
fundamental studies of the chemical factors affecting immunochemical 
interactions in the immunobiosensor. 
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Appendix 1 - Preparation of Buffers 
PBS/f: 10 mM phosphate buffered saline pH 7.4, 0.05%w/v Tween 20, NaCl 138 
mM, KCI 2.7 mM. Prepared by dissolving commercial sachet (Sigma P-3563) in 
1 L of deionised water. Other pH by adjustment with base or acid as required. 
Phosphate buffer, pH 7.2: 36.0 mL of 0.2 M Na2HP04 mixed with 14.0 mL of 0.2 
MNaH2P04 
pH 7.4: 40.5mL of 0.2 M Na2HP04 mixed with 9.5 mL of 0.2 M NaH2P04 
HBS-EP: 0.95 g N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid] 
(HEPES), 3.51 g NaCl, 0.44 g EDT A, 200 µL of P-20 surfactant added to 400 mL 
of deionised water and pH adjusted to 7 .4. 
0.1 M borate buffer pH 8.5: 0.31 g of boric acid in 25 mL of deionised water, 
adjusted to pH= 8.5 with 0.1 M NaOH and then made up to 50 mL in deionised 
water. 
0.1 M sodium formate buffer pH 4.3: 0.35 g of sodium formate in 25 mL of 
deionised water, adjusted to pH 4.3 with formic acid and then made up to 50 mL 
in deionised water. 
0.1 M sodium acetate buffer pH 4.0: 18 mL of 0.2 M sodium acetate is mixed 
with 82 mL of 0.2 M acetic acid and the pH adjusted to 4.0. 
Bicarbonate Buffer pH 9.6: 0.85 g of sodium carbonate and 1.47 g sodium 
bicarbonate dissolved in 500 mL of deionised water. 
0.1 M Sodium Acetate Buffer pH 5.4 
1.6406 g of sodium acetate dissolved in 200 mL of deionised water. Add 120 µL 
of glacial acetic acid. Adjust the pH with acetic acid or sodium acetate as 
necessary. 
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TMB Colour Reagent 
50 mg of TMB was dissolved in 5 mL of DMSO and protected from light. 250 
µL of this stock solution was added to 25 mL of acetate buffer, pH=5.2, along 
with 250 µL of hydrogen peroxide stock (38 µL of 30% hydrogen peroxide in 2.5 
mL of deionised water). The reagent was used immediately. The TMB stock 
lasts up to three months. The hydrogen peroxide stock must be freshly made each 
time. 
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Appendix 2 - BCA Assay 
This assay was done using a standard BCA assay kit from Pierce (Rockford, 
USA) and following the enclosed instructions. 
1. BSA standards were prepared at 0, 25, 125, 250, 500, 750, 1000, 1500, 2000 
µg/mL in PBS/f. 
2. 0.1 mL of standard or sample was added to glass tubes and mixed with 2 mL 
of working reagent. 
3. The tubes were incubated for 30 min at 37 °C and then cooled to room 
temperature. 
4. The absorbance was then measured at 562 nm. 
5. Blank corrected plots of absorbance vs protein concentration were prepared 
for the BSA standards and OVA concentrations determined by applying the 
appropriate correction factor. 
Note: BSA standards should be used because they are of high purity and in 
combination with the correction factor give accurate results with un-modified 
antibody. 
Appendix 3 - BIAcore Wizards 
l?:4 KEYWORD From_lD 
if=FLOW 20 
,g_ TRANSFER ' Antibody Gold' Mix_lD 70 
~ TRANSFER From_lD Mix_lD 70 
Q MIX Mtx ID AutoMix 
~ WAIT300 
~ f -60 BASELINE Baseline 5 
JI-' INJECT Mix. ID 60 
ffo INJECT END 
~ WAIT60 
~ 1 · 10 RESPONSE Bound 5 
jF QUICKINJECT ' Regen' 20 
x- OUICKINJECT END 
~o EXTRACLEAN 
JI'\ QUICKINJECT ' Regen 2' 20 
~ QUICKINJECT END 
~o EXTRACLEAN 
1! 120 RESPONSE Regen 5 
~ WAIT300 
Figure A3.1 Pre-incubation Assay Wizard 
~ KEYWORD Mix_lD 
if= FLOW 20 
!!, f -60 BASELINE Baseline 5 
jF OUICKINJECT ' Antibody" 60 
ifr, OUICKINJECT END 
1
-10 RESPONSE Bound 5 
jF OUICKINJECT M,x ID 30 
x- OUICKINJECT END 
S"o EXTRACLEAN 




OUICKINJECT 'Regen 1" 20 
QUICKINJECT END 
QUICKINJECT ' Regen 2' 20 
QUICKINJECT END 
OUICKINJECT 'Regen 3' 20 
QUICKINJECT END 
EXTRACLEAN 
Figure A3.2 Sequential Assay Gold Wizard 
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l::J> KEYWORD From_lD 
if= FLOW 20 
.iQ_ TRANSFER "Antibody" Mix_lD 70 
.[!:! TRANSFER From_lD Mix_lD 70 
MIX Mix_lD AutoMix 
~ WAIT300 
f! r-60 BASELINE Baseline 5 
F INJECT M,x_lD 60 
ito INJECT END 
if= FLOW 10 
JI' I QUICKINJECT "lgG" 60 
x- OUICKINJECT END 
11ii> EXTRACLEAN 
if= FLOW 20 
3° WAIT 30 
~ f -20 RESPONSE Bound 5 
JI' QUICKINJECT 'Regen· 20 
0 OUICKINJECT END 
Figure A3.3 Secondary Antibody Enhanced Assay Wizard 
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Appendix 4 - NMR Spectra 
For the purposes of compound purity analysis, the conventions of the Journal of 
Organic Chemistry have been followed. Purity is shown either by HPLC purity 
analysis where stated or by giving the NMR spectra of the pure compounds as 
appended below. Quantitative GC-MS was not possible as most of the compounds 
were thermally unstable under the GC-MS temperature conditions, and elemental 
analysis was made difficult by the nature of the products (mostly either oils or 
waxy solids) or in the case of the bromoestrogens and catecholamines because it 
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Figure A4.8 1H NMR Spectrum of (15) 
For (16) see Chapter 3 
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Figure A4.9 13C NMR Spectrum of (17) 
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